annual report proud work respiratory portfolio know important medicines lives patients julie gsk respiratory packaging operator ware ukoverview significant year gsk without challenges reflected trading performance although pleased group responded standout event year proposed threepart transaction novartis accelerate strategy making gsk simpler stronger balanced platform longterm growth sir andrew witty chief executive officer read ceo statement performance summary bn bn bn bn group turnover core operating profitb total operating profit returned shareholders via cera cera cer dividends share buybacks bn p p core earnings per shareb total earnings per share around new molecular new product sales primarily reflecting entities phase ii iii noncash adjustments st st access medicine index countries fully company file regulatory dow jones sustainability index implemented new sales approval malaria vaccine score putting us top force compensation model candidate pharmaceutical sector e xcluding divestments completed reconciliation b number adjusted measures used report performance core results excluding divestments completed total results business measures defined reconciliation set core results total results set front cover story julie pictured gsk delivering medicines leads years works respiratory training programme covers quality packaging operator manufacturing safety patient impact helping site ware uk years employees appreciate importance role help ensure gsks respiratory medicines millions lifesaving medicines copd adults children asthma ventolin seretide julie one many people within recently four new medicines gsk helped us remain leader administered ellipta inhaler respiratory medicine years relvarbreo anoro incruse arnuity continuously striving generate always highest quality scientific insights help us develop new available patients across world medicines inhalers meet needs need patients launched new julie gsk respiratory key part julies role help colleagues respiratory medicines past two years packaging operator gsk understand patient previous years combined ware uk end supply chain offering greater choice healthcare critical contribution every employee professionals patients gsk annual report mission gsk mission contents strategic report improve quality human chairmans statement ceos statement life enabling people global marketplace feel better live longer business model strategic priorities performed risk management businesses developing innovative responsible business group financial review products improving access healthcare governance remuneration patients around world board corporate executive team chairmans letter board report shareholders committee reports remuneration report chairmans annual statement annual report remuneration remuneration policy report financial statements directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap investor information quarterly trend five year record product development pipeline product competition intellectual property risk factors share capital share price dividends tax information shareholders annual general meeting us law regulation shareholder services contacts glossary terms cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results accordance legal regulatory obligations including uk listing rules disclosure transparency rules financial conduct authority group undertakes obligation update forwardlooking statements whether result new information future events otherwise reader however consult additional disclosures group may make documents publishes andor files sec readers wherever located take note disclosures accordingly assurance given particular expectation met shareholders cautioned place undue reliance forwardlooking statements forwardlooking statements subject assumptions inherent risks uncertainties many relate factors beyond groups control precise estimate group cautions investors number important factors including document could cause actual results differ materially expressed implied forwardlooking statement factors include limited discussed risk factors pages annual report forwardlooking statements made behalf group speak date made based upon knowledge information available directors date annual report find wwwgskcom number adjusted measures used report performance business measures defined reconciliation core results total results set gsk annual report gsk annual report strategic report governance remuneration financial statements investor information chairmans statement behalf board pleased risk management commitment returns report saw good progress ethical behaviour groups strategy building board aims assure integrity shareholders diversified business delivering gsks business operations products value simplifying rigorous processes systems remain key operating model year risk management key part boards discussions notwithstanding also recognise priority fundamental changes trading audit risk committee plays critical environment group operates role overseeing issues challenges board particularly us faced management team including impacted performance however resolution investigation set dividend board continues believe chinese authorities business management team put place illegal activities gsk china p per share appropriate strategy respond clear breach gsks governance challenges compliance procedures wholly contrary values standards increase board particularly pleased expected gsk employees approve proposed threepart implemented substantial changes transaction novartis chinese business consequence transform future shape group making balanced providing board expects group remain better opportunity broadly based sales vigilant compliance issues fully growth delighted shareholders supports managements efforts overwhelmingly voted favour encourage employees concerns transaction december speak investigate allegations made continue invest returns shareholders remain key improved procedures priority board management team despite challenging trading doubt commercial success environment focus cost financial directly linked operating responsible efficiencies allowed board way meets changing expectations set dividend p per share society respect board increase year expect supports action management maintain dividend p per share taken delink compensation sales also return billion net proceeds representatives number proposed novartis transaction prescriptions written board also appropriate approvals gained recognises industry leading work group fundamentally total since billion change relationship returned shareholders doctors customers removing dividends share buybacks perception conflict interest forward looking approach exemplified work worlds first malaria vaccine await news regulators efforts part global response ebola crisis examples show dedication skill expertise gsk make real difference peoples lives worldwidegsk annual report strategic report governance remuneration financial statements investor information board diversity male female year efforts improve succeeded nominations prospects corporate reporting incorporated committee chairman january closing behalf board would information responsible lead refreshment board like thank sir andrew executive business approach performance reflect requirements future team continuing commitment within annual report move reshaped group continue challenging year towards aligning principles provide sir philip committee demonstrated ability integrated reporting addition support continuity stand deliver groups strategy responsible business supplement board agm last report chairman published march providing detail well welcoming sir philip gsk would like thank topics setting progress board also pleased announce shareholders support throughout group made october urs rohner would join tenure time chairman responsible business commitments board nonexecutive director seen many changes much governance remuneration effect january already progress whether delivery chairman committed gsk bringing great value board using companys rd organisation efforts seeking operate highest standards experience chairman credit suisse improve access medicines corporate governance independent group ag broad business evolution commercial model evaluation undertaken board background coupled strong committees im pleased commitment shareholder returns would like thank sir deryck maughan say results positive agreeing remain board look forward integration confirmed board operates additional year senior independent new elements following completion effective manner director assist transitioning role proposed threepart novartis remuneration committee chairman sir philip transaction restructuring operated accordance binding utilise considerable experience innovation still come rd pipeline remuneration policy received knowledge gsks businesses provide remain confident gsk deliver overwhelming shareholder support continuity balance considerable longterm value agm report found returns shareholders thanks also go jing ulrich dedicated service board jing board changes composition decided seek reelection agm number changes finally tom de swaan stands board year agm nine years valuable following extensive rigorous committed service included search sir philip hampton appointed exemplary chairmanship audit risk successor sir philip joined remuneration committees would sir christopher gent board nonexecutive director like thank tom advice chairman start january become deputy support years wish chairman april chairman well future end agm may sir philip brings enormous expertise board including chairing number global companies operating complex highly regulated environments gsk annual report strategic report governance remuneration financial statements investor information ceos statement since reshaping trading performance challenging proposed gsk help us deliver sustainable pharmaceutical vaccines sales sales earnings performance grew emerging markets threepart increased innovation products japan europe flat better access medicines offset us sales declining transaction patients worldwide result continued pricing contracting pressure particularly marked progress novartis respiratory business objectives notably proposed innovative threepart transaction worked hard improve fundamentally novartis fundamentally formulary positioning coverage reshape company major step us move reshape group towards fulfilling strategy creating starting see early encouraging simpler stronger balanced signs help us regain market major step platform longterm growth share deliver improved performance respiratory addition continue trading conditions continue make good progress transitioning towards fulfilling challenging particularly us primary new portfolio respiratory medicines care market led sales year recently launched two new products strategy declining cer billion incruse ellipta copd arnuity core earnings per share cer ellipta asthma await regulatory p sales pressure decision mepolizumab potentially mitigated delivery cost important product financial efficiencies continue make returns shareholders priority within hiv viiv healthcare grew year increased dividend p sales tivicay triumeq reaching per share expect hold million launches level products among best class future success group underpinned rd organisation performance consumer healthcare continues productive business impacted supply addition substantial advanced issues sales year falling pipeline large number increasing last quarter exciting early phase assets key following progress remediation therapeutic areas rapidly issues expect see increasing benefit moving forward clinic improved supply situation remain confident also kept pace outlook business innovation business model continuing evolve relationships reshaping company doctors customers ensure sustainable future meet societys expectations april announced proposed global pharmaceutical company innovative threepart transaction novartis acquire vaccines business form joint consumer healthcare company sell novartis marketed oncology products excluding divestments completed gsk annual report strategic report governance remuneration financial statements investor information proposed transaction give addition organic programmes operating emerging markets substantial global scale consumer proposed novartis transaction especially challenging given issues healthcare business become allow us target synergies billion many countries face funding market leader countries per year fifth year following maturity respective healthcare well number one company completion identified systems however continue believe worldwide overthecounter medicines billion annual cost savings robust compliance systems delivered next three years working closely local governments currently worlds leading also reshape pharmaceuticals presence markets help vaccine manufacturer proposed rd organisation improve access medicines broader transaction strengthens position healthcare allowing us expand portfolio business remains cash generative notably meningitis build net cash inflow operations broadening access medicines geographic reach particularly us billion although enabling broadest possible access bring together expertise virology impacted global currency fluctuations medicines remains priority bacterial infection research particularly strength sterling delighted topped first half access medicine index selling marketed oncology assets fourth consecutive time nothing better novartis billion realised evolution business model demonstrated commitment innovation attractive price part well making financial savings access everything business fast growing restructuring programmes also work vaccine malaria subscale benefit part seeking modernise ways working filed rapid established oncology company continued response ebola crisis working challenge expect complete proposed candidate ebola vaccine agenda transaction week commencing able achieve around ten months march made substantial progress rolling would otherwise taken several years changes compensate pay tribute everyone gsk involved sustainable rd pipeline sales representatives changes build two projects support future growth reforms started us last years rd outlook two years ago pleased organisation exceptional looking focused see recent healthcare practitioner period productivity since successful execution strategic satisfaction research showing gsk achieved fda approvals priorities closing proposed novartis ranks first us among new molecular entities nmes transaction clearly key alongside peer group value bring company consolidating building early practitioners work progress seeing respiratory following approvals received adding fully well successfully launching new respiratory products breo ellipta implemented commitment stop products also need ensure anoro ellipta tafinlar mekinist paying doctors speak behalf consumer healthcare business continues oncology tivicay hiv instead deliver new multichannel recover supply issues received four approvals system transform doctors incruse ellipta arnuity ellipta sales headwinds faced receive information us respiratory triumeq hiv tanzeum group continue adversely type diabetes undertaking reforms affect performance ensure patients put first everything greater impact first half year awaiting fda decisions breo eliminate perception however annualisation ellipta use asthma mepolizumab conflict interest believe factors successful execution firstinclass antiil treatment changes right thing priorities expect stronger performance severe eosinophilic asthma continue also competitive second half year see significant organic pipeline delivery advantage follow initiatives year expect phase ii also making decision clinical trial data transparency iii starts whether undertake minority initial companies also making public offering viiv healthcare advanced pipeline see significant clinical study results available potential example vaccine addition following closure operating values prevent shingles triple combination proposed novartis transaction plan operate important us therapy copd new long acting hold investor day issue delivering financial performance thats hiv treatment cabotegravir addition specific earnings guidance year issues saw china last year number exciting profile medium longterm shape wholly disappointing caused early stage assets therapy areas opportunities gsk harm groups reputation immunoinflammation immunooncology taken significant steps rectify issues finally would like thank cardiovascular disease number identified chinese business employees partners suppliers prophylactic therapeutic vaccine apply appropriate lessons operations continued commitment support candidates elsewhere given complexity cost control financial efficiencies sector challenges working remain focused cost control global healthcare continue improving financial efficiencies face risks year delivered around million incremental savings compared various restructuring initiatives ongoing cost reduction efforts sir andrew witty chief executive officer gsk annual report strategic report governance remuneration financial statements investor information business scienceled global healthcare company researches develops innovative pharmaceuticals vaccines consumer healthcare products global reach structured significant global commercial turnover region three primary areas presence markets business commercial operations network manufacturing sites structured combination countries large rd centres regional units areas focus uk usa belgium china businesses benefit gsks global commercial infrastructure since reshaped global international supply networks innovative footprint improve access high growth rd significant scale potential markets including usa asia pacific latin america japan pharmaceuticals vaccines operate europe emerging markets combined business geographical japan segments consumer healthcare bn global unit viiv healthcare specialist hiv company majority pfizer shionogi group turnover cera employees region shareholders trading turnover includes canada puerto rico australasia central vaccine tender sales contract manufacturing sales employees turnover segment bn excluding divestments completed usa pharmaceuticals vaccines europe emerging markets us japan europe emerging markets japan viiv healthcare established products trading consumer healthcare research sustain grow business consumer healthcare business investment rd people also underpinned science development work rd roles across group innovation launched spent billion new market products including noncoreb items billion total sensodyne true white horlicks search develop innovative medicines variations bn vaccines consumer products core rd expenditure pharmaceuticals around allocation new molecular entities phase ii core rd expenditure phase iii therapeutic areas pharmaceuticals respiratory immunoinflammation vaccines hiv cardiovascular disease consumer healthcare vaccines currently phase iiii b calculation core results noncore items set preclinical phase ii nmes prevent shingles hepatitis c tb novel mechanisms action respiratory syncytial virus exacerbations copd malaria ebolagsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals pharmaceuticals business develops makes medicines treat broad range acute chronic diseases portfolio made innovative established medicines leading global positions respiratory disease hiv read sales therapy area bn respiratory oncology cardiovascular metabolic urology total turnover immunoinflammation pharmaceuticals viiv healthcare hiv established products group turnover vaccines vaccines business one largest world broad portfolio paediatric adolescent adult travel vaccines distributed approximately million doses countries read sales product line bn infanrixpediarix boostrix cervarix total turnover fluarix flulaval hepatitis rotarix synflorix group turnover consumer consumer healthcare business one largest world driven science values develop market products four categories healthcare wellness oral health nutrition skin health brands available countries read sales category bn wellness oral health nutrition total turnover skin health group turnover gsk annual report strategic report governance remuneration financial statements investor information global marketplace opportunities challenges demand medicines healthcare treatments remain strong coming years global economic review consumer healthcare markets emphasis cost led increased global economy grew gsk operates estimated pricing pressures competitive intensity slightly worth billion projected within private marketplace grow per annum next well public programmes makes however recovery uneven five yearsc essential manufacturers across regions growth major demonstrate value medicines economies strong us grew global trends impacting healthcare vaccines bring patients market economic growth changing healthcare system usa uk grew demographics emerging markets develop innovative products offer growth weaker euro area increasing demand healthcare products significant improvements existing japan demand expected grow options access healthcare also remains significantly faster markets key priority evidenced initiatives longer term mature emerging markets showed stronger new health insurance marketplaces markets countries become richer economic growth developed markets expansion medicaid programme increased consumption food alcohol continuing longterm trend financial penalties people tobacco combined less exercise china still shows robust growth purchase insurance however leading growth chronic diseases compared americans access respiratory cardiovascular low income countries continued grow healthcare coverage access medicines disease europe rising public debt robust pace example growth continues challenge government austerity programmes continue subsaharan africa patients across healthcare system create pressure healthcare spending including private marketplace us focus cost value global healthcare market leading payers reduce price restrict europe global pharmaceutical market access demand differentiated europe european medicines agency continued grow sales products manufacturers must develop ema regulates new medicines billion jansep innovative products offer significant issued positive opinions billion jansep cera improvements existing options recommending marketing authorisation medicines containing new active north america remains largest globally populations ageing taking substances pharmaceutical market share increasingly active role managing global sales health creating demand given public funding healthcare europe showed slight decline healthcare products rising individual countries continued pressure period empowerment growing expectations government budgets led flat emerging markets asia pacific society also mean patients reduced investment healthcare continued represent global consumers want healthcare companies pharmaceuticals across europe spending sales japan represented operate high standards order hospital medicines increased previous yeara build trust mostly driven increased use oncology biological products decreased global vaccines market pricing regulation primary care highpriced medicines increased around billionb prescription medicines vaccines generated significant public debate market expected continue highly regulated ensure patients users particular focus oncology growing represent around billion access safe effective medicines treatments hepatitis c b individual governments determine products marketed countries inequality access medicines many stateregulated systems european countries within total global sales medicines governing product pricing patient populations remains significant regiona concern despite much debate usa new pricing approach could reduce us food drug administration fda approves new medicines inequality concrete progress limited practical challenges approved novel medicines parallel trade international reference increase pricing remain year ema healthcare landscape usa launched adaptive pathways pilot undergoing substantial change help accelerate patient access valuable much stronger focus improving quality new medicines several countries including controlling costs impact uk france also considering particularly significant issue unilaterally usa creating challenging conditions europe industry emerging markets asia pacific japan footnotes reference ims data jansep b reference evaluatepharma c reference ims evaluatepharma internal analysismacroeconomic social trends population growth ageing populations rapid technological advances rise individual empowerment rising public debt western markets economic growth emerging markets climate change resource depletion lifestyle changes global competition talent opportunities challenges healthcare sector strategic response gsk annual report strategic report governance remuneration financial statements investor information responding longterm global opportunities challenges changing lifestyles leading new disease burden rising public debt leading pressures healthcare spending growing demand emerging markets payer focus value leading demand differentiated products ageing population leading increased demand rise individual empowerment meeting healthcare societys growing expectations emerging markets key focus creating innovative products since reshaped business enhance committed developing innovative new products access highgrowth markets asia pacific offer significant improvements existing treatments latin america japan emerging markets sales focus research efforts areas grown c turnover today science presents best opportunities address unmet medical need preclinical phase ii nmes novel mechanisms action addressing affordability changing work healthcare professionals committed tackling affordability barriers modernising work healthcare least developed countries cap prices professionals hcps ensure actions always patented medicines vaccines prices interests patients sales staff directly charged developed countries developed markets interact prescribing hcps incentivised pioneered novel reimbursement approaches knowledge expertise business performance rather widen access newer medicines priced individual sales targets stopped current treatments direct payments hcps speak medicines vaccines gsk annual report strategic report governance remuneration financial statements investor information global marketplace opportunities challenges continued adoption new vaccines remains intellectual property consumer healthcare products slow many countries coverage patent protection development timeline consumer rates vary significantly journey scientific breakthrough healthcare products shorter approved new medicine vaccine pharmaceuticals vaccines japan takes years incur significant intellectual property protections japan pharmaceutical medical costs ensure reasonable return available importance device agency pmda regulates new investment researchbased healthcare effectiveness different consumer medicines approved april companies rely protection healthcare products also covered december intellectual property patents national regulation regarding testing april japanese ministry rights approval manufacturing labelling health labour welfare conducted marketing advertising patents generally year term biyearly review pricing medicines filing sometimes challenged consumer healthcare products strong resulting reduction excluding expire cases legal reliance brand loyalty trade mark impact consumption tax increase proceedings see legal proceedings protection create value especially national health note financial statements emerging markets brands play important insurance pricing scheme based role business many leading governments market price survey patent expiry early loss patent brands including sensodyne panadol lead availability generic premium new drug development horlicks polident paradontax tums version product often introduced trial eno niquitinnicorette abreva zovirax cheaper generic manufacturer basis remained place aquafresh moreover brands typically incur significant rd costs distinct heritage horlicks emerging markets developed markets generics rapidly years old eno years old emerging markets prescription capture large share market market medicines regulated variety erosion may less emerging markets competition ways however approval process automatic substitution methods competition prescription products continues evolve aligning developed patients may also comes companies researching closely usa europe japan quality safety concerns therefore making patentprotected medicines terms format content prefer established medicine brand indications treat similar diseases countries china india medicines principal research markets operate russia vietnam nigeria require based pharmaceutical vaccines intellectual property rights particularly local clinical data order fulfil competitors include abbvie amgen patents data protection less regulatory requirements astra zeneca bayer bristolmyers squibb enforceable governments seek eli lilly johnson johnson merck co economic growth changing control prices increase access novartis novo nordisk pfizer roche demographics markets medicines limiting rights holdings sanofi takeda increasing demand healthcare products example india brazil argentina demand expected grow significantly implemented considering main consumer healthcare faster markets longer practices restrict availability competitors include colgatepalmolive term mature markets patents addition countries johnson johnson procter gamble considering widespread use reckitt benckiser novartis see full governments across regions compulsory licensing individual list continue seek ways improve access company use anothers patent healthcare time addition many locally operating without consent pays patent manage healthcare expenditure including companies compete gsk owner set fee licence spending medicines countries certain markets indonesia china india looking vaccines biological products expand population covered currently face degree governmentfunded health schemes generic competition partly due increases opportunities high complex research manufacturing volume tenders also impacts pricing processes compared medicinesgsk annual report strategic report governance remuneration financial statements investor information business model create value success depends ability research develop innovative healthcare products make accessible many people possible resources businesses operating outputs model mission pharmaceuticals rd benefits patients underpinned discovering customers developing innovative values healthcare products financial returns people vaccines manufacturing profits cashflow financial resources making shipping quality products strategic priorities around world shareholder value partnerships consumer healthcare commercialisation expertise distribution wider benefits society improving access products reinvestment mission improve quality operating model outputs human life enabling people innovation key success developing innovative products feel better live longer transformed rd organisation maximising access delivers direct recent years agile since benefit patients consumers resources weve medicines approved deliver mission must align successfully lead healthcare company resources behind strategic priorities profitable sustainable performance many development turn allows us generate value depend expertise also implemented different ways returns shareholders enables enthusiasm employees supporting rd example opening us reinvest business patients embrace new ways working forge access expertise facilities consumers continue benefit partnerships offer fresh insights even intellectual property best combat worlds collaborate external wider society benefits healthcare challenges organisations since healthy people communities essential building strong sustainable expect everyone put values bring innovations patients societies also create value making heart decision making consumers manufacture billions direct indirect economic social means acting transparently respectfully products highquality standards contributions countries integrity putting supply countries operate tax employment interests patients consumers first worldwide charitable support deliver success commercial success depends important achieve market presence customer understanding made good progress expanding access seek make strategic priorities established products accessible countries grow diversified global business levels income development deliver products value least developed countries simplify operating model includes capping prices developed market levels reducing businesses prices highvolume contracts scienceled healthcare developed markets pioneered company operating three main areas novel reimbursement approaches widen pharmaceuticals vaccines access newer medicines priced consumer healthcare current treatments gsk annual report strategic report governance remuneration financial statements investor information strategic priorities deliver strategy designed increase growth reduce risk improve longterm financial performance strategic priorities progress since progress key challenges key performance priorities grow total group sales broadly stable proposed major threepart transaction increased pricing pressure us implement proposed transaction bn despite significant sales losses novartis bolster vaccines consumer market changes competitor novartis diversified business generic competition healthcare businesses announced dynamics contracting improve commercialisation new aim create balanced diversification delivering organic growth transition new respiratory portfolio continued pricing pressure europe group turnover respiratory hiv consumer business product portfolio emerging market sales c underway launch relvarbreo due government austerity programmes healthcare products capable delivering sustainable turnover today ellipta anoro ellipta incruse ellipta unanticipated supply continuity drive growth emerging markets sales growth centred three billion returns paid shareholders arnuity ellipta challenges consumer healthcare p across three businesses business areas pharmaceuticals including billion dividends viiv healthcare sales vaccines consumer healthcare billion buybacks dividend successful launches tivicay triumeq core earnings per share capitalise product supply resumption consumer healthcare business p p reconciliation core results total results set deliver created agile productive significant new product approvals disappointing phase iii results continue progress midstage pipeline rd organisation product respiratory diseases hiv diabetes mage darapladib programmes phase iiiii starts expected products value approvals healthcare malaria candidate vaccine rtss integrate proposed novartis vaccines company since aim research develop submitted regulatory approval new product approvals major markets pipeline high quality products offer improved rd investment rate return valuable improvements treatment positive phase iii study results patients consumers shingles candidate vaccine hzsu healthcare providers pharmaceuticals vaccines around new molecular entities phase ii iii simplify billion cumulative annual cost million incremental savings unanticipated supply continuity execute pharmaceuticals restructuring savings delivered range delivered restructuring initiatives challenges consumer healthcare programme save billion per annum operating model restructuring programmes since ongoing cost reduction three years complexity rolling new systems aim reflect reduced complexity disposing global enterprise resource planning scale across many markets days increase working capital continue streamlining product portfolio business changing transforming noncore brands integrating supply system erp rolled markets embedding common processes operate reduce complexity chains across businesses bn continue rollout erp system become efficient introducing new workplace efficiencies speed decision making execute restructuring programme frees resources reinvest elsewhere business cumulative annual savings made related proposed novartis transaction restructuring programmes since save billion per annum fifth year closing adjusted exclude divestments completed impact intangible asset impairment responsible relentless focus access healthcare collaborated partners accelerate rebuilding business china following continue enhance governance business first access medicine index development ebola vaccine candidate criminal conviction china affiliate compliance quality proactive since violation chinese law risk management qualityled culture delivered global rollout new sales force responsible business evolved commercial model compensation approach meeting value chain carbon emission deliver new commercial model globally central strategy changing ways working target sales products changing way work hcps launched new africa strategy reach deliver success important healthcare professionals incentives high carbon footprint ventolin subsaharan african least improve leadership effectiveness achieve sales force increasing developed countries population quality talent ensuring values embedded led increasing transparency clinical early extended price continue progress development culture decision making trial data first company sign freeze commitment years ebola vaccine candidate helps us better meet alltrials campaign gavigraduating countries expectations societygsk annual report strategic report governance remuneration financial statements investor information strategic priorities progress since progress key challenges key performance priorities total group sales broadly stable proposed major threepart transaction increased pricing pressure us implement proposed transaction bn despite significant sales losses novartis bolster vaccines consumer market changes competitor novartis generic competition healthcare businesses announced dynamics contracting improve commercialisation new diversification delivering organic growth transition new respiratory portfolio continued pricing pressure europe group turnover respiratory hiv consumer emerging market sales c underway launch relvarbreo due government austerity programmes healthcare products turnover today ellipta anoro ellipta incruse ellipta unanticipated supply continuity drive growth emerging markets billion returns paid shareholders arnuity ellipta challenges consumer healthcare p across three businesses including billion dividends viiv healthcare sales billion buybacks dividend successful launches tivicay triumeq core earnings per share capitalise product supply resumption consumer healthcare business p p reconciliation core results total results set created agile productive significant new product approvals disappointing phase iii results continue progress midstage pipeline rd organisation product respiratory diseases hiv diabetes mage darapladib programmes phase iiiii starts expected approvals healthcare malaria candidate vaccine rtss integrate proposed novartis vaccines company since submitted regulatory approval new product approvals major markets pipeline improved rd investment rate return positive phase iii study results shingles candidate vaccine hzsu pharmaceuticals vaccines around new molecular entities phase ii iii billion cumulative annual cost million incremental savings unanticipated supply continuity execute pharmaceuticals restructuring savings delivered range delivered restructuring initiatives challenges consumer healthcare programme save billion per annum restructuring programmes since ongoing cost reduction three years complexity rolling new systems reduced complexity disposing global enterprise resource planning scale across many markets days increase working capital continue streamlining product portfolio noncore brands integrating supply system erp rolled markets embedding common processes chains across businesses bn continue rollout erp system introducing new workplace efficiencies speed decision making execute restructuring programme cumulative annual savings made related proposed novartis transaction restructuring programmes since save billion per annum fifth year closing adjusted exclude divestments completed impact intangible asset impairment relentless focus access healthcare collaborated partners accelerate rebuilding business china following continue enhance governance first access medicine index development ebola vaccine candidate criminal conviction china affiliate st compliance quality proactive since violation chinese law risk management qualityled culture delivered global rollout new sales force evolved commercial model compensation approach meeting value chain carbon emission access medicine index deliver new commercial model globally changing ways working target sales products changing way work hcps launched new africa strategy reach healthcare professionals incentives high carbon footprint ventolin subsaharan african least improve leadership effectiveness sales force increasing developed countries population quality talent led increasing transparency clinical trial data first company sign early extended price dow jones sustainability index score continue progress development alltrials campaign freeze commitment years placing us top sector ebola vaccine candidate gavigraduating countries gsk annual report strategic report governance remuneration financial statements investor information new pharmaceuticals vaccines group turnover turnover major growth areasb new product approvals major markets product performanceb bn performed bn definition approvals definition bn definition turnover excluding measure focuses major growth major market defined usa new products launched last divestments prior year lower areas vaccines consumer healthcare eu andor japan five years rolling basis pharmaceutical vaccines emerging markets japan following products longer performed sales us established performed first regulatory approvals included calculation arzerra products partly offset growth lamictal xr potiga prolia votrient b emerging markets japan viiv w groe w ta hw nc eon mti en ru ge ind g p mha ar rm kea tc e au nt dic ja als p eta lln ipz te au n n tc rir uu mse e qe llipta arnuity performed healthcare consumer healthcare w aa h kle eys tw os jr eme c l p ivow ere oar fn ot ur strategy v w inaa e tl ec er rec r u bn w pe r eo ts ira ea n n il smyd fl pc ato c n tc es dou n bs ye u r sm h ue pe r pa h yt eh ac la thre c w orhh gisy nmit es aa ti im ou nrp e ssr ht da en w lit vs e h rio nw g nth ee w r p rod ucts tn ua r nle oos vf eo p rf h gn ae r rew mw ap cr eo ud tu cc ns ld aw nree dpr e vr e c e c n int e eb sil lion deliver sustainable broadlysourced drive growth group important important sales growth highlights progress delivering measure shows delivery strategy create broadbased sales year products sales growth resilient launched prior five years volatility rolling basis creates incentives improved rd performance reported growth cer share total turnover reported growth cer b reported growth total operating profit margin free cash flowb cash returned shareholders bn performed bn definition bn performed total operating profit billion calculation free cash flow gsk returned billion excluding currency effects described shareholders via dividends share total operating margin declined reconciliation provided buybacks percentage points primarily calculation cer important reflecting higher sga costs lower described b profits disposal business b performed w dive id c eo nn dt gu roe w th f oc veu rs hn e loe nli gv e teri rn mg products noncash adjustments free cash flow billion returning free cash flow shareholders contingent consideration relation decline reflecting impact share buybacks viiv healthcare result higher strength sterling lower profits offers attractive return sales outlook tivicay triumeq including impact divestments alternative investments important measure shows cash generate available return shareholders reinvest business well effectiveness converting earnings cash effective working capital control investment discipline reported growth cer b reported growth sdnedivid sdnedivid sdnedivid performed key performance indicators measure performance number key performance indicators excluding divestments completed excluding divestments completed core operating profit margina bn performed core operating profit billion excluding currency effects core operating margin declined percentage points primarily reflecting increase sga b percentage sales despite decline actual sales important opu er r ab tinje gc leiv e rre agm ea tn os e um rep r oo pv ee r ating profit growth performs ahead sales performance margin indicates costs managed percentage sales reported growth cer reported growth b reported growth excluding divestments completed core earnings per sharea total earnings per share definition performed p core results exclude number items p total earnings per share p total results full definition compared p primarily core results found reflecting noncash adjustments reconciliation core contingent consideration relation results total results provided viiv healthcare result higher b b sales outlook tivicay triumeq well unfavourable comparison performed product asset disposal gains core eps decreased cer compared cer decline turnover result cost financial efficiencies important earnings per share key indicator performance returns generating shareholders reported growth cer reported growth cer b reported growth excluding divestments completed b reported growth gsk annual report strategic report governance remuneration financial statements investor information new pharmaceuticals vaccines group turnover turnover major growth areasb new product approvals major markets product performanceb bn performed bn definition approvals definition bn definition turnover excluding measure focuses major growth major market defined usa new products launched last divestments prior year lower areas vaccines consumer healthcare eu andor japan five years rolling basis pharmaceutical vaccines emerging markets japan following products longer performed sales us established performed first regulatory approvals included calculation arzerra products partly offset growth lamictal xr potiga prolia votrient b emerging markets japan viiv w groe w ta hw nc eon mti en ru ge ind g p mha ar rm kea tc e au nt dic ja als p ea lln ipz te au n n tc rir uu mse e qe llipta arnuity performed healthcare consumer healthcare w aa h kle eys tw os jr eme c l p ivow ere oar fn ot ur strategy v w inaa e tl ec er rec r u bn w pe r eo ts ira ea n n il smyd fl pc ato c n tc es dou n bs ye u r sm h ue pe r pa h yt eh ac la thre c w orhh gisy nmit es aa ti im ou nrp e ssr ht da en w lit vs e h rio nw g nth ee w r p rod ucts tn ua r nle oos vf eo p rf h gn ae r rew mw ap cr eo ud tu cc ns ld aw nree dpr e vr e c e c n int e eb sil lion deliver sustainable broadlysourced drive growth group important important sales growth highlights progress delivering measure shows delivery strategy create broadbased sales year products sales growth resilient launched prior five years volatility rolling basis creates incentives improved rd performance reported growth cer share total turnover reported growth cer b reported growth total operating profit margin free cash flowb cash returned shareholders bn performed bn definition bn performed total operating profit billion calculation free cash flow gsk returned billion excluding currency effects described shareholders via dividends share total operating margin declined reconciliation provided buybacks percentage points primarily calculation cer important reflecting higher sga costs lower described b profits disposal business b performed w dive id c eo nn dt gu roe w th f oc veu rs hn e loe nli gv e teri rn mg products noncash adjustments free cash flow billion returning free cash flow shareholders contingent consideration relation decline reflecting impact share buybacks viiv healthcare result higher strength sterling lower profits offers attractive return sales outlook tivicay triumeq including impact divestments alternative investments important measure shows cash generate available return shareholders reinvest business well effectiveness converting earnings cash effective working capital control investment discipline reported growth cer b reported growth sdnedivid sdnedivid sdnedivid reported growth reported growth b growth excluding legal settlements total earnings per share footnotes performed use number adjusted measures report performance b remuneration executives linked marked key indicators p total earnings per share p business include core results used management information executive pay policy found compared p primarily planning reporting purposes may directly comparable remuneration policy report reflecting noncash adjustments similarly described measures used companies reconciliation contingent consideration relation core results total results set viiv healthcare result higher b sales outlook tivicay triumeq well unfavourable comparison product asset disposal gains relative total shareholder return table responsible business external benchmarking first access medicine retained position cdps member ftsegood scored dow index topped biannual ftse climate disclosure since jones sustainability index reported growth cer index since began leadership index seventh year putting gsk top b reported growth sector gsk annual report strategic report governance remuneration financial statements investor information risk management approach risk rigorous risk management processes systems help us assure integrity business operations committed conducting business europe emerging markets review implementing accordance applicable laws initiated wideranging review required improvement plans address regulations manner internal controls confirm risks strengthen controls also consistent values company standards local laws continued satisfy corporate integrity established risk management framework regulations understood adhered agreement obligations office address operational legal compliance countries regions took part inspector general north america risks inherent nature business specific internal control framework strategic ambitions risk management c heo lu pp sl e ud w mi ath tau ir n ot ue rr n foa cl uc n ot nr pl rf ora dm uce tw ork e nterprise oversight internal control quality safety sustainability independent assurance f wra itm h e ow uro vrk l uin e sc hn eju lpn sc ti oo n h c c u w vanoo ledn uw e ear p r rw p ea ls ie b n n c ay om sop mu ega r dmn e l ai ta c biph tg ue e p ee ss r r nwr tasi eos ct ak h h b sn eoa td ao iuc n na rr r gr id c os ks u ra e rg n p lad eas pn oik dy ng ee v se rar im sbn l u la ae eel rn es disi ci epn l ni fond c e eap mn ede ntnden sb seu r ss ss mi kn ee ns ts csn ot nai tnt rodwo lsar rr dti sten ng e w cn u sa e ns r pn u db ear uu r cge e cs te tt os enh r u n deia b sk b js e aw nc ae edtc xe tt ao f ew v u f de ntc ae tct li ov e nl dy u ct responsible embedding business parties including regulatory c e suu n sl st tu u ar r ie nn gd b e p ilc ir toi ys ao u rn c e fq ua nuk dai ln aitg ea nn td f ae lh tyo w w ud work ot p ro blem ser sp nding activities training cg oe e nn q trc u oi le c fs ry mt oo f e ws u os r kns e w rt nh eae l b eu ms pin loe ys es e ad ree l ccountable working na itg oe rm ine gnt communication f tr ac kt eiv e athl py e p rd oed par rce iats tvs ei tfi cien osd r ri eng cd ts v e established standards identifying actions improve escalating encountered risks internal controls across appropriately managed group company comprehensive learning programmes ensure employees gsk values suitably trained including mandatory key training gsk code conduct individual accountability antibribery corruption policies line management accountability compliance business management accountability compliance progress audit assurance learnt lessons compliance board responsible system corporate issues experienced recent years directors governance strategy risk management financial performance continue look ways strengthen internal control framework proactively manage audit risk responsible reviewing approving principal risks example committee adequacy effectiveness risk china implemented new management internal controls governance model increased dedicated compliance resources put place corporate supports ceo managing business additional controls monitoring local executive team activities ways working financial transactions central dedicated antibribery corruption team provide external risk oversight authorised board assist audit risk insight standards training expertise compliance committee overseeing risk management business globally also council internal control activities group strengthened internal investigations team create three regional hubs provide consistent approach investigations business units responsible identifying assessing across group allowing us respond managing risks within businesses quickly consistently emerging issues enhanced approach risk management ensure appropriate internal controls independent business monitoring detect compliance effective risk management implemented abnormal inappropriate financial flows boards complemented country executive risk boards better within europe emerging markets ensure consistent approach risk management across local geographies gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser governance structure risk managementgsk annual report strategic report governance remuneration financial statements investor information principal risks principal risks listed believe could cause results differ materially expected historical results listed order significance full description definition context potential impact mitigating activities principal risks set pages principal risk definition manage risk patient safety failure appropriately collect review follow chief medical officer leads large global report adverse events potential sources safety pharmacovigilance team maintains act relevant findings timely applicable global policies guide staff worldwide manner intellectual property failure appropriately secure protect global patents group continually analyses intellectual property rights ensures changes patent laws regulations incorporated processes obtaining maintaining enforcing global patent protection product quality failure comply current good manufacturing chief product quality officer leads practices inadequate controls governance global network quality councils implements quality applicable policies assures single quality management system defines quality across businesses supply chain continuity failure deliver continuous supply compliant closely monitor inventory status finished product delivery products help ensure customers medicines vaccines consumer products need supply chain governance committees financial reporting failure report accurate financial information internal controls financial information disclosure compliance accounting standards reporting overseen regional management applicable legislation reviewed financial controller chief financial officer cfo external auditors tax treasury failure comply current tax law incurring tax risk managed set policies significant losses due treasury activities procedures help ensure consistency compliance tax legislation appropriate engage advisors legal counsel review tax legislation applicability business antibribery failure comply applicable local extensive global abac programme corruption abac international abac legislation policy procedures overseen toplevel abac oversight committee part programme significant training provided employees globally regarding antibribery corruption compliance groups abac policies commercial practices failure engage commercial andor scientific harmonised policies standards scientific engagement activities consistent letter govern promotional activities scientific spirit legal industry groups requirements engagement undertaken group relating marketing communications behalf employees worldwide trained medicines therapeutic areas policies implications failure comply policies research practices failure protect inform patients involved implement systems governance human clinical trial research generally controls oversee clinical trial research conduct clinical trials compliance law use biological samples data integrity key systems environment health failure manage ehss consistent global ehss standards support safety sustainability groups objectives policies relevant laws ehss policy overseen members ehss regulations cet employees globally routinely trained groups ehss policies information protection failure protect maintain access critical chief information security officer oversees sensitive computer systems information global information policy programme regularly assesses changes closely monitoring systems external briefings crisis continuity inability recover sustain critical operations established crisis continuity management following disruption respond crisis management ccm governance board incident timely manner team ccm experts ensure critical business operations crisis continuity plans place thirdparty oversight failure maintain adequate governance chief procurement officer oversees policy oversight thirdparty relationships framework governing buy goods services management thirdparty relationships gsk annual report strategic report governance remuneration financial statements investor information businesses leading capabilities pharmaceuticals vaccines consumer healthcare driven scienceled innovation innovative science forefront whether investigating potential new treatments respiratory patients conducting research develop worlds first malaria vaccine rhiannon pictured works laboratory ware uk researching potential treatments leishmaniasis disease currently affects around million people worlds poorest countriesgsk annual report strategic report governance remuneration financial statements investor information gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines growth emerging markets japan viiv healthcare offset challenging environment usa leading pharmaceuticals hiv business managed vaccines vaccines businesses underpinned viiv healthcare global specialist vaccines business one largest substantial rd organisation company hiv majority world broad portfolio significant commercial presence pfizer shionogi paediatric adolescent adult usa europe japan emerging shareholders viiv healthcare travel vaccines four largest vaccines markets since increased leading global company hiv sales infanrix diphtheria investment emerging markets significant recent success tetanus hepatitis rotarix rotavirus account c group turnover regulatory approval industry leading synflorix pneumonia c recent years launches dolutegravirbased vaccines business particularly launched important new medicines medicines tivicay singlepill strong developing world vaccines respiratory hiv oncology treatment triumeq viiv healthcare vaccines produce diabetes influenza number antiretroviral medicines distributed developing countries clinical development including pharmaceuticals includes least developed low cabotegravir detail see pharmaceuticals business develops middle income countries viiv healthcare makes medicines treat broad tiered pricing approach based range acute chronic diseases beyond respiratory hiv countries gross national income enables portfolio made innovative portfolio pharmaceutical countries maintain expand established medicines products treatment conditions commitment immunisation leading global positions respiratory lupus benlysta benign prostatic economies grow gsk also one disease hiv hyperplasia avodartjalyn type diabetes largest contributors gavi vaccine recently launched tanzeumeperzan leader respiratory alliance publicprivate partnership bacterial infections augmentin disease years improve access vaccines developing portfolio mature products past six years built countries countries seretideadvair ventolin flovent significant oncology business recent growing economies graduate recent years strengthened years multiple regulatory gavi support january broadened respiratory portfolio approvals global product launches announced year price freeze addition new medicines relvarbreo including tykerbtyverb votrient gavi graduating countries ellipta inhaled corticosteroid ics promactarevolade arzerra tafinlar proposed novartis transaction longacting beta agonist laba mekinist strengthen vaccines portfolio combination anoro ellipta longacting part proposed novartis acquisition novartiss muscarinic antagonist lama laba transaction agreed divest vaccines business excluding influenza dual bronchodilator incruse ellipta lama marketed oncology portfolio related rd adding number vaccines meningitis arnuity ellipta ics activities rights akt inhibitors several travel vaccines well number respiratory currently development billion strengthening manufacturing network products pipeline including represents unique opportunity combined business also benefit mepolizumab investigational antiil crystallise value shareholders increased exposure key markets monoclonal antibody treat severe leverage global scale novartis usa novartis eosinophilic asthma closed therapy area improve strong presence track record triple combination treatment treat patient outcomes regulatory approvals proposed copd remain confident novartis transaction enhance addition established maintain leadership respiratory gsks vaccine rd pipeline bringing products portfolio epp includes disease well next decade together expertise virology bacterial offpatent products well infection different adjuvant platforms branded generics business local products products important part emerging markets business gsk brand important differentiatorgsk annual report strategic report governance remuneration financial statements investor information sales hepatitis vaccines vaccines sales europe fell grow million due supply lower sales infanrix cervarix constraints boostrix flu vaccines reflecting increased strategy remains grow business million due competitor competitive pressures broadly based sales challenging returning market year partly offset sales growth trading conditions notably supply constraints rotarix products boostrix us meant group turnover declined sales declined million due part competitor billion however positive result cdc stockpile withdrawal supply issue first half year performances year emerging q markets japan europe flat emerging markets pharmaceuticals europe pharmaceuticals vaccines turnover increased regional performance vaccines turnover flat million pharmaceuticals global sales pharmaceuticals million pharmaceutical sales flat vaccines markets vaccines fell million strong growth outside asia showed strong growth million pharmaceuticals oncology sales million notable performances brazil turnover declined growth led votrient promacta newly million rest emerging markets japan viiv launched tafinlar avodart latin america million healthcare offset franchise million sales china fell due effects lower sales us established offset fall respiratory sales government investigation products pharmaceuticals sales europe million newly launched year continued growth flat global vaccines sales relvar ellipta recorded sales million respiratory oncology products declined due lower reported sales year seretide sales declined respectively europe japan despite million result avodart franchise grew positive performance emerging increasing competitive pressures vaccines growth strong tender markets us vaccines sales flat transition respiratory portfolio sales boostrix rotarix synflorix year newer products particularly largely offset lower sales us pharmaceuticals vaccines latter part year cervarix result lost tenders turnover million supply constraints pharmaceuticals vaccines flat pharmaceutical sales impacted continued price contracting pressures primary care market primarily affecting respiratory sales putting patients customers first sales advair decline volume decline price mix fundamentally transforming also investing continue increase access modernising way sell market healthcare professionals stop new portfolio respiratory medicines medicines meet information paying external experts speak january medicare part needs healthcare professionals behalf prescription medicines coverage breo ellipta ensure put patients interests first medical science liaisons anoro ellipta starting believe changes msls already stepping see early indications right thing deliver talks physicians increased coverage new portfolio competitive advantage us recently launched medicines us help us regain market share deliver one benefit new way working improved performance respiratory gsk led industry internal experts may changing way reward oncology products made strong sales representatives focusing direct knowledge clinical contribution us performance sales quality information trials led approval million benefiting sharing healthcare professionals medicine customers attended good performances votrient overall business performance talks anoro ellipta delivered promacta recent launches rather individual sales targets gsks medical staff given tafinlar mekinist sales immuno approach rolledout presentations high marks times rating inflammation treatment benlysta grew countries operate even effective million generic competition usa led external speakers thus far us continued impact sales healthcare professionals surveyed programmes attracting dermatology products ranked gsk first among number attendees externalled million mepron reported major pharmaceutical companies presentations past sales decline million value bring changes allow us continue us sales infanrixpediarix vaccines better meet needs healthcare grew million benefiting customers tell us valuable professionals patients favourable cdc stockpiling compared source information want absence competitor provide information ways particularly first half year better meet needs exploring digital realtime channels provide information way customers want want gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines continued japan pharmaceuticals vaccines turnover grew million pharmaceuticals sales vaccines pharmaceuticals sales benefited strong growth oncology products avodart respectively partially offset lower sales respiratory portfolio turn affected weaker allergy season beginning year increased competitive pressures new prescription share increased following substantial increases new prescriptions relvar ellipta lifting ryotan prescribing restrictions sales year relvar ellipta million overall respiratory sales fell million lower vaccines sales reflected impact cervarix continued suspension recommendation use hpv vaccines although higher sales rotarix partly compensated respiratory continue develop enhance leading way respiratory respiratory portfolio new product launches await fda decisions gsk forefront many years previous years breo ellipta use asthma advances respiratory disease since combined offering greater choice mepolizumab firstinclass antiil launch ventolin years ago healthcare professionals patients treatment severe asthma overall continue expect total sales broadest portfolio medicines add strength respiratory portfolio return growth marketed respiratory medicines globally respiratory portfolio potential add two number assets currently late stage firstinclass medicines development confident respiratory sales fell coming years respiratory pipeline continue million year deliver new treatment options seretideadvair sales transformed respiratory able meet evolving needs million flixotideflovent sales pipeline years scientific research patients well next decade fell million ventolin sales approved medicines grew million xyzal sales potential benefit millions meanwhile continue work hard almost exclusively made japan patients living asthma copd ensure mainstay treatments year gained approval seretide ventolin remain million incruse ellipta usa europe important treatments millions usa respiratory sales fell arnuity ellipta usa also patients across world want face continued price contracting gained eu approval anoro ellipta ensure accessed pressures market sales advair europe following us approval broadest number patients million fall success builds approval example reducing pack sizes volume decline price relvarellipta first enable smaller amounts mix flovent sales medicine delivered ellipta purchased creating lowcost ventolin sales newly inhaler achievement even formulations launched products breo ellipta recorded significant given amassed sales million anoro ellipta recognise still much unprecedented regulatory approvals sold million year achieved overcome relvar ellipta global burden respiratory disease committed helping people ongoing commitment respiratory disease optimise investment scientific research treatment achieve best possible working collaboration external clinical outcome experts remain forefront expanded portfolio respiratory respiratory medicine medicines enabling clinicians commitment scientific tailor treatment patients individual leadership help transform needs fact recent approvals lives patients enabling mean launched new feel better live longer respiratory medicines past twogsk annual report strategic report governance remuneration financial statements investor information european respiratory sales declined categories vaccines largely due increased competition sales cardiovascular metabolic vaccines sales seretide sales fell million urology category million year although decrease volume negative million year avodart declines europe japan impact price result increasing franchise grew million partly offset growth competitive pressures transition increase sales duodartjalyn emerging markets sales respiratory portfolio newer although avodart sales declined usa flat emerging markets products latter part year sales levitra fell million helped strong performances relvar ellipta recorded sales million year sales prolia synflorix boostrix rotarix year million following infanrixpediarix grew million agreement amgen terminate joint respiratory sales emerging markets growth usa offset sales commercialisation selected markets grew sales seretide decline europe emerging markets million helped improved regionally sales usa boostrix sales increased performance china sales growth million although million growth regions except ventolin million emerging markets grew us sales fell largely due veramyst million million japan also grew sales return competitor product offset flixonase sales fell million europe flat rotarix sales grew million largely due sales decline million driven tender shipments europe china sales immunoinflammation emerging markets although japan respiratory sales fell products grew million helped decrease usa impacted million sales million sales increase benlysta cdc stockpile withdrawal fourth relvar ellipta offset impact million year therapy quarter synflorix sales also increasing competitor action adoair areas million million mainly due strong fell million growth largely reflecting generic competition tender performance emerging markets xyzal million dermatology products sales hepatitis vaccines fell offset lower sales elsewhere established products million partly due supply respiratory portfolio however new sales established products fell constraints affecting us emerging prescription share increased million generic competition markets fluarix flulaval sales following substantial increases new lovaza million million due lower prescriptions relvar lifting seroxatpaxil million production levels increased ryotan prescribing restrictions valtrex million competition cervarix sales declined oncology contributed fall category million largely due fall oncology sales grew million sales emerging markets japan regionally sales usa year contributions well increasing competitive pressures million sales europe votrient sales million japan fell million promacta sales million million respectively sales arzerra fell million emerging markets performance tykerbtyverb sales declined category declined million million new launches compensated generic competition hycamtin argatroban tafinlar mekinist recording sales million million respectively us oncology grew million contributions votrient million promacta million tafinlar million mekinist million europe oncology sales grew million led votrient sales million emerging markets sales million japan sales grew million gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines continued new indications also approved darapladib also investigational deliver regulators existing oncology medicines cardiovascular medicine arzerra firstline treatment chronic successful phase iii studies rd organisation delivered lymphocytic leukaemia combination development terminated number new medicines vaccines chemotherapy treatments usa patients expanded treatment along partners mmv started europe promacta usa options additional indications phase iii study investigate safety treatment severe aplastic anaemia several existing products also filed efficacy tafenoquine singledose number latestage assets regulators hivaids investigational radical cure plasmodium significant new assets progressed viiv healthcare gained eu approval vivax malaria form disease final stages development tivicay dolutegravir integrase inhibitor occurs primarily south south east followed approval usa asia latin america horn africa progress gives us continued confidence approval also given triumeq pipeline potential new medicines also continued pursue usa europe triumeq remains strong sustainable new indications existing medicines singlepill regimen treatment continue deliver value patients within oncology phase iii study began hiv combining dolutegravir gsk pharmaceuticals vaccines evaluating promactarevolade patients nucleoside reverse transcriptase inhibitors currently around new molecular myelodysplastic syndromes mds nrtis abacavir lamivudine entities nmes phase iiiii clinical type cancer bone marrow development diabetes make enough healthy blood cells tanzeum new glp treatment type also submitted regulatory files seeking product approvals diabetes received approval usa additional indications medicine respiratory offering onceweekly injectable option severe aplastic anaemia europe within respiratory anoro ellipta patients product chronic immune idiopathic oncedaily medicine combining two name eperzan also approved thrombocytopenia itp paediatric bronchodilators longacting muscarinic europe setting usa phase iii study antagonist lama longacting beta agonist laba single inhaler pipeline newsflow subcutaneous ofatumumab patients pemphigus vulgaris rare autoimmune approved europe chronic obstructive pharmaceuticals skin disorder also began pulmonary disease copd followed regulatory files submitted approval usa end usa europe first biologic also submitted regulatory file incruse ellipta first monotherapy lama respiratory mepolizumab investigational ema variation marketing approved oncedaily treatment antiil monoclonal antibody administered authorisation volibris medicine copd including chronic bronchitis andor every four weeks treat patients pulmonary arterial hypertension pah emphysema usa europe severe eosinophilic asthma asset include use initial combination launched usa first quarter also evaluated two phase iii therapy pah patients finally arnuity ellipta oncedaily studies one treatment eosinophilic alongside advances late inhaled corticosteroid medicine treat granulomatosis polyangiitis egpa stage pipeline also see significant asthma approved usa first rare disease characterised widespread potential cabotegravir hiv see asthma treatment new respiratory inflammation walls small blood information sirukumab portfolio gained approval vessels vasculitis adjunctive antiil monoclonal antibody respiratory medicines therapy adults severe copd rheumatoid arthritis prolyl administered using innovative breo ellipta oncedaily fixed dose hydroxylase inhibitor anaemia patented dry powder inhaler ellipta combination inhaled corticosteroid exvivo stem cell gene therapy treatment oncology ics longacting beta agonist potential cure adascid rare mekinist mek inhibitor gained approved usa copd disease affecting children would european approval treatment filed usa treatment gsks first product using cell gene braf mutant metastatic melanoma asthma also announced start therapy technology fastmoving area first medicine class licensed phase iii programme evaluate science one believe europe oral targeted therapy also efficacy safety closed triple potential deliver number received approval usa combination treatment icslama transformational medicines fdas accelerated approval process laba patients copd first vaccines use combination tafinlar evaluate oncedaily triple combination within vaccines business previously approved oral targeted therapy treatment inhaled corticosteroid announced pivotal phase iii study results accelerated approval contingent two longacting bronchodilators shingles candidate vaccine hzsu results phase iii trial single inhaler showed reduced risk shingles designed evaluate clinical benefits phase iii study began evaluate adults aged years combination positive overall survival effects losmapimod acute coronary older compared placebo study results announced february syndrome losmapimod inhibitor started august ongoing phase iii combid study p mitogen activated protein map countries involves results submitted regulatory kinase enzyme understood play individuals evaluating authorities review central role acute inflammation filing strategy vaccine occurs heart attack developed shortterm treatment administered quickly possible heart attack reduce risk subsequent cardiac eventgsk annual report strategic report governance remuneration financial statements investor information reached major milestone development programme malaria candidate vaccine rtss submission regulatory file july european medicines agency see case study since ebola crisis began march gsk working closely world health organization regulators partners respond outbreak accelerate development investigational ebola vaccine also contributing overall humanitarian effort taking steps support small number employees region phase studies investigational ebola vaccine demonstrated acceptable safety profile produced immunological response healthy adult volunteers tested large phase iii clinical trial sponsored us national institutes health nih liberia april announced decision stop development investigational magea antigenspecific cancer immunotherapeutic treatment nonsmall cell lung cancer phase iii study failed meet efficacy endpoints following strategic review vaccines submitting regulatory application candidate immunotherapeutics unit included malaria vaccine available data developments current environment investigation additional technologies decided july reached major milestone rtsss development involved one pursue new research efforts submission regulatory biggest vaccine trials ever antigen specific immunotherapy application candidate malaria conducted africa number vaccine rtss european additional steps still need earlystage pipeline medicines agency ema key completed anticipate pharmaceuticals continue see moment gsks year journey vaccine could available substantial improvements novelty develop worlds first malaria vaccine implementation early adopter earlystage pharmaceutical research submission follows ssa countries programmes announcement phase iii data showing preclinical phase ii nme projects gsk invested hundreds millions rtss almost halved number novel mechanisms action dollars date rtss cases clinical malaria young developing multiple earlystage programme also received funding children aged months first assets therapeutic areas bill melinda gates vaccination months see significant opportunity immuno foundation international vaccination inflammation specifically diseases nonprofit organisation path rheumatoid arthritis inflammatory rtss intended exclusively use contributed financial scientific bowel disease psoriatic arthritis plasmodium falciparum managerial field expertise multiple assets development malaria parasite prevalent development rtss including gmcsf monoclonal antibody subsaharan africa ssa around committed price rtss number rip kinase inhibitors estimated deaths malaria cover cost manufacturing il receptor monoclonal antibody occur ssa vaccine together small return immunooncology range children age five around reinvested assets targeting haematological rd second generation malaria date licensed vaccine cancers solid tumours including vaccines vaccines available prevention malaria ox icos tlr well tropical diseases positive opinion cell therapy partnership ema granted world health biotechnology company adaptimmune organization indicated cancer epigenetics three policy recommendation may clinical programmes addressing beti possible end ezh lsd targets positive opinion ema also basis marketing authorisation applications nras ssa gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines continued vaccines continue integrate collaborating external partners core pharmaceutical investment earlystage assets following acquisition become critical component rd biotechnology company okairos strategy recent years novel adenovector platform involved partnerships external shown potential diseases ebola companies individuals academics hepatitis c respiratory syncytial virus ever enables us access rsv rsv one remaining increase understanding new paediatric infectious diseases areas science share risk vaccine yet exist recent development phase data vaccine candidate pharmaceuticals rd business demonstrated value employs approximately people exploratory work pharmaceuticals core rd discovery pharmaceuticals rd approach expenditure billion decline development pharmaceuticals rd business compared previous year facilities central support dynamic organisation believe resulting execution changes leading built sustainable pipeline innovative continued efficiency improvements nimble personalised units new medicines focus earlystage research fundamental step away traditional cuttingedge science earlystage research drug discovery hierarchical rd business model help highly selective rd crucial first step exploring new us maintain flexibility research investments concentrate areas medicines one greatest investment focusing believe science presents us challenges identify biological promising scientific opportunities opportunities likely deliver mechanisms involved development budget greater significant medical advances essential diseases create small accountability projects progress continue challenge areas molecules biopharmaceuticals dpu business plans regularly work recognising interact disease targets reviewed discovery investment announced programme ultimately leading new medicines board dib group senior rd sharpen focus rd activities research working commercial management alongside eliminating areas low probability external scientists making external individuals life science success also announced plans progress improving understanding investment expertise understanding change geographical rd footprint disease targets believe payer perspectives bringing significant rd operations improve success rate discovering latestage development together two global centres one new medicines see case study p compound demonstrated philadelphia usa discovery performance units potential proof concept works stevenage area uk believe dpus responsible discovery must decide whether advance vital enable scientists work development potential new laterstage development portfolio worldclass facilities medicines earlystage clinical investment board pib assesses trials completion phase iia technical commercial investment dpus case project progress scientists working particular development disease pathway area science timeline development stages pharmaceutical research drug regulatory approval postmarketing preclinical clinical trials discovery review launch surveillance phase phase phase compounds compounds compounds number patients approved new medicine years years yearsgsk annual report strategic report governance remuneration financial statements investor information stage called commit medicine development typically takes place harnessing advances technology drive phase iia trials compound tested small number patients drug discovery development particular condition disease phase iii studies largerscale studies patients continue build scientific currently estimated examine compounds efficacy technical capabilities enable us compounds entering clinical trials never safety often different therapeutic doses make better decisions earlier drug reach patients medicines determine may appropriate discovery development increasing often biological target stages successful use probability success reducing drug well understood one results studies combined attrition rate significantly greatest challenges drug discovery key scientific information submit improved proportion high quality need understand better regulatory file review possible drug candidates progress clinical mechanisms body related approval regulatory agencies development ensuring select disease improve develop best candidates prioritising effective medicines time work optimise resources progress compounds physical properties promising potential medicines cttv scientists combining formulation produced expertise explore interpret large efficiently sufficient quantities also capitalising major volumes data aim improving manufacturing process technology advances help ability define biological targets cases research may include researchers take crucial first step range diseases wellcome developing new inhalers devices exploring new medicines finding trust sanger institute contributing deliver medicines start launched unique understanding role centre therapeutic target genetics health disease responsibility guiding validation cttv european european bioinformatics institute investigational medicine later bioinformatics institute integrating huge streams experimental stages development filing rests wellcome trust sanger institute data create bioinformatics insights medicines development teams mdts pioneering research initiative contributing expertise disease small units people harnessing big data genome biology translational medicine drug pharmaceuticals new sequencing improve success discovery also made molecular entities nmes phase iiiii rate discovering new medicines multimillion pound contribution clinical development fund initial wave projects governance length time costs involved drug discovery development make investment rd essential highly selective invest focus resources rd executive team oversight focus productivity continue improve financial strategic issues overall budget remain committed improving efficiency rd february management across rd number productivity rd develop announced estimated irr governance boards manage investment innovative new products continue target decisions life cycle rd greater efficiency longerterm basis early commercialisation investment decisions begin discovery rd investment decisions estimated irr important phase dib continue based see best measure financial discipline pib described earlier opportunities considered patient strategic progress improve need market opportunity economics rd also underpins pib cochaired president scientific understanding believe strategy create flexibility around pharmaceutical rd president effective determining pricing new medicines global pharmaceuticals also investment requirements basis includes heads pharmaceutical calculation recent irr fixed proportion sales region along head global included products launched manufacturing legal counsel rd productivity key challenge january december industry believe compounds phases iib additional governance committees also important provide greater level iii development process assess technical scientific commercial transparency regarding rd decision yearend calculation investment decisions projects making rd returns based actual sales development commercial forecast sales operations new medicine rate return rd determined adjusted reflect expected failure rates launched assessing costs involved broadly line standard discovering developing latestage industry failure rates cost base pipeline projects profits used calculation comprised medicines vaccines estimate attributable rd costs approved launched actual projected milestone payments calculated appropriate estimated rd internal rate return irr stated longterm aim increasing gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines continued vaccines rd approach discovery development oversight key decisions rests vaccine rd work focuses discovery development new two bodies vaccine development discovering developing new vaccine complex process typically commercial board vdcb prophylactic therapeutic vaccines takes years vaccine vaccine investment board vib help protect treat people discovery begins identifying new vdcb reviews research infectious diseases cancers chronic antigens specific structures development project strategy advises disorders also look life cycle pathogens viruses bacteria parasites scientific technical commercial management maximise potential cancer cells recognised opportunity assessment overall existing vaccines broadening immune system produce view early advanced life cycle geographic availability advancing pathogens yeast bacteria development projects vdcb formulation approach allows us mammalian cells genetically manipulate recommendations progress projects increase value products bring purified one stage next submitted extending reach adapting formulated vaccine antigen vib ensure meet needs patients creates bodys immune response vib cochaired president manage prioritise investment cases formulation vaccine vaccines chairman global decisions best meet needs involves mixing antigens gsk vaccines board makes final customers help address proprietary adjuvant systems use decision whether invest project remaining global health challenges adjuvants improve immune systems evaluating vdcbs recommendation core vaccine rd investment response antigens contained vaccines alongside public health benefit business million innovating area opportunity development costs risks reflects decision stop development adjuvant systems years project timing overall evolution magea see formulations candidate vaccines portfolio vaccines scientists working across usually combination several antigens vaccine rd organisation currently final composition vaccine vaccines development antigens adjuvant may change range diseases time also continue explore potential governance early stage assets acquired several key decision points okairos novel adenovector vaccine development process commit platform complements existing vaccine research decide initiate full research adjuvant technology expertise enabling programme commit candidate us continue work developing next development decide invest resources generation vaccines may allow towards exploring potential vaccine tackling new diseases number clinical trials commit early clinical development phase ii commit phase iii commit registration launch vaccines research development cycle registration identify produce preclinical phase phase ii proof phase iii file postmarketing antigens antigens testing concept surveillance research including immunology preclinical development clinical development including postmarketing surveillance transfer process manufacturing years years years yeargsk annual report strategic report governance remuneration financial statements investor information latestage pipeline pipeline remains extensive summary pharmaceuticals vaccines phase iii regulatory set comprehensive list medicines vaccines phases iii development available pages compound indication us eu respiratory relvarbreo ellipta ffvi asthma filed june approved nov vilanterol vi copd ph iii ph iii mepolizumab severe eosinophilic asthma filed nov filed nov copd ph iii ph iii ffumecvi copd ph iii ph iii vaccines nimenrix menacwy menacwy prophylaxis ph ii approved apr magea melanoma ph iii ph iii herpes zoster shingles prophylaxis ph iii ph iii mosquirix rtss malaria prophylaxis na filed july oncology arzerra ofatumumab cll relapsedrelapsed maintenance ph iii ph iii nhl fl ph iii ph iii mekinist trametinib tafinlar metastatic melanoma approved jan ph iii dabrafenib combination use adjuvant melanoma ph iii ph iii promactarevolade myelodysplastic syndrome mds ph iii ph iii severe aplastic anaemia approved aug filed nov cardiovascular metabolic retosiban threatened preterm labour ph iii ph iii losmapimod acute coronary syndrome acs ph iii ph iii immunoinflammation benlysta sc systemic lupus erythematosus ph iii ph iii benlysta iv vasculitis ph iii ph iii sirukumab rheumatoid arthritis ph iii ph iii rare diseases adenosine deaminase severe combined immune deficiency ph iiiii ph iiiii exvivo stem cell gene therapy adascid mepolizumab eosinophilic granulomatosis polyangiitis egpa ph iii ph iii infectious diseases tafenoquine treatment relapse prevention plasmodium vivax malaria ph iii na dermatology ofatumumab sc pemphigus vulgaris ph iii ph iii gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines continued manufacturing supply common processes simplify gsk pharmaceutical across pharmaceuticals vaccines vaccine sites countries making business continued streamline core committed reducing complexity pharmaceutical vaccines products processes boost efficiency key step business helps us people involved establishment core efficient allows us respond manufacture supply activities commercial cycle programme key needs patients consumers enterprisewide planning decision quickly effectively within pharmaceuticals vaccines making process brings together manufacturing organisations aim last years commercial finance supply chain consistently deliver outstanding quality undertaken broad range restructuring ensure meet expected service value patients simplification programmes across demand products customers group reduced consolidation supply base also operational complexity delivered total sales performances helps simplify pharmaceutical billion annual savings date certain pharmaceuticals vaccines manufacturing supply chain operations impacted supply constraints reshaping business reduced number identified significant simplification manufacturing network thirdparty suppliers manufacture synergy opportunities continue review global medicines behalf gsk consumer healthcare vaccine pharmaceuticals manufacturing compared also businesses proposed novartis supply network ensure effectiveness continued reduce complexity transaction completes targeting efficiencies supply base standardising specifications total annual savings transaction goods materials buy year continued invest billion fifth year closing pursuing integrated sourcing processes network ensure capacity key including related oncology areas example respiratory continued initiative reduce expect approximately committed build new manufacturing complexity pharmaceutical product delivered year three facility montrose scotland provide portfolio allows us simplify also undertaking restructuring additional capacity newest supply chain commercial operations programme refocus global products relvarbreo ellipta anoro reduce risk complexity pharmaceuticals business following ellipta incruse ellipta arnuity ellipta increasing service levels divestment oncology products antibiotics continued invest achieved reduction changing dynamics us manufacturing capacity active baseline equates respiratory market cost base ingredients finished products discontinued packs rescale commercial operations global site notre dame de commitment quality support functions relevant rd bondeville france left network strongly committed meeting manufacturing across pharmaceuticals change announced highest quality standards stringent intended improve performance quality control quality insurance establishing streamlined agile endtoend supply chain processes medicines vaccines business expect deliver annual endtoend supply chain programme manufactured according current cost savings billion three years began designed good manufacturing practice cgmp expected reform simplify supply chain regulations approved file introduced processes part programme reshape includes commitments authorities improve coordination across stage global pharmaceutical operations internal quality standard production sourcing create two franchises respiratory procedures two gsk sites cork manufacturing efficient delivery speciality pharmaceuticals ireland ste foy canada received products patients consumers sit alongside established products warning letters us food portfolio global businesses introduced gsk production drug administration fda year respiratory franchise continue system gps across pharmaceutical taking comprehensive actions focus existing emerging manufacturing sites gps standard resolve issues respiratory portfolio newly way working identify eliminate procurement created specialty pharmaceuticals root causes accidents defects procurement organisation continues business comprise latestage waste standardised way working support delivery greater value pipeline assets newly launched improve processes performance external expenditure global medicines cardiovascular example site cairo egypt procurement savings performance core metabolic neurosciences cvmns deployment programme resulted external operating expenditure increased immuno inflammation infectious increase production additionally diseases iiid oncology discovery decrease manufacturing interruptions september launched category dermatology create leaner councils comprising business finance commercial operation simplify processes procurement leaders eliminate duplication enhance procurement process accelerate performance drive right rigour buying decisions help strengthen relationships external partners critical part business modify processes causing inefficiencieserachtlaeh viiv drawyah ytak otohp gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines viiv healthcare growing dolutegravirbased hiv portfolio includes tivicay triumeq contributed strong year viiv healthcare viiv healthcare specialist global hiv company delivering advances treatment care people living hiv established majority owned gsk pfizer shionogi shareholders company focuses hiv viiv healthcare delivered strong performance proven ability deliver standalone company gsk announced intention explore potential undertake initial public offering minority share viiv healthcare business around million people worldwide still living hiv according latest available figures unaids million died aidsrelated causes however global efforts helped reduce rate new hiv infections since aidsrelated deaths since today disease prevalent subsaharan africa adult population infected nearly people infected hiv living lowincome countries subsaharan africa increasing access treatment increasing access hiv treatments priority access hiv treatments major adults mpp collaboration grow focus viiv healthcare includes two approaches first viiv company supported people living healthcare apply established viiv healthcare turnover hiv countries royaltyfree voluntary licensing billion growth generated variety approaches address dolutegravir second specific tivicay epzicomkivexa together needs people living hiv middleincome countries including newly launched triumeq different parts world india company established offset impact generic competition firstever mpp licence tiered older viiv healthcare products including company offers royaltyfree royalty structure country pays combivir trizivir core operating profit voluntary licences access pricing small percentage sale grew viiv healthcares growth lowincome leastdeveloped price based gdp outpacing hiv global market growth countries subsaharan africa viiv healthcares core operating countries people children viiv healthcare profit includes rd costs excludes hiv currently live middleincome granted mpp voluntary licence noncore items contingent countries viiv healthcare takes countries generic manufacturers consideration payable shionogi casebycase approach based develop paediatric formulations relation sales tivicay triumeq burden disease gdp per dolutegravir without paying royalty person medicines including tivicay recorded sales million pipeline new treatments company continued uptake tivicay led tivicay triumeq support community industry usa markets covered access policy projects worldwide positive including germany japan compared action positive action children recent hiv medicine launches april months approval fund positive action southern initiative sales triumeq new singlepill tivicay eu usa paediatric innovation seed fund treatment launched usa viiv healthcare announced new august european countries collaborations medicines september million patent pool mpp increase access epzicomkivexa abacavir lamivudine dolutegravir countries grew million children adults celsentriselzentry maraviroc hiv developing world live flat million gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines viiv healthcare continued regionally sales north america grew hiv treatment regimens often combine simplify driven strong performances three different antiretrovirals improve tivicay triumeq well continued convenience patients triumeq decision create viiv healthcare growth epzicom tivicay triumeq drug combine dolutegravir company focus hiv performing strongly dynamic nrtis abacavir lamivudine allowed everyone company totally segments patients initiating switching singlepill regimen dedicated innovating making therapy achieving joint share viiv healthcare entered collaboration difference people living hiv treatment naive patients janssen develop two switch patients viiv healthcare also maintained drug single tablet combining dolutegravir nimble model europe first time since viiv janssens rilpivirine nonnucleoside specialist organisation focused healthcares creation sales growing reverse transcriptase inhibitor core capabilities relies relationships faster market result research compare efficacy three shareholders particular excellent performance tivicay twodrug regimen compared gsk allowing operate approved january achieving threedrug regimen maintaining viral simplified operating model reimbursements european markets suppression patients already virally successful initial uptake triumeq suppressed threedrug regimen combining model lean countries launched management structure globally locally also began two phase ii studies continued growth kivexa company reduced complexity experimental longacting injectable maximised efficiency viiv healthcare pays international region sales also grew integrase inhibitor cabotegravir previously services provided three owing growth portfolio celsentri known gsk one studies shareholders armslength contracts kivexa tivicay contribute investigating potential cabotegravir twothirds regions revenue prevention hiv negative men model extends organisation japan australia launched combination longacting conducts research partnership tivicay second half year rilpivirine treatment people living gsks hiv discovery performance unit seen particularly impressive sales hiv cabotegravir offers possibility pharmaceutical biotech companies performances treatment via injection might allow well academic researchers people switch daily oral use monthly potentially less frequent form deliver treatment important regulatory approvals dolutegravirbased portfolio year tivicay dolutegravir approved eu following us approval triumeq combining dolutegravir two nucleoside reverse transcriptase inhibitors nrtis also approved usa eu innovative antiretroviral treatment tivicay integrase inhibitor used antiretroviral medicines treatment adults adolescents living hiv tivicays clinical development programme included people living hiv new treatment naive well already treated hiv medicines experienced infected virus developed resistance previously available integrase inhibitors cited dolutegravir one longterm developmental priorities child antiretroviral treatmentsgsk annual report strategic report governance remuneration financial statements investor information consumer healthcare strong innovation focus geographic expansion new routes market led continued growth several key categories gsks consumer healthcare business april announced proposed major new gsk consumer healthcare already among largest world threepart transaction novartis business geographically well products reach millions people completed create new joint matched strong presence every day countries venture consumer healthcare company us emerging markets topselling brands including sensodyne significant scale reach making cis central eastern europe panadol horlicks one worlds largest consumer combined business world healthcare companies operating leading consumer healthcare company across four categories wellness markets estimated grow approximately number one positions specialist oral health nutrition skin health per annum next five years oral health otc across markets brands exist help people feel better live longer wellness category focuses pain management respiratory health gastrointestinal health smokers health panadol topselling paracetamol brand globally tums antacid brand usa global leader specialist oral health leading positions sensitivity sensodyne acid erosion pronamel denture care gum health nutrition horlicks brand years old leading nutritional supplement indian subcontinent finally skin health brands abreva zovirax hold leading positions flonase allergy relief worlds largest markets expanding access proven medicines focus combine best pharmaceutical fast moving consumer healthcare business flonase contains prescribed consumer goods fmcg capabilities focused helping people allergy treatment ingredient otc become worlds first best world improve everyday health treatment temporary relief fast moving consumer healthcare symptoms hay fever upper fmch company driven science one way making respiratory allergies first values realise vision prescription medications rx otc nasal spray provides relief implementing strategy five easily available consumers nasal ocular symptoms key growth levers switching overthecounter otc flonase inhibits six key substances products rx otc switch building category defining brands part allergic response unlike removing need people see consumers love means building common otc allergy pills healthcare professional order get strong global brands leadership target one histamine alone medicines need switches positions reduce overall cost healthcare usa million people improving lives scientific addition rx otc switches suffer serious nasal allergies innovation strong pipeline enable people manage variety estimated treat new products everyday health conditions symptoms prescription otc treatments however half becoming first choice shoppers past years drawn sufferers report completely retail partners experts specialist knowledge scientists satisfied current method researchers consumer delivering high quality products treatment presenting significant healthcare pharmaceuticals right time cost opportunity gsk provide businesses make switches additional new option consumers living values developing possible expanding access widely people high performance culture used products smokers health expect flonase allergy relief weight loss skin conditions pain growth driver consumer healthcare business used strong heritage provide wellestablished allergy scientific strength discovering treatment consumers continue developing respiratory products used launch brand otc product patients worldwide bring prescription markets flonase consumers usa overthecounter medicine gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare continued leading positions skin health wellness sales deliver family nutrition key brands like million impacted significantly sensodyne parodontax polident voltaren supply particularly smokers health innovation portfolio comprising theraflu panadol otrivin horlicks zovirax gastrointestinal products grew new products unique line extensions abreva total new company even though impacted launched last three years critical major brands annual supply constraints eno saw growth consumer healthcare revenues excess us million strong growth emerging markets business especially india brazil pain approximately half business management grew driven double focused creating continued otc medicines creating worlds digit growth fenbid china offset pipeline new scientifically differentiated otc business half new supply interruption bactroban products across four categories company comprise fmcg brands china launching newtomarket products areas oral health nutrition throughout year innovation skin health increased speed skin health sales portfolio accounted market investment new products million driven primarily bactroban consumer healthcare global sales business greater supply interruption china physiogel invested million core consumer opportunities deliver revenue growth sales healthcare rd consistently market rates regional performance key innovation launches regional level us business grow declined million impacted included horlicks kesar badam sensodyne true white sensodyne supply disruptions primarily wellness complete pronamel multiaction overall consumer healthcare turnover oral health grew led strong sales fenbid mg sustained release million sensodyne successful launches primarily result supply pronamel multiaction sensodyne major contributors innovation disruptions however began see repair protect sales include sensodyne repair protect early signs supply recovery fourth niquitin flash strips panadol extra europe sales fell quarter growth generating panadol advance zovirax duo million due combination positive momentum business factors including supply competitive continue benefit scientific move pressures particularly oral health strengths pharmaceutical business category performance political disruption central us fda approval flonase allergy oral health sales grew million eastern europe market growth relief allergy spray otc use based driven strong growth rates slowed year new drug application nda sensodyne sensitivity acid erosion included data clinical studies rest world markets including india gum health global postmarketing experience china latin america middle east grew sensodyne maintained prescription nonprescription markets africa million despite leading position sensitive teeth overall slowdown emerging markets part focus ensuring category consumption grew ahead particular note india business consumers heart business market regions growth seen grew year year invested rollout across emerging developed executed successful restage horlicks new fullyintegrated platform single markets notable successes focusing increased nutritional benefit point consumer contact across phone china north america sensodyne consumed every day improved social media digital allow repair protect sensodyne formula dissolves easily hot us listen better interact complete key drivers growth cold milk also launched new consumers gather insights combination strong brand innovation variant horlicks kesar badam saffron ultimately drive product improvement successful marketing approach using almond india specifically designed marketing strategy innovation dentist testimonials continues drive meet unique tastes indian deployed new platform brands success consumers continue focus new countries collecting nearly two million data nutrition category grew routes market expanding distribution points led creation multiple million led horlicks boost model better reach rural consumers new marketing promotional campaigns grew respectively products across brand portfolio year began process reflecting strong innovationdriven helping maintain horlicks position adding gsk branding performance continued focus indias leading nutritional supplement consumer healthcare products expanded rural distribution india latin america sales strong advertising promotional materials leading uk protein brand maxinutrition performances oral health wellness research shown work proven driven strong innovation value brands expect increased distribution majority product packaging carry gsk branding end gsk annual report strategic report governance remuneration financial statements investor information simplify faced challenges year several consumer healthcare manufacturing sites primarily north america however affected supply lines fully operational expect see increasing benefit resumption supply undertaken comprehensive operational review supply network investing heavily multiyear programme ensure future sustainable supply including improvements systems capacity training people addition new roles particularly key areas quality engineering also working reduce exposure single source supply continued rollout gsks commercial enterprise resource planning erp system across consumer healthcare business new platform allows us make better commercial decisions drive financial efficiencies standardise consolidate data innovative approach rural distribution india forecast plan system save time money system maintenance upgrades become consumer healthcare short span three years efficient business constantly innovating give built huge distribution network customers consumer consumers access widest today cover villages directly healthcare markets added available range high quality healthcare supplying products across range global consumer healthcare revenue products committed wellness oral health nutritional system expect fully expanding geographic reach products right size price complete rollout achieving greater flexibility around small mediumsized villages product offering format price order deliver high quality products eight ten retail outlets weve order reach consumers customers right time created network rural cost focusing reducing traditional distribution model used subdistributors regularly number packs within product build business india worked delivering gsks products portfolio provides shoppers rural hardtoreach villages village retailers even smaller simpler easier choices based currently represent indias villages populations clear brand propositions billion population retail outlets created distribution channel goes also simplifies supply chain resulting goal build strong directly homes easier better forecasting less infrastructure time trained local women set inventory resulting lower warehousing improving consumer awareness distribution business selling directly costs increased capacity factories health nutrition information households helping build lower cost goods markets thereby building sustainable income source achieved net pack reduction sustainable business end women going forward also expect deliver wanted go beyond existing trained though programme estimated total annual cost saving direct distribution network cover million result proposed villages previously novartis transaction delivery serviced distributors giving little savings phased five years insight products purchased achieved year three retailers communication customers received gsk annual report strategic report governance remuneration financial statements investor information responsible business success depends ability research develop innovative medicines vaccines consumer healthcare products make accessible people worldwide responsible way partnership save children aims help save lives one million children one programmes democratic republic congo health workers like head nurse jacqueline mankenda pictured directly reaching thousands children including hardest reach communitiesnerdlihc eht evasedaw yerbua otohp gsk annual report nerdlihc eht evas nohal yvi otohp strategic report governance remuneration financial statements investor informationtax businesses increasingly challenged ensure contribute tax system societies operate provide information tax management principles policies understand responsibility pay appropriate amount tax fully support efforts ensure companies appropriately transparent tax affairs managed substantial business employment presence many countries around globe pay significant amount tax including corporation business taxes well tax associated employees time responsibility shareholders financially efficient deliver sustainable tax rate part approach look align investment strategies countries already substantial economic activity government policies promote tax regimes attractive business investment pay considerable amount tax uk significant proportion global corporate functions rd manufacturing activities located uk includes corporation tax profits generated well indirect tax employment taxes although precise amounts fluctuate year year gsk annual report strategic report governance remuneration financial statements investor information responsible business approach conduct business important financial performance responsible business central responsible business priorities strategy conduct priorities responsible business business important us approach sit within context macro financial results achieve strive economic social trends put values heart every impacting wider society companies decision make meet exceed trends present opportunities expectations society challenges global healthcare companies like gsk see commitment starts top ceo corporate executive team report progress across four areas dedicated boardlevel corporate health behaviour people responsibility committee crc led planet responsible business chairman see priorities identified report crc understanding issues important business success creating value society stakeholders detail developing innovative products analysis see responsible business maximising access delivers direct supplement gskcomresponsibility benefit patients consumers successfully deliver profitable developed longerterm sustainable business performance commitments across four areas turn allows us generate value reflect global health needs returns shareholders reinvest aligned strategic priorities business wider values transparency respect society benefits since healthy people people integrity patient focus communities essential building report detailed progress strong sustainable societies commitments responsible also contribute significant value business supplement available making direct indirect economic gskcomresponsibility contributions countries assessed commitments communities operate progressing well six track tax see box employment two work one people charitable support total review charitable contributions year set details corporate tax charges year publish full details position taxnerdlihc eht evasedaw yerbua otohp gsk annual report strategic report governance remuneration financial statements investor information access healthcare ensuring access determined drive access products reach patients consumers matter live ability pay medicines vaccines consumer health products improving quality life patients consumers around world millions people still getting vaccines treatments need afford still many diseases impact poorest treatments exist play part tackling global health challenge drive access products people pioneering new business models collaborating strengthen healthcare infrastructure innovating tackle diseases disproportionately affect poorest affordability availability improving access healthcare central business evolved approach increase access patients consumers tackling affordability availability barriers maximise patient benefits sustain business least developed countries ldcs lower pricehigher volume approach capped prices products developed market levels responding ebola outbreak seek regulatory approvals established products developing since ebola crisis began march protects volunteers hoped countries catch gsk working closely could contribute significantly programme bridge gap access world health organization controlling outbreak future compared developed countries regulators partners use mass vaccination campaigns investment local manufacturing respond outbreak depend whether capability building also increases accelerate development regulators stakeholders availability locally relevant vaccines investigational ebola vaccine satisfied vaccine candidate medicines also contributing overall provides protection ebola supply vaccines gavi vaccine humanitarian effort taking steps without causing significant side effects alliance significantly reduced prices support small number quickly large quantities use worlds poorest countries employees region vaccine made committed provide gavi phase studies investigational actively exploring million vaccine doses ebola vaccine demonstrated relevant organisations partners reduced prices help protect million acceptable safety profile produced opportunities accelerate children developing world immunological response healthy development manufacturing also committed year adult volunteers tested industrial scale trials price freeze gavi graduating countries large phase iii clinical trial sponsored successful position countries growing national institute health nih significantly rampup production economies graduate gavi support began liberia february vaccine candidate help combat trial expected involve future ebola outbreaks people onethird receive gsks candidate ebola vaccine compare candidate vaccine control vaccine assess whether immune response seen phase trials actually translates meaningful protection ebola nerdlihc eht evasedaw yerbua otohp gsk annual report strategic report governance remuneration financial statements investor information access healthcare continued also investing new formulations uk taken considered smaller packs different distribution approach pricing relvar ellipta st models make products affordable anoro ellipta incruse ellipta available since introduced priced line less singledose capsules help respiratory alternatives gsk topped access medicine index patients spread cost inhalers strengthening healthcare systems fourth consecutive time index ventolin rotacaps become worlds poorest countries lack measures performance top widely distributed gsk product trained healthcare workers diagnose pharmaceutical companies efforts philippines diseases administer treatment improve access medicines tiered pricing approach preventing many patients accessing healthcare developing countries prescription medicines vaccines lifesaving medicines vaccines since last index countries pay different prices based regardless cost taken steps help widen access ability pay determined reinvesting profits ldcs medicines include filing gross national income gni per person enable broad access gsk train front line healthcare workers malaria vaccine candidate regulatory medicines vaccines globally aim improve access healthcare approval forming groundbreaking million people invested fiveyear partnership save middle income countries like brazil million based profits children launching africa ncd mexico indonesia india work total million since open lab putting patients governments healthcare reinvestment programme began centre sales marketing efforts providers provide reimbursement healthcare workers payment assistance patients trained partners amref health afford medicines relvar africa care international save ellipta benlysta revolade children collaboration country ministries health improved access overall total contribution developed markets pioneered healthcare million people represents decline largely due fewer novel reimbursement approaches widen us patients enrolling gsks patient access newer medicines addition committed assistance programs primarily priced current treatments train additional health workers result new coverage options available kenya ghana nigeria example usa list price patients via affordable care act currently supporting unbacked diabetes medicine tanzeum even new coverage options one million community health workers lower medicines class usa gsk continues help support campaign run earth institute diabetes affects nearly million adults patient access medicines also columbia university grant age nearly provides services help interested patients type diabetes potentially eligible enrollees understand multiple treatment therapies provide additional support alternative coverage options separate cost aim vulnerable communities product partnership save children mindful healthcare costs work financial donations partnership save children increase access affordability contributions totalled million formed aims help save reflect value innovative quality million included lives one million children worlds medicines bring patients support nearly people poorest countries combining patient assistance programs usa scientific expertise global reach million tablets albendazole charitys ontheground knowledge prevent lymphatic filariasis soil transmitted helminths part together established two signature commitment combat neglected tropical programmes democratic republic giving diseases million products congo drc kenya aim tackle valued cost support humanitarian challenges supply demand aid countries distributed effective healthcare contribute nonprofit partners reduction maternal newborn five deaths exploring antiseptic used corsodyl mouthwash reformulated prevent infected umbilical cords newborns cash product inkind time management total gsk annual report strategic report governance remuneration financial statements investor information investing africa gsk investing africa increase investing million create increase local capability access medicines build capacity worlds first africa noncommunicable capacity manufacture medicines deliver sustainable growth diseases open lab gsk investing million vision make gsk products available scientists external researchers expand existing facilities kenya population subsaharan work together improve understanding nigeria build new factories africa least developed countries noncommunicable disease variations elsewhere ensure sustainable philanthropy seen african patients hoped production medicines africa new way business enable researchers across academia african people facilities industry develop new medicines make locally relevant products including next five years invest address specific needs african antibiotics respiratory hiv million africa working patients invest medicines create jobs boost partners aim provide portfolio academic chairs forms support longterm economic prospects relevant products support african students programmes research rd expertise increase local also work partners train across range healthcare related manufacturing capacity capability healthcare workers kenya disciplines initiatives ghana nigeria addition promote expansion pharmaceutical trained ldcs sciences public health engineering reinvestment programme logistics african universities innovation diseases impacting know sharing insights applying open developing world collaborating partners innovation model target areas committed innovation potential make progress faster open need traditional commercial diseases disproportionately affect innovation strategy offers external scientists model appropriate worlds poorest even access compound library tb announced plans create worlds potential commercial malaria resources promote first africa ncd open lab also return rd investment research diseases developing continue collaborate partners world since external researchers accelerate development new drugs pipeline includes worlds first worked alongside gsk scientists alzheimers disease new antibiotics malaria vaccine candidate filed open lab spain built combat growing resistance regulatory approval well portfolio research projects vaccine candidate tuberculosis tb also accelerating development ebola vaccine unprecedented rate see received regulatory approvals respiratory oncology hiv aids diabetes help address changing health burden developing countries innovations promise deliver treatments needed worlds vulnerable people gsk annual report strategic report governance remuneration financial statements investor information behaviour putting needs patients consumers first changing way work embed values everything expect employees act medicines potential risks well transparently respectfully integrity benefits robust policies values put interests patients governance framework help us detect consumers first times act side effects may patient focus associated medicines aim put core values put patient safety first clinical trials integrity heart everything every decision make way wherever take place respect people conduct research approach trial protocols reviewed transparency sales marketing way interact independent ethics committee patients doctors policymakers power reject stop trial maintain global risk register help code conduct research teams around world monitor firstly january completed code conduct accompanying quality safety controls appropriately rollout changes way training seeks ensure everyone conducted audits sales teams compensated sales gsk understands put values trial sites third parties carrying trials professionals around world longer practice mandatory training behalf ensure high ethical quality individual sales targets instead code helps employees gain safety standards assessed rewarded primarily based confidence make right decisions technical skills scientific report concerns maintain strict quality safety knowledge quality service deliver speak programme standards manufacturing sites hcps broader business quality culture puts patient speak programme offers people performance usa gsk centre efforts deliver right first within outside gsk range ranked first among major pharmaceutical time also essential ingredients channels voice concerns report companies hcps value materials go products misconduct without fear reprisal bring customer satisfaction safe high quality include telephone internet survey see case study channels run independent external expect suppliers uphold secondly changing support operators enable anonymous reporting high standards set education doctors commitment standardised monitor monitor performance medical education remains unchanged contacts made global compliance compliance processes quality move away direct sponsorship management system report potential risk assessments individual hcps arms length funding allegations ask questions counterfeit medicines vaccines example via thirdparty independent significantly increased monitoring healthcare products pose significant medical organisations activities globally led threat patient consumer safety increase contacts made thirdly longer pay well reputation counterfeiting contacts hcps speak prescribers crime work closely medicines instead using updated code conduct appropriate law enforcement customs channels including digital realtime reinforce critical role agencies combat largescale often applications provide information values play protecting reputation highly organised counterfeiters medicines vaccines way commercial success extended introduced fingerprint hcps want want cover complementary workforce endtoend supply chain serialisation required complete training expert medical doctors within programme apply unique serial gsk also take role talk fingerprints many products answer questions medicines suppliers also expected follow unique identifiers recorded peers responsible standards increasing focus database product measured providing right responsible procurement new scanned verified information support safe effective initiative simplify standardise database point supply chain use medicines approach managing thirdparty risk end packaging lines globally focus supply chain risk sites serialisation capability clinical research transparency also one key areas need sharing information clinical research modernising sales marketing address part ongoing helps build trust supports modernising way sell commitment un guiding principles research benefit medical science market medicines transforming business human rights patient care business model industry rigorous patient consumer safety many years changing since shared information patient safety number one priority reward sales representatives trials results regardless development testing manufacturing engage healthcare professionals whether outcomes might considered use products hcps meet customer needs positive negative online ensure patients interests come first clinical study register made good progress commitments three key areas announced december gsk annual report strategic report governance remuneration financial statements investor information increases instances addressing misconduct exposed activities interactions bribery corruption risk given complexity sector part commitment cases retraining extended challenges working global healthcare transparency report annually employees colleagues prevent continue face risks operating addressed misconduct within making similar mistakes emerging markets especially challenging business standardised breaches external codes given issues many countries capture number contacts gsk found breach face funding maturity made global compliance external industry government respective healthcare systems however management system employees promotional codes times continue believe robust use report potential allegations compared times compliance systems working closely ask questions led breaches consumer local governments presence increase contacts made healthcare products primarily markets help improve access contacts breaches country specific regulations medicines broader healthcare employees codes regarding local advertising antibribery corruption abac disciplined policy violations guidelines remaining breaches programme designed prevent majority prescription products including noncompliance controls practical attendance payroll violations breaches promotional materials guidance mandatory training total disciplined advertising breaches local country year gsk employees complementary dismissed agreed leave specific regulationscodes workers completed basic level training company voluntarily policy violations investigate every breach high riskroles completed related sales marketing codes external code take steps prevent advanced abac training accounted dismissals reoccurrence may include total disciplined governance structures strong retraining corrective action employees received documented focus responsible behaviour designed disciplinary action warning prevent ethical breaches sometimes things still go wrong happens primary reason increase types policy violations act promptly decisively number disciplinary cases particularly documented warnings september gsk china investment related code conduct violations co ltd gskci found guilty increased number reports according chinese law bribing china nongovernment personnel verdict increases china related followed investigations initiated chinas investigation chinese ministry public security june authorities strengthening included fine million monitoring systems introduction deeply disappointing quarterly knowledge test sales matter us illegal activities representatives failure pass test gskci clear breach gsks results employee receiving attendancepayroll arketing governance compliance procedures documented warning employees sales force receive documented code conduct promotional activities wholly contrary values training completion standards expected employees warning disqualified sales g ood manufacturing published statement apology incentive programme months practicesgood f alsification distribution practices documents chinese government people employees remain l ocal work regulation travel expenses website company following policy violation violations fraud focus learning issue receive retraining increased monitoring support taken steps comprehensively rectify issues identified gskci including changing engagement activities healthcare professionals expanding gsk became first company expanded include data nine review monitoring invoicing publish formal reports basis companies researchers must payments use robust compliance submissions regulatory agencies submit proposals independent systems work closely government known clinical study reports csrs review panel ensure data continue innovate improve access register includes used appropriately commit medicines establish gskci model summaries csrs publishing results work reform chinas healthcare industry following improvements design antibribery corruption also sought apply appropriate utility register seen exposed bribery lessons operations elsewhere increase number pages viewed corruption risk global given complex global environment per visit duration visit business operations markets operate continue government structure rule face risks first company provide law less developed researchers detailed data sit bearing bribery behind clinical trials results researchers corruption risk exposure addition request access detailed anonymised global nature business patientlevel data healthcare sector highly trials online system competitive subject regulation gsk annual report strategic report governance remuneration financial statements investor information people respect people one gsks core values ensure right people right skills focus talent leadership performance engagement talent leadership engaging employees mission working hard attract develop values strategy gives everyone retain skilled talented people gsk clear sense help need levels organisation drive business forward ceo women management positions members corporate executive employees early stage team cet keep employees informed careers offer many opportunities strategy progress throughout including apprenticeships internships year also encourage employee graduate schemes track feedback improve experience achieve global target recruit reduction injury illness rate conducted interim surveys students year onto early covering around employees last years talent programmes indicated managers leading acknowledging global commitment people effectively increasing apprentice population decided include engagement formal consultation groundbreaking global partnership early talent community alongside employees representatives prevention pp programme aims future leaders graduates esprit unions works councils particularly create healthier workforce postgraduate programme participants important periods restructuring differentiate gsk employer continue work closely pp offers preventive healthcare leadership development programmes groups proposed threepart services immunisations cancer provide employees levels transaction novartis lead screenings preventive examinations skills need become effective considerable change around employees families leaders management essentials novartis employees join business multinational company offer new management employee transfers take place benefits scale advanced leading business around countries key priority making good progress towards target experienced leaders coaching limit number redundancies implement pp globally programmes helped participants offer support redundancies strengthen leadership capabilities inclusion diversity unavoidable assist cases see case study inclusive employer value employees need find new employment information approach different perspectives experiences leadership health safety resilience working styles global workforce take progressive approach addition flagship pulse volunteer aim improve gender balance protecting health wellbeing partnership enables employees work levels organisation people focus sustaining full time nonprofit organisation focused creating opportunities strong health safety culture charity three six months women management proportion last ten years experience adds new dimension women management continued halved reportable injury development people provides increase see women illness rate reduced insights expertise organisations continued represent cet figure incidents per working address major healthcare board gsk ranked joint hours worked means challenges since sent fifth uk governments report achieved target year early employees countries work womens representation boards nonprofits provided health safety culture seeks ftse companies million worth skilled services ensure employees aware health employeeled womens leadership partners employees safety risks continued initiative brought together virtually volunteered organisations invest leadership training help regional hubs people leaders countries manage performance engagement gsk senior leaders inaugural risks effectively improving way manage global conference encourage employees performance new global recognising challenge balancing action womens career development performance system sets clear objectives personal professional responsibilities coaching sponsorship programme aligns delivering strategy run energy resilience programmes supported female managers complete underpinned six gsk expectations globally help employees lead individual group coaching sessions promote individual responsibility healthier lives home work also encourage senior leaders defining require everyone since global workforce sponsor female managers support gsk putting emphasis across countries participated career development results way results achieved initiative plan increase strengthens connection participation individual performance rewardgsk annual report strategic report governance remuneration financial statements investor information creating pipeline strong leaders levels business support leaders developing leading delivery programme helps small number leaders bestpractice management capabilities middle managers leading demonstrating business acumen valuesbased decision making managers translate business leadership capabilities range leadership strategy action drive performance appointed cet one programmes clarify build capabilities enhance trust direct reports participate expected leaders delivering team members colleagues enterprise leadership programme strategy helping patients highly customised twoyear global experienced highpotential leaders customers feel better learning experience leading business programme equips live longer manage support diverse introduced new strengthened common language crosscultural highperforming programme enable female leaders created gsk leadership teams translating strategy enhance network clarify expectations leadership programmes effective actions business units career ambitions build also ensure exceptional month period participants confidence become strong senior diverse leaders levels business undertake immersive experience leaders believe programme mumbai london focusing helps organisation make better management essentials first balancing numerous leadership decisions reducing risk line leader programmes provide new responsibilities increasing innovation managers thorough grounding essential management responsibilities women management positions also working hard ensure people employ emerging understand needs people markets asia pacific japan represent disabilities developing employment workforce svpvp opportunities established global consumer healthcare business india director disability council support aim pharmaceutical business latin manager become disability confident organisation america made particularly good progress total attracting developing local talent founding member business disability international social enterprise also increased proportion people employees gender number involving global businesses gsk emerging markets participating male female total helping develop global standards development programmes joining board measure businesss disability performance company graduate managementa ensure leadership teams represent mba programmes total diverse markets serve building talent pipeline includes management senior managers defined people range cultural ethnic companies act strategic report backgrounds currently eight nationalities directors report regulations includes persons responsible planning represented corporate directing controlling activities executive team board company strategically significant part company board including directors undertakings included consolidated accounts gsk annual report strategic report governance remuneration financial statements investor information planet reducing environmental impacts set ambitious goals reduce carbon water waste across value chain carbon helping suppliers reduce aim achieve carbon neutral carbon emissions critical achieving external benchmarking value chain reducing value chain carbon goal better operational carbon emissions understand impacts gsk pharmaceutical company engaging suppliers patients collected carbon well water achieved carbon trusts consumers cut emissions associated waste data standards cutting carbon emissions sourcing raw materials use largest materials suppliers water use products patient consumer use products reduced scope metered dose inhalers accounts emissions within operations carbon emissions across million tonnes co e value chain inhaler recycling reduction compared scheme complete cycle running reducing water scope emissions six countries allows us reduce waste year year associated raw materials sent landfill prevent remaining gsk one two pharmaceutical logistics business travel use inhaler propellant released companies included cdps ftse metered dose inhalers use hfa greenhouse gas climate disclosure leadership index propellant increased water increase compared cut operational water use tackling scope emissions represents continues challenge sales reduction baseline propellantbased inhalers continue means met target cut grow operational water use year early reducing energy use carbon measuring reducing wider water emissions associated generating impact across value chain supply chain particularly energy purchase key cutting amount use challenging sourcing raw materials uses operational carbon impact address completed extensive estimated million water investing renewable energy assessment prioritise future efforts partnered teri ngo infrastructure using waste fuel regard india develop diagnostic water energy example cork site impact tool used use million ireland installed metre wind identify opportunities largest water per year operations turbine cut sites electrical suppliers reduce water impacts systematically audit sites identify carbon footprint work suppliers opportunities cut usage already saved energy teri extend process cut water use average costs suppliers four higheruse sites worked carbon trust pilot new ways reduce water impacts sites piloted approach eight sites tonnes coea scope emissions scope emissions scope emissions intensity ratios scope emissions sales revenue tonnes coem scope fte tonnes coefte carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised editiongsk annual report strategic report governance remuneration financial statements investor information waste goal halve operational waste actively eliminating reusing recycling waste well generating energy waste generated tonnes waste operations less less continue explore ways cut waste bring us back track achieve target total waste went landfill three sites achieved zero waste landfill status bringing total means manufacturing major research development sites send zero waste landfill track hit wastetolandfill target work achieve zero landfill sites recognise need continue reducing waste complex regulatory environments mean takes several years make required improvements manufacturing processes reducing environmental impacts improving rather sending waste landfill focus reusing waste possible access medicines recycling incinerating generate energy proportion waste antibiotics third biggest amoxicillin production site recycled disposed positive carbon footprint products based quality road singapore benefit increased volume sold introducing new process journey change way make eliminate chlorinated solvents cut looking ways save energy amount waste produced reduce cut water impact waste improve carbon emissions using yields reduce costs unrecoverable solvent waste fuel achieved reduction generate electricity steam antibiotics carbon footprint per pack jurong factory singapore last five years increasing site worthing uk formulate production volumes package antibiotic augmentin irvine scotland fermentation amoxicillin clavulanic acid takes place make penicillin putting six tablets foil blister clavulanic acid introduced strip instead four reduced wind turbines two combined heat foil use pack size power plants reduce carbon enabling us put packs emissions energy use pallet also installed anaerobic digester treats fermentation waste generate biogas used fuel mw combined heat power plant save site million year together changes mean irvine producing around product using energy amount water reduction carbon emissions gsk annual report strategic report governance remuneration financial statements investor information group financial review group financial review discusses financial architecture operating financial performance group financial resources returns shareholders hockpeng senior maintenance technician tuas vaccines manufacturing site singapore make hundreds thousands doses synflorix year use around worldgsk annual report strategic report governance remuneration financial statements investor informationstrategic report governance remuneration financial statements investor information group financial review cfos statement financial architecture designed support execution strategy enhance returns shareholders clearly challenging year positive side saw strong highlights number factors combining create progress several parts business significant headwinds us particularly investing especially greater expected contracting viiv healthcare emerging bn competitive pressure us respiratory markets oncology portfolio business launch lovaza generics boosted new product launches also supply disruption saw grew strongly sales consumer healthcare business cer excluding divestments year operating leverage cer including divestments ability deliver operating leverage despite pressures saw strong improved profitability heavily impacted performances number overall trend sales particularly areas business progress affected changes mix regional p rd delivery multiple new product product contributions launches well continued delivery significant factor sales core earnings per share operating financial efficiencies decline driven primarily higher margin cer excluding divestments restructuring cost base us products advair lovaza result core operating profit time also protected lower cer terms investments need make across turnover decline despite p business behind new launches around million incremental cost future growth drivers savings delivered year total earnings per share financial architecture various restructuring initiatives ongoing cer financial architecture designed cost reduction efforts support consistent execution savings reinvested strategy enhance returns new launches improvements delivers shareholders simplification manufacturing capabilities capacity focused delivering sustainable line strategic priorities highlights sales growth across company improving balance sufficient however offset operating leverage profitability impact mix changes lower sales enhancing financial efficiency result core operating margin bn order drive growth eps ahead percentage points lower sales performance convert excluding currency effects earnings cash margin decreased percentage cumulative annual savings use invest business return points primarily reflected increase restructuring achieved since shareholders wherever see sga percentage sales despite attractive returns decline actual spend clear set priorities ensures remain focused managing markets consistency allocate capital cost base effectively operational across different businesses within excellence programme initiated already supported core business gsk investment decisions rigorously completed delivering services representing gsk sales benchmarked using cash flow return billion annual savings together investment cfroi framework major change programme announced delivered sales performance billion annual savings date sales declined cer october announced excluding divestments decline programme refocus pharmaceuticals proportion gsk sales already reflects significant headwinds business deliver additional billion running new global erp platform us respiratory lovaza generics annual savings supply disruption consumer gsk annual report strategic report governance remuneration financial statements investor information gsk financial architecture driving improved returns shareholders sales growth operating leverage eps returns shareholders financial efficiency free cash flow cashflow growth reducing complexity business also continue align tax strategy returns shareholders remains central strategy evolving business profile gsks commitment use free cash allows us enhance efficiency implemented number measures flow support increasing dividends reduce operating costs improve centralise pharmaceutical intellectual long term undertake share repurchases consistency execution reducing property product inventory ownership returns attractive complexity also allows us create uk helped us reduce reinvest business including bolton flexibility cost base well core tax rate acquisitions decision releasing savings easily lower tax rate also allocate cash flow rigorously reallocate resources behind key reflects resolution number benchmarked using returnsbased investment opportunities matters benefited year framework based cfroi comparisons multiple new launches earnings per share returned billion cash find details simplification increased flexibility shareholders including million initiatives throughout report restructuring programmes financial dividends million share implementation endtoend efficiencies delivered allowed us repurchases total ordinary dividend supply chain organisational redesign offset substantial proportion top declared p per share addition initiatives line pressure year deliver increase dividend per share establishing core business services core eps also protecting full year expected cbs bring together support investments business maintained level functions order streamline total eps p primarily following completion novartis standardise functional support reflects noncash adjustments transaction gsk intends return business six cbs regional business contingent consideration due relation shareholders billion net centres already support markets viiv healthcare result improved proceeds company expect representing gsk sales sales outlook tivicay triumeq make ordinary share repurchases enterprise resource planning erp well unfavourable comparison platform implementing product asset disposal gains replacing large number separate future shape business outdated systems across company cash conversion proposed threepart transaction giving us common databases business remains highly cashgenerative novartis accelerates strategy also standard business processes continue focus improving clearly meets objectives financial help us simplify operations drive conversion earnings cash architecture particular provide efficiencies give us detailed analytics greater focus cash generation working better balanced broader range improve daytoday operations capital control capital allocation growth drivers significant synergy decision making operating leverage efficiencies continued net cash inflow operations financial efficiencies balanced financial efficiency billion year sustainable cashflow financial efficiencies delivered sterling terms reflected negative significant value contributed positive impact strength sterling well closure transaction remains leverage reported core eps lower profits including impact track completion week divestments currency effect abated commencing march continued take advantage fourth quarter also saw era low interest rates secure fuller review financial results improved working capital position attractive longterm funding without losing set pages flexibility overall reduced net funding costs percentage points since continue target credit rating ap believe target balances equity returns interests stakeholders including bond holders optimising access simon dingemans capital markets chief financial officer gsk annual report strategic report governance remuneration financial statements investor information group financial review core cer growth rates calculated compared group performance core results excluding divestments unless otherwise stated group financial review discusses operating financial reconciliations core results total results presented performance group financial outlook financial resources compare results year primarily core results reporting aligns business performance reporting results preceding year around underlying trading performance group order illustrate underlying performance practice primary growth drivers removing volatility inherent many discuss results terms constant exchange rate cer noncore items growth represents growth calculated exchange core results reporting utilised basis internal rates used determine results overseas companies performance reporting core results presented sterling remained unchanged used previous discussed group financial review believe year cer represents growth constant exchange rates approach provides investors clearer view underlying represents growth actual exchange rates trading performance group also believe growth rates included report constant approach make groups results comparable exchange rates cer unless otherwise stated cer growth majority peers many use similar forms discussed underlying performance reporting discuss results although precise calculations may differ group financial use number adjusted measures report performance review also presents discusses total results group business measures used management planning reporting purposes discussions free cash flow presentations investment analysts rating agencies free cash flow net cash inflow operating activities less defined measures defined ifrs capital expenditure interest dividends paid noncontrolling may comparable similarly described measures used interests plus proceeds sale property plant companies equipment dividends received joint ventures associated undertakings free cash flow growth calculated core results reporting sterling basis reconciliation presented reported core results performance measured core results excluding divestments working capital conversion cycle completed working capital conversion cycle calculated number days sales outstanding plus days inventory outstanding less core results exclude following items total results days purchases outstanding amortisation impairment intangible assets excluding computer software goodwill major restructuring costs order illustrate underlying performance practice including costs following material acquisitions legal discuss results terms constant exchange rate cer charges net insurance recoveries expenses growth represents growth calculated exchange settlement litigation government investigations rates used determine results overseas companies operating income royalty income disposals sterling remained unchanged used previous associates products businesses acquisition year cer represents growth constant exchange rates accounting adjustments material acquisitions together represents growth actual exchange rates tax effects items addition charge additional year us branded prescription drug fee accordance final regulations issued irs year recorded noncore item normal ongoing charge remains core results major restructuring costs charged arriving operating profit include costs arising operational excellence restructuring programme initiated expanded substantially complete end major change restructuring programme initiated restructuring costs following acquisitions human genome sciences inc august stiefel laboratories inc july pharmaceuticals restructuring programme announced october rescale commercial operations global support functions relevant rdmanufacturing operations across pharmaceuticals following proposed divestment oncology products changed dynamics us respiratory market gsk annual report strategic report governance remuneration financial statements investor information financial review pharmaceuticals vaccines usa group turnover business turnover bn restated growth growth cer pharmaceuticals vaccines group turnover pharmaceuticals vaccines consumer healthcare divestments cer growth total cer represents growth constant exchange rates represents growth actual exchange rates total group turnover declined million operating profit bn pharmaceuticals vaccines turnover fell pharmaceuticals turnover declined growth emerging bn markets japan viiv healthcare offset lower sales us established products europe pharmaceuticals flat year worldwide vaccines operating profit turnover declined positive performance emerging markets offset lower reported sales europe japan us vaccines sales flat consumer healthcare turnover million year compared cer growth group turnover geographic region restated growth growth cer us breakdown turnover europe growth cer emerging markets respiratory japan oncology cardiovascular metabolic urology immunoinflammation group sales outside usa europe accounted pharmaceuticals total turnover reported growth adversely impacted vaccines sales decline japan weaker market conditions supply constraints emerging markets performance us pharmaceuticals vaccines turnover declined group turnover segment million pharmaceuticals vaccines flat pharmaceutical sales impacted continued price restated growth growth contracting pressures primarily affecting respiratory sales cer volume decline negative impact pharmaceuticals vaccines price mix sales advair decline us volume decline price mix europe oncology products us contributed strongly year emerging markets sales million benefiting strong japan performances votrient promacta recent viiv healthcare launches tafinlar mekinist benlysta sales grew established products million generic competition us continued impact trading sales dermatology products declined million unallocated pharmaceuticals mepron declined million sales infanrix pharmaceuticals pediarix grew million benefiting favourable cdc stockpile movements compared absence vaccines competitor particularly first half year sales consumer healthcare hepatitis vaccines million impacted supply constraints boostrix million reflecting return market competitor total group turnover including divestments completed year supply constraints rotarix fell million pharmaceuticals vaccines result cdc stockpile withdrawal q consumer healthcare gsk annual report strategic report governance remuneration financial statements investor information group financial review continued pharmaceuticals vaccines europe pharmaceuticals vaccines emerging markets turnover bn turnover bn group turnover group turnover flat cer growth cer growth operating profit bn operating profit bn bn bn operating profit operating profit cer growth cer growth breakdown turnover breakdown turnover growth growth cer cer respiratory respiratory oncology oncology cardiovascular metabolic urology cardiovascular metabolic urology immunoinflammation immunoinflammation pharmaceuticals pharmaceuticals vaccines vaccines performance performance europe pharmaceuticals vaccines turnover flat emerging markets pharmaceuticals vaccines turnover million pharmaceutical sales flat million increased million pharmaceuticals strong growth oncology avodart franchise vaccines markets outside asia showed strong growth million offset decline respiratory sales notable performances brazil million newly launched relvar ellipta recorded sales million rest latin america million sales year offset lower sales china fell reflecting effects government investigation seretide million volume decline year continued growth respiratory negative impact price reflecting increasing competitive products oncology avodart franchise pressures transition respiratory portfolio vaccines growth strong tender sales boostrix newer products particularly latter part year oncology rotarix synflorix largely offset lower sales cervarix sales million led votrient promacta result lost tenders supply constraints newly launched tafinlar vaccines sales fell lower sales infanrix cervarix flu vaccines reflecting increased competitive pressures partly offset sales growth number products including boostrix due part competitor supply issue first half year gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines japan viiv healthcare turnover bn turnover bn group turnover group turnover cer growth cer growth operating profit bn operating profit bn bn bn operating profit operating profit cer growth cer growth breakdown turnover breakdown turnover growth growth cer cer respiratory combivir oncology epzicomkivexa cardiovascular metabolic urology lexivaagenerase pharmaceuticals selzentry vaccines tivicay triumeq performance trizivir japan pharmaceuticals vaccines turnover grew million pharmaceuticals sales increasing products vaccines sales declining pharmaceuticals sales benefited performance strong growth avodart oncology products viiv healthcare turnover grew million growth growth partially offset lower sales generated tivicay epzicom together newly launched respiratory portfolio affected triumeq offset impact generic competition older weaker allergy season beginning year increased viiv healthcare products including combivir trizivir competitive pressures decline vaccines sales reflected impact cervarix continued suspension recommendation use hpv vaccines partly offset higher sales rotarix gsk annual report strategic report governance remuneration financial statements investor information group financial review continued established products consumer healthcare turnover bn turnover bn group turnover group turnover cer growth cer growth operating profit bn operating profit bn bn bn operating profit operating profit cer growth cer growth breakdown turnover breakdown turnover growth growth cer cer imigranimitrex wellness lamictal oral health lovaza nutrition seroxatpaxil skin health valtrex performance zeffix consumer healthcare turnover million products compared reflecting impact number supply interruptions year growth rest world performance markets also affected weaker market conditions established products turnover fell million sales sales europe us us million europe directly result supply issues million emerging markets million japan million generic competition lovaza million seroxatpaxil million valtrex million contributed decline category gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals turnover europe oncology grew million led sales votrient increased million year restated growth growth promacta grew million sales tafinlar cer million respiratory emerging markets japan oncology sales year oncology grew million million respectively cardiovascular metabolic cardiovascular metabolic urology urology sales category fell million avodart immunoinflammation franchise grew million growth sales pharmaceuticals duodartjalyn decline sales avodart levitra viiv healthcare hiv fell million year sales prolia fell established products million due agreement q amgen terminate joint commercialisation number european markets mexico russia respiratory regional basis decline us million respiratory sales declined million partly offset emerging markets million seretideadvair sales million japan million europe flat million flixotideflovent sales decreased million ventolin sales grew million xyzal sales almost immunoinflammation exclusively made japan grew million immunoinflammation sales grew million benlysta turnover year million us benlysta us respiratory sales declined volume decline sales million negative impact price mix primarily reflecting continued price contracting pressures market sales pharmaceuticals advair million decline volume therapy areas million principally decline price mix flovent sales reflecting generic competition dermatology products ventolin sales primarily reflecting primarily affected sales soriatane us decline impact net favourable adjustments previous accruals sales mepron rare diseases category declines returns discounts breo ellipta recorded sales million partly offset growth relenza sales primarily anoro ellipta sold million year us inclusion theravance milestone income million million european respiratory sales primarily reflecting increasing competition seretide sales declined viiv healthcare hiv million decline volume negative impact viiv healthcare sales increased us price reflecting increasing competitive pressures europe japan emerging markets transition respiratory portfolio newer products tivicay recorded sales million epzicomkivexa sales latter part year relvar ellipta recorded sales million increased million selzentry sales flat year million launch triumeq well underway recorded sales million year growth partly respiratory sales emerging markets grew seretide grew offset declines mature portfolio mainly driven generic million helped improved performance china competition combivir million sales growth ventolin million veramyst trizivir million million offset decline flixonase largely driven lower sales china established products established products turnover fell million sales japan respiratory sales fell million sales us million europe newly launched relvar ellipta million offset impact million emerging markets million increasing competitor action adoair fell japan million million growth xyzal million offset lower sales elsewhere generic competition lovaza million respiratory portfolio seroxatpaxil million valtrex million contributed decline category oncology oncology sales grew million votrient sales grew million promacta sales grew million arzerra sales fell million tykerb tyverb sales fell million generic competition hycamtin argatroban offset new launches tafinlar mekinist recorded sales million million respectively us oncology grew million votrient sales grew million sales promacta grew million tafinlar mekinist sales million million respectively gsk annual report strategic report governance remuneration financial statements investor information group financial review continued vaccines turnover new products launched last five years inclusive sales new products million growth growth grew year represented pharmaceuticals cer vaccines turnover q sales new products infanrix pediarix million grew represented pharmaceuticals boostrix vaccines turnover cervarix q breo ellipta launched us copd fluarix flulaval relvar ellipta launched europe copd asthma hepatitis q addition anoro ellipta launched us rotarix april treatment copd synflorix q tivicay launched us subsequently launched europe q triumeq launched vaccines sales us europe q vaccines sales fell million declines europe consumer healthcare turnover japan partly offset growth emerging markets us flat emerging markets performance primarily reflected strength synflorix boostrix restated growth growth cer rotarix wellness infanrixpediarix grew million growth us oral health benefited favourable comparison nutrition impacted withdrawal cdc stockpile offset skin health declines europe emerging markets boostrix sales increased million reflecting growth regions except us us sales fell reflecting return competitor year supply constraints restated growth growth cer cervarix sales declined million largely usa reflecting declines emerging markets japan increasing europe competitive pressures particularly tender market row fluarix flulaval sales declined million due lower production levels impact increased competitive pressures consumer healthcare turnover reflecting impact supply issues comparison strong cold flu sales hepatitis vaccines fell million part season early slowing markets rest world reflecting supply constraints impacted us estimated global market growth approximately emerging markets wellness rotarix sales million growth driven wellness sales million primarily due tender shipments europe emerging markets partly offset supply issues product recalls significantly impacted sales decline us impacted cdc stockpile products smokers health alli withdrawal q oral health synflorix sales grew million primarily reflecting oral health sales grew million continued growth strong tender performance emerging markets sensodyne partly offset decline sales sales new pharmaceutical vaccine launches aquafresh impacted supply issues europe us together increased competition growth growth cer nutrition pharmaceuticals nutrition sales grew million horlicks respiratory relvarbreo ellipta reflecting continued growth india boost anoroellipta skin health oncology tafinlar sales products skin health million mekinist primarily due lower sales bactroban china cvmu duodartjalyn regional performance eperzantanzeum sales us europe respectively immuno reflecting supply issues product recalls primarily inflammation benlysta affecting products smokers health alli growth rest world markets restricted slower economic pharmaceuticals environment reflect growth across markets viiv healthcare tivicay partly offset reduction sales china triumeq decline sales smokers health products primarily vaccines nimenrix due supply issues synflorix gsk annual report strategic report governance remuneration financial statements investor information core results research development use core reporting basis manage performance group definition core results set restated growth review groups total results set pages reconciliation total results core results presented turnover turnover cer research development cost sales core rd expenditure declined million turnover compared million turnover restated growth excluding currency effects rd percentage declined turnover turnover cer percentage points reflecting phasing ongoing project cost sales spending well completion number programmes continuing cost management benefits core cost sales percentage turnover compared net adverse currency translation remain focused delivering improved return effects cost sales percentage increased percentage investment rd sales contribution reduced attrition cost points reflected adverse price mix movements reduction important drivers improving internal rate particularly decline pharmaceuticals sales us return rd expenditure determined percentage costs supply remediation activities continuing investments sales instead capital allocated using strict returnsbased new launch capacity future manufacturing technology criteria depending pipeline opportunities available partly offset benefit ongoing cost reduction operations pharmaceuticals rd broadly split programmes discovery activities completion phase iia trials selling general administration development work phase iib onwards supported specific common infrastructure shared services restated growth appropriate phase iv costs administrative expenses reported sga included turnover turnover cer table selling general table analyses core rd expenditure administration categories core sga costs percentage sales percentage points higher excluding currency effects restated sga percentage increased percentage points sga declined turnover decline reduction sga discovery reflected continued investments multiple new product development launches partly offset benefits restructuring facilities central support functions programmes ongoing cost management efforts pharmaceuticals rd vaccines rd advertising promotion decreased primarily reflecting consumer healthcare rd reduced activity established products category ongoing cost management efforts partly offset new product research development launches selling distribution decreased investments proportion pharmaceuticals rd investment made product launches offset savings ongoing latestage portfolio decreased pharmaceuticals rd cost reduction programmes general administration expenses costs reflecting completion increased primarily due higher phase iv expenditure partly number latestage programmes offset benefits restructuring programmes royalty income royalty income million million reflecting conclusion number royalty agreements also included prior year catchup adjustment gsk annual report strategic report governance remuneration financial statements investor information group financial review continued core operating profit business net finance costs restated growth finance income margin margin interest income cer fair value movements pharmaceuticals vaccines pharmaceuticals finance expense vaccines interest expense consumer unwinding discounts liabilities healthcare remeasurements fair value movements finance expense corporate unallocated costs core operating profit core net finance expense million compared million reflecting gsks strategy improve core operating profit segment funding profile group despite average net debt marginally higher restated growth share tax profits associates joint ventures turnover turnover cer share profits associates joint ventures pharmaceuticals million million reflecting reduced vaccines shareholding aspen group currency movements number oneoff adjustments usa europe core profit taxation emerging markets japan restated growth viiv healthcare turnover turnover cer established products core profit tax pharmaceutical rd taxation trading tax core profit amounted million reflected unallocated effective core tax rate reduction pharmaceuticals effective rate included resolution number matters pharmaceuticals benefited year increase benefit intellectual vaccines property incentives consumer healthcare core earnings per share core eps p decreased cer terms compared corporate decline operating profit result financial unallocated costs efficiencies core operating profit dividend core operating profit million lower board declared four interim dividends resulting dividend cer terms turnover decline core operating year pence pence increase dividend margin percentage points lower see note financial statements dividends excluding currency effects margin decreased percentage profit forecast points primarily reflected increase sga class circular dated november issued percentage sales lower royalty income sga costs shareholders connection proposed threepart declined driven targeted cost management benefit transaction novartis included following profit forecast ongoing restructuring programmes sga also included respect gsk expects deliver full year core credit reported q million release eps cer exdivestment basis broadly similar last year reserves following simplification groups entity structure base p adjusted divestments completed trading arrangements structural savings approximately million realised actual results core eps declined cer broadly line last year excluding divestments completed gsk annual report strategic report governance remuneration financial statements investor information core results reconciliation december acquisition core intangible intangible major legal accounting total results amortisation impairment restructuring charges results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions core results reconciliation december restated core results acquisition core intangible intangible major legal accounting total divestments divestments results amortisation impairment restructuring charges results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs profit disposal interest associates joint ventures share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information group financial review continued total results operating income net operating expense million million growth income included following improved sales performance turnover turnover cer tivicay triumeq increase liability contingent turnover consideration acquisition former shionogiviiv cost sales healthcare joint venture increased billion selling general resulting charge year million million liability represents present value expected administration future payments shionogi paid number research years vary line sales products contain development dolutegravir net income included profits royalty income disposals lucozade ribena business certain operating anticoagulant products aggregate million income operating profit following announcement proposed novartis transaction gsk entered number forward exchange contracts net finance costs protect sterling value net us dollar proceeds due profit disposal group completion transaction december interest associates contracts loss position resulted share tax recognition unrealised loss million profits associates included net operating expense joint ventures contracts remain loss position maturity loss partly profit taxation offset gain expected sterling value proceeds taxation received group result favourable exchange total profit movements since inception forward contracts taxation year maturity contracts gain position gains partly total profit attributable offset losses sterling value proceeds received group result unfavourable exchange shareholders movements since inception forward contracts earnings per share p earnings per ads operating profit us total operating profit million compared million noncore items resulted net charge cost sales million million excluding trading profits cost sales percentage turnover compared products divested net charge included net adverse currency translation effects profits disposals lucozade ribena business cost sales percentage decreased percentage points anticoagulant products aggregate million reflected adverse price mix movements particularly intangible asset amortisation increased million decline pharmaceuticals sales us costs supply million reflecting accelerated amortisation remediation activities continuing investments new launch lovaza intangible asset impairments million capacity future manufacturing technology offset million included writeoffs several rd commercial lower intangible writeoffs benefit ongoing cost assets reduction programmes lower intangible impairments major restructuring charges million million selling general administration included million operational excellence programme sga costs percentage sales million major change programme million percentage points higher excluding currency effects new pharmaceuticals restructuring programme sga percentage increased percentage points sga increased turnover decline increase sga operational excellence programme initiated reflected continued investments multiple new product expanded substantially complete launches higher legal costs restructuring costs charge end total cost billion delivered annual million additional catchup year us branded pretax savings approximately billion major change prescription drug fee accordance final regulations programme announced focuses opportunities issued irs q partly offset benefits simplify supply chain processes build groups capabilities restructuring programmes ongoing cost management efforts manufacturing rd restructure european pharmaceuticals business programme expected advertising promotion decreased reflecting reduced cost billion noncash charges expected activity established products category ongoing cost million delivered approximately billion annual management efforts partly offset new product savings remains track deliver annual pretax savings launches selling distribution decreased investments least billion product launches offset savings established products general administration expenses increased new pharmaceuticals restructuring programme announced due higher phase iv expenditure legal restructuring costs october rescale commercial operations global support partly offset restructuring benefits functions relevant rdmanufacturing operations across pharmaceuticals programme expected cost billion research development predominantly cash charges approximately billion new rd expenditure declined million annual cost savings expected next three years turnover compared million turnover around delivered excluding currency effects rd percentage declined percentage points reflecting lower intangible writeoffs legal charges million million included phasing ongoing project spending well completion million fine paid chinese government settlement number programmes continuing cost management existing antitrust matters higher litigation costs benefits lower intangible impairments gsk annual report strategic report governance remuneration financial statements investor information acquisition accounting adjustments resulted net critical accounting policies charge million income million included increase liability contingent consideration consolidated financial statements prepared accordance acquisition former shionogiviiv healthcare joint ifrs adopted use european union also venture million million net credit ifrs issued iasb following accounting policies included profits disposal lucozade ribena approved board described note financial business anticoagulant products aggregate statements accounting principles policies million items also included charges related major acquisitions equity investment asset disposals oneoff required required make estimates assumptions affect regulatory charges rd certain adjusting items amounts assets liabilities revenue expenses reported financial statements actual amounts results could differ net finance costs estimates finance income critical accounting policies information interest finance income judgements estimates made given note financial fair value movements statements key accounting judgements estimates relevant detailed notes financial statements indicated relate following areas finance expense turnover interest expense taxation note unwinding discounts liabilities legal disputes notes remeasurements fair value movements impairments goodwill intangible assets finance expense notes business combinations note pensions postemployment benefits note profit disposal interest associates information judgements estimates made areas pretax profit disposals associates nil given note financial statements key accounting million profit reflected disposal million judgements estimates ordinary shares aspen pharmacare million turnover share tax profits associates joint ventures respect turnover accounting policy largest business share tax profits associates million us pharmaceuticals vaccines us market million principally arose groups holdings complex arrangements rebates discounts aspen pharmacare allowances following briefly describes nature arrangements existence us pharmaceuticals profit taxation vaccines business taking account net finance costs profit disposal interest associates share profit associates profit arrangements certain indirect customers whereby taxation million compared million customer able buy products wholesalers cer decrease decrease sterling reduced prices chargeback represents difference terms invoice price wholesaler indirect customers contractual discounted price accruals estimating taxation chargebacks calculated based terms agreement historical experience product growth rates customer rebates offered key managed care group uk current taxation purchasing organisations gpo direct indirect overseas current taxation customers arrangements require customer achieve total current taxation certain performance targets relating value product total deferred taxation purchased formulary status predetermined market shares taxation total profits relative competitors accrual customer rebates estimated based specific terms agreement charge taxation total profits amounted million historical experience product growth rates represented total effective tax rate reflecting differing tax effects various noncore items us medicaid programme stateadministered including number nonrecurring tax items programme providing assistance certain poor vulnerable patients medicaid drug rebate program tax relating acquisition accounting adjustments established reduce state federal expenditure included deferred tax increased liability expected prescription drugs patient protection future payments shionogi recognition deferred tax asset affordable care act became law participate providing respect tax losses expected used completion rebates states accruals medicaid rebates calculated novartis transaction tax credits arising resolution based specific terms relevant regulations number tax matters tax authorities including matters related patient protection affordable care act prior year acquisitions disposals cash discounts offered customers encourage prompt uk current tax credit includes benefit resolution payment accrued time invoicing number tax matters prior year adjustments adjusted subsequently reflect actual experience earnings per share record accrual estimated sales returns applying total eps p compared p historical experience customer returns amounts invoiced included p arising gains equity investment asset together market related information stock levels disposals remaining difference p due currency wholesalers anticipated price increases competitor activity gsk annual report strategic report governance remuneration financial statements investor information group financial review continued reconciliation gross turnover net turnover us legal disputes pharmaceuticals vaccines business follows respect accounting policy legal disputes following briefly describes process determine restated restated level provision necessary margin margin margin accordance requirements ias provisions contingent liabilities contingent assets provide gross turnover anticipated settlement costs outflow resources considered probable reliable estimate may made market driven likely outcome dispute legal expenses arising segments claims group may become involved government significant legal proceedings respect possible mandated state make reliable estimate expected financial effect programs could result ultimate resolution proceedings cases appropriate disclosure cases would cash discounts included annual report provision would made customer returns position could change time therefore prior year assurance losses result outcome legal proceedings exceed material amount amount adjustments provisions reported groups financial statements items total deductions like many pharmaceutical companies faced various net turnover complex product liability antitrust patent litigation well investigations operations conducted various governmental market driven segments consist primarily managed care regulatory agencies throughout year general counsel medicare plans gsk negotiates contract pricing group head groups legal function honoured via rebates chargebacks mandated segments senior vice president head global litigation group consist primarily medicaid federal government programs responsible litigation government investigations receive government mandated pricing via rebates routinely brief chief executive officer chief financial chargebacks officer board directors significant litigation pending group governmental investigations balance sheet accruals rebates discounts allowances group returns us pharmaceuticals vaccines business us element established products managed meetings appropriate detail status significant combined basis december total accrual litigation government investigations review matters amounted million million number claims notified us information potential claims yet notified assessment validity claims monthly process operated monitor inventory levels progress made settling claims recent settlement levels wholesalers abnormal movements process uses gross potential reimbursement insurers sales volumes prescription volumes based third party data sources information received key wholesalers aim meetings also include assessment whether maintain inventories consistent level year sufficient information available us able make year based pattern consumption reliable estimate potential outcomes disputes often external counsel assisting us various litigation matters basis us pharmaceuticals vaccines inventory levels investigations also assist briefing board wholesalers distribution channels december senior management following discussions estimated amount approximately five weeks matters possible make reliable estimate turnover calculation uses third party information accuracy amount provision may required level totally verified believed sufficiently provision legal disputes reviewed adjusted reliable purpose appropriate gsk annual report strategic report governance remuneration financial statements investor information property plant equipment financial position resources business sciencebased technologyintensive highly regulated governmental authorities allocate significant financial resources renewal maintenance property assets plant equipment minimise risks interruption production noncurrent assets achieve compliance regulatory standards number property plant equipment processes use chemicals hazardous materials goodwill total cost property plant equipment intangible assets december million net book value investments associates joint ventures million land buildings represented million plant equipment million assets investments construction million invested million deferred tax assets new renewal property plant equipment mainly derivative financial instruments related large number projects renewal improvement noncurrent assets expansion facilities various worldwide sites property total noncurrent assets mainly held freehold new investment financed liquid resources december contractual current assets commitments future capital expenditure million inventories operating lease commitments million believe current tax recoverable facilities adequate current needs trade receivables observe stringent procedures use specialist skills derivative financial instruments manage environmental risks activities environmental liquid investments issues sometimes dating operations modified cash cash equivalents discontinued reported planet assets held sale note financial statements legal proceedings total current assets goodwill total assets goodwill decreased year million december million decrease reflects liabilities goodwill allocated oncology business transferred current liabilities assets held sale following decision sell business shortterm borrowings novartis trade payables intangible assets derivative financial instruments intangible assets include cost intangibles acquired current tax payable third parties computer software net book value shortterm provisions intangible assets december total current liabilities million million decrease reflected transfer million assets held sale reflect noncurrent liabilities proposed novartis transaction capitalised development costs longterm borrowings million amortisation impairment existing deferred tax liabilities intangibles million million respectively pensions postemployment benefits investments provisions held investments including associates joint ventures derivative financial instruments carrying value december million noncurrent liabilities million market value december total noncurrent liabilities million million largest total liabilities investments associate aspen pharmacare holdings limited book value december net assets million million investments theravance equity inc theravance biopharma inc book value share capital december million million investments include equity stakes companies share premium account research collaborations provide access retained earnings biotechnology developments potential interest interests reserves companies arise business divestments shareholders equity noncontrolling interests total equity gsk annual report strategic report governance remuneration financial statements investor information group financial review continued derivative financial instruments assets net debt noncurrent current derivative financial instruments held fair value million million majority amount related interest rate swaps cash cash equivalents liquid investments foreign exchange contracts designated nondesignated borrowings repayable within one year intercompany loans deposits accounting hedges borrowings repayable one year inventories net debt inventory million increased million year net debt increased million reflected aggregate increase primarily reflected impact stock building new consideration million paid increase shareholding product launches remediation consumer healthcare groups indian pharmaceutical subsidiary supply chain partly offset favourable exchange impact acquisition remaining groups trade receivables indonesian consumer healthcare business held third party trade receivables million decreased together reduction cash generated operations reflecting receipt deferred receivable aspen groups cash generation liquidity enabled payment respect inventory manufacturing site formed ordinary dividends million share repurchases part disposal anticoagulants products business million together improved recoveries receivables various markets favourable exchange impacts movements net debt derivative financial instruments liabilities held noncurrent current derivative financial instruments fair value million million net debt beginning year primarily related foreign exchange contracts decreaseincrease cash bank overdrafts designated nondesignated intercompany loans decrease liquid investments deposits acquisitions disposals external debt legal net increase longterm loans provisions accounting hedges net repayment shortterm loans trade payables debt subsidiary undertakings acquired trade payables amounting million decreased exchange movements million reflecting effect increased movements shareholding groups indian pharmaceutical subsidiary net debt end year accrued partly offset effect increase returns rebates accrual together favourable exchange total equity impact december total equity decreased provisions million december million decrease arose carried deferred tax provisions shortterm principally increase pension deficit million noncurrent provisions million december impact dividends paid year million respect estimated future liabilities summary movements equity set million million related legal disputes provision made legal disputes indemnified disposal liabilities employee total equity beginning year related liabilities costs restructuring programmes total comprehensive income year extent balance sheet date legal constructive obligation existed could reliably estimated dividends shareholders shares issued pensions postemployment benefits changes noncontrolling interests account pension postemployment forward contract relating noncontrolling arrangements accordance ias deficits interest net surpluses allowing deferred taxation million million pension arrangements shares purchased cancelled held million million unfunded treasury shares postemployment liabilities increases deficits shares acquired esop trusts predominantly driven lower discount rates sharebased incentive plans used discount value liabilities tax sharebased incentive plans december uk scheme purchased insurance distributions noncontrolling interests contract guarantee payment specified pensioner total equity end year liabilities contract valued million december noncurrent liabilities noncurrent liabilities million december million include million million contingent consideration payable primarily respect acquisition former shionogiviiv healthcare joint venture gsk annual report strategic report governance remuneration financial statements investor information share purchases commitments respect loans future interest payable employee share ownership plan esop loans disclosed taking account effect trusts acquired million shares glaxosmithkline plc derivatives million shares held trusts satisfy future entered number research collaborations exercises options awards group share option develop new compounds pharmaceutical companies award schemes proportion shares held trusts terms arrangements include upfront fees equity respect awards rules scheme require us investments loans commitments fund specified levels satisfy exercises market purchases rather issue research addition often agree make payments new shares shares held trusts matched options future milestones achieved awards granted company also transferred million treasury shares trust agreements relate compounds early stages development potential obligation make milestone december esop trusts held million payments continue number years compounds million gsk shares future exercise move successfully development process generally share options share awards carrying value closer product marketing approval greater million million deducted probability success amounts shown within reserves market value shares intangible assets represent maximum would paid million million milestones achieved include billion million shares repurchased cost relates externalised projects discovery portfolio million see note share capital share premium number new commitments made account december held million shares licensing agreements including arrangement treasury shares million shares cost adaptimmune ltd million million reached agreement trustees deducted retained earnings uk pension schemes make additional contributions following completion novartis transaction expected three year period including eliminate pension week commencing march intend return deficit identified december actuarial funding shareholders billion net proceeds company valuation deficit persists contributions would expect make ordinary share repurchases payable following four years depending level deficit ordinary shares purchased period january table includes commitment excludes normal february ongoing annual funding requirement uk approximately million information pension obligations see commitments contingent liabilities note financial statements pensions post financial commitments summarised note financial employment benefits statements commitments contingent liabilities obligations respect short longterm debt set contingent liabilities note financial statements contingent liabilities following table sets contingent liabilities comprising note financial statements net debt discounted bills performance guarantees letters credit items arising normal course business amounts provided pensions postretirement benefits expected expire set note financial statements pensions postemployment benefits amounts provided restructuring total yr yrs yrs yrs programmes legal environmental disputes set note financial statements provisions guarantees contractual obligations commitments contingent liabilities following table sets contractual obligations total commitments december fall due payment normal course business provided various indemnification guarantees respect business disposals total yr yrs yrs yrs legal disputes subsequently arisen loans provision made outflow resources considered interest loans probable reliable estimate made likely outcome dispute included note financial finance lease obligations statements provisions finance lease charges operating lease provide outcome tax legal disputes commitments outflow resources considered probable reliable estimate outflow may made december intangible assets disputes provision made property plant equipment possible make reliable estimate potential investments outflow funds might required settle disputes purchase commitments possibility outflow remote pensions ultimate liability matters may vary significantly commitments amounts provided dependent upon outcome total litigation proceedings negotiations relevant tax authorities discussed risk factors pages notes financial statements taxation legal proceedings gsk annual report strategic report governance remuneration financial statements investor information group financial review continued cash generation conversion investment appraisal summary consolidated cash flow set formal process assessing potential investment proposals order ensure decisions aligned overall strategy process includes assessment cash flow net cash inflow operating activities return investment cfroi well net present value net cash outflowinflow investing activities npv internal rate return irr timeline project long term also consider impact earnings net cash outflow financing activities credit profile relevant decreaseincrease cash bank overdrafts discount rate used perform financial analyses decided cash bank overdrafts beginning year internally allow determination extent investments decreaseincrease cash bank overdrafts cover cost capital specific investments discount rate exchange adjustments may adjusted take account country risk weightings cash bank overdrafts end year capital expenditure financial investment cash bank overdrafts end year cash payments tangible intangible fixed assets amounted comprise million million disposals realised million million cash payments acquire cash cash equivalents equity investments million million made overdrafts year sales equity investments realised million million net cash inflow operating activities year future cash flow million million decrease primarily expect future operating cash flow sufficient fund reflected impact strength sterling profits operating debt service costs satisfy normal levels lower profits including impact divestments capital expenditure meet obligations existing licensing agreements meet expenditure arising major free cash flow restructuring programmes precise timing free cash flow amount cash generated business uncertain outlined note financial statements meeting obligations interest tax dividends paid major restructuring costs meet routine outflows noncontrolling interests capital expenditure property including tax dividends subject risk factors discussed plant equipment intangible assets pages may time time additional demands finance acquisitions share repurchases access sources liquidity free cash flow short longterm capital markets banks free cash flow growth financial institutions addition cash flow operations needs free cash flow million year decrease primarily reflected impact strength sterling lower working capital profits including impact divestments paid dividends shareholders million spent million working capital percentage turnover repurchasing shares working capital conversion cycle days reconciliation net cash inflow operating activities closest equivalent ifrs measure free cash flow shown working capital programme continued make progress improvements collection receivables effective management payables balances reconciliation free cash flow year number initiatives implemented across supply chains supporting pharmaceutical vaccines consumer healthcare businesses provided stronger endtoend net cash inflow operating activities accountability case programmes early purchase property plant equipment stage already reduced volatility improved purchase intangible assets responsiveness allowing better inventory management disposal property plant equipment reported working capital conversion cycle days distorted interest paid divestments made intangible asset impairments interest received included denominator used conversion cycle dividends received joint ventures computation yearend conversion cycles associated undertakings adjusted factors around days around distributions noncontrolling interests days respectively increase days predominantly due stock building behind new launches remediation free cash flow consumer healthcare supply chain compounded reduction denominator arising translation effect stronger sterling overseas revenue costs contributed increase seven days gsk annual report strategic report governance remuneration financial statements investor information maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bonds usd bonds commercial paper bank borrowings leases treasury policies longterm credit rating moodys investors service report sterling pay dividends sterling profits moodys stable outlook standard poors rate us role corporate treasury monitor manage stable outlook shortterm credit ratings external internal funding requirements financial risks p standard poors moodys respectively support strategic objectives operate global liquidity basis primarily subsidiary companies manage december cash liquid investments capital ensure subsidiaries able operate held follows going concerns optimise returns shareholders appropriate balance debt equity treasury activities governed policies approved board directors bank balances deposits recently july treasury management group tmg meeting chaired chief financial officer takes place us treasury treasury repo monthly basis review treasury activities members receive money market funds management information relating treasury activities corporate debt instruments government securities capital management financial strategy supports groups strategic priorities regularly reviewed board manage capital cash liquid investments billion including amounts held structure group appropriate mix debt viiv healthcare held centrally december equity free cash flow conversion improved earnings excluding net debt billion december aftertax legal charges legal settlements table summarises cash gross debt however free cash flow lower billion effects hedging compared billion reflected impact strength sterling lower profits including impact divestments consequence well billion cash liquid investments paid increase shareholding indian pharmaceutical gross debt fixed subsidiary acquisition remaining floating indonesian consumer healthcare business held noninterest bearing third party net debt increased billion net debt december billion december policy borrow centrally order meet anticipated funding requirements cash flow forecast funding requirements monitored tmg monthly basis strategy diversify liquidity sources using range facilities maintain broad access funding markets day sweep cash number global subsidiaries central treasury accounts liquidity management purposes gsk annual report strategic report governance remuneration financial statements investor information group financial review continued treasury operations counterparty risk management objective treasury activity manage posttax net set global counterparty limits banking cost income financial operations benefit earnings investment counterparties based longterm credit ratings use variety financial instruments finance operations moodys standard poors corporate treasurys usage derivative financial instruments manage market risks limits monitored daily corporate compliance officer operations derivatives principally comprising forward cco operates independently corporate treasury foreign currency contracts foreign currency options interest breach limits would reported cfo immediately rate swaps used swap borrowings liquid assets cco also monitors credit rating counterparties currencies required group purposes manage exposure changes ratings occur notifies corporate treasury financial risks changes foreign exchange rates changes made investment levels authority interest rates limits appropriate addition relationship banks credit ratings reviewed regularly report presented annually hold issue derivatives speculative purposes tmg approval treasury policies specifically prohibit activity transactions financial instruments undertaken manage risks arising underlying business activities strategic report speculation strategic report approved duly authorised interest rate risk management committee board directors february objective minimise effective net interest cost signed behalf balance mix debt fixed floating interest rates time policy interest rate risk management limits amount floating interest payments prescribed percentage operating profit simon dingemans used interest rate swaps redenominate one fixed chief financial officer rate bonds matured floating interest rates february duration swaps matched duration principal instrument interest rate derivative instruments accounted fair value hedges relevant liability foreign exchange risk management foreign currency transaction exposures arising internal external trade flows generally hedged objective minimise exposure overseas operating subsidiaries transaction risk matching local currency income local currency costs possible internal trading transactions matched centrally manage intercompany payment terms reduce foreign currency risk foreign currency cash flows hedged selectively management corporate treasury tmg include hedges foreign exchange risk arising acquisitions disposals assets possible manage cash surpluses borrowing requirements subsidiary companies centrally using forward contracts hedge future repayments back originating currency order reduce foreign currency translation exposure seek denominate borrowings currencies principal assets cash flows primarily denominated us dollars euros sterling certain borrowings swapped currencies required borrowings denominated swapped foreign currencies match investments overseas group assets may treated hedge relevant assets forward contracts major currencies also used reduce exposure investment overseas group assets tmg reviews ratio borrowings assets major currencies monthly gsk annual report strategic report governance remuneration financial statements investor information governance remuneration section board corporate executive team chairmans letter corporate governance framework board report shareholders oversight stewardship future actions leadership effectiveness committee reports audit risk nominations corporate responsibility remuneration report chairmans annual statement annual report remuneration remuneration policy report ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statements investor information board diversity experience international experience composition tenure nonexecutives scientific global executive years finance usa nonexecutive years industry europe male years emap female years sir christopher gent skills experience chairman sir christopher many years experience leading global businesses track record delivering outstanding performance nationality highly competitive industries appointed managing director british vodafone plc became chief executive officer appointment date retirement sir christopher also june chairman nonexecutive director ferrari spa member british january airways international business advisory board committee membership external appointments corporate responsibility sir christopher senior adviser bain co committee chairman nominations remuneration finance sir philip hampton skills experience chairman designate prior joining gsk sir philip chaired major ftse companies including j sainsbury plc also served group finance nationality director lloyds tsb group bt group plc bg group plc british british gas british steel plc sir philip previously appointed appointment date executive director lazards nonexecutive director rmc january deputy group plc belgacom sa chairman uk chairman april financial investments limited manages uk governments nonexecutive chairman shareholdings banks may external appointments committee membership sir philip currently chairman royal bank scotland group nominations committee plc also senior independent director anglo american plc chairman finance chairman remuneration committee member audit committee sir andrew witty skills experience chief executive officer sir andrew joined gsk worked uk south africa usa singapore various senior roles nationality appointed president europe joined gsks corporate british executive team sir andrew served lead nonexecutive board appointment date member department business innovation skills january december also president european federation chief executive officer pharmaceutical industries associations july may external appointments committee membership sir andrew member prime ministers business advisory finance group also appointed uk business ambassador group school economics management advisory board sem tsinghua university beijing china sir andrew chancellor university nottingham simon dingemans skills experience chief financial officer prior joining gsk simon years experience investment banking sg warburg goldman sachs nationality time advised broad range large corporates across number british industry sectors including pharmaceuticals consumer healthcare appointment date simon advised gsk decade appointment january chief closely involved number gsks key strategic projects financial officer april external appointments committee membership simon chairman group member corporate finance development council national theatre gsk annual report strategic report governance remuneration financial statements investor information dr moncef slaoui skills experience chairman global vaccines moncef joined gsk vaccines engineered development robust vaccines pipeline led worldwide nationality business development pharmaceutical products moroccan belgian american appointment lead rd given overall responsibility appointment date gsks oncology business gsk vaccines may global franchises moncef advised us presidents council advisors science technology member committee membership board agency science technology research astar finance january phd molecular biology immunology universit libre de bruxelles published scientific papers presentations prior joining gsk moncef professor immunology university mons belgium external appointments moncef member phrma biotechnology industry organization boards usa member advisory committee director national institutes health also adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef serves nonexecutive director international aids vaccine initiative iavi sir deryck maughan skills experience senior independent sir deryck wealth international corporate investment nonexecutive director banking experience previously served chairman chief executive officer citigroup international salomon nationality brothers inc served vice chairman new york stock british exchange sir deryck former senior adviser appointment date partner kohlberg kravis roberts co previously served june senior nonexecutive director thomson reuters independent nonexecutive external appointments director may sir deryck nonexecutive director blackrock inc trustee committee membership british museum new york university langone medical center audit risk nominations remuneration finance professor sir roy anderson skills experience independent nonexecutive professor sir roy worldrenowned medical scientist advanced director scientific expert knowledge infectious disease epidemiology currently professor infectious disease faculty medicine imperial nationality college london fellow royal society academy british medical sciences royal statistical society honorary appointment date fellow institute actuaries foreign associate member october institute medicine us national academy sciences french academy sciences professor sir roy brings scientific committee membership expertise boards deliberations nominations finance external appointments professor sir roy member international advisory board holdingham group trustee natural history museum london also member vaccine international advisory board vacciab aj pharma holding sdn bhd malaysia dr stephanie burns skills experience independent nonexecutive stephanie recognised global business leader served director chairman president ceo dow corning corporation retirement end strong scientific background nationality phd organic chemistry organosilicon specialty american advocate science education stephanie previously sat us appointment date presidents export council officer society chemical february industry american section well past honorary president ukbased parent society stephanie also officer chairman committee membership american chemistry council corporate responsibility remuneration finance external appointments stephanie appointed nonexecutive director corning inc january nonexecutive director kellogg company february gsk annual report strategic report governance remuneration financial statements investor information board continued stacey cartwright skills experience independent nonexecutive stacey chartered accountant significant experience director global consumer businesses corporate finance served executive vice president chief financial officer burberry group plc nationality july prior joining burberry group plc stacey held british role chief financial officer egg plc appointment date worked various financerelated positions april granada group plc committee membership board determined stacey recent relevant financial audit risk finance experience agreed appropriate qualifications background audit committee financial expert external appointments stacey chief executive officer harvey nichols group companies lynn elsenhans skills experience independent nonexecutive lynn wealth experience running global business director significant knowledge global markets gsk operates served chair president chief executive officer sunoco nationality inc prior joining sunoco president american chief executive officer lynn worked royal dutch shell appointment date joined held number senior roles including july executive vice president global manufacturing committee membership external appointments audit risk corporate lynn nonexecutive director baker hughes inc responsibility nominations flowserve corporation director texas medical center finance nonexecutive director first tee greater houston also trustee united way greater houston trustee rice university judy lewent skills experience independent nonexecutive judy extensive knowledge global pharmaceutical industry director corporate finance joined merck co served chief financial officer retired nationality judy previously nonexecutive director purdue pharma inc american napp pharmaceutical holdings limited certain mundipharma appointment date international limited companies december judy april previously served nonexecutive director dell inc quaker oats company committee membership audit risk committee board determined judy recent relevant financial chairman nominations experience agreed appropriate qualifications remuneration finance background audit committee financial expert external appointments judy nonexecutive director thermo fisher scientific inc motorola solutions inc also trustee rockefeller family trust chairperson audit committee rockefeller financial services life member massachusetts institute technology corporation member american academy arts sciences dr daniel podolsky skills experience independent nonexecutive daniel worldrenowned researcher advanced knowledge director scientific expert underlying mechanisms disease new therapies gastrointestinal disorders formerly mallinckrodt professor nationality medicine chief gastroenterology massachusetts general american hospital harvard medical school previously served appointment date chief academic officer partners healthcare system daniels july current responsibilities leading large academic medical centre give relevant insight healthcare delivery daniel brings scientific committee membership expertise board audit risk committees deliberations audit risk corporate responsibility finance external appointments daniel president university texas southwestern medical center holds philip obryan montgomery jr md distinguished presidential chair academic administration doris bryan wildenthal distinguished chair medical science member institute medicine us national academy sciences member board southwestern medical foundation director antibe therapeutics inc also member national academies sciences board army science technology gsk annual report strategic report governance remuneration financial statements investor information urs rohner skills experience independent nonexecutive urs broad range business legal experience served director chairman number boards recently credit suisse world leading financial services company prior joining credit nationality suisse urs served chairman executive board swiss ceo prosieben prosiebensat media ag followed appointment date number years private practice major law firms switzerland january usa admitted bars canton zurich state new york committee membership remuneration finance external appointments urs currently appointed chairman board credit suisse group ag chairmans governance committee also appointed chairman member board trustees credit suisse research institute credit suisse foundation tom de swaan skills experience independent nonexecutive tom long distinguished career european banking director industry member managing board chief financial officer abn amro tom held various executive nationality positions dutch central bank nonexecutive director dutch financial services authority financial conduct authority appointment date previously nonexecutive director january kpmgs public interest committee also vice chairman supervisory board chairman audit committee royal ahold committee membership remuneration committee board determined tom recent relevant financial chairman audit risk experience agreed appropriate qualifications nominations finance background audit committee financial expert external appointments tom chairman supervisory board van lanschot bankiers chairman board directors zurich insurance group also member supervisory board royal dsm senior adviser ondra partners jing ulrich skills experience independent nonexecutive jing managing director vice chairman asia pacific jpmorgan director chase advises firms senior global clients across asset classes building relationships executives asias leading nationality enterprises jing one prominent advisers large global american asset management companies sovereign wealth funds multinational appointment date corporations works lines business jpmorgan chase july foster greater crossborder collaboration strengthen senior client relationships asia pacific rest world committee membership audit risk finance jing managing director chair global markets china jpmorgan jing worked deutsche bank managing director head greater china equities previously held financial positions specialising asia pacific region clsa asia pacific markets emerging markets investors corporation educated harvard stanford universities external appointments jing currently independent director ermenegildo zegna spa member bocconi universitys international advisory council hans wijers skills experience independent nonexecutive hans broad range business economic political director experience served chief executive officer chairman akzo nobel nv hans long nationality distinguished career academia public service strategy dutch consulting served senior partner boston consulting appointment date group april external appointments committee membership hans chairman supervisory board heineken nv also corporate responsibility deputy chairman nonexecutive director royal dutch shell remuneration finance chairman supervisory board afc ajax member supervisory board hal holding nv gsk annual report strategic report governance remuneration financial statements investor information corporate executive team sir andrew witty deirdre connelly roger connor simon dingemans chief executive officer president north america president global manufacturing chief financial officer pharmaceuticals supply see board see board deirdre joined gsk cet roger joined cet president north america appointed president global pharmaceuticals february manufacturing supply gms working eli lilly company working year years held variety president designate gms positions including president roger joined gsk us operations senior vice president astrazeneca worked global commercialisations finance manufacturing strategy womans health senior vice roles including gsk sites president human resources cork ireland ware uk deirdre holds bachelors degree prior position gms roger marketing economics vice president office lycoming college pennsylvania ceo corporate strategy graduated harvard february universitys advanced management holds degree mechanical program manufacturing engineering serves director queens university belfast phrma board board masters manufacturing leadership macys inc harvard cambridge university university public health policy also chartered accountant council deirdre native san juan puerto rico deirdre announced retirement gsk stepped cet february nick hirons abbas hussain bill louv david redfern senior vice president global president global pharmaceuticals senior vice president core chief strategy officer ethics compliance business services abbas joined cet david joined cet chief strategy nick appointed cet appointed president global bill joined cet officer may september senior vice pharmaceuticals october appointed april create responsible corporate president global ethics joined company lead core business services cbs development strategic planning compliance responsible president emerging markets integrates shared services addition current role compliance risk management asia pacific june joined global support functions made chairman board corporate security investigations viiv healthcare ltd board viiv healthcare ltd april october aspen board joined company nick joined gsk december vice president medical data previously senior vice international auditor uk sciences held increasingly president northern europe later head audit assurance previously spent years senior roles rd responsibility managing gsks combined five separate eli lilly held positions pharmaceutical businesses audit functions independent including president europe prior joining gsk bill region prior senior team operating common vice president europe marion merrell dow earlier vice president central riskbased methodology june also held positions eli lilly associate professor eastern europe david joined gsk nick took role china australia usa india turkey university alabama medical center finance director established new germany several roles including bill bachelor science european business governance model china business development sales degree biology college business created consistent marketing management william mary master david bachelor science approach compliance degree medicinal science doctor philosophy degree bristol university nick fellow chartered chemistry pharmacology degrees statistics uk chartered accountant cs cti otu ut ne ao nf tm sanagement l bo ou rng h inb mor ao du rg ah u inn div ie ar sity u fh en e bi v b uor ri r yt dy f f f r l io vr eid r l h gie c j inin ce apn p inf te eb dr u aa sr n n e xe ca uv tii vd e w da irs e ctor aspen pharmacare holdings ltd south africa based global generics company gsk holds minority equity stake gsk annual report strategic report governance remuneration financial statements investor information dr moncef slaoui claire thomas phil thomson chairman global vaccines senior vice president senior vice president human resources communications see board government affairs claire appointed cet senior vice president human phil joined cet resources may appointed senior vice president claire joined company communications government affairs senior manager human responsibility media resources sales marketing relations investor relations corporate group uk pharmaceuticals responsibility internal communications becoming director human product communications resources uk pharmaceuticals government affairs appointed senior joined glaxo wellcome trainee vice president human resources moving pharmaceutical brand pharmaceuticals europe marketing product communications senior vice president human became director media resources international relations glaxo wellcome plc prior joining company director investor relations worked ford motor company returned holding various positions human corporate media relations vice resources president phil worked numerous corporate product reputational claire bachelor science matters gsk degree economics management industrial relations phil earned degree english university wales history durham university dan troy patrick vallance emma walmsley senior vice president president pharmaceuticals rd president consumer healthcare general counsel patrick joined cet emma joined gsk may dan joined gsk cet appointed president pharmaceuticals appointed cet president senior vice president general rd january prior consumer healthcare counsel september senior vice president medicines business october discovery development emmas leadership business previously partner new strategy become washington law firm sidley austin patrick joined company leading fast moving consumer llp represented mainly head drug discovery healthcare company pharmaceutical companies trade focused organisation science associations matters related best chance leading april gsk announced us food drug administration new medicines created small interconditional deal novartis fda government regulations multidisciplinary teams called includes proposal create dan formerly chief counsel discovery performance units joint venture companies fda served transforming gsks approach consumer healthcare businesses primary liaison white house late stage clinical trial design provisional deal completed us department health execution emma would ceo joint human services joining gsk patrick venture member board dan graduate cornell clinical academic university prior joining gsk emma worked universitys school industrial college london director loreal years labor relations earned genome research limited degree classics modern law degree columbia languages oxford university university school law dan named legend law burton awards gsk annual report strategic report governance remuneration financial statements investor information corporate governance letter shareholders addition judy lewent chairs audit risk committee provided overview work committee sir deryck maughan senior independent director provided insights boards culture dynamics listening views shareholders receiving feedback sessions held run corporate reporting season helps us shape key areas governance remuneration disclosures uk corporate governance code reviewed responsibilities reporting requirements new standards included financial reporting councils updated uk corporate governance code published september effective financial year principal changes relate going concern viability statements internal control risk management areas bring code uptodate new remuneration reporting practices review indicated strong position comply fully dear shareholder new standards board report formally next chairman board committed gsk seeking years annual report implementation operate highest standards corporate governance believe governance structure underpins ability appointment chairman designate deliver strategy grow diversified business deliver welcome appointment sir philip hampton designated products value simplify operating model successor joined board january become create additional longterm value shareholders deputy chairman april sir philip due succeed may end agm less important board need firmly undergoing thorough wideranging induction process embed valuesbased conduct behaviour employees tailored role background governance structure want ensure everything detailed provided firm basis board employees guided commitment make valuable early contribution board deliberations values compliance local laws fully conversant businesses environment regulations within operate foundations operate becomes chairman meantime commitments laid code conduct working closely sir philip support sir strengthened reissued january available deryck maughan senior independent director governance area website draws together number handover period ensure smooth seamless transition key company policy principles provides working guide way apply values across global operations china investigations abac chinese authorities reached conclusion investigations highlight key corporate governance priorities chinese business september board addressed deeply disappointing matter gsk cooperated fully board evaluation authorities took steps comprehensively rectify issues independent external evaluation undertaken board identified operations china audit risk committee committees pleased report results board member attends fully appraised dr tracy longs review positive confirming board developments continues closely monitor groups abac operating well effective dealing various activities details set judy lewent challenges faces time significant transition audit tendering company board two key priorities board regularly reviewed developments uk eu level close proposed threepart transaction novartis reform audit market particularly relation regulations track complete week commencing march governing audit contract tendering audit firm rotation integrate novartis vaccines consumer healthcare also taken consideration views shareholders businesses existing governance arrangements part overall assessment auditors performance audit risk committee reviewed implications tendering manage orderly refreshment board result external audit contract details conclusions set number planned retirements board next committee intend initiate tender two three years address several identified additional exercise due significant level change skills experience gaps company experiencing expects however initiate sir philip hampton chairman designate succeeded preparations tender process second half nominations committee chairman immediately order new auditor could take audit focus tailoring refreshment board requirements following pages outline approach governance future reshaped group lead next practices underpin delivery strategy structure chapter development evolving external landscape corporate governance report maintained continue serve committee provide continuity statutory risk disclosures previously appeared support sir philip details dr longs key findings report continue referred shareholder information action points board agreed address section pages risk management section set pages respectively annual investor meetings commend report shareholders sessions held november pleased discuss corporate governance practices largest shareholders tom de swaan remuneration committee sir christopher gent chairman covered executive remuneration arrangements chairman february gsk annual report strategic report governance remuneration financial statements investor information corporate governance framework board coherent corporate governance framework clearly defined responsibilities accountabilities designed safeguard enhance longterm shareholder value provide robust platform realise groups strategy grow deliver simplify internal control risk management arrangements described pages integral part gsks governance framework board committees order board operate effectively give full consideration key matters board committees established board summary role board committee set table full terms reference committee available website reports membership work undertaken audit risk remuneration nominations corporate responsibility committees given pages board chief executive officer chairman executive independent directors nonexecutive directors corporate executive team corporate corporate administration audit risk remuneration nominations responsibility finance transactions committee committee committee committee committee committee reviews reviews reviews reviews reviews reviews responsible recommends recommends external issues approves approves financial internal board board potential annual report matters reporting processes overall executive structure size serious impact upon form f connection integrity remuneration policy composition gsks business convening administration financial statements appropriate fees board reputation agm groups system internal chairman appointment management quarterly results business controls directors committee announcements certain corporate annual governance identification determines members cet oversight gsks certain major transactions management terms service members responsible business licensing capital risks external remuneration succession commitments transactions internal audit executive directors board cet changes processes members groups investment initiating audit cet instrument tenders counterparty limits selection reviews appointment approves external auditors remuneration remuneration report oversight work gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued board report shareholders oversight stewardship future actions board board pleased report full compliance requirements uk corporate governance code see respect position audit tendering board responsible longterm success company corporate governance strategy risk management financial performance accountable shareholders ensuring group appropriately managed governed delivers gsks strategy grow deliver simplify board programme board met six times board member attended scheduled board meetings board agendas shaped create time strategic discussion debate closely managing time allocated routine items ensure focused consideration strategic priorities agendas board meetings included following business month strategy board risk oversight governance january approval plan review financial results review internal outlook board evaluation report reappointment auditors secretarys report including regulatory governance updates march review gms performance secretarys report including strategy update regulatory governance updates deep dive pipeline launches may deep dive india review financial results preparation agm patent protection year date secretarys report including regulatory governance updates july credit profile distribution policy annual emap vaccines secretarys report including review funding strategy business reviews regulatory governance updates treasury policy rd annual update review pensions strategy north american review insurance strategy pharmaceuticals annual update october review output annual threepart novartis transaction board cet strategy meeting shareholder approval process review talent leadership secretarys report including regulatory development strategy governance updates december review plan europe annual update review external board evaluation secretarys report including regulatory governance updates year board members invited attend audit risk committee meetings risk matters routinely discussed board performance board identified certain actions assist adding value deliberations performance board actions set actions progressachievement strategy proposed transformational threepart novartis transaction board would look take longer term view ten years exploring ipo minority interest viiv healthcare enhance future key strategic issues facing company strategic flexibility reshaped group demonstrate boards longer term strategic positioning gsk ii board meetings consideration regular annual business unit updates time spent routine matters would managed board adjusted focus principally strategic issues enable strategicbusiness discussions take priority assurance risk management aspects updates ensuring critical areas oversight maintained considered audit risk committee meetings attended full board iii annual boardcet meetings format sessions refined simplified presentations structure format sessions would reviewed shortened made cet member responsible ensure appropriately geared realising maximum proposed shape direction strategic issue value terms strategic insights direction setting consideration increased time challenge develop strategy greater depth enhanced personal accountability proposed direction setting iv china review board remains committed reviewing implementing appropriate actions would reviewed board appropriate recommended actions ropes grays implemented necessary conclusion external independent review actions already undertaken china investigation ropes gray independent review set actions set full gsks annual report discusses internally facilitated evaluation boards activities senior independent director gsk annual report strategic report governance remuneration financial statements investor information board report shareholders oversight stewardship future actions continued agms key highlights glance agm held may qeii conference centre agm held may qeii conference centre london london full director attendance sir christopher gent tom de swaan jing ulrich stand billion votes cast resolution issued board ten nine three years service share capital respectively sir robert wilson stood ten years service sir philip hampton urs rohner stand election board directors retired reelected board receiving directors stand reelection board least votes cast favour board believes director effective demonstrates h ighest votes favour reelect number directors commitment role l owest votes favour reduce required notice director formally evaluated chairman general meeting standing reelection chairman designate induction programme sir philip hampton sir philips induction programme designed arranged chairman consultation company secretary ceo based principles used companys new nonexecutive director induction programme customised take account sir philips designated leadership role gsk seeks build clear comprehensive view industry gsks strategy positioning induction programme rolled phases set area understanding induction content pharmaceutical industry briefing industry external consultant investors perspectives businesses teachin sessions heads global pharmaceuticals consumer healthcare vaccines operating model teachin sessions heads rd gms corporate operations onetoone meetings cfo heads hr remuneration corporate strategy communications government affairs legal global ethics compliance core business services senior executives responsible tax treasury pensions ir media government affairs audit assurance security shareholders external programme meetings arranged stakeholders advisers induction underpinned thorough grounding corporate governance arrangements includes meetings board director reviewing current past board evaluations attending meetings committees member assess understand corporate governance framework boardroom culture dynamics addition induction activities supplemented extensive programme visits principal rd gms vaccines sites meeting external advisers board performance action points main findings agreed action points arising board evaluation review externally facilitated dr tracy long boardroom review limited progress disclosed gsks annual report set key findings agreed action points composition board due change chairman designate together nominations committee seek enhance next two three years governance processes relating board composition tenure size require carefully planned thoughtfully executed refreshment programme review seek develop objective specifications plans boards roles alignment strategy external landscape companys evolving circumstances directors identified gaps boards closing knowledge experience gaps considered part process current composition relating us pricing recruitment new nonexecutive directors combined refreshment designated healthcare emerging markets consumer specialist roles board medical scientific expertise senior independent healthcare knowledge director sid given speed complexity external critical skill sets potential candidates international markets cultural experience landscape changes potential surprises crisis stakeholder management considered composition choices peer group highly experienced nonexecutive directors boards benchmarked crucial component boards composition replacement current sid due chairman designate leading search involving internal external candidates role retire agm priority issue sid specification developed balances replacement existing knowledge ability work well chairman designate conduct robust board evaluations interact well shareholders able commit necessary time role consideration given reducing aspiration considered refreshed board competenceskills matrix size board judged used part board refreshment programme linked companys strategy strong enough composition dynamic consideration given enhancing chairman designate lead process consider best practice techniques nonexecutive director evaluation process combination annual individual peer evaluations gsk annual report corporate governance continued senior independent director leadership effectiveness sir deryck maughan senior independent director sid since may sir derycks role act sounding board board chairman trusted intermediary board met six times member attending directors also available additional point contact follows shareholders responsibilities include evaluation number number performance chairman request chairman meetings held whilst meetings board member attended evaluating board committees collaboration sir christopher gent committee chairmen years evaluation conducted internally sid also works process selection sir andrew witty new chairman appropriate chairs nominations simon dingemans committee agreeing recommendation board dr moncef slaoui chairmans successor details sids role professor sir roy anderson process undertaken select sir philip replace sir christopher dr stephanie burns chairman available stacey cartwright sir deryck maintains understanding issues concerns lynn elsenhans major shareholders meetings reports judy lewent investor relations team briefings company sir deryck maughan secretary corporate governance issues dr daniel podolsky tom de swaan ceo sir andrew responsible management business jing ulrich developing groups strategic direction consideration hans wijers approval board implementing agreed strategy sir robert wilson assisted members corporate executive team cet addition scheduled meetings board also met meets least times year often required quorate basis occasions consider corporate transactions short biographies members cet given including threepart novartis transaction chinarelated corporate executive team pages developments approve appointments sir philip hampton urs rohner board company secretary company secretary victoria whyte solicitor sir philip hampton urs rohner appointed fellow institute chartered secretaries administrators nonexecutive directors effect january victoria formerly deputy secretary secretary sir robert wilson retired board may remuneration committee acted secretary board boards committees since appointment chairman company secretary january role chairman lead manage business board provide direction focus ensuring victoria supports chairman designing induction new clear structure effective operation board directors delivery corporate governance agenda committees sets agenda board discussions particular planning agendas annual cycle board promote effective constructive debate support committee meetings ensuring information made sound decisionmaking process ensuring board receives available board members timely basis victoria advises accurate timely clear information particular directors board procedures corporate governance matters companys performance arranges nonexecutive directors meet investors discuss aspects corporate governance arrangements chairman works closely chief executive officer request also arranges attend internal management sir andrew witty ensure strategies actions meetings make visits business operations enhance agreed board effectively implemented also provides knowledge understanding business support advice sir andrew respecting executive responsibility managing group division responsibilities company secretary responded various chairman ceo agreed board consultations evolving global governance corporate set governance section website reporting agenda behalf group engaged shareholders ensure fully understood gsks governance chairman responsible shareholders performance remuneration arrangements group leads discussions development independence relations board considers nonexecutive directors sir philip hampton joined board january independent character judgement free become deputy chairman april succeed business relationship could materially interfere sir christopher gent chairman effect end exercise judgement sir christopher gent sir agm may philip hampton satisfied independence test respective nonexecutive directors appointments board nonexecutive directors provide strong independent independence nonexecutive directors served element board well placed constructively board six years subjected rigorous review challenge support management shape proposals strategy succession planning bring particular board considered sir deryck maughan independent judgement breadth skills experience served board nine years continued demonstrate gained senior levels international business characteristics independence challenging management operations academia taking part rigorous debate whilst possessing outstanding knowledge companys business affairs gsk annual report strategic report governance remuneration financial statements investor informationstrategic report governance remuneration financial statements investor information board composition diversity time allocation seek build effective complementary board whose nonexecutive director letter appointment capability appropriate scale complexity strategic sets terms conditions directorship positioning business process board appointments chairman nonexecutive directors expected led nominations committee described pages devote time necessary proper performance duties precise timings given vary mindful need balance composition board year year depending companys activities directors committees refresh progressively time expected attend board meetings additional draw upon experience longer serving directors meetings required tapping new external perspectives insights also expected attend meetings committees recent appointees bring boards deliberations members audit risk committee meetings nonexecutive directors drawn wide range industries open directors furtherance risk backgrounds including pharmaceutical healthcare medical compliance responsibilities strategy sessions make research academia retail insurance financial services visits operational sites appropriate experience complex organisations global external evaluation board reach considerable experience pharmaceutical board carries evaluation performance industry recent appointees bring new approach committees every year evaluation facilitated group board discussions externally every third year evaluation carried boards diversity policy set details independent external facilitator dr tracy long boardroom gender diversity gsks global workforce see review limited connection company responsible business indepth process involved dr long board induction business awareness training conducting individual interviews current company secretary assists chairman designing directors exception sir philip hampton urs facilitating tailored induction programme new directors rohner joined board january company ongoing training chairman designate induction secretary key senior executives regularly attend programme devised sir philip hampton board committee meetings commenced joined board presented reviewing past papers minutes induction programme nonexecutive directors typically includes meetings members cet senior attending board committee meetings september executives explain companys business commercial october included annual board cet regulatory environment operate investors strategy session perspective well guidance duties obligations compiling output external evaluation report director listed company visits business operations contained findings recommendations also feature induction programme also held ensure nonexecutive directors develop maintain greater insight understanding business individual feedback sessions director invited attend internal management meetings including session led sid nonexecutive directors meetings cet research development executive ceo without chairman present product executive scientific review board portfolio investment board commercial accountability board session chairman risk oversight compliance council also meet finally collective feedback session entire board employees informally visits groups operations areas principal focus recommended receptions held around board meetings action points discussed detail formally chairman also meets director annually considered agreed board december meeting onetoone basis discuss ongoing training dr longs report focused principally culture development requirements environment boardroom together composition board kept uptodate legal regulatory governance tenure board succession planning arrangements matters regular papers company secretary overall view boards performance positive presentations internal external advisers confirmed board effective dealing year board briefed various regulatory challenges faced quality decision making corporate governance developments principally included contribution board members influenced anticipated impact new uk eu rules auditing market open culture strong support boards senior roles reform financial reporting councils consultation subsequent publication updated uk corporate governance thoughtful disciplined approach use code associated guidance covering remuneration going management time concern internal control risk management improving risk control remuneration oversight board members undertook specific refresher training dr longs report noted good engagement provisions corporate integrity agreement issues management interacted well board cia new board member required part committees responding positively constructive challenge induction programme receive comprehensive training enquiry aspect board dynamics cia sir philip hampton urs rohner taken considered outstanding compared boards part training session january part induction programmes gsk annual report corporate governance continued however dr longs report stressed time briefing process place nonexecutive directors significant transition company board context managed chairman focus sector specific issues within board operated changing boards general shareholder preferences modus operandi would need evolve future challenges year aspects corporate governance included boards ability arrangements raised investors discussed anticipate changes external landscape relevant board directors included manage transition sir christopher sir philip board composition refreshment including process used search sir christophers replacement chairman refresh composition board including senior roles board china companys abac procedures practices agreed action points dr longs report focused mainly external audit contract tendering arrangements addressing challenges disclosed reporting annual bonus performance description chairman nonexecutive director evaluation operation malusclawback mechanism nonexecutive directors led sir deryck met separately without sir christopher present discuss performance accountability considered leadership performance overall contribution high standard continues internal control framework full support board recognises responsibilities present fair chairman met nonexecutive director discuss balanced understandable assessment groups individual contributions performance together training position prospects development needs board accountability reviewing approving addition chairman met nonexecutive directors effectiveness internal controls operated group independently executive directors including financial operational compliance controls risk management relations shareholders gsk internal control framework framework means gsk assures compliance laws work engage effectively shareholders regular regulations reliability financial reporting communications agm investor relations activities effectiveness risk management framework assists identification evaluation management principal risks announce financial results quarterly basis annual required uk corporate governance code uk code results included annual report shareholders receive designed manage rather eliminate risk annual summary advises annual report achieving business objectives fitforpurpose internal control notice annual general meeting available website framework conjunction embedding gsk values year sir andrew witty simon dingemans gave speak reporting lines ensures principal risks presentations institutional investors analysts media actively effectively controlled information see full year results also available via webcast risk management pages teleconference first second third quarter results framework designed ensure risks associated hold webcast teleconferences audience conducting business activities effectively controlled line results available website gsks risk appetite believe framework provides investor relations department offices london reasonable absolute assurance material philadelphia acts focal point communications misstatement loss investors ceo cfo chairman maintain continuous ensure effective governance ethical culture gsk dialogue institutional shareholders performance plans established risk oversight compliance council rocc objectives programme regular meetings team senior leaders authorised board assist year held individual meetings investors audit risk committee committee overseeing risk also hosted approximately group meetings investors management internal control activities also provides potential investors business framework risk management upward reporting company secretary acts focal point communications significant risks gsk values policies reporting upwards corporate governance matters also small central rocc risk board structure within business unit corporate responsibility cr team coordinates strategy global support function risk management policy development reporting specifically respect cr compliance boards rmcb responsible local tone matters team communicates socially responsible top risk management internal controls investors stakeholders rocc rmcbs assisted global ethics chairman also meets regularly institutional shareholders compliance gec responsible supporting hear views discuss issues mutual importance risk management development implementation communicates views members board practices facilitate employees compliance laws sid nonexecutive directors available policy gec also provides assistance help employees meet meet shareholders high ethical standards operating accordance values comply applicable laws regulations chairman remuneration audit risk committee corporate responsibility chairmen sid company secretary head human resources held annual meetings major shareholders november discuss executive remuneration corporate governance matters gsk annual report strategic report governance remuneration financial statements investor informationstrategic report governance remuneration financial statements investor information e n erprise oversight g ies k ss uu rad nit c e tos su er na oc r e aa n aa g e mpr eo nv tid ae ns tn h eo b bj oe ac rt div e fv ow w control fra inmdeepweonrd kent assurance r g r fohei n nts f f fp h hs reeh lk c r te ee e h tic c su r hi ea c br es kh nr ed sta soe sb iv nt ron ym iae ai n ec dc ns srmki nl dtm e te eo e ri g l r ih r mp mty tta cn tto hem hl em oa ra l oee e vla b fo et c e rn u frti e ip n rt ea e gt nr ei ps ang e c th ha en mn te e ra rs rres bd h net vi sa lb e aa e wsa li n tc l oc hi c od nftr h r ru ii ooo f n e k se oa r b nms u spa ls au ls ti aao n g ri na nln l owc rt lnd nyth le tisf ii ufie tnn u tu e hh acf gg il ag nr e afie lao tl l sct rl hnl r mp r ri hoo n u ee c p es nu g p r peb b sit sp n orh u w k rdr rei u en tt tieim ii tir dvt rn rl h ei g nae e n n ro ws dohre e al ia oe u e n n ce uw e nr ee u rd pg tt opi h g ht ni tt sh n tr ei f ehh oc tt eea eo u ehe h ta f hpr f haen tn f f e eh e esa et sd aas e c eg v c dn g ee ar tc ars ie v sr n rve oee f e eod pi n ud mog nn oe p eh r e fs ns st ot p ro b ledi ms si er sc pi nep dn l n ii nf gond c e eap mn mede n otn n nd itge oa ebn rot p ro mb iled nat ci mu er sc p e gs nb ep dtn l n ni nfs gonde iru te cre es vieais p nmnn n mem ii dek cdn n otn ee ne oe ne ip tr ge es oae ebp n rs msn inat cr u eu gsm bi ts ne nss e iiu n r cse vics st nso ii inka cnaio et reo one dwo iln sav mr es rs tr dti stse u men sn rr g utm raa ini ns ng ci csc og tt inae onth ro ndwo lsar rrt dti sten ng training approval board boards review focuses company subsidiaries extend material associated undertakings joint ventures investments although considers risk companys participation activities established procedures controls gsk valguse ks values place identify entities whose results must consolidated groups results key key individual acc u nintdaibviidliutayl accountability believe process followed board reviewing line management accountability compliance line management accountability compliance system internal controls accords guidance internal business management accountability compliance business man g eamudeitn aascscuoraunncetability compliance control issued turnbull committee accordance audit assurance provisions uk code provide board responsible determining nature extent significant risks willing take achieving strategic objectives board provides oversight help ensure group maintains sound risk management internal control systems framework operation whole year continues operate date approval annual report review groups risk management approach discussed risk management section strategic report pages management principal risk explained risk factors section financial report pages committee reports reports audit risk nominations corporate responsibility committees describing activities committees year set pages remuneration report remuneration report comprises remuneration committee chairmans annual statement annual report remuneration set pages addition reproduced convenience remuneration policy report set pages gsk annual report corporate governance continued enhancing abac arrangements audit risk committee report remained high priority committee continue review lessons learned recent investigations particularly chinese operations ask improve effectiveness antibribery corruption abac approach significant steps committee taken strengthen abac capabilities controls across group include detailed review operations ongoing presence higher risk territories enhancing ongoing monitoring compliance abacrelated controls targeted emerging market territories help identify implement enhanced controls appropriate emerging markets european general managers completing reviews key controls documenting dear shareholder adherence gsks values policies procedures well last years committee report stressed importance applicable local laws regulations specific improvement vigilance continuous improvements internal control plans also identified process financial reporting risk management processes systems implemented number countries however committee also focused number creation specialist abac centre excellence provide activities associated beyond core remit order training due diligence expert guidance capabilities review risk environment exposures across group senior management across group comprehensively overseen implementation number planned changes enhancements expanding footprint capabilities global ethics governance principally around compliance risk compliance gec organisation designated higher risk management policies procedures well close monitoring emerging markets ongoing transformation finance processes control ensuring resources capabilities abac environment including extensive upgrades updating investigations team strengthened systems also considered implications changes us market environment particularly pricing increasing oversight third party suppliers dynamics implementation ongoing cyber initiation new risk assessment monitoring protection programme infoprotect framework rolled across group refocusing rocc inclusion enterprise risks review progress external ropes gray committee strengthened key areas risk internal china investigations management structure following review risk oversight ongoing year half continued compliance councils rocc purpose practices standing agenda item committee meetings throughout membership representation business units adjusted committed implementing ropes grays ensure membership appropriately aligned conclusions many actions already implemented changing shape business particular cet new management team including enhanced procedures representation increased providing much stronger strategic monitoring use third party suppliers local financial direction roccs deliberations increasing ability transactions committee continue monitor progress consider cross enterprise risk exposures alongside existing related investigations closely concluded reviews gsks principal risks leadership global compliance audit assurance reinforce approach committee agreed rocc risk management boards supported global implement designation six enterprise risks specifically compliance operations reorganised consider particular risk potential exposures across global ethics compliance leadership nick gsk whole well within individual business units hirons previously head audit assurance functions rocc committee especially audit assurance aa function also reorganised focused assessing managing compounding new leadership function reports cfo consequential factors directly accountable committee providing incountry risk oversight board effective assurance recent external benchmarking operational level committee also approved confirmed aa team provided assurance also establishment country executive risk boards cerbs identified number areas enhancement including local provide means different business units operating coverage frequent shorter audit reviews alongside particular country manage principal risks might regular detailed reviews enhance flexibility improve impact one business unit effectively visibility believe changes improve committees country perspective work complements work ability identify emerging risks proactively existing risk management compliance boards rmcbs wellembedded major business units cerbs rmcbs report rocc regular review cycle gsk annual report strategic report governance remuneration financial statements investor informationstrategic report governance remuneration financial statements investor information finance transformation role committee continued focus ongoing enhancement finally role chair committee continue widen programme finance processes including creation deepen knowledge understanding group stronger shared service capabilities within core business external environment gsk operates together best services cbs operation programme targeted improving practice developments addition holding regular meetings control environment standardising finance policies key senior executives attending range management processes updating changing shape meetings including cet rocc finance leadership team business programme includes substantial upgrading meetings also attended briefing meetings external platforms particular enterprise resource planning auditors discussed aspects committees work erp systems create common platforms across shareholders networked audit committee chairmen business units together improvements deliver peers exchange views regulatory market developments consistent processes controls allow business principally risk management compliance arena manage financial risks effectively judy lewent implementation programme created significant change audit risk committee chairman business committee reviewed progress detail february input external auditors ensure effective controls remain place transition year end reviews membership attendance identified material concerns membership committee together appointment us pricing dates attendance meetings set light significant changes seen year attendance full us market place committee reviewed implications meetings changes principal risks particular carry members committee member since significant provisions returns rebates offered us customers judy lewent chairman times significant change need especially january april carefully monitored ensure aligned current lynn elsenhans january experience investments new platforms recent years stacey cartwright april allowed us remain responsive year despite often rapid sir deryck maughan january change external environment committee believes dr daniel podolsky january provisioning area remains appropriate adequate tom de swaan january infoprotect jing ulrich may company well underway multiyear programme addition six scheduled meetings committee also met enhance strengthen cyber security defences committee quorate basis five occasions review approve matters reviewed progress programme detail recently associated annual report form f preliminary appointed chief information security officer made quarterly results announcements significant progress despite increasing level threat additional investments agreed support effort details members financial accounting scientific experience given biographies board pages proposed threepart novartis transaction preparation transformative transaction committee entire board invited attend committee meetings reviewed roccs assessments risk profile attendees include novartis businesses become part group review regular attends utilised principal enterprise risks framework attendee attendee required detailed mitigation plans place risk issues identified chairman ensure incoming novartis businesses successfully ceo incorporated gsk risk monitoring framework none cfo risks identified expected give rise material exposures general counsel although position monitored closely transaction financial controller integration planning teams rocc place plans head audit assurance review progress managing risks regular basis company secretary secretary committee committee review shortly closing ensure chairman global vaccines standards values culture properly embedded head global ethics compliance reshaped enlarged organisation chief medical officer external auditors chief product quality officer would also like assure shareholders seriously external auditor committee takes role responsibility appointing assessing monitoring performance companys auditors accordance uk code board determined committee usual reviewed pwcs performance stacey cartwright judy lewent tom de swaan recent year audit process undertook believes relevant financial experience board also agreed continue provide high quality service company appropriate qualifications background audit shareholders committee therefore recommended committee financial experts defined us sarbanesoxley act reappointment year given current level change determined independent within business committee concluded appropriate meaning us securities exchange act amended put audit tender however reviewed addition judy lewent sir deryck maughan tom de swaan relative merits conducting tender recent changes also members remuneration committee allows regulations area committee concluded provide input committees review groups move towards tender new auditors target performance oversight risk factors relevant new firm taking audit financial year deliver remuneration matters objective expect start prepare tender second half gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued work undertaken committee committee worked largely recurring structured programme activities agreed conjunction committee chair management external auditors start financial year programme comprised standing items committee required consider meeting matters timed coincide key events annual financial reporting cycle business events committee considered discussed made decisions relation number matters year significant set global internal control governance month financial reporting compliance external auditors risk matters january integrity draft financial annual internal control assessment external china investigations compliance uk statements compliance report auditors effectiveness abac update corporate governance appropriateness l itigation report external audit process emerging risk review code accounting policies c orporate integrity r eappointment latest annual report draft annual agreement cia update auditors proposed regulations report f approval agm c orporate governance annual summary leaflet e xternal auditor update irectors expenses yearend audit findings private meeting external auditors february g oing concern arbanesoxley uditnonaudit assumption confirmation expenditure p reliminary results e xternal auditor announcement sarbanesoxley control approval annual findings report form f external auditor annual annual summary report form f leaflet findings march approach sarbanes p erformance china investigations private meeting oxley compliance expectations abac update external auditors external auditors emerging risk review gms business unit rocc meeting update report audit assurance aa work plan l itigation report april st quarter results e xternal auditor announcement st quarter results review findings may c ia compliance external audit plan c hina investigations private meeting l itigation report fee proposal abac update external auditors p roduct quality enterprise risk vaccines emerging markets business unit risks e merging risk review rocc meeting update july g oing concern controls gsk listed e xternal auditor china investigations c orporate governance assumptions jv subsidiaries nd quarter results abac update update nd quarter results l itigation report review findings patient safety enterprise private meeting announcement r pharmaceuticals risk external auditors north american emerging risk review pharmaceuticals rocc meeting update business unit reports september japan consumer china investigations private meeting healthcare business unit abac update external auditors reports ehss enterprise risk e xternal independent e merging risk review review aa rocc meeting update evolution emerging markets compliance model cia update reports october rd quarter results l itigation report e xternal auditor announcement rd quarter results review findings gsk annual report strategic report governance remuneration financial statements investor information global internal control governance month financial reporting compliance external auditors risk matters december key accounting issues europe business unit external auditor phase china investigations corporate governance appropriateness report one findings abac update update accounting policies global support preapproval budget abac commercial tax strategy review functions business unit auditors provide practices scientific external committee report nonaudit services engagement enterprise evaluation litigation report update risks private meeting budget infoprotect review external auditors operational excellence collective meeting programme review heads aa emerging risk review gec individual meetings heads aa gec respect financial reporting activities committee reviews recommends finance committee approval financial results announcements considering quarterly financial results announcements annual financial results contained annual report committee reviewed significant issues judgements made management determining results committee reviewed papers prepared management setting key areas risk actions undertaken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues relating financial statements significant issues considered relation financial statements year ended december set following table together summary financial outcomes appropriate addition committee external auditors discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis committee considered outcome managements halfyearly reviews current forecast net debt preparation financial positions various financing facilities options available group following review risk statements potential impact unforeseen events committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including committee reviewed managements approach timing recognition revenue accruals returns rebates rar customer returns rebates us pharmaceuticals vaccines accrual returns rebates accruals billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters committee received detailed reports actual potential litigation internal external legal including recent government counsel together number detailed updates concerning government investigations relation china investigations relation management outlined levels provision corresponding disclosure considered necessary respect china extent potential adverse litigation outcomes also areas yet possible determine provision determined necessary amount december provision legal matters billion set note financial statements provisions provisions tax issues committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december groups balance sheet included tax payable liability billion impairments intangible committee reviewed managements process reviewing testing goodwill intangible assets assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details provisions pension committee reviewed significant assumptions adopted management valuations obligations postemployment obligations groups largest pension postretirement healthcare schemes uk us together resultant net obligation amounts calculated external actuaries groups net deficit december amounted billion set note financial statements pensions post employment benefits us branded prescription committee reviewed concurred managements assessment additional charge necessary drug fee account year fee accordance final regulations issued us irs year valuation contingent committee considered managements judgement following improved sales performance tivicay consideration triumeq necessary increase liability pay contingent consideration acquisition former shionogiviiv healthcare joint venture december groups balance sheet included net contingent consideration liability billion see note financial statements acquisitions disposals details gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued effectiveness external audit process robustness audit process evaluating effectiveness audit process prior making quality delivery recommendation reappointment external auditors quality people committee reviews effectiveness performance quality service criteria agrees conjunction management reviewed feedback provided beginning years audit mechanisms outlined noted areas improvement undertaking review committee considers overall implemented respect team following years quality audit independence auditors whether audit provided committee exhibited appropriate level challenge satisfied effectiveness auditors external scepticism work audit process annual committee evaluation seeks feedback committee satisfied auditors independence appropriate level members independently relationship auditors qualifications expertise resources quality insight provide committee work whether committee sufficient access auditors without considered whether best interests shareholders executive management company initiate defer tender finally committee considers feedback prior years consider recommending board external audit survey seeks views financial reappointment auditors forthcoming agm management team corporate business unit level covers detailed criteria committee uses judging four key areas effectiveness external auditors overriding responsibility deliver smooth running thorough efficiently executed audit set performance expectations gsks external auditor specific auditor responsibilities wider auditor responsibilities discuss approach areas focus advance early p rovide uptodate knowledge technical issues providing engagement understanding implications gsks new accurate timely advice operating model erve industry resource communicating best practice ensure sarbanesoxley scope additional procedures industry trends reporting discussed endorsed management communicated dhere independence policies including gsks policies timely basis within gsk pricewaterhousecoopers llp pwc financial reporting councils isa applicable avoid surprises timely reporting issues levels within securities exchange commission standards group eliver focused consistent audit approach globally ensure clarity roles responsibilities reflects local risks materiality auditors local management l iaise gsks audit assurance team avoid duplication work global ethics compliance team ensure common respond issues raised management timely basis understanding audit outcomes meet agreed deadlines p rovide consistency advice levels organisation provide continuity succession planning key employees auditors provide sufficient time management consider draft auditor reports respond requests queries employ consistent communication local central audit teams audit tendering however given integration challenges threepart novartis pwc remained place auditors since groups transaction ongoing finance transformation service inception december performance enhancements made pwc received competitive reviewed annually audit partner rotation requirements audit fee proposals pwc committee agreed observed since time however audit contract currently preference distract management put tender period committee undertaking tender stage however committee also concluded would plan undertake tender observe financial reporting councils current transitional process second half view appointing arrangements audit tender tied end cycle new firm effect january current rotating audit partner current audit partner held position two years implications transitional nonaudit services arrangements competition markets authoritys sarbanesoxley act prohibits engagement audit contract tender regulations eu audit firm rotation external auditors provision certain services legal requirements also assessed committee considered actuarial internal audit outsourcing financial information systems putting audit contract tender design external auditors permitted provide nonaudit services auditrelated tax services addition part committees review evolving market committee ensures auditor objectivity independence practice changing expectations shareholders safeguarded policy requiring preapproval also noted committee services contractual similar obligations restricting groups choice external auditors gsk annual report strategic report governance remuneration financial statements investor information nonaudit services put competitive auditnonaudit service three year comparison graph tender financial service providers external auditors line groups procurement process unless skills experience external auditors make suitable supplier nonaudit service consideration case request proposal submitted relevant cet member cfo approval following policy guidelines engaging external auditors provide nonaudit services observed ascertaining skills experience external auditors make suitable supplier nonaudit services ensuring adequate safeguards place objectivity independence group audit threatened compromised ensure total fee levels exceed annual audit fee except special circumstances would clear advantage companys auditors undertaking additional work audit assurance services services including tax regulatory compliance year fees nonaudit service work carried treasuryrelated services pwc annual audit fee exceptional level services related threepart novartis transaction reflects considerable services pwc provided relating reporting accountant role connection class circular threepart novartis transaction excluding novartis work code conduct reporting lines pwcs nonaudit service fees would represented also number well established policies including annual audit fee committee considered hiring pwc code conduct available governance section undertake class circular work best interests website confidential speak reporting lines shareholders reporting investigation unlawful conduct updated version code conduct published january pwc possessed type expertise experience size international scope required handle major class fair balanced understandable assessment transaction scale complexity one key compliance requirements groups financial company benefited specifically pwcs indepth statements annual report fair balanced knowledge understanding vaccines consumer understandable coordination review groupwide healthcare oncology businesses processes contributions annual report follows well established compliance environment documented process performed parallel formal process undertaken external auditors management time would otherwise devoted educating another firm companys business committee received summary approach taken operations could instead spent delivering transaction management preparation gsks annual report substantially strengthen two groups core ensure met requirements uk code enabled businesses create significant new options increase value committee board confirm gsks shareholders annual report taken whole fair balanced understandable committee could leverage pwcs capabilities negotiate advantageous costeffective price committee evaluation committees annual evaluation externally facilitated addition noted million novartis dr tracy long boardroom review limited supplemented related fees due pwc arose work done novartis questionnaire circulated committee members auditors also pwc committee chairman concluded committee maintain external auditors independence objectivity continued operate effectively terms enhancements class circular workstreams self review threat committees deliberations agreed following identified independent partner involved audit areas considered underpin committees appointed lead management reviewed effectiveness considered pwcs findings pwc make decisions regular updates new emerging issues behalf management additionally pwc input anticipating streamlined reporting process respect production financial information subsequently potential risk audit issues used audit team increase focus setting monitoring adjusting risk appetite fees paid companys auditor associates set details given note financial widening deepening committees exposure certain statements operating profit areas business external landscape increase understanding potential threats opportunities possible accounting firms engaged undertake nonaudit services enhance training requirements committee members consider division focus risk areas board committee gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued following key attributes identified nominations committee report experience running listed global organisation highly regulated industry clear collegiate style leadership possessing comprehensive knowledge understanding uk corporate governance arrangements sir philip hampton nominations committee deep appreciation uk shareholder media chairman perspectives treating role primary commitment view membership serving role medium long term membership nominations committee committee criteria deemed key success new together appointment dates attendance meetings appointee mwm specialises recruitment high set calibre board directors engaged ensure widest possible pool candidates available select mwm attendance full meetings provides recruitment consultancy services committee members committee member since work validated timetotime ensure sir philip hampton gaps search process committee chairman receiving best possible market advice key appointment search initiated chairman senior independent january january director sid support head human resources professor sir roy anderson october company secretary search progressed drew lynn elsenhans january conclusion led sid regular oversight sir christopher gent process exercised committee shareholders chairman january briefed search criteria used progress made january december committee identifying suitable candidates judy lewent may pool suitable candidates reduced shortlist sir deryck maughan july briefing reports shortlisted candidates reviewed tom de swaan october candidates met key board members became clear sir robert wilson march board committee sir philip hampton sir robert wilson retired board may suitable candidate succeed sir christopher chairman addition scheduled meetings committee also met september accordance committees quorate basis two occasions consider recommend terms reference sir deryck maughan sid chaired board appointments sir philip hampton urs rohner meeting nominations committee recommended chairman designate nonexecutive director sir philips appointment nonexecutive director successor sir christopher attendees committee meetings may include feedback investors sought committee regular attends made recommendations board positively attendee attendee required supported sir philips appointment chief executive officer head human resources subsequent appointment recommendation received unanimous board approval september company secretary secretary committee announced sir philip would join board nonexecutive appropriate external advisers director effect january would become chairman succession deputy chairman effect april succeed unanimously agreed extend sir christopher sir christopher nonexecutive chairman effect gents appointment chairman five years end agm may effect january subject annual reelection sir philip met independence requirements set uk shareholders time board enter corporate governance code appointment able programme progressive refreshment ensured continuity dedicate requisite time role board leadership period several nonexecutive directors approaching end tenure also new nonexecutive director appointment reflected committees desire plan shape addition search successor composition balance board longer term sir christopher chairman committee searched another nonexecutive director part phased committee commenced search sir refreshment board christophers successor intention would step chairman end search process broad selection criteria used focused achieving balance continental start search process committee drew european uk us emerging markets experience job specification role chairman job specification individuals expertise capabilities developed various drafted emphasise importance board sectors specialities committee placed chairman overseeing companys strategy time industry continued evolve pace gsk annual report strategic report governance remuneration financial statements investor information mwm egon zehnder korn ferry engaged conduct committee responsible developing measurable search dossiers potential nonexecutive appointees objectives support implementation boards diversity considered committee egon zehnder korn ferry policy including gender monitoring progress towards provide recruitment consultancy services committee achievement objectives terms gender diversity candidates shortlisted interview merit assessing exceeded target least set relevant qualifications time commitments may pleased maintained female board level representation seek interviewing selected candidates committee least maintain level going forward pleased recommend board urs rohner nonexecutive director appointed board also good representation women management effect january board considered positions illustrated part gender broad business background extensive seniorlevel experience diversity gsks global workforce continue support multinational companies achieved aim appointing efforts increase pipeline women senior candidate experience running highly regulated positions within gsk also support engagement organisation understanding investor perspectives executive search firms mwm egon zehnder korn would bring fresh insights boards deliberations ferry signed voluntary code conduct gender diversity best practice board committee changes refreshment board resulted orderly changes cet changes composition board committees set terms executive succession planning committee also recommended appointment nick hirons cet sir robert wilson stand reelection agm may september senior vice president global ethics ten years service sir christopher gent tom de swaan compliance nick joined company internal jing ulrich stand reelection agm auditor uk taking roles increasing seniority ten nine three years service respectively given appointed head audit assurance june current stage board refreshment programme three took role china responsible board members stepped board may establishing new governance model china business sir deryck maughan agreed stand reelection shareholders one year stepping part ensuring focused management companys board agm provide continuity balance consumer healthcare vaccines pharmaceuticals businesses composition board given significant knowledge advance completion threepart transaction experience gsks business affairs sir deryck novartis nominations committee recommended brought style role sid discharged april emma walmsley currently president responsibilities role great diligence also play consumer healthcare appointed ceo consumer important part smooth transition sir christopher healthcare joint venture business member board sir philip transaction successfully completed board confirmed sir deryck continues demonstrate appointments october dr moncef slaoui characteristics independence carrying role abbas hussain chairman global vaccines head board search replacement sid succeed currently global pharmaceuticals respectively abbas subsequently conducted committee assumed responsibility us pharmaceuticals part sir philip succeeded sir christopher chairman role february moncef previously chairman global nominations committee january sir christopher rd vaccines continues provide scientific counsel continue serve member committee pharmaceuticals rd activities ceo board remainder tenure board successor tom de abbas previously president europe japan emap swaan chairman remuneration committee following announcement deirdre connelly president retires board agm appointed north america pharmaceuticals february membership remuneration committee intention retire gsk given recent change appointments recommended committee include global pharmaceuticals role replaced lynn elsenhans joining audit risk committee effect cet january nominations committee effect committee evaluation january judy lewent also appointed committees annual evaluation externally facilitated nominations committee effect may day dr tracy long boardroom review limited concluded sir robert wilson stepped committee committee continued operate effectively key finding board diversity dr longs evaluation concerned tenure committee committed diversity boardroom members committee accountability safeguarded similarly committed equal opportunities employees majority committee members serve alongside new levels organisation diversity inclusiveness board appointees medium long term committee workforce promoted throughout gsk agreed continue refresh membership suitable balance longer serving directors key requirement effective board comprises recent appointees support new committee chairman range balance skills experience knowledge gender shaping board independence individuals prepared challenge work team needs backed diversity personal attributes including character intellect sound judgement honesty courage gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued main responsibilities corporate responsibility committee report main responsibilities corporate responsibility committee set committee rolling agenda receives reports members cet senior managers ensure progress meeting gsks corporate responsibility commitments sir christopher gent set reviewed annual basis corporate responsibility commitments grouped across four areas committee chairman health innovating address currently unmet health needs improving access products irrespective membership people live ability pay controlling eliminating membership corporate responsibility committee diseases affecting worlds vulnerable people committee together appointment dates attendance behaviour putting interests patients consumers meetings set first driven values everything backed robust policies strong compliance processes attendance full meetings people enabling people thrive develop members committee member since individuals deliver mission sir christopher gent chairman planet growing business reducing january december environmental impact across value chain dr stephanie burns december committee also reviews approves responsible lynn elsenhans october business supplement available reference dr daniel podolsky july wwwgskcomresponsibility hans wijers october work committee sir robert wilson may committee focused attention several issues including sir robert wilson retired board may hans wijers unable attend one committee meeting due cr focus area committees area focus prior business commitment health f lexible open rd approach diseases attendees committee meetings may include developing world areas great medical need antibiotics regular attends dementia attendee attendee required trategic partnerships address access chief executive officer child mortality eg save children chairman global vaccines neglected tropical diseases trategic approach drive access general counsel medicines africa including pricing capacity head governance ethics assurance building health system strengthening head global communications v accines strategy support global public government affairs health priorities including pricing models head global corporate responsibility malaria vaccine ebola response company secretary secretary committee v iiv healthcare ltds strategy drive innovation access hiv medicines executives independent external corporate behaviour g lobal incentive compensation programme responsibility adviser selling competency model c hanges gsk engages independent external corporate responsibility adviser healthcare professionals augment gsks engagement stakeholder opinion may f urther embedding valuesbased decision sophia tickell appointed independent external making organisation including training adviser committee position held previously compliance march july ms tickell extensive experience p rogress addressing human rights pharmaceuticals industry improving health systems c onduct public disclosure clinical productivity sustainability energy supply distribution research transparency detailed data behind climate change policy shorttermism financial markets trial results patient safety r eplacement refinement reduction use cofounder director meteos animals research development directs pharma futures series aims align better societal shareholder value holds number people rganisational change employee relations board advisory roles nclusion diversity l eadership development approach ms tickell attended meetings committee provided performance management independent advice guidance corporate responsibility e mployee health safety wellbeing matters chairman ceo v olunteering planet e nvironmental performance across carbon water waste impacts gsk annual report strategic report governance remuneration financial statements investor information committee evaluation committees annual evaluation externally facilitated dr tracy long boardroom review limited concluded committee continued operate effectively part review noted nominations committee would identify recommend new committee chairman succeed sir christopher gent retires board end agm may directors report purposes uk companies act directors report glaxosmithkline plc year ended december comprises pages corporate governance report directors responsibility statements pages pages investor information entitled companies act board chosen set strategic report matters required disclosed directors report considers strategic importance company follows risk management objectives policies pages likely future developments company throughout strategic report research development activities pages inclusion diversity pages provision information consultation employees pages carbon emissions pages addition disclosures relating appointment replacement directors directors powers year end required uk corporate governance code disclosed information following table also incorporated directors report location details annual report interest capitalised financial statements notes publication unaudited financial information group financial review details longterm incentive schemes remuneration report waiver emoluments director applicable waiver future emoluments director applicable non preemptive issues equity cash applicable non preemptive issues equity cash unlisted major subsidiary applicable undertaking parent company participation placing listed subsidiary applicable contracts significance shareholder information provision services controlling shareholder applicable shareholder waiver dividends financial statements notes shareholder waiver future dividends financial statements notes agreements controlling shareholders applicable directors report drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law directors report approved duly authorised committee board directors february signed behalf sir christopher gent chairman february gsk annual report strategic report governance remuneration financial statements investor information remuneration report chairmans annual statement vesting psp dabp deferred annual bonus plan matching awards impacted tsr adjusted free cash flow performance thresholds set positive note key investments longterm success group sacrificed overall vesting level achieved threshold performance rd new products business diversification performance measures pleased report executives continue align personal interests shareholders sir andrew elected year defer maximum permitted amount dabp share ownership requirement sor hold four times base salary gsk shares currently holds times base salary gsk shares ie two three times level required details remuneration executives related dear shareholder performance annual bonus longterm incentives psp awards dabp matching awards given pages chairman remuneration committee committee pleased present remuneration report executive remuneration following year change new remuneration key changes structure remuneration reporting regulations year stability disclosed last years report awards time year committee operated binding remuneration policy horizon psp awards executive directors revised received overwhelming shareholder support extension vesting period five years awards agm ease reference shareholders included continue subject threeyear performance period copy approved remuneration policy report end already implemented malus clawback provisions prior document confirm structure incentive plans years changes required regard comply remains unchanged exception extension recent updates uk corporate governance code time horizons psp awards granted executive directors agenda include three year performance period five year vesting period structural changes proposed year committee decided salary levels executive directors would agm may shareholders asked show increased although management awarded support annual report remuneration average increase employees uk usa remuneration outcomes respect level cet financial perspective total turnover threepart transaction novartis expected billion challenging trading conditions faced completed week commencing march group particularly us primary care market core operating wideranging implications executive remuneration gsk profit core group pbit cer cost savings anticipated adjusted free cash flow rd new product financial efficiencies offset substantial proportion targets psp dabp awards impact top line pressures year helped business diversification target award need deliver core eps also protecting investments revised reflect nature business business dividend year increased transaction committee aware potential challenges making adjustments appropriately engage although challenging year gsk shareholders regarding points due course notable examples company delivered positive outcomes including great progress key product launches committee keep executive remuneration improved formulary positioning well continued progress arrangements review ensure continue meet respiratory pipeline newly launched products including needs business committee proud track tivicay triumeq viiv healthcare tafinlar mekinist record listening views shareholders tanzeum contributed billion turnover cer continue engage shareholders executive remuneration represent pharmaceutical vaccine sales matters ensure remuneration policy operated furthermore responding ebola crisis gsk longterm interests held annual meeting clear leader developing vaccine happened gsks largest investors listen views feedback alongside efforts complete transformational threepart corporate governance matters take transaction novartis approach later background key decisions made respect finally retiring nonexecutive director gsk performance committee highlighted agm consequently presenting final report chairman committee successor appointed bonus outcome executive directors determined committee take work forward would like take group operating profit group pbit achieved opportunity thank fellow committee members performance threshold target delivered shareholders support tenure chairman significantly reduced bonus payments ceo cfo committee compared vaccines performance rd value driver delivered ontarget performance look forward receiving support annual report also resulted reduced bonus payment dr slaoui remuneration agm always would also welcome compared strong performance details shareholders feedback report bonus awards given pages tom de swaan remuneration committee chairman february gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration total remuneration audited value earned annual longterm total salary benefits pension bonus incentive remuneration awards fixed pay b pay performance c pension total remuneration executive director set table dr moncef slaoui sir andrew witty simon dingemans chairman ceo cfo global vaccines total total total total total total fixed pay salary benefits total fixed pay b pay performance annual bonus including amount deferred value earned lti awards matching awards deferred annual bonus plan na performance share plan total value earned lti awards total pay performance c pension total remuneration notes certain expenses incurred normal course business considered taxable benefits uk hm revenue customs table includes figures details provided analysis value ltis earned sir andrew witty simon dingemans dr moncef slaoui set pages f ull details pension contributions pensions accrued date executive directors given committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee reduction outstanding awards vesting levels malus applied respect executive directors following sections provide details element total remuneration including implemented remuneration policy approved shareholders may applied gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued comparator groups pay performance salary committee uses two primary pay comparator groups average salary increase budget employees considering executive pay level cet approximately uk usa uk crossindustry global pharmaceutical comparator group comparator group committee decided increase executive directors salaries anglo american france sanofi astrazeneca switzerland novartis table sets base salaries executive bg group roche holdings directors last two years bhp billiton uk astrazeneca base salary bp usa abbvie change british american tobacco amgen sir andrew witty diageo bristolmyers squibb simon dingemans reckitt benckiser eli lilly dr moncef slaoui rio tinto johnson johnson royal dutch shell merck co benefits audited sab miller pfizer following table shows breakdown grossed cash tesco value benefits received executive directors unilever vodafone sir andrew simon dr moncef amgen abbvie included remuneration benchmarking witty dingemans slaoui included tsr comparator group benefits global pharmaceutical comparator group also used basis tsr comparator group features longterm employee benefits incentive awards travel benefits primary pay comparator group executive total benefits directors shown table benefits primary pay comparator group employee benefits uk global director crossindustry pharmaceutical travel sir andrew witty benefits simon dingemans international assignment dr moncef slaoui total benefits reviewing ceos remuneration committee also employee benefits include healthcare car allowance personal financial references pay group leading european companies whose advice life assurancedeath service selection based size complexity travel expenses include car travel family spouse partner costs associated accompanying director gsk business summary total package competitive positioning ceo deemed taxable benefits individual benefits comprise expenses incurred ordinary course total remuneration benchmarking business deemed taxable benefits individual included table dr slaoui includes uk accommodation dr moncef slaoui seconded uk november order enable closer vaccines business assumed operational responsibility part group secondment ended december line senior gsk expatriates received appropriate assignment expenses including accommodation location allowance relocation specific financial advice tax equalisation significant changes provision benefits proposed details please refer policy report see uk crossindustry global pharmaceutical european crossindustry group group group lower quartile median median upper quartile current position benchmarking includes salary expected value incentives based committees agreed benchmarking methodology gsk annual report strategic report governance remuneration financial statements investor information pay performance audited annual bonus majority annual bonus opportunity based formal ipm set committee taking account review performance stretching financial targets performance individual objectives multiplier may outcome adjusted reflect individual performance set generally year applying individual performance multiplier ipm executive director performed strongly objectives would expected would receive financial measures bonus threshold target ipm towards top range maximum payable achievement target bonus threshold reflects stretching nature bonus targets performance targets annual bonus based following financial performance measures weightings core group operating core group pbit vaccines performance rd value driver profit sir andrew witty simon dingemans dr moncef slaoui actual financial targets linked companys financial strategic plan committee believes targets remain commercially sensitive specific targets therefore disclosed however following illustrates performance achieved year target four measures individual performance multipliers set also substantially lower performance performance performance performance target performance measure threshold target range performance threshold target range maximum maximum core group operating profit core group pbit vaccines performance rd value driver financial performance core group operating profit core group profit interest tax face major headwinds impacting group performance terms core group operating profit core group profit interest tax resilient strong sales performances delivered several important parts business including emerging markets japan viiv healthcare oncology europe helped benefits refocusing commercial organisation delivered another relatively stable performance despite ongoing government competitive pressures addition tight rein costs added delivery incremental savings restructuring structural initiatives approximately million helped offset substantial portion impact top line pressures importantly protecting key investments required longterm success group vaccines performance rd value drivers targets year around pipeline growth value achieved reflects four important approvals incruse ellipta arnuity ellipta respiratory triumeq hiv tanzeum type diabetes two important regulatory filings breo ellipta use asthma us mepolizumab firstinclass antiil treatment severe asthma filed us europe start three major phase iii programmes triple combination therapy copd mepolizumab copd losmapimod acute coronary syndrome global sales vaccines several strong performances boostrix rotarix synflorix infanrixpediarix offset impact ongoing suspension hpv vaccines japan return market competing vaccines supply constraints business also delivered exciting phase iii data groups vaccine prevent shingles achieved major milestones programmes malaria ebola gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued table sets matters committee considered respect individual objectives set executive director personal performance sir andrew witty sir andrews bonus reflects financial performance developments offer opportunity positively reshape groups business managements response issues challenges faced course year included groups financial performance response challenging trading conditions year included greater expected contracting competitive pressures us respiratory business launch lovaza generics supply disruptions consumer healthcare sales billion core eps cer p helped delivery cost financial efficiencies initiation innovative proposed threepart transaction novartis accelerates groups strategy reshape business provide better balance broader range growth drivers synergy operating leverage opportunities financial efficiencies increased balance sustainability cash flow commencement new restructuring programme simplify gsks global pharmaceuticals business approximately billion annual cost savings expected delivered next years million net incremental cost savings delivered existing restructuring programmes structural savings establishment new executive management structure simplify organisation ensure focus across three core global businesses global pharmaceuticals consumer healthcare vaccines group also continued restructure ways working global rollout measures modernise gsks commercial model interaction healthcare professionals sustained delivery rd approvals filings key products major markets including continued build new products core pharmaceutical areas respiratory hiv sustained progress assets advanced pipeline advanced assets viewed high potential closed triple combination respiratory iosmapimod acute coronary syndrome mepolizumab severe asthma copd sirukumab ra vaccine prevent shingles cabotegravir hiv anaemia strengthening gsks business contribution public health middleincomedeveloping countries year company filed candidate vaccine prevent malaria developed candidate ebola vaccine help respond crisis west africa launched new longterm africa strategy investment launched new pricing approaches vaccines gsk placed st access medicine index fourth consecutive year groups response china investigation reform subsidiary business implementation steps strengthen abac monitoring controls procedures markets impact investigation also considered evaluation sir andrews remuneration overall evaluation sir andrews performance leadership group led committee award bonus represents reduction compared bonus award simon dingemans gsk delivered core eps line revised financial guidance provided july also protecting ongoing investments new launches additional manufacturing capabilities capacity longterm success group simon continued drive operating financial efficiencies helped lead planning new restructuring programme expected deliver billion annual savings gsk able return billion cash shareholders roll gsks erp system establishment core business services bring together support functions order streamline standardise functional support business continued significant pace dr moncef slaoui dr moncef slaoui delivered year good performance rd number candidate selections commit medicines development files approved line ahead rds fill flow targets first time human submissions slightly target new product sales encouraging dr slaoui transitioned leadership rd dr vallance following planned period development dr slaouis leadership vaccines business delivered strong performance line plan gsk annual report strategic report governance remuneration financial statements investor information following table shows actual bonuses earned compared opportunity bonus opportunity total bonus bonus paid base salary target maximum salary salary salary salary sir andrew witty simon dingemans dr moncef slaoui operation annual bonus plan line policy performance measures based relevant business unit performance given change dr moncef slaouis responsibilities dr slaouis financial performance measures weightings follows core group operating core group pbit vaccines performance rd value driver profit dr moncef slaoui changes proposed operation annual bonus plan inevitably targets linked directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus targets year however details performance achieved disclosed annual report longterm incentive plans audited deferred annual bonus plan matching awards performance share plan levels participation respect table shows performance share plan psp award executive directors shown table together levels executive director maximum matching awards granted respect deferrals bonuses total bonus deferred award level award level matching shares ads award award base salary base salary sir andrew witty shares sir andrew witty shares simon dingemans shares simon dingemans shares dr moncef slaoui ads dr moncef slaoui ads vesting matching awards performance period ended sir andrew wittys psp award subject december shown pages twoyear vesting period five years total psp awards made executive directors subject three year performance conditions matching awards made performance period five year vesting period deferred annual bonus plan dabp performance share plan described psp dabp matching awards subject performance continued employment gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued awards performance period ended december audited committee reviewed performance psp dabp matching awards granted executive directors targets set performance achieved three years december actual vesting levels set table committee previously provided estimates vesting awards gsks annual reports estimates based performance achieved time following reflects performance achieved course whole performance period discretion exercised determining vesting levels due commercial sensitivities targets rd new products business diversification disclosed time grant committee committed disclosing time vesting targets shown table performance vesting measures relative weighting performance targets performance achieved maximum award business business diversification measure based aggregate threeyear revenue diversification target vaccines consumer healthcare dermatology emerging markets asia performance pacific japan vesting schedule shown aggregate sales period billion target vesting maximum billion billion billion threshold billion rd new product rd new product performance measure based aggregate threeyear performance revenue target new product sales new products defined products launched performance period two preceding years therefore products launched years included vesting schedule shown aggregate sales period billion target vesting maximum billion billion billion threshold billion adjusted free adjusted free cash flow afcf three years billion line cash flow committees agreed principles included adjustments number material performance distorting items including legal settlements exchange rate movements special pension contributions afcf vesting schedule disclosed time grant threshold award vests achieving afcf billion achieving billion achieving billion maximum achieving billion straightline vesting points relative tsr gsks tsr rank position th comparator group ten pharmaceutical performance companies gsk nine companies vesting schedule comparator group set awards total vesting respect straightline vesting applies points use malus clawback companys policy malus clawback set remuneration policy report committee jurisdiction malus clawback respect executives recoupment committee exercises authority wider employee base comprised senior executives relevant oversight appropriate experience including senior vice president global ethics compliance senior vice president general counsel january respect financial year committee disclose whether recoupment committee exercised clawback malus disclosure made matter subject public reports misconduct fully resolved legally permissible disclose made without unduly prejudicing company therefore shareholders committee determined release shares lti plans may delayed case leavers reinforce implementation malus clawback policy also case deferred bonus awards dabp granted executives retire made redundant vesting awards normally delayed vest original timescales rather vesting earlier end year termination date falls gsk annual report strategic report governance remuneration financial statements investor information update performance ongoing awards committee reviewed performance psp dabp matching awards granted executive directors following tables provide estimate vesting taking account performance date actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels also noted relation measures adjustments may required following close threepart transaction novartis expected complete week commencing march reflect impact transaction business awards performance period ending december performance measures relative weighting performance update business business diversification performance awards measures aggregate threeyear sales across vaccines consumer diversification healthcare emerging markets asia pacific japan threshold performance results vesting maximum performance performance threshold results vesting good sales two years business areas based aggregate sales period based performance measure definitions vesting currently estimated maximum element rd new product rd new product sales performance measures aggregate threeyear sales new products launched threeyear performance performance period preceding two years ie threshold performance results vesting maximum performance threshold results vesting strong sales new products two years based aggregate sales new products two years based performance measure definitions vesting currently estimated adjusted free afcf vesting schedule awards disclosed time grant cash flow threshold award vests achieving afcf billion achieving billion achieving performance billion maximum achieving billion straightline vesting points based afcf two years performance measure definitions vesting currently estimated threshold relative tsr period january december gsks tsr rank position th comparator group ten performance pharmaceutical companies gsk nine companies vesting schedule comparator group set awards ranking position remains level vesting would threshold current estimate potential total vesting awards vesting awards performance period ending december performance measures relative weighting performance update rd new product rd new product sales performance measures aggregate threeyear sales new products launched threeyear performance performance period preceding two years ie threshold performance results vesting maximum rd performance threshold results vesting strong sales new products year based aggregate sales new products year based performance measure definitions performance currently estimated maximum vesting level ie element adjusted free adjusted free cash flow afcf vesting schedule awards disclosed time grant cash flow threshold award vests achieving afcf billion achieving billion achieving performance billion maximum achieving billion straightline vesting points rd based afcf year performance measure definitions vesting currently estimated threshold relative tsr period january january gsks tsr rank position th comparator group ten performance pharmaceutical companies gsk nine companies vesting schedule comparator group set rd awards ranking position remains level vesting would threshold current estimate potential total vesting awards vesting gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued performance targets awards inevitably measures linked directly strategy commercially sensitive particular committee consider appropriate disclose targets rd new product performance grant may result competitive harm however targets disclosed full gsks annual report end performance period together details extent met committee provide updates estimated vesting targets performance period performance targets vesting schedules set table awards performance period ending december performance measures relative weighting link strategy vesting schedule rd new product recognises importance rd future business performance performance growth threshold vesting rd revenue target based new product sales maximum incentivise better rd performance new products threshold defined products launched performance period two preceding years therefore performance period products launched years included measurement aggregate threeyear revenue target awards new product sales reflect growth historic performance new product sales adjusted free recognises importance effective working capital performance targets measure determined cash flow cash management communicated following close implementation performance threepart transaction novartis expected complete rd week commencing march anticipated communicated end july relative tsr focuses delivery value shareholders tsr ranking performance relative tsr using comparator group within comparator rd comprising gsk nine global group vesting pharmaceutical companies maximum st nd rd relative tsr measured three years using th twelvemonth averaging period tsr measured local currency threshold th median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies threshold vesting therefore achieving median performance gsk annual report strategic report governance remuneration financial statements investor information historical vesting gsks ltis following table shows historical vesting levels companys longterm incentive plans deferred annual bonus plan matching awards performance share plan share option plan respect awards made executives since share deferred annual bonus plan performance share plan option plan vesting vesting vesting vesting vesting total adjusted free rd new business total year vesting tsr cash flow product diversification vesting eps grant performance period na na na na na na na na na na na na na na na na na na na na na na na na dabp awards subject wholly tsr performance awards subject performance measures psp awards allemployee share plans payments past directors audited executive directors participate various allemployee share payments past directors plans including sharesave sharereward payments loss office audited sharesave plan hm revenue customs approved plan payments loss office directors open uk employees participants may save share ownership requirements month net salaries fixed term three years align interests executives shareholders end savings period option buy gsk executives required build maintain significant shares discount market price set holdings shares gsk time launch savings contract sir andrew witty simon dingemans contribute month sharesave executives required continue satisfy shareholding plan requirements minimum months following retirement company sharereward plan hm revenue customs approved plan open uk employees terms participants current share ownership requirements sor set contribute month gross salaries table purchase gsk shares company matches number gsk shares bought month arrangement share ownership requirement sir andrew witty simon dingemans contribute ceo x base salary month buy shares sharereward plan executive directors x base salary cet members x base salary dilution limits awards made plans incorporate dilution executive directors shareholdings purpose sor limits consistent guidelines provided investment february achievement sor based upon average association formerly provided association british share price working days preceding date set insurers limits rolling ten year period following table audited plans rolling ten year period executive share plans estimated dilution existing awards made last holdings sor ten years december follows purposes increase achievement february december shareholding sor gsk employee share plans executive share plans sir andrew witty simon dingemans dr moncef slaoui outstanding share awards still subject performance criteria continued employment included shareholdings purpose sor actual limit gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pension audited arrangements current executive directors set table pension arrangements sir andrew witty sir andrew witty member glaxo wellcome defined benefit pension plan accrual rate th final pensionable salary plan closed new entrants since section plan sir andrew member provides normal retirement age maximum pension value rds pensionable salary since april pensionable earnings increases limited per annum members including sir andrew simon dingemans simon dingemans member gsk pension plan pension contributions instead receives cash payment lieu pension base salary line gsks defined contribution pension plan rates simon dingemans receives death service illhealth insurance provided part pension plan included employee benefits dr moncef slaoui dr slaoui member us cash balance pension plan supplemental cash balance pension plan provides executive pension credit gsk makes annual contributions dr slaouis pension plans base salary plans provide cash sum retirement fund increases interest rate set annually advance based year us treasury bond rate plan entitlement spouses pension pension increases dr slaoui active member belgium ag insurance exfortis plan may deferred member since plan defined benefit plan lump sum payable normal retirement age company contributions plan dr slaoui also member gsk k savings scheme open us employees executive supplemental savings plan essp savings scheme open executives accrue benefits us government limits imposed gsk k plan contributions plans invested range funds combined contribution rate plans core contributions plus match total base salary bonus less bonus deferred deferred annual bonus plan following table shows breakdown pension values set sir andrew witty simon dingemans dr moncef slaoui pension remuneration values uk defined benefit us defined benefit belgian defined benefit employer cash contributions member contributions defined benefit plans total pension remuneration value pension remuneration figures calculated accordance methodology set remuneration regulations calculating defined benefit pension values difference accrued pension december accrued pension december increased inflation uk defined benefit us defined benefit belgium defined benefit multiplied results negative value deemed zero calculating total values amounts translated euros us dollars using exchange rate b sir andrew details regarding pension values set table accrued pension accrued pension pension remuneration sir andrew witty december pa december pa value uk funded uk unfunded total sir andrew joined gsk predecessor companies progressed roles increasing seniority within gsk appointed ceo may time built pensionable service different tiers glaxo wellcome pension plan current pension entitlement product service progression within gsk please note figures small adjustment made following change inflationary measure used value funded pension total pension number unchanged c dr moncef slaoui details regarding pension values set table accrued pension accrued pension pension remuneration dr moncef slaoui december pa december pa value us funded us unfunded belgium funded us k essp total dr slaoui joined gsk predecessor companies progressed number senior roles within gsk appointed chairman research development june chairman global vaccines october time built pensionable service belgium ag insurance exfortis plan us cash balance plan supplemental pension plan annual employer cash contributions made k plan executive supplemental savings plan essp current pension entitlement product service progression within gsk gsk annual report strategic report governance remuneration financial statements investor information performance graph table percentage change remuneration ceo following graph sets performance company sir andrew witty uk employees relative ftse index pharmaceutical performance comparator group sixyear period change change december graph prepared accordance salary remuneration regulations indication benefits likely vesting awards granted companys annual bonus incentive plans indices selected comparison purposes reflect index gsk reflects salary earned benefits received annual constituent industry operates bonus earned respect compared wider uk employee population salary increase includes annual salary review well additional changes year eg promotion increase benefits uk employees reflects change benefits policies levels year reflect changes level benefits individual may received result change role eg promotion uk population considered relevant comparison closely reflects economic environment encountered ceo relative importance pay following table sets percentage changes groups dividends paid shareholders share buyback total employee pay change total employee pay gsk total return dividends gsk pharma peers total return index share buyback ftse total return index index comprises astrazeneca bristolmyers squibb eli lilly figures table set pages johnson johnson merck co novartis pfizer roche holdings sanofi dividends declared respect million million ie increase determining remuneration table specific share repurchase levels company considers development free cash flow year given impact sustained strength sterling free cash flow company ceo suspended share repurchase programme sir andrew witty following completion threepart novartis transaction ceo single figure gsk intends return shareholders billion net remuneration proceeds company expect make ordinary annual bonus award share repurchases maximum total employee pay group employees globally vesting lti awards maximum external appointments executive directors bonus amounts include amounts paid operational efficiency bonus place years overall board encourages executive directors hold one external maximum bonus receivable subject limit base directorship become established role salary broaden experience development help increase respect psp award sir andrew also pool nonexecutive director candidates outside outstanding award share options granted appointments considered nominations committee lapsed full included total ensure would cause conflict interest vesting percentage due distorting effect aggregating approved chairman behalf board conditional shares share options companys policy remuneration earned n respect psp award sir andrew also appointments may kept individual executive director outstanding award share options granted lapsed full included total dr moncef slaoui received relation vesting percentage due distorting effect aggregating membership qatar biomedical research institute scientific conditional shares share options advisory committee also earned honorarium respect threeyear element psp award attending board meeting advisory committee director national institute health external n respect fouryear element psp award appointments receives remuneration threeyear element psp award dabp sir andrew witty simon dingemans hold matching award external appointments remunerated respect fouryear element psp award threeyear element psp award dabp matching award respect psp dabp matching awards gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued adviser committee remuneration committee committee access external advice required role committee committee carried formal review independent advisers role committee set companys remuneration committee result review committee policy gsk able recruit retain motivate reappointed deloitte llp provide independent advice executives remuneration policy regularly reviewed executive remuneration committee chairman agrees ensure consistent companys scale scope protocols deloitte provides advice committee operations supports business strategy growth plans satisfied advice received deloitte helps drive creation shareholder value objective independent terms reference deloitte member remuneration consultants group committees full terms reference available voluntarily operates code conduct relation companys website terms reference reviewed executive remuneration consulting uk code conduct least annually last revised december reflect found wwwremunerationconsultantsgroupcom best practice corporate governance developments deloitte provided independent commentary matters governance consideration committee updates market practice board considers members committee legislative requirements deloittes fees advice provided independent nonexecutive directors accordance committee fees charged uk corporate governance code exception sir time materials basis deloitte llp also provided consulting christopher gent chairman company considered tax assurance services gsk year however independent appointment committee satisfied compromise independence advice received deloitte committee met six times scheduled meetings member attending follows towers watson provided additional market data committee commitment shareholders attendance committee full committee engages regular dialogue shareholders member meetings holds annual meetings gsks largest investors discuss members since take feedback remuneration policy particular tom de swaan may committee discusses significant changes policy dr stephanie burns may measures used assess performance sir christopher gent january shareholder votes remuneration matters judy lewent january sir deryck maughan july votes total votes total votes total votes withheld hans wijers october agm cast billion million remuneration report sir deryck maughan unable attend one committee meeting remuneration policy due prior business commitments urs rohner appointed committee january attend meetings addition six scheduled meetings committee met quorate basis four occasions approve formal grant longterm incentive awards employees corporate executive team deferred investment awards share value plan awards materials use annual investor meetings committee meetings usually include closed session members committee present individuals may also invited attend committee meetings year executives committee attendees involved decisions present discussions regarding remuneration attendees committee meetings include regular attends attendee attendee required ceo cfo head human resources head reward company secretary secretary committee committee adviser deloitte llp gsk annual report strategic report governance remuneration financial statements investor information principal activities matters addressed committees principal activities matters addressed set remuneration items specific governance month overall annual bonus ltis matters january pprove executives r eview approve r eview draft remuneration including executives bonuses remuneration report salaries cet members et ceo bonus new remuneration policy executives lti objectives statement shareholder award levels feedback r emuneration environment p rivate session update committee members february r eview lti performance pprove outcomes approve remuneration report vesting outstanding lti awards lti awards pprove lti measures targets awards grant awards executive directors march r emuneration environment verview bonuses r eview shareholder update including employees cet feedback consideration new et committees agenda reporting regulations p rivate session committee members july u pdate new remuneration r eview lti design r eview agm feedback reporting regulations performance measures external environment including early drafting comparator group time pprove committee remuneration report horizons evaluation process c et remuneration review g rant interim lti r eview implications r eview executive directors awards executives threepart novartis pay competitiveness transaction r eview chairman p rivate session deputy chairman fees committee members september g rant interim share value plan awards executives october u pdate remuneration u pdate lti vesting u pdate remuneration report disclosures awards report disclosures gree key messages annual investor meeting november raft messages disclosures performance pay annual meeting investors december nnual benchmarking dministrative changes r eview feedback competitiveness review dabp investor meetings pprove executive directors r eview findings salaries committee evaluation c onsider cet remuneration r eview draft changes remuneration report papers provided u pdate implications committee examining threepart novartis equivalent remuneration transaction elements operate c orporate governance employees cet update p rivate session committee members gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued letters appointment nonexecutive directors terms engagement nonexecutive directors chairman nonexecutive directors set letters appointment available inspection company aims provide chairman non companys registered office agm executive directors fees competitive paid nonexecutive director initial appointment companies equivalent size complexity subject subsequent reappointment subject election thereafter limits contained gsks articles association periodic reelection shareholders chairmans fees nonexecutive directors letters appointment sir christopher gent took role chairman january contain provision notice periods compensation chairmans fees last increased january appointments terminated approximately sir following table shows date initial letter christophers total fees delivered shares appointment nonexecutive director deferred steps board later nonexecutive director date letter appointment chairman designate sir philip hampton appointed non executive director effect january takes sir christopher gent may role deputy chairman april receive sir philip hampton september standard annual cash retainer nonexecutive director professor sir roy anderson september becomes deputy chairman april dr stephanie burns february receive fees per annum appointment stacey cartwright march chairman september latest receive lynn elsenhans may fees per annum elected take judy lewent march fees gsk shares sir deryck maughan may dr daniel podolsky july nonexecutive director fees urs rohner october nonexecutive director fees last increased january increases supplemental fees minimum tom de swaan december fees continue delivered shares deferred jing ulrich may nonexecutive director steps board hans wijers january nonexecutive directors fees applying since january table audited sets value fees benefits set received nonexecutive directors form cash shares ads details nonexecutive directors per annum share allocation plan set standard annual cash retainer fee supplemental fees chairman audit risk committee senior independent director scientificmedical experts chairmen remuneration corporate responsibility committees nonexecutive director undertaking intercontinental travel meetings per meeting sir christopher gent chairman corporate responsibility committee receive additional fee listed nonexecutive directors fees fees emoluments audited cash sharesads benefits total cash sharesads benefits total professor sir roy anderson dr stephanie burns stacey cartwright lynn elsenhans sir christopher gentc judy lewent sir deryck maughan dr daniel podolsky tom de swaan jing ulrich hans wijersd sir robert wilsond sir crispin davisd benefits primarily consist travel subsistence costs incurred normal course business relation meetings board committee matters gskhosted events considered taxable overseasbased nonexecutive directors includes travel meetings uk b nonexecutive directors fees paid gbp converted using exchange rate set annually based average rate last quarter year prior payment rate reviewed moves significantly year c amounts benefits total emoluments respect sir christopher gent restated resulting increase amounts recorded remuneration report sir crispin davis retired board may hans wijers joined board april sir robert wilson retired board may gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited following interests directors company office december connected persons shown total share plan interests december total directors interests sharesads options aunvested unvested aunvested unvested february december january subject subject subject subject vested exercised performance performance performance performance exercised year executive directors shares sir andrew wittyb c f g simon dingemansb c f dr moncef slaouig ads dr moncef slaouic e h nonexecutive directors sharesj professor sir roy anderson dr stephanie burns stacey cartwright sir christopher gent tom de swaan hans wijers adsj dr stephanie burns lynn elsenhans judy lewent sir deryck maughan dr daniel podolsky jing ulrich unvested shares ads unvested options held executive directors subject performance reflect bonus deferrals dabp sharesave share value plan svp awards b total directors interests include shares purchased glaxosmithkline sharereward plan sir andrew witty simon dingemans awarded shares plan balance shares within plan follows sharereward plan shares february december january sir andrew witty simon dingemans dr moncef slaoui eligible participate sharereward plan c total directors interests includes shares ads resulting deferral bonus subsequent reinvestment dividends dabp totals shown table include bonus deferrals exclude unvested matching awards subject ongoing performance criteria amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities deferred annual bonus plan bonus deferrals february december january sir andrew witty shares simon dingemans shares dr moncef slaoui ads total directors interests february include shares ads vested due performance elements psp awards less sold satisfy tax liabilities vested amounts see pages details e dr moncef slaoui total directors interests include ads purchased within k plan us executive supplemental savings plan essp ads awarded dr slaouis connected person svp relevant balances follows dr moncef slaoui ads february december january us retirement savings plans share value plan executive director dr moncef slaoui eligible receive awards svp svp awards shown reflect holdings dr slaouis connected person also employee gsk awards subject threeyear vesting periods vesting contingent continued employment within gsk gains arising vesting included dr moncef slaouis total remuneration figures year connected person granted ads september grant price face value dr slaouis total share plan interests also include psp awards held connected person awards subject performance criteria relevant employees cet december connected person held ads psp comprising awards made ads ads ads amounts including dividend reinvestment gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued sharesave plan f f sir andrew witty simon dingemans unvested options subject performance include holdings respectively sharesave plan participate terms employees sharesave awards granted sir andrew witty simon dingemans granted options plan october remainder unvested options subject performance relate bonus deferrals structured nilcost options dabp share option plan g f executive directors following table provides details vested unexercised options december share option plan sop gsk granted options plan executive directors annual basis number shares option date grant lapse date exercise price sir andrew witty dr moncef slaoui h ads vested unexercised options totalling dr moncef slaoui represents ads options held dr moncef slaouis connected person following table sets details options including nilcost options dabp exercised executive directors simon dingemans exercise options year first nilcost options dabp become exercisable number shares market gain exercise type award date grant option date exercise grant price price exercise sir andrew witty sop sop dabp deferral dabp matching dr moncef slaoui sop respect options sop sharesave plans remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares ads total value shares ads vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share ads price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration options vested executive directors respect nilcost options dabp bonus deferred director recorded remuneration annual bonus year relates gain recorded exercise nilcost option comprises remuneration total amounts received reinvested dividends prior vesting gains losses resulting movements share price dates grant exercise initial bonus amount deferred dates dividend reinvestment exercise reinvested dividends matching element dabp remuneration director recorded year performance criteria end represents number vested shares multiplied price vesting gain recorded exercise nilcost option comprises total remuneration gain loss resulting movement share price vesting exercise sir andrew witty total gain following exercise options granted sop comprises remuneration nil respect share options granted december subject performance criteria three year period ended vested february vesting price investment gain gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment loss relating movement share price vesting exercise dates dr moncef slaoui total gain following exercise options granted sop comprises remuneration respect options vested investment gain j nonexecutive directors total interests include shares ads received part fees nonexecutive director share allocation plan see details balances note dividends received shares ads plan converted shares ads december gsk annual report strategic report governance remuneration financial statements investor information deferred annual bonus plan matching awards deferred annual bonus plan dabp matching awards made annually executive directors based individuals mandatory deferral voluntary bonus deferral election company match shares ads oneforone depending companys performance threeyear performance period performance conditions vesting levels described pages report awards ukbased executive directors made form nilcost options award vests ukbased executive director may choose exercise award time years date grant awards usbased executive directors made conditional awards ads amount remuneration receivable respect matching shares ads calculated using share ads price date relevant award vests award vests date remuneration report calculation performed using average share ads price last quarter financial year executive director chooses exercise nilcost options vesting date subsequent increase decrease amount realised due movements share price vesting date date exercise increase decrease value result investment decision recorded remuneration dividends reinvested nilcost options conditional awards shares ads made executive directors date vesting following tables provide details executive director respect dabp matching awards market price grant vesting represent closing share prices dates performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested february vested shares number shares market price vesting gain remuneration remuneration due vest march estimated vesting price used calculating remuneration actual vesting price reported remuneration report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued deferred annual bonus plan matching awards continued performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested unvested december granted face value grant dividends reinvested vested lapsed unvested february vested shares number shares market price vesting gain remuneration ue vest march estimated vesting price used calculating remuneration actual vesting price reported remuneration report performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested february vested ads number ads market price vesting gain remuneration remuneration ue vest march estimated vesting price used calculating remuneration actual vesting price reported remuneration report gsk annual report strategic report governance remuneration financial statements investor information performance share plan awards performance share plan psp awards made executive directors annual basis terms psp number shares ads vesting determined following end relevant performance period dependent gsks performance period performance conditions vesting levels described pages dividends reinvested performance shares ads awarded executives throughout performance period date vesting vesting uk participants receive relevant number shares us participants may defer receipt part vested awards amount remuneration receivable respect performance shares calculated using share ads price date relevant psp award vests psp awards made sir andrew witty three year performance periods however deeds award specify awards subject two year vesting period five years total two year period additional performance criteria awards lapse sir andrew dismissed cause remuneration respect awards therefore considered realised full following determination remuneration committee vesting levels initial awards ie full remuneration recognised end threeyear performance period awards whole award made executive director three year performance period vest five years final two years vesting period award director lapse dismissed cause remuneration respect awards therefore recognised end three year performance period ie remuneration report following tables provide details executive director respect psp awards market price grant vesting represent closing share prices dates performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested february vested shares number shares market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued performance share plan awards continued performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested february vested shares number shares market price vesting gain remuneration remuneration performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested february vested ads number ads market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information nonexecutive directors share allocation plan table sets accumulated number shares ads held nonexecutive directors december share allocation plan relation fees received board members together movements accounts year number shares ads december dividends allocated december share allocation plan nonexecutive directors footnote paid reinvested elected shares professor sir roy anderson stacey cartwright sir christopher gent tom de swaan hans wijers sir robert wilson ads dr stephanie burns lynn elsenhans judy lewent sir deryck maughan dr daniel podolsky jing ulrich ir robert wilson retired board may elected receive shares nonexecutive directors share allocation plan immediately upon retiring board dividend entitlements respect q q q dividends paid cash accordance plan rules gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members corporate executive team company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various share plans set table awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan performance share plan deferred investment awardsa b share value planb february group following interests shares ads company holdings issued various executive share plans described note financial statements employee share schemes interests february shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awardsa b share value planb notional shares ads b executive directors eligible receive deferred investment awards participate share value plan basis preparation remuneration report prepared accordance companies act large mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts annual report remuneration subject audit total remuneration figures executive directors including details element remuneration salary benefits annual bonus longterm incentive awards pension nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections remuneration report subject audit pages referred within audited sections remuneration report approved board directors signed behalf tom de swaan remuneration committee chairman february gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report companys remuneration policy report approved may gsks annual general meeting received overwhelming vote favour shareholders remain place another policy presented approved shareholders changes made policy however certain confirmatory statements operate policy made public described pages report committee satisfied refinements would provide additional payments permitted approved policy line best practice interests shareholders copy shareholder approved policy available wwwgskcom investors section total remuneration executive director comprises following elements value earned annual longterm total salary benefits pension bonus incentive remuneration awards committee may specific circumstances line stated principles apply clawbackmalus determines appropriate future policy table companys remuneration policy may respect elements outlined table salary benefits international assignment policy purpose link strategy purpose link strategy purpose link strategy provide core reward role levels set recruit retain high calibre gsk may require executive directors individuals execute business strategy relocate order meet business set level appropriate secure retain requirements high calibre individuals needed deliver operation groups strategic priorities executive directors eligible receive operation benefits line policy line policy employees operation employees may vary location secondment travel expenses provided individuals role experience performance include car allowances healthcare executives overseas placement independently sourced data relevant life assurancedeath service facilitate relocation process comparator groups considered provided part individuals pension provide continued standard living determining salary levels arrangements personal financial advice assignment salary increases typically take effect contractual postretirement benefits international assignment allowances cover first quarter year executive directors also eligible relocation costs accommodation based participate allemployee share schemes salaries normally paid currency size family appropriate security eg sharesave sharereward plan executive directors home country location allowance relocationspecific tax subject financial advice school fees tax opportunity terms employees equalisation formal maximum limit however order recognise high business ordinarily salary increases broadly opportunity travel requirements role executive line average increases wider relocation benefits dependent directors also entitled car travel gsk workforce number factors home host may accompanied spousepartner country family size duration however increases may higher reflect business trips benefits include assignment change scope individuals role expenses incurred ordinary course responsibilities experience salary business deemed taxable therefore possible provide typical adjustments may also reflect wider market benefits individual values limits conditions geography benefit provision tailored reflect market performance measures individual operates practice geography none salary levels set executive director based different annual report policies may apply current future executive directors based different performance measures country overall performance individual key consideration determining opportunity salary increases formal maximum limit benefits costs fluctuate depending changes provider cost individual circumstances details current benefits costs set annual report remuneration performance measures none gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued pension purpose link strategy opportunity us pension arrangements provide pension arrangements existing eligible benefits us competitive level retirement income executive directors follows senior executives operation sir andrew witty member legacy cash balance pension plan pension arrangements structured glaxo wellcome defined benefit plan supplemental cash balance pension accordance plans operated accrual rate th final plan including executive pension credit country individual likely pensionable salary per annum april provide maximum contribution retire individual chooses pensionable earnings increases base salary across pension plans become member pension plan limited per annum members cash lieu relevant pension including sir andrew witty gsk k plan formerly us contribution paid instead retirement savings plan simon dingemans member executive supplemental savings plan new executive directors uk gsk pension plan pension core contributions salary entitled either join defined contributions instead receives cash bonus matched contributions contribution pension plan receive payment salary lieu pension salary bonus cash payment lieu pension contribution contribution global dr moncef slaoui member us individual member gsk cash balance pension plans gsk eligible appropriate equivalent legacy defined benefit plan defined k plan executive arrangement excess contribution plan alternative pension supplemental savings plan also usuk arrangements plan arrangement subsequently deferred member belgium fortis performance measures appointed board may plan none remain member plan policy new external recruit uk salary contribution defined contribution plan matched contributions line policy members plan salary cash payment lieu pension contribution annual bonus purpose link strategy deferred bonus shares eligible performance measures incentivise recognise execution dividend equivalents date vesting based financial targets individual business strategy annual basis performance objectives committee may apply judgement rewards achievement stretching making appropriate adjustments individual based core group profit annual financial strategic business annual bonus amounts interest tax executive directors targets delivery personal objectives ceo cfo balance clawback andor malus provisions apply based core group operating profit operation described annual executive directors balance financial operational business targets report based relevant business unit set start year opportunity performance committee bonus levels threshold maximum bonus determined committee based individual performance objectives opportunities executive directors performance targets multiplier based achievement follows threshold maximum individual performance targets applied individual objectives set start bonus bonus bonus awarded performance year committee performance objectives assessed base base financial operational targets salary salary committee ceo executive directors required defer cfo bonus earned shares ads appropriate three years chairman global may defer additional bonus rd vaccines earned ie overall maximum deferral deferred shares vest end three year performance period gsk annual report strategic report governance remuneration financial statements investor information deferred annual bonus plan dabp performance share plan psp purpose link strategy opportunity performance measures incentivise recognise delivery dabp three equally weighted performance longer term business priorities financial maximum bonus deferral annual measures growth increases shareholder value bonus mandatory rd new product performance compared pharmaceutical additional voluntary companies adjusted free cash flow maximum matching opportunity level addition provide alignment one share one share basis subject relative tsr shareholder interests retention element performance criteria three years vests threshold encourage longterm shareholding psp maximum performance discourage excessive risk taking normal maximum award limit six comparator group currently operation times base salary per annum comprising gsk nine global dabp maximum initial value performance pharmaceutical companies vesting deferred shares may matched subject shares may granted psp median rising vesting upper achievement performance conditions individual one year quartile performance three years matching awards may details unvested psp rules allow committee conditional shares nilcost options awards see pages make awards salary eligible dividend equivalents pages annual exceptional circumstances respect performance period report current award levels psp executive directors follows conditional awards made annually vesting dependent achievement salary performance conditions three years ceo awards onwards vested awards cfo must held two years ie five years total prior release chairman global rd vaccines ceos psp awards subject additional twoyear vesting period awards eligible dividend equivalents date vesting confirmatory statement issued april state flexibility performance targets dabp exceptional circumstances psp set start used relation external recruits performance period details set clawback andor malus provisions apply approach recruitment section described clawback malus effect annual bonus payable executive directors required defer minimum annual bonus dabp event triggering event eg significant misconduct way violation regulation law significant gsk policy code conduct company ability claw back three years annual deferred bonuses well vested unvested ltis separate recoupment committee established investigate relevant claims misconduct additionally continuity responsibility initiation adverse event emergence problem adverse event taken account assessing annual bonus awards lti vesting levels year problem identified future periods committee may make appropriate adjustments individual annual bonuses well grant vesting levels lti awards reflect thisments individual annual bonus amounts gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued longterm incentive measures committee selected three equally weighted performance measures focus executive directors longterm remuneration delivery gsks key strategic priorities psp dabp awards made executive directors based rd new product performance adjusted free cash flow relative tsr addition setting robust targets committee implemented number safeguards ensure targets met sustainable way performance reflects genuine achievement targets therefore represents delivery value shareholders performance measure impact acquisition divestment quantified adjusted event major adjustment calculation performance measures disclosed shareholders vesting principal safeguards detailed measure chairman audit risk committee members also members remuneration committee provide input audit risk committees review groups performance oversight risk factors relevant remuneration decisions rationale behind performance measure calculated follows vesting schedules please see annual report remuneration performance measure rationale calculation methodology rd new recognises importance rd future business target based sales new products launched product growth performance period preceding two years performance one key indicators used assess performance aggregate threeyear revenue target reflect growth pharmaceutical industry strength companys product historic performance pipeline rd new product performance measure recognises importance rd future business growth vesting may reduced insufficient progress included measure order incentivise rd performance made performance period towards gsks target drive development sales new products return rd investment committee believes robust appropriate measure reflects actual delivery pipeline launch committee recognises time time may excellence appropriate company respond emerging pandemic supports gsks ethical responsibilities values impact revenue included unless committee considers add shareholder value provided underlying performance sufficiently positive adjusted free recognises importance effective working capital aggregate threeyear adjusted free cash flow target cash flow cash management adjustments may made materially distorting items performance use cash flow performance measure intended may include exchange rate movements major legal recognise importance effective working capital management taxation settlements special pension contributions generating cash assets future valuecreating investments returns shareholders relative tsr focuses delivery value shareholders relative tsr measured three years using performance committee recognises delivery value month averaging period tsr measured local shareholders key priority relative total shareholder return currency peer group global pharmaceutical companies selected order closely align interests executive directors investors committee regularly reviews composition tsr comparator group gsk annual report strategic report governance remuneration financial statements investor information annual bonus measures annual bonus designed drive achievement gsks annual financial strategic business targets delivery personal objectives majority annual bonus opportunity based formal review performance stretching financial targets outcome adjusted reflect individual performance applying individual performance multiplier reasons commercial sensitivity specific personal objectives kept confidential financial performance individual performance committee believes important majority ceo ceo cfos financial targets based core group operating profit individual performance objectives sir andrew witty set smaller element based core group profit interest tax board january year board focuses strategic reflect wider responsibility driving profitable investments priorities developed group following associates joint ventures end financial year board reviews performance bonus measures rd employees including dr moncef slaoui generally set objectives determine linked pipeline performance robust governance structure appropriate bonus payable performance established ensure bonus payable fairly reflects rd executive directors productivity performance ceo sets individual objectives executive recognise dr moncef slaouis current dual responsibility global directors line company strategy makes rd vaccines element bonus currently based vaccines recommendations committee regarding performance performance consistent executive directors element objectives end year bonus also currently based core group profit interest recommendations considered committee tax determines level bonuses payable approach recruitment remuneration committee determines remuneration package new committee mindful sensitivity relating recruitment executive directors casebycase basis depending packages particular buying rights relating role market operate experience previous employment signon payments therefore total remuneration levels set reference relevant pay seek minimise arrangements however certain comparator group appropriate allow future circumstances enable recruitment exceptional talent development role committee may determine arrangements best interests company shareholders arrangements expected new executive directors participate short possible likeforlike basis forfeited longterm incentive plans basis existing awards arrangements therefore vary depending plans directors however exceptional circumstances committee arrangements put place previous employer may reserves flexibility set incentive limit new executive form cash shares may may subject director additional existing limits performance conditions explanations provided committee retains flexibility recognition high payments made either compensation previous levels variable pay gsks global pharmaceutical competitors remuneration forfeited signon payment however committee use flexibility remuneration arrangements newly appointed executive considered best interests company director disclosed soon practicable investors appointment confirmatory statement issued april state following policy principles apply roles chairman committee anticipates ability grant awards nonexecutive director psp six times salary exceptional chairman circumstances would used recruitment fees set level competitive paid executive director outside gsk limit set companies equivalent size complexity fees ie psp awards maximum nine times salary paid partly shares nonexecutive directors pension arrangements external appointments executive fee levels new nonexecutive directors set director set remuneration policy table basis existing nonexecutive directors annual report company subject local laws regulations fees benefits provided line policy existing paid partly shares executive directors event nonexecutive director different role required meet business needs relocation support responsibilities appointed fee levels benchmarked provided line company policy set reference comparable roles companies equivalent size complexity internal appointments entitlements existing remuneration elements continue including pension entitlements outstanding awards however already case internal appointments required move executive director contractual terms including termination provisions gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued loss office payment policy following table sets contractual framework executive directors terms specifically relating termination set detail policy duration company policy fixed term contracts generally contracts new appointments expire line contracts applicable policy retirement age since contracts existing executive directors expire dates shown annual report notice period notice period termination employing company executive director calendar months mitigation ability impose month noncompete period nonsolicitation restriction executive director considered important company ability protect groups intellectual property staff light committee believes would appropriate provide mitigation contracts termination employment event executive directors employment company terminates following policies payments apply element remuneration loss office payment policy termination termination notice months annual salary payable termination company prorated part notice payment period worked termination payment made respect part notice period extends beyond contract expiry date bonus element normally included termination payment however terms contracts seek balance commercial imperatives best practice company enforces noncompete clause current ceo chairman global rd vaccines months ontarget bonus payable redundancy termination notice uk statutory redundancy pay apply us general severance policy apply retirement death illhealth injury disability termination payment lti awards psp dabp matching awards governed plan rules approved shareholders termination notice unvested awards lapse redundancy retirement generally awards vest original timescales subject original performance conditions awards made last months forfeited death illhealth injury disability generally awards vest following end financial year normally taking account performance date awards may prorated time event change control psp dabp matching awards vest taking account performance date normally taking account proportion performance period elapsed alternatively awards may exchanged new awards annual bonus termination notice individual individual serves notice termination date falls december bonus forfeited termination notice company redundancy retirement death illhealth injury disability termination date falls financial year eligible prorated ontarget bonus employed december bonus payable based actual results dabp deferred termination notice deferred shares vest full date termination bonus awards redundancy retirement death illhealth injury disability generally deferred shares vest full end financial year termination date falls benefits generally benefits continue apply termination date termination notice company retirement us executives line policy applicable us senior executives chairman global rd vaccines may become eligible future date receive continuing medical dental insurance terminationretirement termination mutual agreement certain circumstances best interests company board manage proactively succession planning development senior talent pipeline circumstances board may therefore agree executives departure mutual agreement order apply committee need satisfied executive demonstrated performance line expectations required contributed orderly succession completed least years service group termination date case executive director would treated good leaver purposes gsks longterm incentive plans termination date falls financial year would eligible prorated ontarget bonus employed december bonus payable would based actual results case ceo member uk defined benefit pension scheme pension would payable later termination date age without actuarial reduction gsk annual report strategic report governance remuneration financial statements investor information committee anticipate exercise discretion differences remuneration policy provided psp dabp plan rules respect termination executive directors employees payments however may unforeseen circumstances best interests company setting remuneration levels executive directors shareholders necessary exercise discretion committee considers prevailing market conditions explanations provided competitive environment comparison executive director leaves company committee remuneration executives companies similar size complexity carry assessment individuals performance international reach positioning relativities pay conduct time role determined individuals employment conditions across broader gsk workforce performance conduct contrary legitimate particular committee considers range base salary expectations company committee reserves right rises workforces parts gsk ceo apply appropriate mechanisms clawback see cfo chairman global rd vaccines employed annual report reduction lapsing outstanding considered relevant comparison incentive awards malus ensure termination payments populations reflect closely economic environments best interests company shareholders encountered individuals case termination cause payments unvested principles apply remuneration policy executive awards forfeited except shares deferred dabp directors employees although remuneration offered vest full date termination accrued salary executive directors policy stronger emphasis expenses performancerelated pay offered employees service contracts group table sets relevant dates current salary benefits including pension tailored local executive directors service contracts available market review companys registered office office hours annual bonus plan applies wider employee population date effective contract date expiry date notes based business individual performance sir andrew contract amended combination performancerelated restricted share witty plans applies wider employee population remove entitlement bonus allemployee share plans available employees uk termination including hm revenue customs approved uk sharesave sharereward plans simon dingemans company conducts regular employee surveys include dr moncef contract replaced feedback remuneration matters slaoui wider organisation aligned performance principally remove reward systems values introduced new entitlement bonus performance system formally evaluates employees termination need also senior people disincentivise unethical working practices using clawback mechanism allows us recover performancerelated pay gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued scenarios future total remuneration ceo charts opposite provide illustrations future total remuneration executive directors respect remuneration opportunity granted policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits pension figures used ie based actual amounts received respect ongoing policy executive director assumed defer annual bonus maximum permitted amount receive fixed expected maximum corresponding matching award dabp included within value lti awards cfo amounts shown value lti awards dabp psp based bonus opportunity relevant multiples salary respectively include amounts respect dividends reinvested factor changes share price vesting period fixed none pay performance annual bonus lti would payable expected annual bonus assumed target financial performance achieved performance executive director would result individual performance multiplier ie increase financial performance element bonus applied results assumed bonus salary sir fixed expected maximum andrew witty simon dingemans dr moncef slaoui respectively chairman global rd vaccines lti awards threshold levels vesting assumed maximum assumed annual bonus would payable maximum level awards dabp psp would vest full fixed expected maximum longterm variable remuneration annual variable remuneration fixed remuneration gsk annual report strategic report governance remuneration financial statements investor information nonexecutive director remuneration policy element purpose link strategy overview chairmans fee provide inclusive flat rate fee formal maximum however fees reviewed annually set competitive paid reference review chairmans performance independently companies equivalent sourced market data size complexity subject remuneration committee responsible evaluating making limits contained gsks articles recommendations board fees payable chairman association chairman participate discussions respect fees fees paid combination cash andor gsk shares ads see details gsks nonexecutive directors share allocation plan basic fee formal maximum however fees reviewed annually set reference independently sourced market data chairman ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors minimum delivered form gsk shares ads see details gsks nonexecutive directors share allocation plan supplemental provide additional compensation additional fees committee chairmen intercontinental travel fees nonexecutive directors senior independent director current fee levels set excluding chairman taking annual report remuneration additional board responsibilities undertaking intercontinental travel meetings benefits facilitate execution travel subsistence costs nonexecutive directors incurred responsibilities duties required normal course business relation meetings board committee role matters gskhosted events overseasbased nonexecutive directors includes travel meetings uk nonexecutive directors may time time accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director nonexecutive enhance link least nonexecutive directors total fees excluding directors share directors shareholders gsk chairman paid form gsk shares ads allocated allocation plan requires nonexecutive directors share ads account receive significant part nonexecutive directors may also take opportunity invest part fees form gsk shares balance fees share ads account ads gsk shares ads notionally awarded nonexecutive directors allocated interest accounts set table annual report included directors interests table annual report accumulated balances gsk shares ads together notional dividends accrued paid nonexecutive directors leave board upon leaving nonexecutive directors receive either gsk shares ads cash amount equivalent value gsk shares ads date leaving date payment later letter nonexecutive directors nonexecutive directors subject annual election reelection appointment chairmans terms engagement normally serve longer nine years date first election set letters appointment shareholders general meeting set table chairman subject annual appointment shareholders annual report may serve longer nine years date first election shareholders general meeting gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued operation scope remuneration policy current remuneration policy policy set pages annual report intended policy gsks executive nonexecutive directors apply close companys annual general meeting may submitted committee approval shareholders committee currently intends operate accordance policy prior annual general meeting exception additional twoyear holding period performance share plan awards apply awards made onwards committee written policy principally relation remuneration arrangements ceo cfo chairman global rd vaccines whilst taking account possible recruitment replacement additional executive director operation policy committee intends policy operate period set entirety however may due consideration seek change policy period believes appropriate longterm success company consultation shareholders sought shareholder approval general meeting drafting policy committee reserves right make remuneration payments payments loss office including exercising discretions available connection payments notwithstanding line policy set terms payment agreed policy came effect ii time relevant individual director company opinion committee payment consideration individual becoming director company purposes payments includes committee satisfying awards variable remuneration relation award shares terms payment agreed time award granted committee may also make minor amendments policy set report regulatory exchange control tax administrative purposes take account change legislation without obtaining shareholder approval amendments statement consideration shareholder views committee engages regular dialogue shareholders holds annual meetings gsks largest investors discuss take feedback remuneration policy governance matters annual meetings held november tom de swaan committee chairman shared updates remuneration matters last months proposals onwards particular covered changes performance conditions applying longterm incentives introduction additional twoyear holding period performance share awards ie five years total apply executive directors awards made onwards policies required disclosed remuneration policy report gsk annual report strategic report governance remuneration financial statements investor information financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap gsk annual report strategic report governance remuneration financial statements investor information directors statement responsibilities directors responsible preparing annual report disclosure information auditors remuneration report group financial statements directors office date annual report accordance applicable law regulations confirmed uk company law requires directors prepare financial far aware relevant audit information statements financial year law directors companys auditors unaware required prepare group financial statements taken steps ought accordance international financial reporting standards taken director make aware ifrs adopted european union preparing group relevant audit information establish companys financial statements directors also elected comply auditors aware information ifrs issued international accounting standards board iasb company law directors must approve confirmation given interpreted accordance group financial statements unless satisfied provisions section companies act give true fair view state affairs group going concern basis profit loss group period pages contain information performance preparing financial statements directors group financial position cash flows net debt position required borrowing facilities information including treasury risk management policies exposures market credit risk select suitable accounting policies apply hedging activities given note financial statements consistently financial instruments related disclosures making make judgements accounting estimates enquiries directors reasonable expectation reasonable prudent group adequate resources continue operational existence foreseeable future reason state group financial statements comply ifrs continue adopt going concern basis preparing adopted european union ifrs issued financial statements iasb subject material departures disclosed explained group financial statements internal control board audit risk committee reviewed prepare financial statements going concern basis assessment risks internal control framework operates unless inappropriate presume group gsk considered effectiveness system continue business internal control operation group year covered directors responsible keeping adequate accounting annual report date approval board records sufficient show explain companys directors transactions disclose reasonable accuracy time uk corporate governance code financial position group enable ensure board considers glaxosmithkline plc applies group financial statements remuneration report principles provisions uk corporate governance code comply companies act article ias maintained financial reporting council described regulation also responsible safeguarding assets corporate governance section pages group hence taking reasonable steps complied provisions board considers prevention detection fraud irregularities annual report taken whole fair balanced group financial statements year ended december understandable provides information necessary comprising principal statements supporting notes shareholders assess groups performance business set financial statements pages model strategy report responsibilities auditors relation group required financial conduct authoritys listing rules financial statements set independent auditors auditors considered directors statement report pages compliance relation points uk corporate group financial statements year ended december governance code specified review included annual report published annual report printed form made available website directors annual report year ended december responsible maintenance integrity annual report comprising report directors remuneration report website accordance uk legislation governing financial statements additional information investors preparation dissemination financial statements access approved board directors signed website available outside uk comparable behalf legislation may different current directors whose names functions listed corporate governance section annual report confirms best knowledge sir christopher gent chairman group financial statements prepared february accordance ifrs adopted eu ifrs issued iasb give true fair view assets liabilities financial position profit group strategic report risk sections annual report include fair review development performance business position group together description principal risks uncertainties faces gsk annual report strategic report governance remuneration financial statements investor information independent auditors report members glaxosmithkline plc report group financial statements audit approach overview opinion materiality opinion group financial statements defined overall group materiality million represents give true fair view state groups affairs profit tax adding back certain nonrecurring items december profit cash flows audit scope year ended audit included full scope audits reporting components properly prepared accordance international specific audit procedures performed financial reporting standards ifrss adopted reporting components european union taken together components audit work prepared accordance requirements performed accounted consolidated revenue companies act article ias regulation consolidated profit tax covered components individually contributed revenue profit separate opinion relation ifrss issued iasb tax explained note group financial statements addition applying ifrss adopted european union areas focus group also applied ifrss issued international rebates discounts allowances returns us accounting standards board iasb pharmaceuticals vaccines business opinion group financial statements comply ifrss transformation groups finance processes issued iasb potential implications alleged illegal acts audited litigation glaxosmithkline plcs group financial statements comprise carrying value goodwill intangible assets consolidated balance sheet december uncertain tax positions consolidated income statement statement comprehensive income year ended scope audit areas focus conducted audit accordance international consolidated statement changes equity year standards auditing uk ireland isas uk ireland ended designed audit determining materiality consolidated cash flow statement year ended assessing risks material misstatement group financial statements particular looked directors made notes consolidated financial statements subjective judgements example respect significant include summary significant accounting policies accounting estimates involved making assumptions explanatory information considering future events inherently uncertain audits also addressed risk management override financial reporting framework applied internal controls including evaluating whether preparation group financial statements comprises evidence bias directors represented risk applicable law ifrss adopted european union material misstatement due fraud risks material misstatement greatest effect audit including allocation resources effort identified areas focus table also set tailored audit address specific areas order provide opinion group financial statements whole comments make results procedures read context area focus appropriate evaluated design tested operating effectiveness key internal controls financial reporting including testing operation systems financial information generated complete list risks identified audit gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued area focus audit addressed area focus rebates discounts allowances returns us obtained managements calculations accruals applicable pharmaceuticals vaccines business schemes validated assumptions used reference groups refer note group financial statements stated commercial policies terms applicable contracts third party data related patient enrolment us government funded benefit schemes group makes sales various customers us fall historical levels product returns certain commercial government mandated contracts reimbursement arrangements significant compared assumptions contracted prices historical rebates medicaid medicare group also provides right return discounts allowances returns levels relevant current customers certain products payment trends also considered historical accuracy groups estimates previous years including evaluation releases accruals arrangements result deductions gross sales arriving following payments settlements us state authorities turnover give rise obligations group provide customers rebates discounts allowances right return formed independent expectation largest elements unsettled amounts recognised accrual accrual december using third party data compared expectation actual accrual recognised group undertaking focused area rebates discounts allowances work considered impact decrease revenue certain returns arrangements complex establishing respiratory products principally advair relevant changes pricing appropriate accrual requires significant judgement estimation billing arrangements commercial government directors directors determined accrual billion healthcare providers necessary december based procedures performed identify material differences independent expectations accrual transformation groups finance processes centrally managed work performed component audit teams group continues rationalise simplify finance processes bpos bscs consisted controls substantive testing including rollout enterprisewide resource planning system conducted oversight visits bsc bpo sites group erp core business services addition financial transaction audit scope namely india malaysia us uk direct work processes continued migrate third party business process performed outsourcing locations bpos related accounting services evaluated design tested operating effectiveness key centralised inhouse business service centres bscs automated manual controls migration changes represent financial reporting risk migrations centralised processing environment including general controls controls happening controls processes established respect data migration erp systems also substantively embedded number years updated migrated tested accuracy completeness data migration new erp new erp environment increased risk breakdown along controls process note significant internal financial controls transition increased risk exceptions inaccurate incomplete migration financial data would turn increase risk material misstatements group financial statements potential implications alleged illegal acts inspected ruling changsha intermediate peoples court refer notes group financial statements hunan province china respect allegations bribery china incorporated risk area focus audit validated amounts paid final settlement liability result allegations illegal acts carried groups chinese consistent ruling pharmaceuticals business addition group conducting using specialist forensic knowledge independently assessed investigations number markets group continued scope findings investigative work performed groups cooperate enquiries department justice doj us external legal counsel respect allegations china considered serious fraud office sfo uk sfo announced output assessment determining audit approach met commenced criminal investigation groups component audit team shanghai china understand evaluate commercial practices addition group announced steps taken group address allegations paid million fine chinese government connection allegations met directors management inhouse legal counsel groups external advisors assess risk occurrence similar acts focused following risks might material impact outside china status ongoing investigations potential group financial statements fines penalties included understanding evaluating illegal acts similar previously alleged china groups internal investigations processes consider risks occurred elsewhere group allegations reported various channels including whistleblowing fines penalties might forthcoming respect hotlines also evaluated enhancements changes ongoing investigations groups commercial practices made control processes business practices since could give rise need additional provisions asset supplement centralised procedures selected territories impairments outside china including certain markets otherwise included group audit scope countryspecific risk corruption bribery deemed high territories obtained specific reporting component audit teams provide us evidence appropriately designed performed audit procedures address audit risk group financial statements might materially misstated due potential financial impact illegal acts discussed status investigations opened doj sfo audit risk committee board directors management inhouse general counsel addition engaged directly groups external advisors corroborate understanding satisfied groups provisioning decisions december adequacy disclosures given status investigations gsk annual report strategic report governance remuneration financial statements investor information area focus audit addressed area focus litigation discussed status significant known actual potential litigation refer notes group financial statements inhouse legal counsel obtained substantively tested pharmaceuticals industry heavily regulated increases evidence support decisions rationale provisions held inherent litigation risk group engaged number legal decisions recognise provisions including correspondence legal actions including product liability antitrust related private counsel counterparties litigation also monitored litigation significant disclosed note considered external information sources identify potential legal actions focused area eventual outcome claims uncertain developed independent expectation litigation provisions positions taken directors based application based product litigation history available evidence material judgement estimation accordingly unexpected adverse challenge valuation completeness provisions recognised outcomes could significantly impact groups reported profit group obtained confirmations external legal counsel balance sheet position confirm understanding settled outstanding litigation asserted claims evaluated significant adjustments legal reserves december group held provisions million recorded year determine indicative respect legal actions management bias disclosed note group financial statements eventual outcome legal proceedings dependent outcome future events therefore position taken group inherently judgemental found context group financial statements taken whole judgements made management reasonable disclosures made respect provisions contingent liabilities appropriate carrying value goodwill intangible assets leveraging specialist valuations knowledge obtained groups refer notes group financial statements impairment analyses tested reasonableness key assumptions group billion intangible assets including significant including profit cash flow growth terminal values impact licenses patents acquired brands billion goodwill expiry patents potential product obsolescence selection december group recognised impairments intangible discount rates challenged management substantiate assets totalling million year assumptions including comparing relevant assumptions industry economic forecasts focused acquired intangible assets significant individually aggregate number indefinite interrogated integrity supporting calculations lives group also recognised goodwill number corroborated certain information third party sources including acquisitions expectations performance certain assets components business carrying values goodwill intangible assets contingent future cash flows risk cash flows obtained evaluated managements sensitivity analyses ascertain meet groups expectations assets impaired impact reasonably possible changes performed impairment reviews performed group contain number independent sensitivity calculations quantify downside changes significant judgements estimates including revenue growth managements models required result impairment focusing success new product launches profit margins cash conversion particular emerging markets sensitive change discount rate changes assumptions might lead change cgus carrying value intangible assets goodwill risk greater result work determined quantum impairment us emerging markets pharmaceuticals vaccines cash recognised appropriate intangible assets including generating units cgus valuation headroom compared goodwill management determined impairment required carrying value lower previous years found judgements supported reasonable assumptions would require significant downside changes additional material impairment necessary uncertain tax positions using specialist uk us international tax transfer pricing refer note group financial statements knowledge evaluated challenged managements judgements group operates complex multinational tax environment respect estimates tax exposures contingencies order assess open tax transfer pricing matters uk overseas adequacy groups tax provisions includes obtaining tax authorities addition time time group enters evaluating certain third party tax opinions group obtained transactions complicated accounting tax consequences assess appropriateness assumptions used including respect judgement required assessing level provisions required steps taken advance proposed threepart transaction respect uncertain tax positions december group novartis ag recognised provisions uncertain tax provisions offset current understanding evaluating managements judgements considered tax assets included within current tax payable million status recent current tax authority audits enquiries million outturn previous claims judgemental positions taken tax returns current year estimates developments tax environment evidence obtained considered level provisioning acceptable context group financial statements taken whole however noted assumptions judgements required formulate provisions mean range possible outturns broad gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued tailored audit scope specific audit procedures central functions identifying areas focus tailored scope group consolidation areas significant judgement including audit ensure performed sufficient work able give taxation goodwill intangible assets treasury postretirement opinion group financial statements whole taking benefits litigation elimination unrealised intercompany account geographic structure group profit inventory directly led group audit team accounting processes controls industry taken together territories functions performed group operates audit work accounted consolidated revenue group financial statements consolidation consolidated profit tax considering reporting units considered component contribution audit evidence performing audit work identified reporting units view required divisional group levels including testing monitoring audit complete financial information due size controls disaggregated analytical review procedures risk characteristics specific audit procedures significant covers significant portion groups smaller lower risk balances transactions performed components directly included group audit reporting units give appropriate coverage material scope addition obtained audit evidence certain balances reporting units supported shared outofscope components procedures undertook financial service centres centres also included groups shared service centres encompassing bpos group audit scope none reporting units included bscs centralised infrastructure group audit scope individually contributed processes standardised consolidated revenue profit tax materiality work performed component auditors scope audit influenced application determined level involvement needed materiality set certain quantitative thresholds materiality audit work reporting units result eight overseas together qualitative considerations helped us components visited senior members group audit determine scope audit nature timing team including groups significant components extent audit procedures evaluate effect us visited least annually alongside belgium china misstatements individually group financial france germany italy addition five shared statements whole service centres supporting reporting components group audit based professional judgement determined materiality scope visited components group audit scope group financial statements whole follows site visit undertaken involvement included review component auditor work papers attendance certain component audit clearance meetings overall group materiality million million determined profit tax million adding back nonrecurring items including remeasurement charge shionogiviiv healthcare contingent consideration million major restructuring costs million legal costs including fine paid china million items income expense relating major acquisition disposal activity net million incremental costs change timing recognition us branded prescription drug fee million impairment intangible assets million rationale benchmark applied groups principal measure earnings comprises core results adds back statutory results number items income expenditure including detailed management uses measure believes eliminates volatility inherent oneoff items taken measure account determining materiality except adjusted profit tax add back amortisation intangible assets certain smaller noncore items view recurring items introduce volatility groups earnings materiality lower last year primarily due effect lower profitability agreed audit risk committee would report misstatements million million identified audit well misstatements amount view warranted reporting qualitative reasons going concern required reporting listing rules required review directors statement set relation going concern consistency information nothing report performed review companies act opinions noted directors statement directors concluded opinion appropriate prepare group financial statements information given strategic report directors using going concern basis accounting going concern report financial year group financial basis presumes group adequate resources remain statements prepared consistent group financial operation directors intend least statements one year date group financial statements signed part audit concluded directors use information given corporate governance statement going concern basis appropriate set pages respect internal control risk management systems share capital structures however future events conditions consistent group financial statements predicted statements guarantee groups ability continue going concern gsk annual report strategic report governance remuneration financial statements investor information isas uk ireland reporting information annual report exceptions materially inconsistent information audited group finanical statements report arising apparently materially incorrect based materially inconsistent knowledge group acquired responsibility course performing audit otherwise misleading statement given directors accordance provision c uk corporate governance exceptions code code consider annual report taken whole fair balanced understandable report arising provides information necessary members assess groups performance business model strategy responsibility materially inconsistent knowledge group acquired course performing audit section annual report required provision c code describing work exceptions audit risk committee appropriately address matters communicated us audit risk committee report arising responsibility adequacy information explanations received reasonableness significant accounting estimates made companies act required report directors opinion received information overall presentation group financial statements explanations require audit exceptions report arising responsibility primarily focus work areas assessing directors judgements available evidence forming directors remuneration judgements evaluating disclosures group companies act required report financial statements opinion certain disclosures directors remuneration specified law made exceptions test examine information using sampling report arising responsibility auditing techniques extent consider necessary provide reasonable basis us draw conclusions obtain corporate governance statement audit evidence testing effectiveness controls listing rules required review part substantive procedures combination corporate governance statement relating parent companys compliance provisions uk corporate addition read financial nonfinancial information governance code nothing report performed annual report identify material inconsistencies review audited group financial statements identify information apparently materially incorrect based materially companies act required report inconsistent knowledge acquired us course opinion corporate governance statement performing audit become aware apparent material prepared parent company exceptions report misstatements inconsistencies consider implications arising responsibility report responsibilities financial statements matters audit reported separately parent company financial responsibilities directors statements glaxosmithkline plc year ended explained fully directors statement december information directors responsibilities set directors responsible remuneration report described audited preparation group financial statements satisfied give true fair view company passed resolution accordance section companies act senior statutory auditors responsibility audit express opinion group name stated financial statements accordance applicable law isas uk ireland standards require us comply auditing practices boards ethical standards auditors pricewaterhousecoopers llp report including opinions prepared chartered accountants statutory auditors companys members body accordance london chapter part companies act february purpose giving opinions accept assume responsibility purpose person report shown whose hands may come save notes expressly agreed prior consent writing maintenance integrity glaxosmithkline plc audit financial statements involves website responsibility directors work carried audit involves obtaining evidence amounts auditors involve consideration disclosures group financial statements sufficient give matters accordingly auditors accept responsibility reasonable assurance group financial statements changes may occurred group financial free material misstatement whether caused fraud error statements since initially presented website includes assessment b l egislation united kingdom governing preparation whether accounting policies appropriate groups dissemination financial statements may differ circumstances consistently applied legislation jurisdictions adequately disclosed gsk annual report strategic report governance remuneration financial statements investor information financial statements consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating income operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december profit year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries deferred tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement lossesgains defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic report governance remuneration financial statements investor information consolidated balance sheet december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board february signed behalf sir christopher gent chairman gsk annual report strategic report governance remuneration financial statements investor information financial statements continued consolidated statement changes equity year ended december shareholders equity non share share retained controlling total capital premium earnings reserves total interests equity january profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive incomeexpense year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expenseincome year total comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report strategic report governance remuneration financial statements investor information consolidated cash flow statement year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal subsidiary interest associate decrease liquid investments interest received dividends associates joint ventures net cash outflowinflow investing activities cash flow financing activities proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation held treasury shares purchase noncontrolling interests increase longterm loans increase shortterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests financing cash flows net cash outflow financing activities decreaseincrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments decreaseincrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report strategic report governance remuneration financial statements investor information notes financial statements presentation financial statements implementation new accounting standards amendment ias offsetting financial assets financial description business liabilities issued december implemented glaxosmithkline major global healthcare group gsk january amendment provides additional engaged creation discovery development manufacture guidance financial assets financial liabilities may marketing pharmaceutical products including vaccines offset material impact current period overthecounter otc medicines healthrelated consumer products gsks principal pharmaceutical products include financial period medicines following therapeutic areas respiratory anti financial statements cover financial year january virals central nervous system cardiovascular urogenital december comparative figures financial metabolic antibacterials oncology emesis dermatology years january december rare diseases immunoinflammation vaccines hiv appropriate january december compliance applicable law ifrs parent company financial statements financial statements prepared accordance financial statements parent company glaxosmithkline companies act article ias regulation plc prepared accordance uk gaap uk international accounting standards ias international accounting presentation company balance sheet presented financial reporting standards ifrs related interpretations accounting policies given adopted european union financial statements also compliance ifrs accounting principles policies issued international accounting standards board consolidation composition financial statements consolidated financial statements include consolidated financial statements drawn sterling assets liabilities results cash flows functional currency glaxosmithkline plc accordance company subsidiaries including esop trusts ifrs accounting presentation financial statements comprise groups share results net assets associates joint ventures consolidated income statement groups share assets liabilities revenue expenses consolidated statement comprehensive income joint operations consolidated balance sheet financial statements entities consolidated made consolidated statement changes equity december year consolidated cash flow statement entities group power direct relevant activities affect returns group generally notes financial statements control financial operating policies accounted composition group subsidiaries group ability exercise joint list subsidiary associated undertakings control rights net assets entities entities opinion directors principally affected amount profit accounted joint ventures group net assets group given note principal ability exercise joint control arrangement rights group companies specified assets obligations specified liabilities arrangement arrangement accounted joint accounting principles policies operation group ability exercise significant financial statements prepared using historical influence entities accounted associates cost convention modified revaluation certain items results assets liabilities associates joint stated accounting policies going concern basis ventures incorporated consolidated financial financial statements prepared accordance statements using equity method accounting groups accounting policies approved board groups rights assets liabilities revenue expenses described note accounting principles policies joint operations included consolidated financial information application accounting policies statements accordance rights obligations including areas estimation judgement given note interests acquired entities consolidated date key accounting judgements estimates group acquires control interests sold deconsolidated preparation financial statements conformity date control ceases generally accepted accounting principles requires management make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date financial statements reported amounts revenues expenses reporting period actual results could differ estimates gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued revenue revenue recognised income statement goods transactions balances subsidiaries eliminated services supplied made available external customers profit tax taken sales subsidiaries orders received title risk loss passed products sold customers outside group customer reliable estimates made relevant deductions relevant proportion profits transactions joint ventures relevant obligations fulfilled joint operations associates also deferred products earnings process regarded complete sold third parties transactions noncontrolling interests recorded directly equity deferred tax relief unrealised turnover represents net invoice value deduction intragroup profit accounted extent discounts allowances given accruals estimated future considered recoverable rebates returns methodology assumptions used estimate rebates returns monitored adjusted regularly goodwill capitalised separate item case light contractual legal obligations historical trends subsidiaries part cost investment case past experience projected market conditions market joint ventures associates goodwill denominated conditions evaluated using wholesaler thirdparty currency operation acquired analyses market research data internally generated cost acquisition fair value information value added tax sales taxes excluded net assets acquired difference recognised directly revenue income statement group copromotes product counterparty business combinations records sale group records share revenue business combinations accounted using acquisition copromotion income within turnover nature copromotion accounting method identifiable assets liabilities contingent activities group records costs sales liabilities acquired measured fair value acquisition date pharmaceutical turnover includes copromotion revenue consideration transferred measured fair value million million million addition includes fair value contingent consideration initial eventbased milestone income excluding royalty income consideration transferred together noncontrolling arising development marketing collaborations groups interest exceeds fair value net assets liabilities compounds products parties recognised contingent liabilities acquired excess recorded goodwill turnover milestone income million included turnover costs acquisition charged income statement million period incurred royalty income recognised accruals basis accordance equity subsidiary acquired non terms relevant licensing agreements controlling interest recognised either fair value expenditure noncontrolling interests share net assets subsidiary expenditure recognised respect goods services casebycase basis changes groups ownership received supplied accordance contractual terms percentage subsidiaries accounted within equity provision made obligation exists future liability foreign currency translation respect past event amount obligation foreign currency transactions booked functional reliably estimated manufacturing startup costs currency group company exchange rate ruling validation achievement normal production expensed date transaction foreign currency monetary assets incurred advertising promotion expenditure charged liabilities retranslated functional currency rates income statement incurred shipment costs inter exchange ruling balance sheet date exchange differences company transfers charged cost sales distribution included income statement costs sales customers included selling general administrative expenditure consolidation assets liabilities including related goodwill overseas subsidiaries associates joint ventures restructuring costs recognised provided translated sterling rates exchange ruling balance appropriate respect direct expenditure business sheet date results cash flows overseas subsidiaries reorganisation plans sufficiently detailed associates joint ventures translated sterling using well advanced appropriate communication average rates exchange affected undertaken exchange adjustments arising opening net assets profits year retained overseas subsidiaries associates joint ventures translated sterling less exchange differences arising related foreign currency borrowings hedge groups net investment operations taken separate component equity translating sterling assets liabilities results cash flows overseas subsidiaries associates joint ventures reported currencies hyperinflationary economies adjustments made material reflect current price levels loss net monetary assets charged consolidated income statement gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued employee share plans incentives form shares provided employees research development share option share award schemes research development expenditure charged income statement period incurred development fair values options awards calculated expenditure capitalised criteria recognising grant dates using blackscholes option pricing model asset met usually regulatory filing made charged income statement relevant vesting periods major market approval considered highly probable property group provides finance esop trusts purchase company plant equipment used research development shares open market meet obligation provide shares capitalised depreciated accordance groups policy employees exercise options awards costs environmental expenditure running esop trusts charged income statement environmental expenditure related existing conditions resulting shares held esop trusts deducted past current operations current reserves transfer made reserves retained future benefit discernible charged income statement earnings vesting periods related share options group recognises liability sitebysite basis awards reflect ultimate proceeds receivable employees reliably estimated liability includes groups exercise portion total costs also portion potentially property plant equipment responsible parties costs probable property plant equipment ppe stated cost able satisfy respective shares cleanup obligation purchase construction less provisions depreciation recoveries reimbursements recorded assets impairment financing costs capitalised within cost virtually certain qualifying assets construction legal disputes depreciation calculated write cost less residual value provision made anticipated settlement costs legal ppe excluding freehold land using straightline basis disputes group outflow resources expected useful life residual values lives reviewed considered probable reliable estimate made appropriate adjusted annually normal expected likely outcome addition provision made legal useful lives major categories ppe expenses arising claims received disputes respect product liability claims related certain products freehold buildings years sufficient history claims made settlements leasehold land buildings lease term years enable management make reliable estimate provision plant machinery years required cover unasserted claims certain cases incurred equipment vehicles years reported ibnr actuarial technique used determine estimate disposal ppe cost related accumulated depreciation impairments removed financial group may become involved legal proceedings respect statements net amount less proceeds taken possible make reliable estimate income statement expected financial effect could result ultimate leases resolution proceedings cases appropriate disclosure cases would included provision leasing agreements transfer group substantially would made costs associated claims made group benefits risks ownership asset treated third parties charged income statement finance leases asset purchased outright incurred assets included ppe computer software capital elements leasing commitments shown obligations pensions postemployment benefits finance leases assets held finance leases costs providing pensions defined benefit schemes depreciated basis consistent similar owned assets calculated using projected unit credit method spread lease term shorter interest element lease rental period benefit expected derived included income statement leases operating employees services consistent advice qualified leases rental costs charged income statement actuaries pension obligations measured present value straightline basis lease term estimated future cash flows discounted rates reflecting goodwill yields high quality corporate bonds pension scheme assets measured fair value balance sheet date goodwill stated cost less impairments goodwill deemed indefinite useful life tested impairment costs postemployment liabilities calculated least annually similar way defined benefit pension schemes spread period benefit expected derived fair value interest acquired entitys assets employees services accordance advice liabilities contingent liabilities exceeds consideration paid qualified actuaries excess recognised immediately gain income statement actuarial gains losses effect changes actuarial assumptions recognised statement comprehensive income year arise groups contributions defined contribution plans charged income statement incurred gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued availableforsale investments liquid investments investments classified intangible assets availableforsale investments initially recorded fair intangible assets stated cost less provisions amortisation value plus transaction costs remeasured subsequent impairments reporting dates fair value unrealised gains losses licences patents knowhow marketing rights separately availableforsale investments recognised directly acquired acquired part business combination comprehensive income impairments arising significant amortised estimated useful lives generally exceeding prolonged decline fair value equity investment reduce years using straightline basis time carrying amount asset directly charged available use estimated useful lives determining income statement amortisation charge take account patent lives disposal impairment investments gains applicable well value obtained periods non losses deferred comprehensive income exclusivity asset lives reviewed appropriate reclassified income statement dividends equity adjusted annually contingent milestone payments recognised investments recognised income statement point contingent event becomes probable groups right receive payment established equity investments development costs incurred group associated recorded noncurrent assets unless expected acquired licences patents knowhow marketing rights sold within one year written income statement incurred unless criteria recognition internally generated intangible asset purchases sales equity investments accounted met usually regulatory filing made major trade date purchases sales availableforsale market approval considered highly probable investments accounted settlement date inventories acquired brands valued independently part fair value businesses acquired third parties brand inventories included financial statements lower value substantial long term brands cost including raw materials direct labour direct costs either contractual legal nature sold separately related production overheads net realisable value cost rest businesses acquired brands amortised generally determined first first basis prelaunch estimated useful lives years except inventory held asset high probability considered useful economic life indefinite regulatory approval product point provision made carrying value recoverable amount costs acquiring developing computer software provision reversed point high probability internal use internet sites external use capitalised regulatory approval determined intangible fixed assets software site supports trade receivables significant business system expenditure leads creation durable asset erp systems software amortised trade receivables carried original invoice amount less seven ten years computer software three provisions doubtful debts provisions made five years evidence risk nonpayment taking account ageing previous experience general economic conditions impairment noncurrent assets trade receivable determined uncollectable written carrying values noncurrent assets reviewed firstly provision available income impairment either standalone basis part larger statement cash generating unit indication assets might impaired additionally goodwill intangible assets subsequent recoveries amounts previously provided indefinite useful lives intangible assets yet credited income statement longterm receivables available use tested impairment annually provision discounted effect material impairment charged income statement year trade payables concerned trade payables initially recognised fair value held impairments goodwill reversed impairment losses amortised cost equates nominal value longterm noncurrent assets reversed payables discounted effect material change estimates used determine recoverable amounts cash cash equivalents extent revised recoverable amounts cash cash equivalents comprise cash hand current exceed carrying values would existed net balances banks similar institutions highly liquid depreciation amortisation impairments recognised investments maturities three months less investments associates joint ventures joint operations readily convertible known amounts cash investments associates joint ventures carried insignificant risk changes value consolidated balance sheet groups share net borrowings assets date acquisition postacquisition borrowings initially recorded amount proceeds retained profits losses together goodwill arising received net transaction costs borrowings subsequently acquisition group recognises rights assets carried amortised cost difference liabilities revenue expenses joint operations proceeds net transaction costs amount due redemption recognised charge income statement period relevant borrowing gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued key accounting judgements estimates taxation preparing financial statements management required current tax provided amounts expected paid make estimates assumptions affect amounts applying tax rates enacted substantively enacted assets liabilities revenue expenses reported financial balance sheet date statements actual amounts results could differ estimates following considered key accounting deferred tax provided full temporary differences arising judgements estimates made tax bases assets liabilities carrying amounts financial statements deferred tax assets turnover recognised extent probable future taxable revenue recognised title risk loss passed profits available temporary differences customer reliable estimates made relevant deductions utilised deferred tax provided temporary differences relevant obligations fulfilled arising investments subsidiaries associates joint earnings process regarded complete ventures except timing reversal temporary gross turnover reduced rebates discounts allowances difference controlled probable temporary product returns given expected given vary difference reverse foreseeable future deferred tax product arrangements buying groups arrangements provided using rates tax enacted substantively purchasing organisations dependent upon enacted balance sheet date submission claims time initial recognition derivative financial instruments hedging sale accruals made time sale estimated derivative financial instruments used manage exposure rebates discounts allowances payable returns made market risks principal derivative instruments used gsk based available market information historical experience foreign currency swaps interest rate swaps foreign exchange amounts estimated may fully reflect forward contracts options group hold issue final outcome amounts subject change dependent derivative financial instruments trading speculative upon amongst things types buying group purposes product sales mix derivative financial instruments classified heldfortrading level accrual reviewed adjusted regularly carried balance sheet fair value derivatives light contractual legal obligations historical trends past designated hedging instruments classified inception experience projected market conditions market conditions cash flow hedges net investment hedges fair value hedges evaluated using wholesaler thirdparty analyses changes fair value derivatives designated cash flow market research data internally generated information hedges recognised comprehensive income future events could cause assumptions extent hedges effective ineffective portions accruals based change could affect future recognised profit loss immediately amounts deferred results group comprehensive income reclassified income taxation statement hedged item affects profit loss current tax provided amounts expected paid net investment hedges accounted similar way deferred tax provided temporary differences cash flow hedges tax bases assets liabilities carrying amounts rates enacted substantively enacted changes fair value derivatives designated fair value balance sheet date hedges recorded income statement together changes fair value hedged asset liability deferred tax assets recognised extent probable future taxable profits available changes fair value derivative instruments temporary differences utilised based qualify hedge accounting recognised immediately managements assumptions relating amounts timing income statement future taxable profits factors affecting tax charge discounting future years set note taxation change time value money material balances groups effective tax rate would changed discounted current values using appropriate rates interest total tax charge year approximately million unwinding discounts recorded finance income group open tax issues number revenue finance expense authorities outflow funds believed probable reliable estimate outcome dispute made management provides best estimate liability estimates take account specific circumstances dispute relevant external advice inherently judgemental could change substantially time new facts emerge dispute progresses gsk continues believe made adequate provision liabilities likely arise open assessments open issues exist ultimate liability matters may vary amounts provided dependent upon outcome negotiations relevant tax authorities necessary litigation proceedings gsk annual report strategic report governance remuneration financial statements investor information key accounting judgements estimates business combinations contingent consideration included consideration continued payable business combination recorded fair value legal disputes date acquisition fair values generally based group provides anticipated settlement costs riskadjusted future cash flows discounted using appropriate outflow resources considered probable reliable interest rates fair values reviewed regular basis estimate may made likely outcome dispute least annually changes reflected income legal expenses arising claims group statement estimates take account specific circumstances december liability contingent consideration dispute relevant external advice inherently amounted million see note acquisitions judgmental could change substantially time new disposals amount million arose acquisition facts emerge dispute progresses details status former shionogiviiv healthcare joint venture various uncertainties involved significant unresolved disputes set note legal proceedings assumptions relating future cash flows discount rates based business forecasts therefore inherently companys directors taken legal advice judgemental future events could cause assumptions used established provisions taking account relevant projections change consequent adverse effect facts circumstances matter accordance future results group accounting requirements respect product liability claims related certain products sufficient history claims pensions postemployment benefits made settlements enable management make reliable costs providing pensions postemployment estimate provision required cover unasserted claims benefits charged income statement accordance group may become involved legal proceedings respect ias employee benefits period benefit possible make reliable estimate derived employees services costs assessed expected financial effect result ultimate basis assumptions selected management resolution proceedings cases appropriate assumptions include future earnings pension increases disclosure cases would included provision discount rates expected longterm rates return assets would made contingent liability quantified mortality rates disclosed note pensions december provisions legal disputes postemployment benefits surplus defined benefit amounted billion billion scheme arises potential surplus arise committed future contributions rights trustees ultimate liability legal claims may vary amounts prevent group obtaining refund surplus future provided dependent upon outcome litigation considered determining whether necessary restrict proceedings investigations possible settlement negotiations amount surplus recognised position could change time therefore assurance losses result outcome expected longterm rates return bonds determined legal proceedings exceed amount provisions based portfolio mix indexlinked government reported groups financial statements material amount corporate bonds equity risk premium added equities goodwill intangible asset impairments goodwill deemed indefinite life discount rates derived aa rated corporate bond yields amortised annual impairment tests cash generating except countries deep market corporate units goodwill allocated performed impairment bonds government bond yields used sensitivity tests based established market multiples riskadjusted analysis provided note pensions post future cash flows discounted using appropriate interest rates employment benefits reduction discount assumptions used impairment tests set rate would lead increase net pension deficit note goodwill approximately million increase annual pension cost approximately million selection different case valuations indicate sufficient headroom assumptions could affect future results group reasonably possible change key assumptions unlikely result impairment related goodwill impairment tests intangible assets undertaken events occur call question carrying values assets brands intangible assets yet available use amortised subject annual impairment tests valuations impairment tests based established market multiples riskadjusted future cash flows estimated useful life asset limited discounted using appropriate interest rates set note intangible assets assumptions relating future cash flows estimated useful lives discount rates based business forecasts therefore inherently judgemental future events could cause assumptions used impairment tests change consequent adverse effect future results group gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued new accounting requirements exchange rates following new amended accounting standards group uses average exchange rates prevailing issued iasb likely affect future annual reports period translate results cash flows overseas exception amendment ias impact subsidiaries joint ventures associated undertakings results financial position group currently sterling period end rates translate net assets assessed undertakings currencies influence translations relevant exchange rates amendment ias defined benefit plans employee contribution issued november implemented group january amendment average rates provides additional guidance treatment contributions us defined benefit plans employees third parties euro expected material impact results financial yen position group amendment ifrs consolidated financial statements period end rates ias investments associates joint ventures us issued september implemented group euro january amendment requires recognition yen full gain loss arising sale contribution business associate joint venture investors share gain loss assets constitute business sold contributed associate joint venture amendment ifrs joint arrangements issued may implemented group january amendment requires acquisition joint operation meets definition business accounted accordance ifrs business combinations ifrs revenue contracts customers issued may implemented group january standard provides single principlesbased approach recognition revenue contracts customers focuses identification performance obligations contract requires revenue recognised performance obligations satisfied ifrs financial instruments issued final form july implemented group january standard replace majority ias covers classification measurement derecognition financial assets financial liabilities impairment financial assets provides new hedge accounting model gsk annual report strategic report governance remuneration financial statements investor information segment information groups operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet individual members cet responsible geographic segment pharmaceuticals vaccines business viiv healthcare established products consumer healthcare business whole respectively established products segment created certain product reclassifications principally otc dermatology brands acquired stiefel business made pharmaceuticals vaccines segments consumer healthcare segment effect january comparative information restated accordingly addition segment turnover profit restated exclude divestments completed rd investment essential sustainability pharmaceutical businesses however segment reporting us europe emerging markets japan established products pharmaceuticals vaccines segment profits exclude allocations globally funded rd well central costs principally corporate functions unallocated manufacturing costs viiv healthcare consumer healthcare operating profits include rd costs groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis trading unallocated pharmaceuticals vaccines includes canada puerto rico australasia central vaccine tender sales contract manufacturing sales together costs vaccines rd central dermatology costs central manufacturing costs attributed segments pharmaceuticals rd reported separate segment corporate unallocated costs represent costs corporate functions working capital relation established products managed within pharmaceutical vaccines segments restated restated turnover segment pharmaceuticals vaccines usa europe emerging markets japan viiv healthcare established products trading unallocated pharmaceuticals pharmaceuticals vaccines turnover consumer healthcare turnover segment turnover excluding divestments divestments completed turnover including divestments restated restated pharmaceuticals vaccines turnover therapeutic area respiratory oncology emesis cardiovascular metabolic urology immunoinflammation pharmaceuticals established products vaccines viiv healthcare hiv gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued segment information continued restated restated consumer healthcare turnover category wellness oral care nutrition skin health us pharmaceuticals vaccines us element viiv healthcare established products made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers segment profit restated restated pharmaceuticals vaccines usa europe emerging markets japan viiv healthcare established products pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines segment profit consumer healthcare segment profit segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring charges legal charges expenses settlement litigation government investigations certain items related major acquisition disposal activity depreciation amortisation segment restated restated pharmaceuticals vaccines usa europe emerging markets japan viiv healthcare established products pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statements investor information segment information continued ppe intangible asset goodwill impairment segment restated restated pharmaceuticals vaccines usa europe emerging markets japan viiv healthcare established products pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines impairment consumer healthcare impairment segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment restated restated pharmaceuticals vaccines usa europe emerging markets japan viiv healthcare established products pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines impairment reversals consumer healthcare impairment reversals segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued segment information continued restated net assets segment pharmaceuticals vaccines usa europe emerging markets japan viiv healthcare established products pharmaceuticals rd trading unallocated assets pharmaceuticals vaccines net operating assets consumer healthcare net operating assets segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets us pharmaceuticals vaccines segment net liability position december principally result accrual million additional year us branded prescription drug fee trading unallocated pharmaceuticals consumer healthcare segments include assets centrally managed pharmaceutical vaccine consumer healthcare manufacturing operations depreciation totalling million million million recovered standard cost product charged businesses geographical information uk regarded groups country domicile turnover location customer uk usa rest world external turnover turnover location subsidiary uk usa rest world turnover including intersegment turnover uk usa rest world intersegment turnover uk usa rest world external turnover gsk annual report strategic report governance remuneration financial statements investor information segment information continued operating profit location uk usa rest world total operating profit net operating assets location uk usa rest world net operating assets noncurrent assets location uk usa rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables operating income impairment equity investments disposal equity investments disposal businesses assets gain settlement preexisting collaborations acquisition hgs gain acquisition shionogiviiv healthcare joint venture fair value remeasurements contingent consideration recognised business combinations fair value adjustments derivative financial instruments incomeexpense disposal businesses assets included gain disposal treximet included gain disposal lucozade ribena business suntory million gain sale worldwide intellectual property rights excluding certain emerging markets anticoagulant products business aspen group million fair value remeasurements contingent consideration recognised business combinations included million related contingent consideration payable acquisition former shionogiviiv healthcare joint venture fair value adjustments derivative financial instruments related foreign exchange forward contracts options taken hedge foreign currency movements sales purchases denominated foreign currencies see note financial instruments related disclosures included unrealised loss million arising loss position number forward exchange contracts entered following announcement proposed novartis transaction protect sterling value net us dollar proceeds due group completion transaction contracts remain loss position maturity loss partly offset gain expected sterling value proceeds received group result favourable exchange movements since inception forward contracts maturity contracts gain position gains partly offset losses sterling value proceeds received group result unfavourable exchange movements since inception forward contracts gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets goodwill net reversals net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements audit companys subsidiaries auditrelated assurance services including attestation sarbanesoxley act audit auditrelated services taxation compliance taxation advice assurance services services addition fees paid respect gsk pension schemes audit services gsk annual report strategic report governance remuneration financial statements investor information employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance charge pension postemployment costs includes credit million following restructuring us postretirement medical obligations charge includes credit million following change policy relating discretionary pension increases certain uk pension schemes introduction limit future pensionable pay increases uk schemes set note pensions postemployment benefits cost sharebased incentive plans analysed follows share value plan performance share plan share option plans plans average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued major restructuring costs major restructuring costs charged arriving operating profit include restructuring costs arising operational excellence programme initiated expanded major change programme initiated pharmaceuticals restructuring programme announced october following proposed novartis transaction announced total restructuring costs million incurred million incurred operational excellence programme million major change programme million pharmaceuticals restructuring programme million preintegration planning proposed novartis transaction following areas restructuring pharmaceuticals business north america emerging markets europe leading staff reductions sales force administration projects rationalise core business services simplify eliminate processes leading staff reduction support functions transformation manufacturing vaccines businesses deliver step change quality cost productivity rationalisation consumer healthcare business remaining costs million incurred restructuring programmes related integration stiefel hgs human genome sciences inc businesses analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs asset impairments nil million million noncash charges totalling million million million noncash items principally accelerated depreciation asset lives shortened result major restructuring programmes charges settled cash include termination leases site closure costs consultancy project management fees finance income interest income arising cash cash equivalents availableforsale investments loans receivables realised gains liquid investments fair value adjustments derivatives fair value profit loss derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias gsk annual report strategic report governance remuneration financial statements investor information finance expense interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value movements derivatives designated hedging instruments fair value adjustments hedged items fair value movements derivatives fair value profit loss unwinding discounts provisions movements amounts owed noncontrolling interests finance expense derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest expense arising derivatives fair value profit loss relates swap interest expense associates joint ventures december group held one significant associate aspen pharmacare holdings limited aspen summarised income statement information respect aspen set turnover profit taxation comprehensive income total comprehensive income results aspen included summarised income statement information represent estimated earnings aspen group year adjusted transactions gsk aspen amounts relating joint ventures principally arise interest one joint venture japan vaccine co ltd daiichi sankyo co ltd aggregated financial information respect associated undertakings joint ventures set associates share turnover share tax lossesprofits share comprehensive income share total comprehensive income joint ventures share turnover share tax losses share comprehensive income share total comprehensive income sales joint ventures associates gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued taxation taxation charge based profits year uk current taxation overseas current taxation total current taxation total deferred taxation recognition deferred tax asset tax losses expected used completion novartis transaction included net deferred tax credit deferred tax credit arose predominantly result non cash items related continuing restructuring supply chain intellectual property ownership following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year information reanalysed presented comparable basis reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits intercompany inventory profit impact sharebased payments benefit previously unrecognised losses permanent differences disposals acquisitions permanent differences reassessments prior year estimates disposal associate tax unremitted earnings deferred tax adjustments restructuring tax charge tax rate group operates countries tax rate differs uk tax rate taxable profits earned tax rates countries vary year year million deferred tax charge related unwinding deferred profit inventory arising reorganisations intellectual property ownership supply chain restructuring presented within differences overseas tax rates impact presented restructuring better reflects nature item group qualifies intellectual property incentives patent box regimes number countries permanent differences associated disposals acquisitions presented separately included benefit lower tax rates applied disposal lucozade ribena business recognition deferred tax asset tax losses expected used completion novartis transaction shown benefit previously unrecognised losses permanent differences include non tax deductible legal settlements reassessments prior year estimates include benefit million resolution number tax matters various countries future tax charges may affected factors acquisitions disposals restructurings location research development activity tax regime reforms agreements tax authorities tax items charged equity statement comprehensive income current taxation sharebased payments deferred taxation sharebased payments defined benefit plans exchange movements fair value movements cash flow hedges fair value movements availableforsale investments total creditcharge equity statement comprehensive income items charged statement comprehensive income except tax share based payments gsk annual report strategic report governance remuneration financial statements investor information taxation continued issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax resolution issues ongoing requirement gsk group continues believe made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate aggregate amount unremitted profits balance sheet date approximately billion billion uk legislation relating company distributions provides exemption tax repatriated profits subject certain exceptions provision deferred tax liabilities million million made respect withholding taxation would arise distribution profits certain overseas subsidiaries unprovided deferred tax unremitted earnings december estimated million million relates taxes payable repatriation levied overseas tax jurisdictions provision made grounds group able control timing reversal remaining temporary differences probable reverse foreseeable future movement deferred tax assets liabilities pensions share accelerated post option net capital contingent intragroup employment tax award temporary allowances intangibles consideration profit benefits losses schemes differences total january exchange adjustments chargecredit income statement chargecredit equity creditcharge statement comprehensive income december recognised tax losses comprises million nil capital losses million million trading losses net temporary differences include accrued expenses tax deduction available paid basis offsetting deferred tax assets liabilities appropriate within territories net deferred tax asset comprises deferred tax assets deferred tax liabilities unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses december deferred tax assets recognised probable future taxable profit available utilise losses gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paidpayable pence paidpayable pence first interim july july july second interim october october october third interim january january january fourth interim april april april total ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december gsk annual report strategic report governance remuneration financial statements investor information property plant equipment continued plant land equipment assets buildings vehicles construction total depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer fromto assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings december leased assets cost million million accumulated depreciation million million impairment million million net book value million million included plant equipment vehicles december leased assets cost million million accumulated depreciation million million impairment million million net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs disposal value use fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate relevant specific risks value use calculations impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately impairment losses charged cost sales million million rd million million sga million million include nil million arising major restructuring programmes reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales carrying value december assets impairments charged reversed year million million gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued goodwill cost january exchange adjustments additions business combinations note transfer assets held sale movements contingent consideration balances cost december net book value january net book value december gsk completed acquisition three business resulting recognition million goodwill majority goodwill related acquisition okairos ag goodwill allocated us europe emerging markets japan pharmaceuticals vaccines cash generating units impairment testing purposes benefits acquired business split cash generating units transfer assets held sale arose anticipated sale gsks oncology business part proposed threepart transaction novartis carrying value goodwill translated yearend exchange rates allocated following cash generated units cash generating unit us pharmaceuticals vaccines europe pharmaceuticals vaccines emerging markets pharmaceuticals vaccines established products pharmaceuticals vaccines consumer healthcare amounts allocated japan pharmaceuticals vaccines pharmaceuticals vaccines viiv healthcare significant relative total balance gsk annual report strategic report governance remuneration financial statements investor information goodwill continued recoverable amounts cash generating units assessed using either fair value less costs disposal model value use model value use calculated net present value projected riskadjusted posttax cash flows plus terminal value cash generating unit goodwill allocated initially posttax discount rate applied calculate net present value posttax cash flows discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific country currency risks fair value less costs disposal calculated using similar discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis higher fair value less costs disposal value use key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows years terminal growth rate discount rate terminal growth rate discount rate us pharmaceuticals vaccines pa europe pharmaceuticals vaccines pa emerging markets pharmaceuticals vaccines pa japan pharmaceuticals vaccines pa viiv healthcare pa established products pa pharmaceuticals vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets terminal growth rates used fair value less costs disposal calculations cash generating units reflect impact future generic competition take account new product launches case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill pharmaceutical vaccines cash generating units comprise collection smaller cash generating units including assets indefinite lives carrying value million million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs transfer tofrom assets held sale cost december exchange adjustments capitalised development costs capitalised borrowing costs additions reclassifications disposals asset writeoffs transfer assets held sale cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs amortisation december impairment january exchange adjustments impairment losses disposals asset writeoffs impairment december exchange adjustments impairment losses disposals asset writeoffs impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december net book value computer software includes million million internally generated costs charge impairments year includes impairments lovaza reflecting reassessment groups expectations likelihood potential generic competition galapagos nanjing meirui retigabine bms middle east carrying value december intangible assets impairments charged reversed year following impairments reversals million million gsk annual report strategic report governance remuneration financial statements investor information intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows dolutegravir benlysta flulavalfluviral selzentry arzerra okairos technology platform lovaza duac toctino others indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows panadol sensodyne stiefel trade name breathe right physiogel polident biotene corega poligrip others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate country currency specific risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals transfer investments distributions received movements lossprofit tax recognised consolidated income statement december investments joint ventures principally arise interest one joint venture japan vaccine co ltd daiichi sankyo co ltd joint venture holds development commercial rights existing preventative vaccines parent companies supply vaccines including human papillomavirus hpv vaccine rotavirus vaccine seasonal flu vaccine mumps vaccine diphtheria pertussis dtp vaccine measles rubella vaccine mrv japan group held one significant associate december aspen pharmacare holdings limited december group owned million shares aspen aspen listed johannesburg stock exchange africas largest pharmaceutical manufacturer major supplier branded generic pharmaceutical healthcare nutritional products southern african selected international markets investment market value million million although group holds less ownership interest voting control aspen group ability exercise significant influence shareholding nominated directors active participation aspen board directors summarised balance sheet information respect aspen set noncurrent assets current assets current liabilities noncurrent liabilities net assets summarised balance sheet information respect aspen based preliminary results information analyst forecasts available december adjustments transactions gsk aspen reconciliation summarised financial information carrying amount aspen investment set january profit year comprehensive income exchange adjustments dividends paid movements december interest associated undertaking goodwill carrying value december gsk annual report strategic report governance remuneration financial statements investor information investments january exchange adjustments additions net fair value movements impairment losses transfer investments associates joint ventures disposals december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets group holds number equity investments entities group entered research collaborations investments include listed investments million million decrease arising disposals fair value adjustments one companies group holds equity investment theravance inc theravance separated certain activities new biopharmaceutical company theravance biopharma inc theravance biopharma theravances ongoing activities focused maximising potential value respiratory assets partnered group including relvarbreo ellipta anoro ellipta theravance eligible receive royalty revenues relvarbreo ellipta anoro ellipta approved commercialised vilanterol monotherapy theravance biopharma carry preseparation activities theravance including development pipeline development assets partnered gsk marketing one approved medicine december group held common stock theravance common stock theravance biopharma accounted equity investments group power exert significant influence activities either company group theravance entered governance agreement related groups investment company terms governance agreement group right appoint director theravance board unless groups holding theravance exceeds must certain limited exceptions vote shares either support recommendation independent directors board proportion shareholders votes cast governance agreement theravance expires september creation theravance biopharma group theravance biopharma entered governance agreement similar terms agreement already place theravance expires agreement group right appoint director theravance biopharma board must certain limited exceptions vote shares either support recommendation independent directors board proportion shareholders votes cast net fair value movements include decreases value investments theravance million theravance biopharma million disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times impairment losses recorded recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement carrying value december investments impaired follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued inventories raw materials consumables work progress finished goods trade receivables trade receivables net provision bad doubtful debts prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million provision bad doubtful debts million provision million due state hospital authorities greece ireland italy portugal spain trade receivables also include million million due associates joint ventures receivables includes million million due associates joint ventures bad doubtful debt provision january exchange adjustments charge year subsequent recoveries amounts provided utilised december cash cash equivalents cash bank hand shortterm deposits assets held sale plant equipment vehicles goodwill intangibles inventory noncurrent assets transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell discussed note proposed novartis transaction gsk announced divest marketed oncology portfolio related rd activities rights akt inhibitors novartis ag subject approvals part threepart interconditional transaction assets associated oncology business divestment classified held sale included within assets held sale assets written fair value less costs sell million nil valuation methodology uses significant inputs based observable market data therefore valuation classified level fair value hierarchy gsk annual report strategic report governance remuneration financial statements investor information trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals contingent consideration accruals customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers including million million respect us pharmaceuticals vaccines accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group december payables include million respect maximum potential amount payable noncontrolling shareholders glaxosmithkline pharmaceuticals ltd groups pharmaceuticals subsidiary india amount estimate prior year settled march million see note trade payables include million million due associates joint ventures pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes net reduction postretirement healthcare schemes cost arises restructuring us postretirement medical obligations reduction uk pension scheme cost relates oneoff adjustments arising capping future pensionable salary increases change basis future discretionary pension increased rpi cpi certain legacy plans details see costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sections gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females usa mortality rates calculated using rp white collar table adjusted reflect recent experience rates projected using scale bbd allow future improvements life expectancy average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment group reviewed investment strategy uk plans asset allocation uk plans adjusted approximately return seeking assets liability matching assets target asset allocation us plans also updated return seeking assets liability matching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix return seeking assets generate future returns liability matching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property bank counterparty risk plan liabilities series future cash flows relatively long duration ias r basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group restructured us postretirement medical obligations active retired members age prior plan participants paid medical expenses excess covered medicare part part b well prescription drugs new arrangement participants instead eligible receive amount age health reimbursement account based years service subject inflation linked maximum per year already retired age also given option switch new arrangement impact change credit income statement million similar reduction postretirement obligation group changed policy towards granting discretionary pension increases smithkline beecham defined benefit schemes year group also introduced limit uk defined benefit schemes per year rate pensionable pay may increase group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service costcredit net interest creditcost gains settlements expenses remeasurements recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service costcredit net interest cost expenses remeasurements recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service creditcost net interest cost remeasurements recorded statement comprehensive income past service credit million includes amount million relation restructuring us postretirement medical obligations past service credit million reflects adjustments million related capping future pensionable salary increases change basis future discretionary pension increases rpi cpi certain legacy plans details see amounts included within past service costs include million nil million augmentation costs arising major restructuring programmes see note provisions gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets october uk schemes entered repurchase agreements gain exposure indexlinked gilts related loan also included within assets value million illion nil uk usa rest world group december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued uk usa rest world group december equities listed property unlisted corporate bonds listed government bonds listed insurance contracts assets fair value assets present value scheme obligations recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk usa rest world group group movements fair values assets assets january exchange adjustments interest income remeasurement employer contributions scheme participants contributions benefits paid settlements curtailments assets december exchange adjustments interest income expenses remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december uk defined benefit schemes include defined contribution sections account balances totalling million december million million group made special funding contributions uk pension schemes totalling million million million nil nil million us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation based funding agreements following valuation additional contributions expected million contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk usa rest world group group movements defined benefit obligations obligations january exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost movements remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments movements remeasurement scheme participants contributions benefits paid obligations december uk defined benefit schemes include defined contribution sections obligations totalling million december million million defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter us postretirement healthcare scheme amended see details impact change oneoff reduction postretirement obligation million december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued movement net defined benefit liability follows present fair value value net assets obligation total january exchange adjustments service cost past service cost interest incomecost settlements curtailments remeasurements return plan assets excluding amounts included interest gain change demographic assumptions loss change financial assumptions experience losses employers contributions scheme participants contributions benefits paid december exchange adjustments service cost past service cost interest incomecost remeasurements return plan assets excluding amounts included interest loss change demographic assumptions loss change financial assumptions experience losses employers contributions scheme participants contributions benefits paid expensesother movements december exchange adjustments service cost past service cost interest incomecost settlements curtailments remeasurements return plan assets excluding amounts included interest loss change demographic assumptions loss change financial assumptions experience losses employers contributions scheme participants contributions benefits paid expensesother movements december remeasurements included within postretirement benefits detailed gainloss change demographic assumptions lossgain change financial assumptions experience gains gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs revisions ias decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation gsk annual report strategic report governance remuneration financial statements investor information provisions legal major employee integration restructuring related manufacturing disputes programmes provisions reorganisation provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes major restructuring programmes group involved substantial number legal october group announced operational disputes including notification possible claims set excellence programme improve effectiveness note legal proceedings provisions legal productivity operations see note major restructuring disputes include amounts relating product liability principally costs substantially complete end relating avandia paxil antitrust principally relating addition group initiated major change wellbutrin xl lamictal government investigations principally restructuring programme focused opportunities simplify relating china settlement secdoj sfo related supply chain processes build groups capabilities investigations contract terminations self insurance environmental manufacturing rd restructure european cleanup property rental pharmaceuticals business charge year million million net new pharmaceuticals restructuring programme announced reversals estimated insurance recoveries included october rescale commercial operations global support million fine paid chinese government provisions functions relevant rdmanufacturing operations across product liability cases regarding paxil products pharmaceuticals commercial disputes various government investigations provisions staff severance payments made discount provisions decreased nil management made formal decision eliminate certain nil calculated using riskadjusted projected positions communicated groups cash flows riskfree rates return movement employees affected appropriate consultation procedures includes increase million nil arising completed appropriate change discount rate year provision made staff severance payments respect product liability claims related certain products made immediately sufficient history claims made settlements enable pension augmentations arising staff redundancies management make reliable estimate provision required million nil charged year cover unasserted claims ultimate liability matters transferred pension obligations provision shown may vary amounts provided dependent upon note pensions postemployment benefits outcome litigation proceedings investigations possible asset writedowns recognised impairments settlement negotiations property plant equipment note property plant nature groups business number equipment majority amounts provided expected matters may subject negotiation litigation utilised next two years many years litigation proceedings including various employee related provisions appeal procedures often take many years reach resolution employee related provisions include obligations certain outofcourt settlement discussions also often protracted medical benefits disabled employees spouses group potential settlement discussions number usa december provision benefits disputes amounts provided based amounted million million employee current assessment progress disputes benefits reflect variety provisions severance costs jubilee estimates billion amount provided december awards longservice benefits settled within one year december provisions expected nil million provision made included provisions insurance provisions legal disputes reimbursed third party insurers million million onerous property lease provisions amount included within receivables balances million million number note noncurrent assets note trade provisions including vehicle insurance regulatory matters receivables discussion legal issues see note legal proceedings gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued noncurrent liabilities accruals deferred income contingent consideration payables contingent consideration primarily relates acquisition share shionogiviiv healthcare joint venture previously held shionogi co ltd contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december nil nil financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant tax legal disputes group party set note taxation note legal proceedings net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings commercial paper bank loans overdrafts obligations finance leases us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange longterm borrowings us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange obligations finance leases net debt gsk annual report strategic report governance remuneration financial statements investor information net debt continued current assets weighted average interest rate current bank loans liquid investments classified availableforsale investments overdrafts december december included us treasury notes weighted average interest rate commercial paper government bonds effective interest rate liquid borrowings december investments december approximately longterm borrowings approximately liquid investment balances yearend gsk longterm borrowings billion december earning interest floating rates amount billion billion billion million million liquid investment balances falls due five years average effective preswap december earning interest fixed rates immaterial interest rate notes issue december million approximately approximately effective interest rate cash cash equivalents longterm borrowings repayable five years carry interest december approximately approximately effective rates repayment cash cash equivalents december earning dates range interest floating fixed rates amount million million respectively million million pledged assets group pledged investments us treasury notes gsks policy regarding credit quality cash cash par value million million million equivalents referred note financial instruments million security irrevocable letters credit related disclosures issued groups behalf respect groups self shortterm borrowings insurance activity provisions respect selfinsurance gsk billion billion us commercial paper included within provisions legal disputes programme billion billion issue discussed note provisions addition million december billion billion gsk also million assets included note billion five year committed mediumterm facilities noncurrent assets form part net debt billion billion day committed facilities pledged collateral future rental payments facilities put place september september operating lease arrangements entered human genome respectively undrawn december sciences inc prior acquisition group liquid investments cash cash equivalents shown table finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes share capital cancelled december issued employee share schemes share capital cancelled december issued employee share schemes december december december number shares issuable employee share schemes note number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million monthly purchases shares follows average share price excluding number shares commission stamp duty february may june total details substantial shareholdings refer gsk annual report strategic report governance remuneration financial statements investor information movements equity retained earnings reserves amounted million december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets december exchange movements overseas net assets december exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries deferred tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests actuarial gains defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive incomeexpense year gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued movements equity continued non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive expenseincome year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts forward contract noncontrolling interest december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts writedown shares held esop trusts december transferred income expense year disposals net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts forward contract noncontrolling interest december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report strategic report governance remuneration financial statements investor information related party transactions gsk held interest aspen pharmacare holdings limited december gsk distributed million million products aspens extensive distribution network december balance due gsk aspen million million balance payable gsk aspen million million addition million due gsk relating consideration sale worldwide intellectual property rights anticoagulant products business aspen group million december gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million million vaccine products joint venture december balance due gsk jvc million balance payable gsk jvc nil aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance income net finance expense depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital increasedecrease inventories decrease trade receivables decreaseincrease receivables increase trade payables increase payables decrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued reconciliation net cash flow movement net debt net debt beginning year decreaseincrease cash bank overdrafts decrease liquid investments net increase longterm loans net repayment shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year january reclass december exchange ifications cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper european us medium term notes debt due one year european us medium term notes net debt information significant changes net debt see note net debt gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given acquisitions acquisitions acquisition integration costs million arising proposed threepart interconditional transaction novartis ag discussed note proposed novartis transaction expensed million paid cash number acquisitions made previous years include contingent consideration payable future follows contingent consideration payable january additions remeasurement goodwill remeasurement income statement settlement december contingent consideration included within trade payables noncurrent liabilities includes contingent consideration million million payable acquisition former shionogiviiv healthcare joint venture remeasurements income statement include million million respect increase liability consideration expected paid number years vary line sales dolutegravir disposals year million received deferred consideration sale anticoagulent business completed million disposal associate gsk also made cash investments million associates business associates acquisitions joint disposals ventures total cash flows cash consideration paid transaction costs paid purchases businesses associates net cash proceeds disposals acquisitions gsk completed acquisition three businesses cash including okairos ag european based biopharmaceutical company focused development specific vaccine technology prophylactic therapeutic fields acquired may total purchase price businesses million included million cash acquired million contingent consideration fair value book value adjustments fair value net assets acquired intangibles property plant equipment inventory trade receivables assets including cash cash equivalents deferred tax provision trade payables goodwill cash consideration paid contingent consideration total consideration gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued acquisitions made beginning year estimated group turnover would increased approximately million year okairos fully integrated gsk business practicable separately identify impact group profit year acquisitions occurred shortly end year material impact group profit year goodwill arising acquisitions reflects potential business synergies value workforce acquired majority goodwill expected deductible income tax purposes results acquisitions reported within us europe emerging markets japan trading unallocated pharmaceuticals vaccines consumer healthcare operating segments transactions accounted using acquisition accounting method acquisition costs expensed totalled million disposals lucozade ribena december gsk completed sale lucozade ribena business including manufacturing site related inventory suntory beverage food ltd million cash recognised profit disposal operating income million lucozade ribena sales excluding retained markets totalled million year ending december cash consideration net assets sold inventory property plant equipment goodwill disposal costs profit disposal anticoagulant business december gsk completed sale anticoagulant business comprising worldwide intellectual property rights excluding china india pakistan fraxiparine arixtra together related inventory manufacturing site aspen group consideration million million received cash million deferred profit disposal million recognised operating income worldwide sales fraxiparine arixtra excluding retained markets million year ending december cash consideration cash consideration receivable net assets sold inventory property plant equipment intangible assets goodwill disposal costs total profit disposal deferral profit profit recognised year gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued investments associates joint ventures november gsk sold one third shareholding aspen representing issued share capital company million cash december gsk held aspen continued recognise investment aspen associate cash consideration net book value shares reclassification exchange comprehensive income reclassification fair value movements comprehensive income profit disposal business associates acquisitions joint disposals ventures total cash flows cash consideration paid cash cash equivalents acquired cash consideration paid net cash acquired total cash consideration payable net cash acquired contingent consideration cash consideration paid net cash acquired total cash proceeds receivable cash proceeds deferred net cash proceeds disposals acquisitions human genome sciences inc august gsk completed acquisition issued share capital human genome sciences inc hgs us based biopharmaceutical company focused development protein antibody drugs treatment immuno inflammation diseases cash goodwill arising acquisition business reflected potential business synergies realisation full value benlysta albiglutide darapladib assets simplifying optimising rd commercial manufacturing operations complete ownership assets goodwill recognised expected deductible income tax purposes results acquired business reported part us europe emerging markets japan trading unallocated costs operating segments transaction accounted using acquisition accounting method proforma turnover hgs business full year million gsk recorded turnover million hgs products hgs products fully integrated gsk business practicable separately identify impact acquisition group profit year gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued acquisition costs expensed arising acquisition amounted million fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax asset trade liabilities goodwill cash consideration paid gain settlement preexisting collaborations total consideration shionogiviiv healthcare joint venture october gsk acquired share shionogiviiv healthcare joint venture previously held shionogi co ltd assets acquired included investigational medicine dolutegravir early stage integrase inhibitor compounds development total consideration comprised equity stake viiv healthcare gsks existing investment joint venture contingent consideration payable cash future together deferred tax asset loss settlement preexisting relationships contingent consideration payable based percentage future sales performance compounds developed joint venture become marketed products total amount payable unlimited results acquired business reported part viiv healthcare transaction accounted using acquisition accounting method acquisition costs expensed arising acquisition amounted million fair value book value adjustments fair value net assets acquired intangible assets deferred tax provision negative goodwill consideration settled shares viiv healthcare contingent consideration deferred tax contingent consideration fair value investment joint venture converted subsidiary loss settlement preexisting relationships total consideration gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued acquisitions gsk completed two smaller acquisitions cash total cash consideration paid million included million cash acquired fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax provision trade liabilities goodwill cash consideration paid contingent consideration fair value equity investment converted subsidiary gain settlement preexisting relationships total consideration acquisitions made beginning year estimated group turnover would increased million year acquisitions fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisitions market participants none goodwill recognised expected deductible income tax purposes results acquisitions reported part europe pharma research development reportable operating segments group recognised settlement gain million result measuring fair value relationships existed prior acquisition date gain recognised operating income income statement acquisition costs expensed arising acquisitions totalled million investments associates joint ventures gsk made cash contributions million shionogiviiv healthcare joint venture prior acquisition subsidiary made cash investments million new joint venture group held share gsk also made cash investments million associates human shionogi total associates genome viiv joint business joint sciences venture acquisitions acquisitions ventures total cash flows cash consideration paid cash cash equivalents acquired cash consideration paid net cash acquired total cash consideration payable net cash acquired contingent consideration cash consideration paid net cash acquired gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued noncontrolling interests group one subgroup material noncontrolling interests viiv healthcare limited subsidiaries viiv healthcare group focused research development worldwide commercialisation hiv medicines summarised financial information respect viiv healthcare group set turnover lossprofit taxation comprehensive incomeexpense total comprehensive expenseincome total comprehensive expenseincome year attributable noncontrolling interests dividends paid noncontrolling interests noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets noncontrolling interests attributable subgroup net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities increasedecrease cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments loss taxation million profit taxation million stated charge million million remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line sales products contain dolutegravir acquisitions noncontrolling interests march gsk increased shareholding glaxosmithkline pharmaceuticals limited pharmaceuticals subsidiary india representing increase shares held price inr per share million carrying amount noncontrolling interests acquired million february gsk increased shareholding glaxosmithkline consumer healthcare ltd india million gsk annual report strategic report governance remuneration financial statements investor information commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted number commitments made licensing agreements including arrangement adaptimmune ltd new arrangements offset reduced commitments due prior year transactions including amendments agreement prosensa nv gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due future payments based deficit position scheme maximum million table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases disclosed million million provided commitments groups balance sheet commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued f inancial instruments related gsks longterm credit rating moodys investors service moodys stable outlook standard poors rate gsk disclosures stable outlook groups shortterm credit ratings gsk reports sterling pays dividends sterling profits p standard poors moodys respectively role corporate treasury monitor manage liquidity risk external internal funding requirements financial risks gsks policy borrow centrally order meet anticipated support strategic objectives gsk operates global funding requirements cash flow forecast funding basis primarily subsidiary companies manages requirements monitored tmg monthly basis capital ensure subsidiaries able operate going strategy diversify liquidity sources using range concerns optimise returns shareholders facilities maintain broad access funding markets appropriate balance debt equity treasury activities governed policies approved board directors december gsk billion borrowings recently july repayable within one year held billion cash cash equivalents liquid investments billion held treasury management group tmg meeting chaired centrally gsk also access shortterm finance chief financial officer takes place monthly basis review billion billion us commercial paper programme treasury activities members receive management information billion billion issue programme relating activities internal audit reviews treasury december gsk billion five year committed internal control environment regularly mediumterm facilities billion billion day gsk uses variety financial instruments finance committed facilities facilities put place operations derivative financial instruments manage september september respectively market risks operations derivatives principally undrawn december gsk considers level comprising forward foreign currency contracts foreign exchange committed facilities adequate given current liquidity options interest rate swaps used swap borrowings requirements liquid assets currencies required group purposes gsk billion european medium term note programme manage exposure financial risks changes foreign december billion notes issue exchange rates interest rates programme group also us shelf registration gsk hold issue derivatives speculative purposes statement december billion treasury policies specifically prohibit activity billion notes issue programme gsks transactions financial instruments undertaken manage longterm borrowings mature dates risks arising underlying business activities day gsk sweeps cash number global subsidiaries speculation central treasury accounts liquidity management purposes capital management market risk gsks financial strategy supports groups strategic priorities interest rate risk management regularly reviewed board gsk manages capital gsks objective minimise effective net interest cost structure group appropriate mix debt balance mix debt fixed floating interest rates equity gsks financial architecture designed ensure time policy interest rate risk management limits amount maximising returns sales four key priorities floating interest payments prescribed percentage sustainable sales growth operating leverage financial efficiency operating profit converting earnings cash free cash flow generated returned shareholders reinvested gsk used interest rate swaps redenominate one fixed business wherever returns look attractive rate bonds matured floating interest rates duration swaps matched duration principal gsks capital allocation decisions rigorously benchmarked instrument interest rate derivative instruments using cash flow return investment framework accounted fair value hedges relevant liability free cash flow conversion improved earnings excluding foreign exchange risk management aftertax legal charges legal settlements foreign currency transaction exposures arising internal however free cash flow lower billion external trade flows generally hedged groups compared billion reflected impact objective minimise exposure overseas operating strength sterling lower profits including impact subsidiaries transaction risk matching local currency income divestments consequence well billion paid local currency costs possible gsks internal trading increase shareholding groups indian pharmaceutical transactions matched centrally intercompany payment subsidiary acquisition terms managed reduce foreign currency risk foreign remaining gsks indonesian consumer healthcare currency cash flows hedged selectively business held third party gsks net debt increased management treasury tmg include hedges billion december billion foreign exchange risk arising acquisitions december disposals assets capital structure group consists net debt billion see note net debt shareholders equity billion see consolidated statement changes equity total capital including provided noncontrolling interests billion gsk annual report strategic report governance remuneration financial statements investor information f inancial instruments related gsk actively manages exposure credit risk reducing surplus disclosures continued cash balances wherever possible part treasury strategy regionalise cash management concentrate cash possible gsk manages cash surpluses borrowing centrally much possible gsk continued maintain requirements subsidiary companies centrally using forward conservative approach counterparty risk throughout period contracts hedge future repayments back originating table sets credit exposure counterparties currency order reduce foreign currency translation exposure rating liquid investments cash cash equivalents group seeks denominate borrowings currencies derivatives gross asset position derivative contract principal assets cash flows primarily denominated considered purpose table although isda us dollars euros sterling certain borrowings agreements amount risk net position swapped currencies required borrowings counterparty table e sets groups financial denominated swapped foreign currencies match assets liabilities offset basis investments group overseas assets may treated hedge billion bank balances deposits invested aa relevant assets forward contracts major currencies aa rated counterparties december significantly also used reduce exposure groups investment lower equivalent december result overseas assets see net investment hedges section note disposal proceeds received end december details tmg reviews ratio borrowings compared last year significantly higher amount bank assets major currencies monthly balances deposits held aa rated counterparties credit risk result gsks increased bank balances deposits held group considers maximum credit risk december deutsche bank result introducing countries million december million european cash pool downgraded aa total groups financial assets exception million cash held baabbb rated counterparties investments comprising equity investments bear includes bank balances deposits hdfc bank state bank equity risk rather credit risk see details india halk bank emirates bank counterparties groups total financial assets december gsks used either local cash management purposes local greatest concentration credit risk billion investment purposes gsk sole shareholder billion hsbc aaaa million held babb rated counterparty relates treasuryrelated credit risk islandsbanki used cash management purposes gsk sets global counterparty limits gsks banking iceland million cash held babb rated investment counterparties based longterm credit ratings counterparty relates gsks bank balances deposits held moodys standard poors corporate treasurys usage banque marocaine du commerce extrieur limits monitored daily corporate compliance officer cco operates independently corporate treasury breach limits would reported cfo immediately cco also monitors credit rating counterparties changes ratings occur notifies corporate treasury changes made investment levels authority limits appropriate addition relationship banks credit ratings reviewed regularly report presented annually tmg approval aaaa aaaa aa aa aabaabbb baabbb babb babb total unrated bank balances deposits us treasury treasury repo money market funds government securities rd party financial derivatives total aaaa aaaa aa aa aabaabbb baabbb babb babb total unrated bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit ratings tables assigned moodys standard poors respectively opinion two rating agencies differ gsk assigns lower rating two counterparty local rating agency data source available ratings converted global ratings equivalent moodys standard poors using published conversion tables gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued f inancial instruments related following methods assumptions used estimate disclosures continued fair values cash cash equivalents approximates carrying amount gsks centrally managed cash reserves amounted billion december available within months excludes liquid investments based quoted market prices billion centrally managed cash held viiv healthcare calculated based observable inputs case marketable owned subsidiary group invested centrally securities based principal amounts case non managed liquid assets bank deposits aaaaaa rated us marketable securities short repricing periods treasury treasury repo money market funds bear investments equity investments traded active credit exposure us government aaaaa rated market determined reference relevant stock exchange wholesale retail credit risk quoted bid price equity investments determined outside usa customer accounts reference current market value similar instruments groups trade receivables balance reference discounted cash flows underlying net assets usa line pharmaceutical companies group sells products small number wholesalers shortterm loans overdrafts commercial paper addition hospitals pharmacies physicians groups approximates carrying amount short sales three largest wholesalers amount approximately maturity instruments turnover us pharmaceuticals vaccines longterm loans based quoted market prices case segment us elements viiv healthcare european us medium term notes fixed rate established products segments december group borrowings level fair value measurement approximates trade receivables due three wholesalers totalling carrying amount case floating rate bank loans million million group exposed loans concentration credit risk respect wholesalers one encounters financial difficulty could contingent consideration business acquisitions materially adversely affect groups financial results january based present values expected future cash flows groups credit risk monitoring activities relating wholesalers include review quarterly financial information interest rate swaps foreign exchange forward contracts standard poors credit ratings development gsk internal options based present value contractual cash flows risk ratings establishment periodic review credit limits option valuation models using market sourced data exchange however group believes credit risk rates interest rates balance sheet date provision required excess normal provision bad receivables payables approximates carrying doubtful debts see note trade receivables amount fair value financial assets liabilities companyowned life insurance policies based cash table presents carrying amounts surrender value fair values groups financial assets liabilities december december lease obligations approximates carrying amount fair values financial assets liabilities included fair value investments gsk shares price would received sell asset paid transfer december employee share ownership plan liability orderly transaction market participants esop trusts held gsk shares carrying value measurement date million million fair value million million based quoted market price shares represent purchases esop trusts satisfy future exercises options awards employee incentive schemes treasury shares fair value million transferred uk esop trust satisfy future awards shareholder approved performance share plan see note employee share schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued carrying fair carrying fair value value value value notes cash cash equivalents e availableforsale investments liquid investments government bonds total liquid investments investments loans receivables trade receivables certain noncurrent assets scope ias b financial assets fair value profit loss noncurrent assets scope ias ab derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts e commercial paper total borrowings excluding obligations finance leases f obligations finance leases total borrowings trade payables provisions certain noncurrent liabilities scope ias c financial liabilities fair value profit loss trade payables provisions certain noncurrent liabilities scope ias ac derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities reconciled relevant notes gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies trade payables noncurrent liabilities classified level comprise contingent consideration business acquisitions level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss trade payables noncurrent liabilities derivatives designated fair value profit loss derivatives classified held trading ias level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss trade payables noncurrent liabilities derivatives designated fair value profit loss derivatives classified held trading ias movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income contingent consideration liabilities businesses acquired year payment contingent consideration liabilities additions disposals transfers level exchange december net losses million million attributable level financial instruments held end year reported operating income million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture net gains nil million reported selling general administration net gains attributable level equity investments reported comprehensive income fair value movements availableforsale investments included million nil respect equity investments held end year gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued net liability position million million respect financial instruments measured using level valuation methods december includes million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line sales products contain dolutegravir regulatory approval product obtained usa canada european union table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuation liability increasedecrease financial liability lossgain income statement change key inputs increase sales forecasts decrease sales forecasts increase market interest rates decrease market interest rates b trade receivables noncurrent assets scope ias following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies nonfinancial instruments includes tax receivables pension surplus balances prepayments outside scope ias fair value non fair value non loans financial financial loans financial financial profit loss receivables instruments instruments total profit loss receivables instruments instruments total trade receivables note noncurrent assets note following table shows age financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days amounts past due greater days provision bad doubtful debts made total million million balance million million relates receivables due state hospital authorities greece ireland italy portugal spain total receivables due state hospital authorities countries current past due net provisions million million c trade payables provisions noncurrent liabilities scope ias following table reconciles financial instruments within trade payables provisions noncurrent liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities nonfinancial instruments includes payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ias fair value non fair value non financial financial financial financial profit loss liabilities instruments instruments total profit loss liabilities instruments instruments total trade payables note provisions note noncurrent liabilities note gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued derivative financial instruments hedging programmes following table sets fair values derivatives held gsk fair value fair value assets liabilities assets liabilities fair value hedges interest rate swaps principal amount nil million net investment hedges foreign exchange contracts principal amount million million cash flow hedges foreign exchange contracts principal amount million million derivatives designated fair value profit loss foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading ias total derivative instruments analysed current noncurrent total foreign exchange contracts classified held trading ias principal amount foreign exchange contracts absolute total outstanding positions balance sheet date groups foreign exchange contracts periods months less december group held outstanding foreign exchange contracts net liability fair value million million asset less million liability december fair value million net liability million asset less million liability following announcement proposed novartis transaction gsk entered number forward exchange contracts protect sterling value net us dollar proceeds due group completion transaction december contracts loss position resulted liability million recognition unrealised loss year million contracts remain loss position maturity loss partly offset gain expected sterling value proceeds received group result favourable exchange movements since inception forward contracts maturity contracts gain position gains partly offset losses sterling value proceeds received group result unfavourable exchange movements since inception forward contracts rest increase liability due additional hedging intercompany loans deposits external debt legal provisions designated accounting hedges fair value movements taken income statement period offset exchange gains losses related intercompany lending borrowing external debt legal provisions fair value hedges group designated series interest rate swaps fair value hedge risk hedged variability fair value bond arising interest rate fluctuations gains losses fair value hedges disclosed note finance expense bond swaps matured april carrying value bonds designated fair value hedging relationship million net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro japanese yen foreign operations shown table carrying value bonds designated hedging relationship includes million million designated hedging instrument net investment hedge relationship cash flow hedges group continued entering forward foreign exchange contracts designated cash flow hedges foreign exchange exposure arising euro us dollar denominated coupon payments relating groups european us medium term notes continuation initial hedging put place addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued year disclosed note hedging transactions nature carried balance reclassified finance costs life bonds gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued e offsetting financial assets liabilities following tables set financial assets financial liabilities subject offsetting enforceable master netting arrangements similar agreements amounts set financial assets liabilities groups balance sheet set trade receivables trade payables derivative financial assets derivative financial liabilities amounts offset balance sheet could offset certain circumstances also set gross net financial gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilities bank loans overdrafts gross net financial gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilities bank loans overdrafts gross financial assets liabilities set balance sheet primarily relate cash pooling arrangements banks amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing group longer holds interest rate swaps designated fair value hedges convert fixed rate debt floating million fixed rate debt maturity less one year hedged manner g sensitivity analysis foreign exchange interest rate sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations december financial instruments affected market risk include cash cash equivalents borrowings trade receivables payables derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes foreign exchange interest rates foreign exchange sensitivity table shows indicative basis groups sensitivity foreign exchange rates us dollar euro yen financial instruments three currencies major foreign currencies gsks financial instruments denominated gsk considered movements currencies concluded cent yen movement rates sterling reasonable analysis financial instruments considered sensitive foreign exchange rates functional currency entity holds obligations finance leases intercompany loans fully hedged maturity certain nonderivative financial instruments net debt excluded present material exposure foreign exchange sensitivity group assets liabilities financial instruments included calculation us dollar denominated financial instruments movement income statement table relates primarily hedges foreign exchange risk acquisitions disposals cash cash equivalents intercompany loans deposits intercompany trading balances hedging instruments legal provisions trade receivables payables denominated functional currency entity holds impacted spot rate changes whilst hedging instruments provide economic hedges related remeasurement legal provisions included calculation increasedecrease increase income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increasedecrease income million million nil million us dollar euro yen exchange rates respectively decrease income million million million gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued movements equity table relate hedging instruments foreign exchange derivatives external debt designated net investment hedge hedge group assets denominated euro yen cash flow hedges increasedecrease decrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increasedecrease equity million million million us dollar euro yen exchange rates respectively nil million million table presents groups sensitivity foreign exchange rates based composition net debt shown note adjusting effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would following impact net debt million million million us dollar euro yen exchange rates respectively million million million interest rate sensitivity table shows indicative basis groups sensitivity interest rates floating rate sterling us dollar euro financial instruments issued debt bank borrowings cash cash equivalents liquid investments gsk considered movements interest rates last three years concluded basis points increase reasonable benchmark debt bank borrowings maturity less one year floating rate calculation interest rate movements derivative financial instruments designated fair value hedges deemed immaterial effect group income statement due compensating amounts carrying value debt hedges hedged bond matured basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates interest rates could decreased currently less maximum increasedecrease income would therefore limited million million million sterling us dollar euro interest rates respectively million nil million decrease interest income due lower levels cash balance sheet date less euro net investment hedging activity foreign exchange forward contracts h contractual cash flows nonderivative financial liabilities derivative instruments following tables provides analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis impact interest rate swaps excluded purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december contractual cash flows respect operating lease vacant space provisions excluded table included commitments noncancellable operating leases table note commitments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued contractual cash flows nonderivative financial liabilities derivative instruments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows increase contractual cash flows nonderivative financial liabilities billion year results principally increase billion forecast future cash flows respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purposes table though practice group uses standard settlement arrangements reduce liquidity requirements instruments amounts receivable payable less one year increased compared december due higher levels hedging intercompany loans hedging acquisitions disposals denominated foreign currency external debt reflected increased principal amounts shown table contractual cash flows derivative instruments due less one year receivables payables receivables payables gross contractual cash flows due less one year employee share schemes group operates share option schemes whereby options granted employees acquire shares ads glaxosmithkline plc grant price savingsrelated share option schemes share award schemes addition gsk operates performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period granting restricted share awards replaced granting options employees cost scheme readily equates potential gain made employee grants share option schemes normally exercisable three ten years date grant grants restricted shares share awards normally exercisable end three year vestingperformance period grants savingsrelated share option schemes normally exercisable three years saving grants share option schemes awards performance share plan normally granted employees acquire shares ads glaxosmithkline plc circumstances settled cash options share option schemes granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant option pricing purposes valuing options arrive share based payment charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives savingsrelated share options share award schemes years years years weighted average share price grants year shares plans dividends reinvested gsk annual report strategic report governance remuneration financial statements investor information employee share schemes continued volatility determined based three five year share price history appropriate fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value january options granted options exercised options lapsed december options granted options exercised options lapsed december options granted options exercised options lapsed december range exercise prices options outstanding year end weighted average market price exercise weighted average remaining contractual life years years years options outstanding share option share option savingsrelated december schemes shares schemes ads share option schemes weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options normally become exercisable three years date grant may certain circumstances vest earlier set within various scheme rules change effective exercise price outstanding options year options exercisable share option share option savingsrelated schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december december december gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted directors members cet performance conditions based four equally weighted measures three year performance period first measure based achievement adjusted free cash flow targets second measure based relative tsr performance comparator group remaining two measures based business specific performance measures business diversification rd new product performance details calculation measures see remuneration report pages awards granted onwards performance conditions based three equally weighted measures three year performance period adjusted free cashflow tsr rd new product performance awards made eligible employees performance conditions based gsks eps growth increase uk retail prices index three year measurement period adjusted free cashflow addition businesses element award based strategic operational business measure three year measurement period specific employees business area fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted dividends reinvested awards exercised awards cancelled december awards granted dividends reinvested awards exercised awards cancelled december awards granted dividends reinvested awards exercised awards cancelled december share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december gsk annual report strategic report governance remuneration financial statements investor information employee share schemes continued employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions treasury shares fair value million transferred uk esop trust satisfy future awards shareholder approved performance share plan costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value proposed novartis transaction april gsk announced threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses part proposed transaction gsk novartis create new consumer healthcare business gsk majority control equity interest addition gsk acquire novartis global vaccines business excluding influenza vaccines initial cash consideration billion subsequent potential milestone payments billion ongoing royalties gsk also divest marketed oncology portfolio related rd activities rights akt inhibitors also grant commercialisation partner rights future oncology products novartis aggregate cash consideration billion terms transaction billion purchase price may returned novartis certain conditions relating combid trial met following positive outcome study announced february gsk believes conditions satisfied transaction expected completed week commencing march gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued principal group companies following represent principal subsidiaries associates glaxosmithkline group december details given principal country operation location headquarters business sector business activities equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline mercury limited ph h brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc phch f brentford smithkline beecham limited phch e h p r brentford wellcome limited phch h brentford glaxo group limited ph h brentford glaxo operations uk limited ph p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford setfirst limited phch h brentford glaxosmithkline trading services limited iv ph e brentford viiv healthcare limited ph h brentford viiv healthcare uk limited ph austria vienna glaxosmithkline pharma gmbh ph belgium wavre glaxosmithkline pharmaceuticals sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxosmithkline sante grand public sas ch e marly le roi viiv healthcare sas ph st amand les eaux glaxosmithkline biologicals sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch munich glaxosmithkline gmbh co kg ph h greece athens glaxosmithkline aebe phch italy verona glaxosmithkline spa ph milan glaxosmithkline consumer healthcare spa ch netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline far east bv phch h poland poznan gsk services spz oo ph republic carrigaline smithkline beecham cork limited ph p r ireland dublin glaxosmithkline consumer healthcare ireland limited ch dublin glaxosmithkline ireland limited ph dungarvan stafford miller ireland limited ch p dungarvan glaxosmithkline dungarvan limited ch p sligo stiefel laboratories ireland limited ph p romania brasov europharm holding sa phch russian moscow glaxosmithkline trading zao ph federation spain madrid glaxosmithkline sa ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa research triangle park stiefel laboratories inc ph h p marietta corixa corporation ph p philadelphia glaxosmithkline llc phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch pittsburgh block drug company inc ch h wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc phch f research triangle park viiv healthcare company ph rockville human genome sciences inc ph p gsk annual report strategic report governance remuneration financial statements investor information principal group companies continued americas location subsidiary sector activity canada mississauga glaxosmithkline inc ph p mississauga glaxosmithkline consumer healthcare inc ch laval id biomedical corporation quebec ph e p r mexico mexico city glaxosmithkline mexico sa de cv phch e p asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h r hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd ch e p india mumbai glaxosmithkline pharmaceuticals limited ph p gurgaon glaxosmithkline consumer healthcare limited ch e p r malaysia selangor glaxosmithkline consumer healthcare sdn bhd ch pakistan karachi glaxosmithkline pakistan limited phch e p r philippines makati glaxosmithkline philippines inc phch e singapore singapore glaxo wellcome manufacturing pte ltd ph e p r singapore glaxosmithkline pte ltd phch e south korea seoul glaxosmithkline korea limited ph ch r thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p r brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch venezuela caracas glaxosmithkline venezuela ca phch middle east africa nigeria lagos glaxosmithkline consumer nigeria plc ii phch e p saudi arabia jeddah glaxo saudi arabia limited ph p south africa johannesburg glaxosmithkline south africa pty limited phch e p turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch middle east africa location associate sector activity south africa johannesburg aspen pharmacare holdings limited iii phch p r e xempt provisions section companies amendment act ireland addition subsidiary companies scheduled table stiefel distributors ireland limited smithkline beecham manufacturing limited glaxosmithkline consumer healthcare investments ireland limited glaxosmithkline consumer healthcare investments ireland glaxosmithkline investments ireland limited glaxosmithkline consumer healthcare ireland ip limited also exempt provisions consolidated group financial statements ii c onsolidated subsidiary accordance section companies act grounds dominant influence iii e quity accounted grounds significant influence iv ncorporated ireland directly held wholly owned subsidiary glaxosmithkline plc key business sector ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service subsidiaries associates listed principally affect figures groups financial statements full details group subsidiaries associates attached companys annual return filed uk registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings december anchen notified group filed anda jalyn paragraph iv certification alleging group involved significant legal administrative patent invalid unenforceable infringed jalyn proceedings principally product liability intellectual property combination dutasteride tamsulosin covered tax antitrust governmental investigations well related three patents cover avodart subsequently group private litigation group makes provision proceedings received similar notices impax laboratories inc impax regular basis summarised note accounting principles watson challenging one patents covering jalyn policies note provisions group may become involved significant legal proceedings respect group filed suit anchen banner impax mylan possible make reliable estimate expected roxane watson united states district court financial effect could result ultimate resolution district delaware infringement avodart jalyn proceedings cases appropriate disclosures patents applicable cases consolidated trial cases would included provision would made august group filed separate suit apotex court infringement patent case respect legal proceedings described consolidated original case provision made group generic defendants may court ordered unable make reliable estimate expected financial apotex case would stayed pending entry judgment effect stage group believe information banner et al case apotex subsequently agreed bound amount sought plaintiffs known would outcome consolidated cases january meaningful respect legal proceedings due group anchen settled litigation terms would number factors including limited stage allow anchen enter market jalyn fourth quarter proceedings entitlement parties appeal decision earlier certain circumstances group previously clarity theories liability damages governing law settled earlier patent challenge avodart teva intellectual property claims include challenges validity pharmaceuticals teva terms allow teva launch enforceability groups patents various products generic dutasteride product fourth quarter earlier processes well assertions noninfringement certain circumstances tevas generic dutasteride product patents loss cases could result loss patent approved fda december protection product issue consequences loss could significant decrease sales product trial consolidated case generic defendants could materially affect future results operations group held january august district court upheld validity patent banner impax mylan legal expenses incurred provisions related legal claims roxane watson appealed decision favour group charged selling general administration costs provisions united states court appeals federal circuit made taking appropriate legal specialist august february federal circuit advice outflow resources considered probable entered decision favour group affirming decision reliable estimate made likely outcome district court concluding matter dispute certain product liability claims group make benlysta provision sufficient history claims made settlements enable management make reliable estimate human genome sciences inc hgs group company holds provision required cover unasserted claims december european patent covering countries including uk groups aggregate provision legal disputes covers antibodies bind blys defined functional terms including tax matters described note taxation eli lilly company eli lilly previously challenged billion ultimate liability legal claims may vary validity patent patent upheld amounts provided dependent upon outcome litigation european patent office uk courts validity proceedings investigations possible settlement negotiations challenges concluded groups position could change time therefore eli lilly also requested declaration supplementary assurance losses result protection certificate spc filed hgs extend term outcome legal proceedings exceed material patent five years based upon eli lillys future marketing amount amount provisions reported groups authorisation antiblys antibody invalid financial statements happen could material uk high court denied lillys motion july october adverse impact results operations group eli lilly announced ceasing development reporting period judgments incurred antiblys antibody hgs applied appeal dismissed settlements entered significant matters november eli lilly consented appeal described courts decision thus ending litigation intellectual property epzicomtrizivirkivexa avodartjalyn november groups affiliate viiv healthcare november banner pharmacaps inc banner notified received notice teva pharmaceuticals usa inc teva group filed abbreviated new drug application filed anda paragraph iv certification epzicom anda market generic version avodart dutasteride combination lamivudine abacavir certification usa banners notification contained paragraph iv certification challenged patent covering hemisulfate salt abacavir alleging two patents expiring one patent expiring expires viiv healthcare sue teva patent covering compound dutasteride patent june viiv healthcare received notice teva invalid infringed banners proposed generic dutasteride amended anda epzicom contain paragraph iv product group subsequently received similar notices certification two additional patents listed orange book anchen pharmaceuticals anchen apotex apotex roxane alleging patents invalid unenforceable infringed laboratories roxane watson laboratories inc watson patents challenged new certification relate method mylan pharmaceuticals inc mylan variously treating hiv using combination expiring certain challenging either patent three patents crystal form lamivudine expiring august viiv healthcare filed suit teva combination patent united states district court district delaware gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued well challenging validity underlying patents teva challenging spcs basis invalid may viiv healthcare received notice lupin ltd due failure comply requirements article lupin filed anda containing paragraph iv certification regulation ec spc regulation tevas trizivir triple combination lamivudine abacavir article contention cases pending germany zidovudine alleging three patents listed orange oral hearing set may france oral book trizivir invalid unenforceable infringed hearing set december final hearing patents relate method treating hiv using triple date yet set italy combination expiring hemisulfate salt abacavir expiring certain crystal form lamivudine november viiv healthcare commenced action expiring june viiv healthcare filed suit uk teva declaration tevas article lupin patent covering triple combination contention concerning kivexa spc incorrect interim united states district court district delaware hearing scheduled march determine whether district court consolidated case relating epzicom questions regarding spc regulation referred case relating trizivir court justice european union december united states district court lexiva district delaware upheld validity us patent april ranbaxy laboratories limited ranbaxy expiry date march covers combination notified viiv healthcare filed paragraph iv certification lamivudine abacavir epzicom triple combination alleging patent claiming polymorphic form fosamprenavir lamivudine abacavir zidovudine trizivir separate calcium active ingredient lexiva invalid infringed component decision judge ruled lupin generic patent expires viiv healthcare sue version trizivir infringe patent lupin subsequently patent launched generic version trizivir teva earlier stipulated july mylan pharmaceuticals inc mylan notified generic version epzicom would infringe patent viiv healthcare filed anda lexiva district court enjoined teva launching generic version paragraph iv certification asserting patents claiming epzicom expiration patent parties appealed active ingredient expiring ii polymorphic form judgments february united states court active ingredient expiring invalid unenforceable appeals federal circuit affirmed decision infringed mylan second generic company file district court anda lexiva first generic company challenge february viiv healthcare received notice lupin basic compound patent active ingredient august filed anda containing paragraph iv certification viiv healthcare licensor vertex pharmaceuticals epzicom alleging three patents listed orange incorporated filed patent infringement suit mylan book epzicom either invalid unenforceable infringed patent claiming active ingredient patent claiming viiv healthcare filed suit lupin march alleging polymorph united states district court district infringement patent covering combination delaware may parties settled case lamivudine abacavir patent covering hemisulfate terms confidential salt abacavir trial date set april october ranbaxy filed petition inter partes june apotex filed petition requesting inter partes review ipr alleging patent claiming active ingredient review ipr combination patent covering epzicom lexiva invalid march uspto granted trizivir united states patent trademark office uspto ranbaxys petition ipr settled october terms granted petition december initiates ipr confidential patent uspto january teva filed december lupin limited filed petition petition uspto join proceedings uspto ipr alleging compound patent covering teva canada apotex challenged patents active ingredient lexiva invalid uspto yet kivexa lamivudineabacavir listed canadian patent ruled whether petition ipr granted register viiv healthcare filed suit infringement product liability party patent covering combination lamivudine preclinical clinical trials conducted abacavir patent covering hemisulfate salt abacavir development potential products determine safety ruling hemisulfate salt patent improperly listed efficacy products use humans following approval resulted delisting patent canadian patent regulatory bodies notwithstanding efforts drugs register viiv healthcare appealed ruling notwithstanding vaccines introduced marketplace unanticipated ruling infringement cases teva canada safety issues may become claimed evident apotex relating validity combination hemisulfate group currently defendant number product liability salt patents proceed hearing infringement case lawsuits related groups pharmaceutical vaccine teva canada scheduled april consumer healthcare products significant hearing infringement case apotex matters described scheduled december group able make reliable estimate addition teva challenged claims combination expected financial effect matters discussed category patent covering kivexa germany france italy also included provision appropriate matters related litigation ongoing united kingdom combination provision legal disputes matters patent litigation involving viiv healthcare teva commenced group made provision also noted note germany december france june provisions italy september combination patent expires across europe addition viiv healthcare corresponding supplementary protection certificate spc kivexa trizivir expire late gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings continued june group informed legal aid agency laa formerly legal services commission avandia considering whether discharge public funding certificate group named product liability lawsuits behalf following recommendation special cases review panel individuals asserting personal injury claims arising use case poor prospects success january avandia federal cases filed group part laa discharged public certificate effectively multidistrict litigation proceeding pending united states ending group action district court eastern district pennsylvania mdl court cases also filed number state courts poligrip beginning number product liability lawsuits claims february group reached agreements filed group state federal courts settle substantial majority federal state cases pending usa including purported class actions alleging zinc us purported class actions avandia pending super poligrip causes copper depletion permanent neurologic canada group reached agreement principle injury federal cases consolidated denture cream resolve single purported consumer class action israel adhesive multidistrict litigation mdl united states district approved court uk litigation court southern district florida established group ended following formal discontinuance june original four putative class actions mdl claims majority claimants court order striking dismissed putative class action filed puerto claims remaining claimants rico removed federal court transferred four purported class actions seeking economic damages mdl remains pending february behalf third party payers asserting claims arising two current exceptions one state court case various state federal laws including racketeer influenced pennsylvania one state court case small claims court corrupt organizations act rico state unfair trade practices tennessee state court cases consolidated andor consumer protection laws mdl court denied philadelphia state court mass tort program mtp february groups motion dismiss three third party payer actions cases currently pending gsk fourth action stayed group appealed philadelphia mtp vast majority individual cases decision united states court appeals third dismissed seven active individual cases one putative circuit one consumer class action brought behalf missouri class action mdl two state court cases still pending residents remains pending mdl court humana medical group usa group humana brought two separate subrogation actions one purported class action mdl court mdl canada one individual lawsuit five purported class actions court denied class certification united health group inc asserting consumer fraud claims also filed brought separate subrogation action group individual lawsuit one putative class action dismissed addition filed unfiled claims paxilseroxat paxil cr turkey uk elsewhere group voluntarily withdrew group received numerous lawsuits claims alleging zinccontaining formulations super poligrip market use paxil paroxetine caused variety injuries early lawsuits recent years alleged use paxil pregnancy resulted birth child birth sales marketing regulation defects health issues lawsuits claims alleged group able make reliable estimate expected patients took paxil committed attempted commit financial effect matters discussed category suicide acts violence patients suffered symptoms included provision matters provision legal discontinuing treatment paxil disputes except noted matters group made provision also noted note provisions pregnancy china investigation group reached agreements settle substantial majority us claims relating use paxil september group announced changsha pregnancy february number claims related intermediate peoples court hunan province china ruled use pregnancy still pending various courts us according chinese law gsk china investment co ltd matters dismissed without payment currently gskci offered money property nongovernment three trials scheduled personnel order obtain improper commercial gains found guilty bribing nongovernment personnel two proposed one certified class actions verdict followed investigations initiated chinas ministry canada action certified national class public security june result courts verdict action british columbia relates cardiovascular defects gskci paid fine rmb billion million appeal certification decision dismissed chinese government october case scheduled tried october secdoj sfo anticorruption enquiries us securities exchange commission sec us acts violence department justice doj initiated industrywide enquiry february eight pending matters including whether pharmaceutical companies may engaged one lawsuit appeal pending united states court violations us foreign corrupt practices act fcpa appeals ninth circuit concerning allegations patients relating sale pharmaceuticals including argentina took paxil committed attempted commit suicide acts brazil canada china germany italy poland russia saudi violence currently trials scheduled arabia group one companies asked discontinuation respond enquiry cooperating sec doj uk late public funding withdrawn group informed doj sec investigation claimants received funding pursue litigation alleging china operations chinese government paxilseroxat caused suffer withdrawal initiated outcome investigation reactions dependency majority claimants discontinued claims gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued august group removed case united states district court eastern district pennsylvania group also advised uk serious fraud office sfo moved dismiss complaint oral argument motion regarding investigation china operations chinese dismiss held february case government outcome investigation sfo stayed pending decision united states court appeals requested information group commercial third circuit overlapping potentially dispositive operations number countries may issue groups thirdparty payer litigation regarding avandia sfo informed group formally opened criminal group made provision matter investigation groups practices group responding sfos requests group unable make reliable manufacturing issues groups plant cidra estimate expected financial effect investigations subject federal state claims group resolved provision made us federal government group compliance obligations corporate integrity agreement us state sales marketing investigations us government group concluded agreement united paxilseroxat states government multiple states district columbia conclude groups significant ongoing united states group settled lawsuit filed new york state federal government investigations group notified attorney generals office alleging group failed disclose consortium us state attorneys general data use paxil children adolescents investigating conduct underlying groups federal group made class settlements lawsuits brought state settlements related products avandia consumers thirdparty payers respectively economic determine group violated state unfair deceptive trade damages allegedly resulting prescriptions paxil children practices statutes group resolved allegations adolescents group denied liability settlements states district columbia civil settlement plaintiffs voluntarily dismissed similar purported class agreements state attorney general actions pending action filed behalf governmental entities paid related matter prescriptions paxil minors avandia remains similar purported class action canada group defending action county santa clara seeking economic damages behalf individuals california brought californias consumer purchased paxil use patients age protection laws seeking civil penalties restitution result certification application part purported class action groups marketing avandia pretrial activities adjourned permit filing evidence continuing case proceeds trial mdl court likely resume send case back california federal court bench trial antitrustcompetition seven lawsuits filed behalf native american tribes group able make reliable estimate relating sale marketing avandia group expected financial effect matters discussed category products group resolved claims included provision matters provision groups december legal disputes except noted matters group made provision also noted note average wholesale price provisions number states respective attorneys general counties new york state filed civil lawsuits eu sector enquiry state federal courts group many european commission launched enquiry pharmaceutical companies claiming damages restitution due investigate possible anticompetitive conditions average wholesale price awp andor wholesale acquisition pharmaceutical sector final report pharmaceutical cost wac price reporting pharmaceutical products covered sector inquiry published july announced states medicaid programmes cases alleged final report commission decided continue monitoring group reported caused reported false awp wac patent settlement agreements originator generic prices turn allegedly caused state medicaid agencies companies relating eu markets result group reimburse providers money covered medicines provided input reports published agencies intended states sought recovery behalf provision made matter states payers cases behalf instate uk competition markets authority investigation patients consumers group resolved awp claims august uk office fair trading known state medicaid programmes almost states competition markets authority cma launched formal groups settlement agreement federal government investigation group pharmaceutical companies announced september multiple additional potential infringement competition act investigation settlements since litigation concerning awp issues focuses whether litigation settlements group continuing two states illinois wisconsin trial potential suppliers generic paroxetine formulations entered involving group scheduled object effect cidra thirdparty payer litigation prevention restriction distortion competition uk july number major us healthcare insurers ii group infringed dominant position making filed suit group philadelphia pennsylvania payments potential suppliers generic paroxetine aim county court common pleas seeking compensation restricting development full generic competition uk reimbursements made medicines manufactured group terminated agreements issue cma groups former cidra plant puerto rico insurers claim investigation covers issues also investigated group knowingly illegally marketed sold european commission respect paroxetine adulterated drugs manufactured conditions noncompliant european union also part european cgmp thirdparty insurers unlawfully commission pharmaceutical sector enquiry induced pay suit alleges us federal various state law causes action gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings continued complaint alleges stiefel officers directors violated us employee retirement income security act erisa march commission announced formally federal state securities laws inducing stiefel employees concluded enquiry action march sell shares employee stock plan back stiefel cma decided focus investigation potential anticompetitive greatly undervalued price without disclosing employees aspects paroxetine settlement agreements dropped stiefel sold group july investigation relation potential abuse dominance however district court denied plaintiffs motion class certification february cma decided reopen dominance aspects matter october district court granted defendants motions summary judgment dismissing one group cooperated cma investigations remaining plaintiffs litigation trial claims one since outset april cma issued statement plaintiff timothy finnerty took place may resulted objections setting decision cma would million jury verdict favour mr finnerty securities propose make allowing affected parties make claims separately group settled mr finnertys erisa claims representations proposed decision cma group appealed verdict court appeals states would propose fine group details eleventh circuit affirmed verdict june petition provided fine might calculated august certiorari filed us supreme court group submitted response rebutting additionally stiefel complete defence verdict fried cmas arguments october cma issued case tried federal court florida october plaintiff secondary statement objections amending theory appealed verdict eleventh circuit decision harm group responded december state court pending two stiefel cases pending florida play meeting january cma informed dismissed bacon case settled group group final decision made january mackay summary judgment continue investigation cmas website indicates granted favour group ruling later upheld final decision made late spring cma th circuit remaining case florida martinolich decides fine group cmas decision may appealed scheduled trial august discovery continues competition appeal tribunal georgia new york suits lawsuits involve claims lamictal similar brought finnerty purported direct indirect purchaser class actions filed addition private litigant suits december united states district court district new jersey us securities exchange commission sec filed formal alleging group teva pharmaceuticals unlawfully complaint stiefel charles stiefel united states conspired delay generic competition lamictal resulting district court district florida alleging stiefel overcharged separate count accuses group principals violated federal securities laws inducing stiefel monopolising market district court denied motion employees sell shares employee stock plan back purported direct purchaser class reconsideration company greatly undervalued price without disclosing order granting groups motion dismiss december employees company sold matter plaintiffs appealed decision united states stayed pending final ruling finnerty appeal court appeals third circuit oral argument heard group made provision stiefel litigation november await decision third circuit environmental matters action purported indirect purchase class suspended pending decision direct purchasers appeal group notified potential responsibility relating past operations past waste disposal practices certain wellbutrin xl sites primarily usa matters subject actions filed biovail corporation biovail litigation including proceedings initiated us federal group united states district court eastern state governments waste disposal site remediation costs district pennsylvania purported classes direct indirect tort actions brought private parties purchasers allege unlawful monopolisation anti trust violations related enforcement biovails patents group advised may responsible party wellbutrin xl filing biovail citizen petitions approximately sites appear national direct indirect purchaser classes certified although priority list created comprehensive environmental motion decertify indirect purchaser class remains pending response compensation liability act superfund district court granted groups motion partial summary proceedings seek require operators hazardous waste judgment primarily immunity grounds facilities transporters waste sites generators hazardous waste disposed sites clean sites sole remaining claim relates plaintiffs allegations reimburse us government cleanup costs group entered anticompetitive reverse payment settlement instances group involved alleged generator resolve patent infringement litigation dispositive motions hazardous waste connection remaining issue case due march although superfund provides defendants jointly severally liable clean costs proceedings commercial corporate frequently resolved basis nature quantity waste group able make reliable estimate disposed generator site groups proportionate expected financial effect matters discussed liability cleanup costs substantially determined category included provision respect matters sites referred provision legal disputes set note provisions groups potential liability varies greatly site site cost investigation study remediation sites could securitieserisa class actions stiefel time significant group routinely accrues amounts july class action suit brought behalf current related share liability matters former employees stiefel laboratories inc stiefel group company filed united states district court southern district florida gsk annual report strategic report governance remuneration financial statements investor information financial statements glaxosmithkline plc prepared uk gaap directors statement responsibilities disclosure information auditors relation companys financial directors office date annual report confirmed statements far aware relevant audit information directors responsible preparing parent company companys auditors unaware glaxosmithkline plc financial statements remuneration taken steps ought report accordance applicable law regulations taken director make aware uk company law requires directors prepare financial relevant audit information establish companys statements financial year law directors auditors aware information elected prepare parent company financial statements confirmation given interpreted accordance accordance united kingdom accounting standards provisions section companies act applicable law united kingdom generally accepted accounting practice company law directors must approve going concern basis parent company financial statements unless satisfied making enquiries directors reasonable give true fair view state affairs company expectation company adequate resources continue period operational existence foreseeable future reason continue adopt going concern basis preparing preparing financial statements directors required financial statements uk corporate governance code select suitable accounting policies apply board considers glaxosmithkline plc applies consistently principles provisions uk corporate governance make judgements accounting estimates reasonable code maintained financial reporting council described prudent corporate governance section pages complied provisions board considers state regard parent company financial statements annual report taken whole fair balanced applicable uk accounting standards followed understandable provides information necessary subject material departures disclosed explained shareholders assess groups performance business parent company financial statements model strategy prepare financial statements going concern basis required financial conduct authoritys listing rules unless inappropriate presume group continue auditors considered directors statement business compliance relation points uk corporate directors responsible keeping adequate accounting governance code specified review records sufficient show explain companys transactions disclose reasonable accuracy time financial position company enable ensure parent company financial statements remuneration report comply companies act also responsible sir christopher gent safeguarding assets company hence taking chairman reasonable steps prevention detection fraud february irregularities parent company financial statements year ended december comprising balance sheet year ended december supporting notes set pages report responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended december included annual report published printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different strategic report risk sections annual report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report strategic report governance remuneration financial statements investor information independent auditors report members glaxosmithkline plc report parent company financial responsibilities financial statements statements audit opinion responsibilities directors opinion parent company financial statements defined explained fully directors statement responsibilities set directors responsible give true fair view state parent companys preparation financial statements affairs december satisfied give true fair view properly prepared accordance united responsibility audit express opinion kingdom generally accepted accounting practice financial statements accordance applicable law isas prepared accordance requirements uk ireland standards require us comply companies act auditing practices boards ethical standards auditors audited report including opinions prepared glaxosmithkline plcs financial statements comprise companys members body accordance chapter company balance sheet december part companies act purpose giving opinions accept assume notes company balance sheet include responsibility purpose person summary significant accounting policies explanatory report shown whose hands may come save information expressly agreed prior consent writing financial reporting framework applied preparation financial statements applicable law audit financial statements involves united kingdom accounting standards united kingdom conducted audit accordance isas uk ireland generally accepted accounting practice audit involves obtaining evidence amounts disclosures financial statements sufficient give reasonable required reporting assurance financial statements free material consistency information misstatement whether caused fraud error includes companies act opinion assessment opinion information given strategic report whether accounting policies appropriate parent directors report financial year companys circumstances consistently applied financial statements prepared consistent adequately disclosed financial statements reasonableness significant accounting estimates made isas uk ireland reporting directors international standards auditing uk ireland isas uk ireland required report overall presentation financial statements opinion information annual report primarily focus work areas assessing materially inconsistent information audited directors judgements available evidence forming financial statements judgements evaluating disclosures financial apparently materially incorrect based materially statements inconsistent knowledge company acquired test examine information using sampling course performing audit auditing techniques extent consider necessary otherwise misleading provide reasonable basis us draw conclusions obtain exceptions report arising responsibility audit evidence testing effectiveness controls substantive procedures combination adequacy accounting records information explanations received addition read financial nonfinancial information companies act required report annual report identify material inconsistencies opinion audited financial statements identify information apparently materially incorrect based materially inconsistent received information explanations knowledge acquired us course performing require audit audit become aware apparent material misstatements adequate accounting records kept parent inconsistencies consider implications report company returns adequate audit received branches visited us matter financial statements part directors reported separately group financial statements remuneration report audited agreement glaxosmithkline plc year ended december accounting records returns company passed resolution accordance section exceptions report arising responsibility companies act senior statutory auditors directors remuneration name stated directors remuneration report companies act opinion opinion part directors remuneration report pricewaterhousecoopers llp audited properly prepared accordance chartered accountants statutory auditors companies act london february companies act reporting companies act required report opinion certain disclosures directors remuneration specified law made exceptions report arising responsibility gsk annual report strategic report governance remuneration financial statements investor information company balance sheet uk gaap december notes fixed assets investments e debtors f cash bank current assets creditors amounts due within one year g net current assets total assets less current liabilities provisions liabilities h net assets capital reserves called share capital share premium account reserves j profit loss account j equity shareholders funds financial statements pages approved board february signed behalf sir christopher gent chairman glaxosmithkline plc registered number gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet expenditure uk gaap expenditure recognised respect goods services received supplied accordance contractual terms presentation financial statements provision made obligation exists future liability description business respect past event amount obligation glaxosmithkline plc parent company gsk major global reliably estimated healthcare group engaged creation discovery investments subsidiary companies development manufacture marketing pharmaceutical investments subsidiary companies held cost less products including vaccines overthecounter otc medicines provision impairment healthrelated consumer products impairment investments preparation financial statements carrying value investments reviewed impairment financial statements prepared going concern indication investment might impaired basis drawn accordance uk generally accepted provision resulting impairment review charged accounting practice uk gaap uk accounting income statement year concerned presentation december comparative figures december appropriate comparative figures share based payments reclassified ensure consistent presentation current issuance company subsidiaries grant year information companys shares represents additional capital contributions company subsidiaries additional investment permitted section companies act subsidiaries results corresponding increase shareholders profit loss account company presented equity additional capital contribution based fair value annual report grant issued allocated underlying grants vesting company included group financial statements period glaxosmithkline plc publicly available advantage taxation taken exemption provided frs cash flow current tax provided amounts expected paid statements revised prepare cash flow applying tax rates enacted substantively statement exemption provided frs related enacted balance sheet date party disclosures disclose related party transactions within group company accounts taxation deferred accelerated reason timing differences originated accounting convention standards reversed balance sheet date deferred tax assets balance sheet prepared using historical recognised extent considered cost convention complies applicable uk accounting recoverable future taxable profits standards deferred tax measured average tax rates expected accounting principles policies apply periods timing differences expected preparation balance sheet conformity generally reverse deferred tax liabilities assets discounted accepted accounting principles requires management make estimates assumptions affect reported amounts financial guarantees assets liabilities disclosure contingent assets liabilities relating guarantees issued company behalf liabilities date balance sheet actual amounts could subsidiaries initially recognised fair value differ estimates amortised life guarantee balance sheet prepared accordance legal disputes companys accounting policies approved board company provides anticipated settlement costs described note b outflow resources considered probable reliable estimate may made likely outcome dispute b accounting policies legal expenses arising claims company foreign currency transactions foreign currency transactions recorded exchange rate c operating profit ruling date transaction forward rate hedged fee relating audit forward exchange contract foreign currency assets company charged operating profit liabilities translated rates exchange ruling balance dividends sheet date forward rate directors declared four interim dividends resulting dividends paid received dividend year pence pence increase dividends paid received included financial dividend details see note group statements period related dividends financial statements dividends actually paid received gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap continued e fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments f debtors amounts due within one year uk corporation tax recoverable receivables deferred tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings deferred tax asset arises result recognition deferred tax tax losses expected used completion novartis transaction g creditors amounts due within one year bank overdraft creditors amounts owed group undertakings company guaranteed debt issued one subsidiary companies receives annual fee subsidiary aggregate company outstanding guarantees billion debt instruments amounts due subsidiary companies relation guarantee fees recovered life bonds disclosed within debtors see note f h provisions liabilities january charge year utilised movements december provisions liabilities relate number legal disputes company currently involved gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap continued called share capital share premium account share premium ordinary shares p account number share capital authorised december december share capital issued fully paid january issued employee share schemes share capital cancelled december issued employee share schemes december december december number shares issuable outstanding options number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million j reserves profit reserves loss account total january profit attributable shareholders dividends shareholders shares purchased cancelled held treasury shares capital contribution relating share based payments december profit attributable shareholders dividends shareholders shares purchased held treasury shares treasury shares transferred esot held subsidiary company december profit glaxosmithkline plc year million million loss dividends million million gave retained profit million million loss cost shares purchased held treasury shares million million effect million treasury shares transferred subsidiary company nil profit loss account reserve december stood million million million unrealised million k adoption financial reporting standard frs reduced disclosure framework following publication frs application financial reporting requirements glaxosmithkline plc required change accounting framework entity financial statements currently uk gaap financial year commencing january considers best interests group glaxosmithkline plc adopt frs disclosures current financial statements would omitted adoption frs gsk annual report strategic report governance remuneration financial statements investor information investor information section quarterly trend five year record product development pipeline products competition intellectual property risk factors share capital share price dividends tax information shareholders annual general meeting us law regulation shareholder services contacts glossary terms index ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statements investor information financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating income operating profit net finance costs profit disposal interest associates joint ventures share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation core results described gsk annual report strategic report governance remuneration financial statements investor information quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating income operating profit net finance costs profit disposal interest associates joint ventures share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation core results described gsk annual report strategic report governance remuneration financial statements investor information financial record continued pharmaceuticals vaccines turnover therapeutic area total usa europe emerging markets japan therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin oncology arzerra mekinist promacta tafinlar tyverbtykerb votrient cardiovascular metabolic urology cvmu avodart immuno inflammation benlysta pharmaceuticals dermatology augmentin antibacterials rare diseases innovative pharmaceuticals vaccines boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix innovative pharmaceuticals vaccines viiv healthcare hiv combivir epzicomkivexa lexivaagenerase selzentry tivicay trizivir established products coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix table includes sales product reported trading unallocated pharmaceuticals segment includes canada puerto rico australasia central vaccine tender sales contract manufacturing sales total column cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines turnover therapeutic area total usa europe emerging markets japan therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin oncology arzerra mekinist promacta tafinlar tyverbtykerb votrient cardiovascular metabolic urology cvmu avodart immuno inflammation benlysta pharmaceuticals dermatology augmentin antibacterials rare diseases innovative pharmaceuticals vaccines boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix innovative pharmaceuticals vaccines viiv healthcare hiv combivir epzicomkivexa lexivaagenerase selzentry tivicay trizivir established products coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix table includes sales product reported trading unallocated pharmaceuticals segment includes canada puerto rico australasia central vaccine tender sales contract manufacturing sales total column cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board established products segment created certain product reclassifications principally otc dermatology brands acquired stiefel business made pharmaceuticals vaccines segments consumer healthcare segment effect january comparative turnover information four years restated accordingly addition core results restated exclude divestments completed comparative information also reported including effect divestments completed restated restated restated restated restated turnover division pharmaceuticals vaccines pharmaceuticals vaccines consumer healthcare divestments total turnover including divestments group turnover geographic region usa europe emerging markets japan divestments total turnover including divestments group turnover segment usa europe emerging markets japan viiv healthcare hiv established products trading unallocated pharmaceuticals pharmaceuticals vaccines consumer healthcare divestments total turnover including divestments pharmaceuticals vaccines turnover restated restated restated restated restated therapeutic area respiratory oncology emesis cardiovascular metabolic urogenital immunoinflammation pharmaceuticals established products vaccines viiv healthcare hiv gsk annual report strategic report governance remuneration financial statements investor information five year record continued restated restated restated restated restated consumer healthcare turnover wellness oral care nutrition skin health financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions millions weighted average number shares issue basic diluted restated restated financial results core turnover operating profit profit taxation profit taxation pence pence pence pence pence pence core earnings per share return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees usa europe emerging markets japan manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average average rate year calculated average pm buying rates day year feb jan dec nov oct sep high low pm buying rate february us gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition pharmaceuticals vaccines product development pipeline key inlicence alliance relationship third party also developed indications another therapeutic area phase evaluation clinical pharmacology usually conducted volunteers month first submission phase ii determination dose initial evaluation efficacy conducted month first regulatory approval maa first eu small number patients approval letter phase iii large comparative study compound versus placebo andor established bla biological licence application treatment patients establish clinical benefit safety maa marketing authorisation application europe nda new drug application usa maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla respiratory phosphoinositide kinase pik inhibitor idiopathic pulmonary fibrosis soluble epoxide hydrolase seh inhibitor chronic obstructive pulmonary disease copd tumour necrosis factor receptor tnfr acute lung injury domain antibody muscarinic acetylcholine antagonist beta agonist copd fluticasone furoate maba glucocorticoid agonist maba copd ii tolllike receptor agonist asthma ii pik inhibitor asthma copd ii recombinant human angiotensin converting acute lung injury ii enzyme danirixin cxcr chemokine receptor antagonist copd ii fluticasone furoate glucocorticoid agonist muscarinic acetylcholine asthma copd overlap syndrome ii umeclidinium antagonist losmapimod p kinase inhibitor oral copd ii mepolizumab il monoclonal antibody nasal polyposis ii fluticasone furoate glucocorticoid agonist longacting beta copd iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab il monoclonal antibody copd iii relvarbreo ellipta longacting beta agonist glucocorticoid agonist copd mortality outcomes iii vilanterol fluticasone furoate vilanterol longacting beta agonist copd iii mepolizumab il monoclonal antibody severe eosinophilic asthma submitted nov nov anoro ellipta muscarinic acetylcholine antagonist longacting copd approved may dec umeclidinium beta agonist vilanterol arnuity ellipta glucocorticoid agonist asthma approved na aug fluticasone furoate incruse ellipta muscarinic acetylcholine antagonist copd approved apr aapr umeclidinium relvarbreo ellipta longacting beta agonist glucocorticoid agonist asthma approved nov jun vilanterol fluticasone furoate paediatric vaccines rsv recombinant respiratory syncytial virus prophylaxis maternal immunisation rsv recombinant viral vector respiratory syncytial virus prophylaxis pneumoniae next recombinant conjugated streptococcus pneumoniae disease prophylaxis ii generation mmr live attenuated measles mumps rubella prophylaxis iii us na mosquirix recombinant malaria prophylaxis plasmodium falciparum submitted jun na malaria rtss dtpahbvipvhib conjugated diphtheria tetanus pertussis poliomyelitis approved na hepatitis b haemophilus influenza ii us nimenrix conjugated neisseria meningitis groups c w approved apr menacwytt disease prophylaxis ii us gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla vaccines malaria next generation recombinant malaria prophylaxis plasmodium falciparum ii nthi recombinant nontypeable haemophilus influenzae prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii hepatitis c recombinant viral vector hepatitis c virus prophylaxis ii ebola recombinant viral vector prevention filovirus haemorrhagic fevers caused iii ebola zaire virus zoster recombinant herpes zoster prophylaxis iii antigenspecific cancer immunotherapeutic magea recombinant treatment melanoma iii immunotherapeutic hiv viiv healthcare cabotegravir hiv integrase inhibitor hiv infections ii longacting parenteral formulation cabotegravir hiv integrase inhibitor hiv preexposure prophylaxis ii longacting parenteral formulation triumeq dolutegravir hiv integrase inhibitor hiv infections fixed dose combination approved sep aug abacavir sulphate reverse transcriptase inhibitors lamivudine fixed dose combination oncology bromodomain inhibitor cancer focal adhesion kinase inhibitor cancer pik inhibitor cancer enhancer zeste homologue ezh cancer inhibitor erbb monoclonal antibody cancer beta cell maturation antigen antibody multiple myeloma drug conjugate lysinespecific demethylase lsd cancer inhibitor fibroblast growth factor ligand trap cancer afuresertib akt protein kinase inhibitor multiple myeloma votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer mk pd monoclonal antibody afuresertib akt protein kinase inhibitor ovarian cancer ii mekinist trametinib mek inhibitor braf protein nonsmall cell lung cancer ii tafinlar dabrafenib kinase inhibitor mekinist trametinib mek inhibitor braf protein rare cancers ii tafinlar dabrafenib kinase inhibitor mekinist trametinib mek inhibitor braf protein colorectal cancer ii tafinlar dabrafenib kinase inhibitor human antiegfr panitumumab monoclonal antibody revoladepromacta thrombopoietin receptor agonist acute myeloid leukaemia ii eltrombopag arzerra ofatumumab cd human monoclonal antibody chronic lymphocytic leukaemia use relapsed patients iii arzerra ofatumumab cd human monoclonal antibody follicular lymphoma refractory relapsed patients iii mekinist trametinib mek inhibitor braf protein metastatic melanoma adjuvant therapy iii tafinlar dabrafenib kinase inhibitor revoladepromacta thrombopoietin receptor agonist myelodysplastic syndromes iii eltrombopag votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii arzerra ofatumumab cd human monoclonal antibody chronic lymphocytic leukaemia first line therapy approved jun apr mekinist trametinib mek inhibitor metastatic melanoma approved jul may mekinist trametinib mek inhibitor braf protein metastatic melanoma approved jan tafinlar dabrafenib kinase inhibitor revoladepromacta thrombopoietin receptor agonist aplastic anaemia approved nov aug eltrombopag gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla cardiovascular metabolic prolyl hydroxylase inhibitor topical wound healing transient receptor potential cation heart failure channel v trpv antagonist selective androgen receptor modulator muscle wasting prolyl hydroxylase inhibitor anaemia associated chronic renal disease ii ileal bile acid transport inhibitor type diabetes cholestatic pruritus ii camicinal motilin receptor agonist delayed gastric emptying ii eperzantanzeum glp agonist type diabetes ii albiglutide losmapimod p kinase inhibitor focal segmental glomerular sclerosis ii otelixizumab cd monoclonal antibody new onset type diabetes ii losmapimod p kinase inhibitor acute coronary syndrome iii retosiban oxytocin antagonist threatened preterm labour iii eperzantanzeum glp agonist type diabetes approved mar aapr albiglutide immunoinflammation il receptor monoclonal antibody autoimmune disease spleen tyrosine kinase syk inhibitor chronic urticaria topical lag monoclonal antibody autoimmune disease rip kinase inhibitor autoimmune disease ccl monoclonal antibody autoimmune disease macrophage targeted histone rheumatoid arthritis deacetylase inhibitor mor granulocyte macrophage colony rheumatoid arthritis ii stimulating factor monoclonal antibody benlysta belimumab b lymphocyte stimulator monoclonal transplant rejection ii antibody iv benlysta belimumab b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc benlysta belimumab b lymphocyte stimulator monoclonal vasculitis iii antibody iv sirukumab il human monoclonal antibody sc rheumatoid arthritis iii rare diseases sap monoclonal antibody amyloidosis sap depleter cphpc exvivo stem cell gene therapy metachromatic leukodystrophy ii exvivo stem cell gene therapy wiscottaldrich syndrome ii ozanezumab neurite outgrowth inhibitor nogoa amyotrophic lateral sclerosis ii monoclonal antibody exvivo stem cell gene therapy adenosine deaminase severe combined immune iii deficiency adascid mepolizumab il monoclonal antibody sc eosinophilic granulomatosis polyangiitis iii volibris ambrisentan endothelin antagonist chronic thromboembolic pulmonary hypertension iii infectious diseases antiviral maturation inhibitor hiv infections nsb polymerase inhibitor hepatitis c type topoisomerase inhibitor bacterial infections ii tafenoquine aminoquinoline plasmodium vivax malaria iii relenza iv zanamivir neuraminidase inhibitor iv influenza iii neurosciences ofatumumab cd human monoclonal antibody sc neuromyelitis optica ii benlysta belimumab b lymphocyte stimulator monoclonal myaesthenia gravis ii antibody iv ofatumumab cd human monoclonal antibody sc multiple sclerosis ii rilapladib lppla inhibitor alzheimer 's disease ii gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla ophthalmology beta amyloid monoclonal antibody geographic retinal atrophy ii dermatology stearoyl coa desaturase inhibitor topical acne vulgaris umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis nonsteroidal antiinflammatory atopic dermatitis psoriasis ii chlorhexidine cationic polybiguanide topical umbilical cord care iii ofatumumab cd human monoclonal antibody sc pemphigus vulgaris iii toctino alitretinoin retinoic acid receptor modulator chronic hand eczema iii na brand names appearing italics trade marks either owned andor licensed gsk associated companies optionbased alliances third parties include assets phase phase iii development company disease area phase adaptimmune cancer cancer research uk cancer isis pharmaceuticals hepatitis b transthyretinmediated amyloidosis iii oncomed pharmaceuticals oncology oncology ii shionogi bacterial infection gsk annual report strategic report governance remuneration financial statements investor information pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands usa eu respiratory anoro ellipta umeclidinium bromide copd spiriva onbrez nce nce vilanterol terfenatate device device formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort asmanex nce nce alvesco device device formulation formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired diskus device diskus device hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva seebri nce nce device device formulation formulation relvarbreo fluticasone furoate asthmacopd symbicort foster ellipta vilanterol terfenatate us copd flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil spiriva expired onbrez diskus device diskus device hfadevice ventolin hfa albuterol sulphate asthmacopd generic companies hfadevice hfadevice antivirals relenza zanamivir influenza tamiflu expired expired valtrex valaciclovir genital herpes coldsores famvir expired expired shingles zeffixepivirhbv lamivudine chronic hepatitis b hepsera expired expired central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired requip xl ropinirole parkinsons disease mirapex expired expired seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro cardiovascular urogenital eperzantanzeum albiglutide type diabetes victoza byetta bydureon lyxumia trulicity avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi lovaza omega acid ethyl esters high triglycerides tricor expired na see risk factors details uncertainty timing followon competition see note financial statements legal proceedings generic competition possible generic competition possible gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands usa eu antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections oncology arzerra ofatumumab refractory chronic mabtherarituxan lymphocytic leukaemia imbruvica mekinist trametinib braf v metastatic yervoy opdivo na melanoma keytruda promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura hepatitis c mabtherarituxan associated thrombocytopenia tafinlar dabrafenib braf v metastatic yervoy zelboraf yet granted melanoma opdivo keytruda tykerbtyverb lapatanib advanced metastatic herceptin breast cancer kadcyla positive patients votrient pazopanib soft tissue sarcoma yondelis sutent metastatic renal cell nexavar afinitor carcinoma temsirolimus rare diseases volibris ambrisentan pulmonary hypertension tracleer revatio na immunoinflammation benlysta belimumab systemic lupus erythematosus vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel na polio hepatitis b polio hepatitis b pentaxim pentavac haemophilus influenzae haemophilus influenzae hexaxim type b type b cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtypes fluzone influvac subtype b antigens aggripal fluad intenza flumist fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv virus subtypes vaxigrip qiv subtype b antigens fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip none none virus subtypes fluzone influvac subtype b antigens aggripal fluad intenza flumist pandemrix derived split inactivated ahnv influenza focetria celvapan na influenza virus antigen prophylaxis adjuvant prepandrix derived split inactivated pandemic hn aflunov vepacel yet granted influenza virus antigen influenza prophylaxis adjuvant synflorix conjugated pneumococcal invasive pneumococcal prevenar prevnar na polysaccharide disease pneumonia acute otitis media gsk annual report strategic report governance remuneration financial statements investor information pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands usa eu hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla stribild combination combination compleraeviplera lexivatelzir fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaids isentress prezista reyataz kaletra triumeq dolutegravir lamivudine hivaids truvada atripla abacavir stribild compleraeviplera trizivir lamivudine zidovudine hivaids truvada atripla abacavir stribild combination combination compleraeviplera see note financial statements legal proceedings generic competition commenced includes supplementary protection certificates patent term extensions granted consumer healthcare products competition brand products application markets competition wellness panadol tablets caplets infant drops paracetamolbased treatment global except us reckittbenckisers nurofen panadol cold headache joint pain bayers aspirin flu fever cold symptoms johnson johnsons tylenol retailer label eno effervescent immediate relief antacid global except us hypermarcas estomazil pfizers gelusil tums chewable tablets immediate relief antacid us sanofis rolaids bayers alkaseltzer retailer label nicorette us lozenges gum treatment nicotine global novartiss nicotinell nicoderm transdermal patch withdrawal aid johnson johnsons nicorette niquitin cq smoking reduction except us nicabate cessation retailer label oral health sensodyne toothpastes toothbrushes treat prevent dental global colgatepalmolives mouth rinse sensitivity acid erosion colgate sensitive pro relief proctor gambles crest sensirelief crest sensistop strips polident denture adhesive denture improve comfort global procter gambles fixodent poligrip cleanser fitted dentures reckittbenckisers kukident corega clean dentures steradent aquafresh toothpastes toothbrushes prevention caries gum global colgatepalmolives colgate mouthwashes disease bad breath procter gambles crest oralb nutrition horlicks malted drinks foods nutritional indian sub continent mondelezs bournvita beverages food uk ireland nestles milo skin health physiogel moisturising creams face body care dry germany france italy loreals la roche posay lotions cleansers sensitive irritated skin poland spain beiersdorfs eucerin pierre fabres avene zovirax topical cream lip care treat prevent global johnson johnsons compeed abreva onset cold sores carma labs carmex blistex incorporateds blistex retailer label gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors principal risks discussed risks uncertainties healthcare products affect cost product relevant business financial condition results operations development also time required reach market may affect performance ability achieve objectives uncertainty successfully factors believe could cause actual moreover rules regulations change governmental results differ materially expected historical results interpretation rules regulations evolves nature operate global basis industry highly particular risk may change changes certain regulatory regimes competitive highly regulated competitors may make may substantial change failure comply significant product innovations technical advances may applicable law regulation could materially adversely affect intensify price competition light competitive environment financial results continued development commercially viable new products similarly business exposes us litigation government development additional uses existing products critical investigations including limited product liability litigation ability maintain increase overall sales patent antitrust litigation sales marketing litigation litigation developing new pharmaceutical vaccine consumer healthcare government investigations including related provisions may products costly lengthy uncertain process however make unfavourable outcomes increases related costs product candidate may fail stage including significant insurance premiums could materially adversely affect financial group economic human resources invested results detail status various uncertainties involved competitors products pricing strategies failure significant unresolved disputes potential litigation set part develop commercially successful products develop note legal proceedings additional uses existing products could materially adversely uk regulations require discussion mitigating activities affect financial results company takes address principal risks uncertainties must also adapt comply broad range laws summary activities group takes manage regulations requirements apply research principal risks accompanies description principal development manufacturing testing approval distribution risk principal risk factors uncertainties listed sales marketing pharmaceutical vaccine consumer order significance patient safety risk definition paramount importance cmo authoritative role failure appropriately collect review follow report adverse events evaluating addressing matters human safety individual potential sources act relevant findings timely medical officers groups substantial global safety manner pharmacovigilance organisation keep track adverse issues reported products course clinical studies risk impact impact risk potentially compromise ability conduct group product approved marketing group robust safety signal detection interpretation ensure extensive postmarketing surveillance signal detection system appropriate decisions taken respect riskbenefit profile information possible side effects medicines received several products including completeness accuracy product labels sources including unsolicited reports health professionals pursuit additional studiesanalyses appropriate could patients regulatory authorities medical scientific literature lead potential harm patients reputational damage product liability media policy employees required report immediately claims litigation governmental investigation regulatory action issues relating safety quality medicines fines penalties loss product authorisation country managers responsible monitoring exception tracking training helps assure collection safety information context reporting information relevant central safety department preclinical clinical trials conducted development accordance group policy legal requirements investigational pharmaceutical vaccine consumer healthcare products determine safety efficacy products use information changes benefitrisk profile one groups humans notwithstanding efforts make determine safety medicines result certain actions characterise communicate products appropriate preclinical clinical trials minimise risk proposed actions discussed regulatory unanticipated side effects may become evident products authorities include modifying prescribing information widely introduced marketplace questions may raised communications physicians healthcare providers ongoing safety surveillance postmarketing studies also restrictions product prescribingavailability help assure safe use governmental agencies thirdparties may analyse publicly sometimes carrying clinical trials certain cases may available clinical trial results appropriate stop clinical trials withdraw medicine market groups global safety board gsb comprising senior group currently defendant number product liability physicians representatives supporting functions integral lawsuits including class actions involve significant claims component system gsb including subsidiary boards damages related products litigation particularly us dedicated consumer healthcare products vaccines reviews inherently unpredictable class actions seek sweep together safety investigational marketed products across group persons prescribed products increase potential liability authority stop clinical trial continued conduct claims pain suffering punitive damages frequently trial ethically scientifically justified light information asserted product liability actions allowed represent emerged since start trial potentially openended exposure thus could materially adversely affect groups financial results addition medical governance framework within group described group uses several mechanisms foster early mitigating activities evaluation mitigation resolution disputes arise chief medical officer cmo responsible medical governance potential claims even arise goal programmes group global policy policy safeguarding create culture early identification evaluation risks claims human subjects clinical trials patients take products actual potential order minimise liability litigation gsk annual report strategic report governance remuneration financial statements investor information intellectual property risk definition depend certain key products significant portion failure appropriately secure protect intellectual property sales one product respiratory pharmaceutical product rights seretideadvair accounts group sales worldwide timing impact entry us generic product risk impact containing combination active substances seretide failure obtain subsequent loss patent protection advair uncertain us patent compositions containing including reducing availability scope patent rights combination active substances seretideadvair expired compulsory licensing government forces manufacturer although us patent component advair diskus license patents specific products competitor could device continues august generic products containing materially adversely affect financial results markets combination active substances seretideadvair absence adequate patent data exclusivity protection could limit metered dose inhalers dry powder inhalers launched opportunity rely markets future sales growth several manufacturers number european markets products could also materially adversely affect timing impact entry us major markets europe financial results followon product seretideadvair uncertain context generic drug manufacturers also exhibited readiness innovative pharmaceutical vaccine consumer healthcare market generic versions many important products products company seek obtain appropriate intellectual prior expiration patents efforts may involve property protection products ability obtain enforce challenges validity enforceability patent assertions patents proprietary rights regard products generic product infringe patents result critical business strategy success pharmaceutical may continue involved legal proceedings vaccine products usually protected copied involving patent challenges may materially adversely generic manufacturers period exclusivity provided affect financial results moreover us become issued patent related intellectual property rights increasingly common patent infringement actions prompt regulatory data protection orphan drug status following claims antitrust laws violated prosecution expiration certain intellectual property rights generic patent litigation involving defence patent manufacturer may lawfully produce generic version product claims direct indirect purchasers payers operate markets intellectual property laws patent typically filed class actions relief sought may include treble offices still developing governments may unwilling damages restitution claims similarly antitrust claims may grant enforce intellectual property rights fashion similar brought government entities private parties following developed regions eu japan us settlement patent litigation alleging settlements developing countries limited threatened limit effective anticompetitive violation antitrust laws successful patent protection pharmaceutical products generally antitrust claim private party government entity could particular therapeutic areas order facilitate early competition materially adversely affect financial results within markets generic manufacturers expiration dates patents major products may face competition manufacturers proprietary generic affect dates generic versions products may pharmaceutical products major markets introduction introduced set pages legal proceedings generic products particularly us highest involving patent challenges set note financial turnover margins typically leads rapid dramatic loss statements legal proceedings sales reduces revenues margins proprietary mitigating activities products nine pharmaceutical vaccine global patents group focuses securing protecting products million annual global sales certain patent rights global group maintains internal processes products generic competition us designed help ensure successful procurement enforcement markets europe may also experience impact sales defence patents goal maintaining exclusive rights one products due expiry loss patent protection markets products product marketed competitor similar product class treatment similar disease condition global patents group monitors new developments international patent law help ensure appropriate protection assets sometimes acting trade associations work local governments seek secure effective balanced intellectual property protection designed meet needs patients payers supporting longterm investment innovation gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued product quality risk definition adopted single quality management system qms failure comply current good manufacturing practice defines quality standards systems businesses cgmp requirements commercial manufacture associated pharmaceuticals vaccines consumer distribution chain gsk contractors suppliers healthcare products rd investigational materials qms inadequate controls governance quality product broad scope covering endtoend supply chain development supporting regulated activities starting materials distributed product applicable throughout complete lifecycle products rd risk impact mature commercial supply failure ensure product quality could far reaching implications terms patient consumer safety delays qms periodically updated based experience evolving launching new products drug shortages product recalls potential regulatory agency expectations requirements improved damage reputation relevant product well scientific understanding help ensure operations comply regulatory legal financial consequences could cgmp requirements globally support delivery materially adversely affect reputation financial results consistent reliable products large network quality compliance professionals aligned business unit context provide oversight assist delivery quality performance patients consumers healthcare professionals trust quality operational compliance management oversight products failure ensure product quality enterprise activities accomplished hierarchy quality council risk applicable across business activities meetings staff trained help ensure standards product quality may influenced many factors including well expected behaviours based values followed product process understanding supply chain security refresher training cgmp issues includes focus consistency manufacturing components compliance gmp issues raised inspectional trends accuracy labeling reliability external supply chain embodiment overarching quality culture internal implemented riskbased approach assessing external environment continues evolve new products new managing thirdparty suppliers provide materials used markets new legislation introduced particularly around finished products contract manufacturers making products security supply good distribution practice product expected comply standards identified group standards inspectional trending national authorities audited help provide assurance expected standards met highlighted focus issues relating data integrity chief product quality officer oversees activities contamination robustness quality investigations gsk quality council serves forum escalate mitigating activities emerging risks share experiences handling quality issues medicines development scientists adopt principles quality businesses help ensure lessons learned design new products devise control strategies assessed deployed globally preparation deployed throughout product lifecycle help ensure implementation new legislation regularly reviewed gsk consistency reliability performance supply quality council advocacy communication programmes used maintain awareness external environment convey consistent messages across group emphasis quality performance metrics culture right first time gsk annual report strategic report governance remuneration financial statements investor information supply chain continuity risk definition failure small number singlesource thirdparty suppliers failure deliver continuous supply compliant finished product service providers fulfill contractual obligations timely manner result regulatory noncompliance physical risk impact disruption logistics manufacturing sites may result delays material interruption supply exclusion healthcare service interruptions programmes could impact patient access products expose us litigation regulatory action materially adversely mitigating activities affect financial results particular incurring fines supply chain model designed help ensure supply disgorgement result noncompliance manufacturing quality security products globally closely monitor practice regulations could also materially adversely affect supply chain governance committees inventory groups financial results result reputational damage status delivery products help ensure customers medicines vaccines products need context safety stocks backup supply arrangements high revenue supply chain operations subject review approval medicallycritical products place practical various regulatory agencies effectively provide licence help mitigate risk addition compliance manufacturing operate failure manufacturing distribution facilities external suppliers routinely monitored order identify suppliers key services materials could lead litigation manage supply base risks regulatory action product recalls seizures interruption supply delays approval new products suspension practical dependencies single sources critical items manufacturing operations pending resolution manufacturing removed reliance single source components logistics issues consumer healthcare business reduced key products qualification particularly smokers health products alli bactroban alternative materials help improve supply chain robustness impacted various supply issues vaccines cases dual sourcing possible inventory strategy business particularly hepatitis vaccines boostrix developed protect supply chain unanticipated impacted supply constraints disruption materials services provided thirdparty suppliers continued implement anticounterfeit systems necessary commercial production products including product serialization accordance emerging requirements active pharmaceutical ingredients api antigens intermediates mitigate risk commodities components necessary manufacture throughout supply chain operating model improved packaging many pharmaceutical vaccine consumer strengthen link commercial forecasting healthcare products thirdparty services procured manufacturing implementation core commercial services provided contract manufacturing organizations cycle methodology action time decrease risk clinical research organisations support development key associated demand fluctuations impacting ability supply products important ensure continuous operation writeoffs associated product exceeding expiry dating businesses although undertake business continuity planning new model node supply chain optimised single sourcing certain components bulk api finished products help ensure adequate safety stock balancing working services creates risk failure supply event capital associated endtoend supply chain regulatory noncompliance physical disruption manufacturing sites logistics system financial reporting disclosure risk definition mitigating activities failure report accurate financial information material events group maintains control environment designed identify compliance accounting standards applicable legislation material errors financial reporting disclosure design operating effectiveness key financial reporting controls risk impact periodically tested provides us assurance noncompliance existing new financial reporting controls key financial reporting disclosure processes disclosure requirements changes recognition income operated effectively expenses could expose us litigation regulatory action could materially adversely affect financial results keep uptodate latest developments financial reporting requirements working external auditors context legal advisors help ensure adherence relevant reporting new revised accounting standards rules interpretations disclosure requirements issued time time international accounting standards board could result changes recognition income shared accountability financial results across expense may materially adversely affect financial results businesses financial results reviewed approved regional management reviewed financial group also required laws various jurisdictions controller chief financial officer cfo allows disclose publicly financial results events could materially financial controller cfo assess evolution affect financial results group regulators routinely review business time evaluate performance plan significant financial statements listed companies compliance judgments reviewed confirmed senior management accounting regulatory requirements group believes complies appropriate regulatory requirements concerning group maintains disclosure committee reports financial statements disclosure material information board reviews groups quarterly results annual however subject investigation potential report determines throughout year consultation noncompliance accounting disclosure requirements legal advisors whether necessary disclose publicly potential restatements previously reported results information group stock exchange could subject significant penalties announcements gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued tax treasury risk definition liquidity risk managed diversifying liquidity sources using failure comply current tax law react rapidly range facilities maintaining broad access funding evolving tax environment incurring significant losses due markets order meet anticipated future funding requirements treasury activities also hold significant amounts cash investments invested line strict investment guidelines risk impact changes tax laws application respect matters interest rate risk managed limiting amount floating rate transfer pricing foreign dividends controlled companies interest payments prescribed percentage operating profit rd tax credits taxation intellectual property restriction mix debt fixed floating interest rates monitored tax relief allowed interest intragroup debt could impact regularly tmg effective tax rate significant losses may arise treasury foreign currency transaction risk arising internal external activities inconsistent application treasury policies trade flows generally hedged internal trading dealing settlement errors counterparty defaults transactions matched centrally manage intercompany changes tax laws application failure comply tax payment terms reduce foreign currency risk foreign currency law significant losses due treasury activities could materially cash flows hedged selectively management adversely affect financial results treasury tmg possible manage cash context surpluses borrowing requirements subsidiary companies treasury group deals high value transactions mostly foreign centrally order reduce foreign currency translation exposure exchange cash management transactions daily basis seek denominate borrowings currencies groups effective tax rate driven rates tax principal assets cash flows tmg reviews ratio jurisdictions higher lower uk borrowings assets major currencies monthly addition many jurisdictions currently offer regimes encourage counterparty risk managed setting global counterparty limits innovation investment science providing tax incentives banking investment counterparties based rd tax credits lower tax rates income derived longterm credit ratings moodys standard poors patents furthermore international business face treasurys usage limits monitored daily corporate risks associated intragroup transfer pricing compliance officer cco operates independently tax charge included financial statements best corporate treasury cco also monitors credit rating estimate tax liability pending audits tax authorities submit counterparties changes ratings occur tax returns according statutory time limits engage tax notifies treasury changes made investment authorities help ensure tax affairs current exceptional levels authority limits appropriate cases matters settled agreement tax details mitigation treasury risks found authorities may resolve disputes formal note financial instruments related disclosures appeals proceedings international business also subject range duties taxes carrying monitor government debate tax policy key similar types risk jurisdictions deal proactively potential future changes tax law tax risk managed set policies procedures increased focus tax position multinational help ensure consistency compliance tax legislation businesses consequence challenging economic engage advisors legal counsel review tax legislation environment priority placed g addressing applicability business allegations unlawful tax avoidance seen increase audits governments seek raise revenues attempt mitigate risk aggressive tax authority corporate taxes line taxes customs duties audits date possible tax affairs audits regardless merit outcomes costly working proactively tax authorities possible divert management attention may adversely impact also moved centralised simplified reputation addition increasing number changes intellectual property ownership trading model model international tax framework could lead increase centralises pharmaceutical intellectual property uk decrease tax costs reducing complexity intercompany arrangements enabling us drive bilateral advance pricing agreements mitigating activities apas uk jurisdictions operate groups treasury function operate profit centre apas give greater certainty application transfer pricing enter financial derivative transactions direct tax affairs hence reduce risks centralised speculative purposes transactions financial instruments team dedicated specialists responsible managing undertaken manage risks arising underlying business transactional tax reporting compliance activities treasury activities governed policies approved board directors compliance regularly reviewed treasury management group tmg chaired cfo gsk annual report strategic report governance remuneration financial statements investor information antibribery corruption risk definition mitigating activities risk gsk personnel third parties acting code conduct values behaviours commitment behalf seek induce improper performance someones role zero tolerance integral mitigate risk light order gain retain gsk business advantage complexity geographic breadth risk offer promise giving bribe goes ethical constantly enhance oversight activities data reinforce standards contrary laws bound employees contractors clear expectations regarding acceptable behaviours maintain ongoing communications risk impact group centre headquarters local markets failure mitigate risk could expose group associated persons governmental investigation regulatory action civil group enterprisewide abac programme designed criminal liability well damage groups reputation respond threat risk bribery corruption shareholder value licence operate particular builds groups values existing standards form jurisdictions could materially adversely affect comprehensive practical approach compliance abac financial results programme supported toplevel commitment group board directors leadership throughout business context ongoing risk assessment global policy control documents exposed bribery corruption risk global address commercial practices give rise abac business operations markets government structure risk due diligence high risk third parties ongoing training rule law less developed bearing communications confidential reporting line monitoring bribery corruption risk exposure addition global compliance investigations team addition programme nature business healthcare sector highly competitive mandates enhanced controls interactions government subject regulation increases instances officials undertaking business development exposed activities interactions bribery transactions programme governance provided groups corruption risk abac oversight committee includes representation previously disclosed group key functional areas business units subject regulatory action media focus regard bribery additionally dedicated abac team responsible investigations china markets september implementation evolution programme response group announced changsha intermediate peoples developments internal external environment court hunan province china ruled according chinese complemented abac investigations abac audit teams law gsk china investment co ltd gskci offered money separate reporting lines property nongovernment personnel order obtain improper commercial gains found guilty bribing continually benchmark abac programme nongovernment personnel verdict followed investigations large multinational companies use external expertise review initiated chinas ministry public security june help improve elements abac programme result result courts verdict gskci paid fine china country investigations group rmb billion million chinese government increased resources centrally located abac team well regional abac teams us uk authorities leading extraterritorial abac inquires certain groups operations investigations discussed note legal proceedings gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued commercial practices scientific engagement risk definition times researchers hcps healthcare organisations hcos failure engage commercial andor scientific activities external experts engage may compensated consistent letter spirit legal industry services expertise provided however payments must groups requirements relating marketing communications excessive must never perceived medicines associated therapeutic areas inducement reward prescribing products consistent appropriate interactions healthcare professionals hcps abac policies also must comply markets patients legitimate transparent transfer value abac laws recipient payment government official risk impact mitigating activities failure comply applicable laws rules regulations may taken action levels group enhance result governmental investigation regulatory action legal improve standards procedures scientific engagement proceedings brought group governmental promotional interactions based values transparency private plaintiffs failure provide accurate complete respect integrity patient focus policies information related products may result incomplete standards governing promotional activities scientific awareness benefitrisk profile medicines possibly engagement undertaken group behalf suboptimal treatment patients consequences activities conduct worldwide must conform high ethical could materially adversely affect financial results medical scientific standards local standards differ practices found misaligned values could global standards stringent two applies also result reputational damage dilute trust established group harmonized policies procedures guide key stakeholders paid billion resolve country commercial practices scientific engagement government investigations us focused large part processes well clarified applicable standards promotional practices engaging markets specific accountability authorisation context scientific engagement resides within medical governance committed legitimate scientific engagement framework overseen medical governance executive ethical responsible commercialisation medicines support committee mgec accountable chief medical officer mission improve quality human life enabling people mgec responsible oversight applicable policies feel better live longer accomplish mission ensuring highest level integrity continuous development engage healthcare community various ways advance scientific engagement gsk commercial practices activities scientific knowledge well provide important oversight business unit risk management information medicines compliance boards rmcbs country executive boards cebs manage risks across incountry business activities group disseminates information products nonpromotional scientific engagement promotional promotional materials activities must reviewed activities former interaction exchange information approved according groups policies standards group partners external communities conducted accordance local laws regulations order advance scientific medical understanding including help ensure materials activities fairly represent appropriate development use products products services group necessary management disease patient care distinct disciplined including termination employees promotional activities may take place authorisation engaged misconduct broadened ability claw new product indication must conducted strictly back remuneration senior management event accordance promotional laws codes groups policy misconduct promotion approved medicines helps ensure hcps globally took proactive risk mitigation steps access information need patients access assure operations reflect values gsk publicly committed medicines need medicines prescribed stop various payments hcps healthcare used manner provides maximum healthcare benefit organisations hcos gsk also committed extended steps patients committed communicating information related already taken us changing sales compensation model approved products responsible legal ethical globally one based sales targets approach manner individually rewards sales force quality interactions healthcare professionals end result gsk annual report strategic report governance remuneration financial statements investor information research practices risk definition mitigating activities failure adequately protect inform patients involved human established office animal welfare ethics strategy clinical trial research conduct objective ethical preclinical oawes led chief animal welfare ethics strategy clinical trials using sound scientific principles guarantee integrity help ensure humane responsible care animals discovery preclinical clinical development data manage increase knowledge application nonanimal alternatives human biological samples according established ethical group oawes embeds framework animal welfare standards regulatory expectations treat animals ethically governance promotes application rs replacement refinement practice good animal welfare appropriately disclose human subject reduction animals research explores opportunities research medicinal products ensure integrity crossindustry data sharing conducts quality assessments regulatory filings data publish report results human subject research risk impact medicines vaccines publicly accessible clinical study impacts risk include harm patients reputational register website governmentrequired repositories damage failure obtain necessary regulatory approvals submit human research results manuscripts publication products governmental investigation legal proceedings peer reviewed scientific journals disclosed product liability suits claims damages regulatory clinical study reports marketed terminated medicines action fines penalties loss product authorisation research results published scientific literature could materially adversely affect financial results register early gsk online system allow researchers request access anonymised patientlevel data context groups clinical trials reconfigured multisponsor research relating animals raise ethical concerns request site wwwclinicalstudydatarequestcom include studies attempt proactively address animal studies remain vital part conducted sponsors end listed research many cases method gsk trials available request used investigate effects potential new medicine living body tested humans generally mandated global human biological samples management hbsm regulators ethically imperative animal research provide governance framework place oversee ethical lawful critical information causes diseases acquisition management human biological samples develop countries require additional animal testing even global hbsm network champions hbsm activities provides medicines approved use elsewhere experienced group support internal sample custodians best practice clinical trials healthy volunteers patients used assess demonstrate investigational products efficacy safety remains important priority enhance data integrity evaluate product approved controls established plans develop new written marketing also work human biological samples standards ensure integrity data across research samples fundamental discovery development safety development rd data integrity committee established monitoring products provide oversight data integrity quality assurance team created provide independent business monitoring internal integrity data essential success stages controls rd activities research data lifecycle design generation recording management analysis reporting storage retrieval chief regulatory officer oversees activities research data governed legislation regulatory regulatory governance board includes promoting requirements compliance regulatory requirements groupwide standards making regulatory services efficient agile research data supporting documents core components aligning regulatory capabilities international various stages pipeline progression decisionmaking also business needs enterprise local levels form content regulatory submissions poor data integrity compromise research efforts innate complexities interdependencies required regulatory filings particularly given global research development footprint rapid changes submission requirements developing countries continue increase complexity worldwide product registration gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued environment health safety sustainability risk definition mitigating activities failure manage environment health safety sustainability corporate executive team responsible ehss ehss risks consistent groups ethics objectives governance group global policy policy policies relevant laws regulations cet ensures systems place manage risks impacts legal compliance issues relate ehss risk impact assigning responsibility senior managers providing failure manage ehss risks could lead significant harm maintaining systems individual managers responsible people environment communities operate making sure ehss management system effective well fines failure meet stakeholder expectations regulatory implemented respective business area fully requirements litigation regulatory action damage compliant applicable laws regulations adequately groups reputation could materially adversely affect resourced maintained communicated monitored financial results additionally employee personally responsible ensuring context applicable local standard operating procedures group subject health safety environmental laws followed expected take responsibility ehss matters various jurisdictions laws impose duties protect people riskbased proactive approach articulated global environment communities operate well ehs standards support ehss policy objective potential obligations remediate contaminated sites discover develop manufacture supply sell products also identified potentially responsible party without harming people environment addition us comprehensive environmental response compensation design provision safe facilities plant equipment liability act number sites remediation costs relating operate rigorous procedures help us eliminate hazards use ownership sites failure manage practicable protect employees health wellbeing environmental risks properly could result litigation regulatory employment practices designed create work place culture action additional remedial costs may materially employees feel valued respected empowered adversely affect financial results see note financial inspired achieve goals statements legal proceedings discussion environmental related proceedings involved continuing efforts improve environmental routinely accrue amounts related liabilities matters sustainability reduced water consumption hazardous waste energy consumption actively manage environmental remediation obligations help ensure practices environmentally sustainable compliant ehss performance results shared public year responsible business supplement information protection risk definition mitigating activities risk groups business activity critical sensitive group global information protection policy computer systems information available needed supported dedicated programme activity increase accessed authorised deliberately changed focus information security group established corrupted information protection privacy function provide strategy direction oversight enhancing global information risk impact security capabilities failure adequately protect critical sensitive systems information may result inability maintain patent rights assess changes information protection risk environment loss commercial strategic advantage damage briefings government agencies subscription reputation business disruption including litigation regulatory commercial threat intelligence services knowledge sharing sanction fines could materially adversely affect pharmaceutical crossindustry companies financial results aim use industry best practices part information context security policies processes technologies invest rely critical sensitive systems data strategies commensurate changing nature corporate strategic plans sensitive personally identifiable security threat landscape information intellectual property manufacturing systems trade also subject various laws govern processing secrets potential malicious careless actions personally identifiable information pll help ensure compliance expose computer systems information misuse crossborder pii transfer requirements groups binding unauthorised disclosure corporate rules bcrs approved uk information commissioners office human resource research activities data bcrs make possible transfer pii internationally groups entities without individual privacy agreements european union country gsk annual report strategic report governance remuneration financial statements investor information crisis continuity management risk definition mitigating activities inability recover sustain critical operations following ccm governance group set forth global policy disruption respond crisis incident timely manner policy business unit functional area head bu ensures effective crisis management business risk impact continuity plans place include authorised response failure manage crisis continuity management ccm recovery strategies key areas responsibility clear effectively lead prolonged business disruption greater communication routes business disruption occurs damage groups assets risk supply disruption additionally bu represented ccm governance board patients medicine could materially adversely performs risk oversight provides vital information affect financial results delays operational activities ccm programme team regarding new threats acquisitions delivery products consumers patients rely significant business organisational changes could also expose us litigation regulatory action materially adversely affect financial results lead dedicated team ccm experts supports business reputational damage responsibilities include chairing governance board coordinating crisis management business continuity training context facilitating exercises monitoring provide global groups international operations partners consistency alignment centrally storing monitoring maintain vast global footprint exposing workforce facilities updates plans supporting critical business processes operations information technology potential disruption activities help ensure appropriate level readiness resulting natural event eg storm earthquake man response capability maintained also develop maintain made event eg civil unrest terrorism global emergency partnerships external bodies like business continuity eg ebola outbreak flu pandemic effective crisis institute un international strategy disaster risk management business continuity planning committed reduction helps improve business continuity initiatives providing health safety people minimising disaster prone areas supports development damage impact group maintaining functional community resilience disasters operations following natural manmade disaster public health emergency continually improve ccm risk management programme tools based learning plan activations example group implemented global disaster monitoring tool monitor disruptions support local crisis teams guidance central support needed regularly evaluate introduce new tools improve ccm practices thirdparty oversight risk definition mitigating activities failure maintain adequate governance oversight thirdparty responsibility activities performed safely relationships failure thirdparties meet contractual compliance applicable laws gsks values standards regulatory confidentiality obligations failure thirdparties code conduct business unit leadership team retains comply law appropriately manage respective ultimate accountability managing third party interactions operations mitigate principal risks group outlined risks appropriately governing interactions working third parties gsk employees expected risk impact manage external interactions commitments responsibly failure adequately manage thirdparty relationships could result expectation embedded values code conduct business interruption exposure risk ranging sub optimal contractual terms conditions severe business help guide enforce global principles interactions sanctions andor significant reputational damage thirdparties place policy framework applicable consequences could materially adversely affect business buying goods services managing external spend operations financial results paying working thirdparties policy framework applies employees complementary workers worldwide context framework complemented technical local standards third parties critical business delivery integral designed help ensure alignment nature third party part solution improve productivity quality service interactions good manufacturing practice adherence innovation rely thirdparties including suppliers distributors local laws regulations independent business monitoring individual contractors licensees pharmaceutical key financial operational controls place biotechnology collaboration partners discovery manufacture supplemented periodic checks companys marketing products important business processes independent audit assurance function however business relationships present material risk help enhance continuous monitoring performance third example share critical sensitive information party interactions established third party oversight marketing plans clinical data employee data specific programme global programme takes enterprise view third parties conducting relevant outsourced business third party related risks help strengthen due diligence operations inadequate protection misuse information efforts third parties improve overall management third parties could significant business impact similarly third party risks lifecycle thirdparty use distributors agents range activities engagement oversight programme provided promotion tendering inherent risks gsks global ethics compliance group inappropriate promotion corruption insufficient internal compliance controls distributors could affect reputation risks increased complexities working large numbers third parties gsk annual report strategic report governance remuneration financial statements investor information shareholder information share capital control share buyback programme board authorised issue allot ordinary shares details issued share capital number shares article companys articles association held treasury december found note power article authority company make financial statements share capital share premium purchases shares subject shareholder authorities account sought annual basis annual general ordinary shares listed london stock exchange meeting agm shares purchased company may also quoted new york stock exchange nyse cancelled held treasury shares used satisfying share form american depositary shares ads ads options grants group employee share plans represents two ordinary shares details listed debt continued longterm buyback programme listed refer note financial statements million shares purchased total cost million net debt date final share purchase june holders ordinary shares ads entitled receive shares purchased period june dividends declared companys annual report february annual summary attend speak general meetings programme covers purchases shares cancellation company appoint proxies exercise voting rights held treasury shares accordance authority restrictions transfer limitations renewed shareholders agm may holding ordinary shares ads requirements company authorised purchase maximum obtain approval prior transfers ordinary shares ads million shares details shares purchased cancelled carry special rights regard control company held treasury shares disclosed note restrictions voting rights major shareholders financial statements share capital share premium account voting rights per share shareholders determining specific share repurchase levels company known arrangements financial rights held considers development free cash flow year given person holder shares known impact sustained strength sterling free cash flow agreements restrictions share transfers voting rights company suspended share repurchase programme shares acquired share schemes plans rank following completion novartis transaction gsk equally shares issue special rights intends return shareholders billion net proceeds trustees employee share ownership plan trusts company expect make ordinary share waived rights dividends shares held trusts repurchases exchange controls limitations market capitalisation affecting security holders market capitalisation based shares issue excluding certain economic sanctions may force treasury shares gsk december time time currently applicable laws decrees billion regulations restricting import export capital affecting date gsk fourth largest company market remittance dividends payments holders capitalisation ftse index companys shares nonresidents uk similarly certain economic sanctions may force time share price time limitations relating nonresidents uk english law companys articles association january right holder vote respect companys december shares decreaseincrease interests voting rights high year stated far aware low year persons significant direct indirect holdings company table sets middle market closing prices information provided company pursuant financial companys share price decreased conduct authoritys fca disclosure transparency rules compares decrease ftse index dtrs published regulatory information service year share price february companys website february company received notifications accordance fcas dtrs following notifiable uk us interests voting rights companys issued share capital percentage issued shares capital blackrock inc legal general group plc p ercentage ordinary shares issue excluding treasury shares acquired disposed interests shares period review connection share buyback programme uk share price uk us ads price us gsk annual report strategic report governance remuneration financial statements investor information nature trading market following tables set periods indicated high low middle market closing quotations pence shares london stock exchange high low closing prices us dollars ads nyse ordinary shares ads pence per share us dollars per share high low high low february january december november october september august quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december february analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bny mellon depositary companys adss listed nyse ordinary shares representing companys adr programme managed depositary registered name bny nominees limited february bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date february number holders ordinary shares usa holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holders gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued dividends uk shareholders summary applies uk resident shareholder holds company pays dividends quarterly continues return shares capital assets cash shareholders dividend policy dividends remain essential component total shareholder return taxation dividends company committed increasing dividend long uk resident shareholders generally subject uk income term details dividends declared amounts tax full amount dividends paid grossed amount payment dates given note financial statements tax credit tax credit may set individuals dividends income tax liability respect gross dividend repayable shareholders tax liability less dividends per share associated tax credit tax year subsequent tax table sets dividend per share per ads years additional rate income tax dividends imposed last five years dividend per ads translated us dollars taxpayers whose income uk resident applicable exchange rates shareholders corporation taxpayers note dividends generally entitled exemption corporation tax year dividend pence us taxation capital gains uk shareholders may liable uk tax gains disposal shares adr disposals individuals subject availability exemption relief annual exempt amount taxable capital gain accruing disposal shares supplemental adr taxed allowable deductions shareholders taxable income tax year exceeds basic supplemental dividend related disposal certain rate income tax limit cases taxable capital gain accruing noncore otc brands north america paid fourth disposal shares adr may taxed quarter ordinary dividend combination rates corporation taxpayers may entitled indexation allowance applies reduce capital gains dividend calendar extent gains arise due inflation indexation ads exdividend exdividend allowance may reduce chargeable gain create quarter date date record date payment date allowable loss q february february february april q may may may july inheritance tax q august august august october individual shareholders may liable inheritance tax transfer shares adr tax may charged amount q november november november january value shareholders estate reduced result transfer way gift disposal less full tax information shareholders market value gift disposal subject summary certain uk tax us federal income tax uk inheritance tax us estate gift tax estate gift consequences holders shares adr citizens tax convention would generally provide tax paid usa uk usa set complete analysis credited tax payable uk possible tax consequences purchase ownership stamp duty sale securities intended general guide uk stamp duty stamp duty reserve tax sdrt subject holders advised consult advisers respect certain exemptions payable transfer shares rate tax consequences purchase ownership sale consideration transfer shares adr consequences state local tax laws usa implications current ukus tax conventions us holders adr generally treated owners underlying shares purposes current usauk double taxation conventions relating income gains income tax convention estate gift taxes estate gift tax convention purposes internal revenue code amended code gsk annual report strategic report governance remuneration financial statements investor information us shareholders stamp duty summary applies shareholder citizen uk stamp duty sdrt subject certain exemptions resident usa domestic corporation person payable transfer shares adr custodian otherwise subject us federal income tax net income basis depository rate amount consideration respect shares adr holds shares adr provided transferred sale value transferred capital assets resident uk uk tax purposes consideration hold shares purposes trade profession sdrt would payable transfer agreement vocation carried uk branch agency transfer adr uk stamp duty payable summary also address tax treatment holders transfer adr provided instrument transfer subject special tax rules banks taxexempt executed remains times outside uk stamp duty entities insurance companies dealers securities currencies transfer adr would payable rate persons hold shares adr part integrated consideration transfer sale underlying shares investment including straddle comprised share adr would subject certain exceptions result liability uk stamp one positions persons directly duty case may sdrt rate indirectly voting stock company annual general meeting taxation dividends gross amount dividends received treated foreign pm uk time thursday may source dividend income us tax purposes eligible queen elizabeth ii conference centre broad sanctuary dividend received deduction allowed us corporations westminster london swp ee dividends adr payable us dollars dividends shares payable pounds sterling dividends paid pounds sterling agm companys principal forum communication included income us dollar amount calculated private shareholders addition formal business reference exchange rate day dividends presentation ceo performance received holder subject certain exceptions shortterm group future development opportunity hedged positions individual eligible us holder subject questions asked board chairmen boards us taxation maximum rate respect qualified committees take questions relating committees dividends investors holding shares nominee service arrange taxation capital gains nominee service appointed proxy respect generally us holders subject uk capital gains tax shareholding order attend vote meeting subject us tax capital gains realised sale adr holders wishing attend meeting must obtain proxy disposal shares adr gains longterm bny mellon depositary notifying request capital gains subject reduced rates taxation individual enable attend vote business holders shares adr held one year transacted adr holders may instruct bny mellon information reporting backup withholding way shares represented adr voted dividends payments proceeds sale shares completing returning voting card provided adr paid within usa certain usrelated financial depositary intermediaries subject information reporting may documents display subject backup withholding unless us holder articles association company directors service corporation exempt recipient provides taxpayer contracts applicable letters appointment identification number certifies loss exemption directors company subsidiaries side occurred nonus holders generally subject information letters relating severance terms pension arrangements reporting backup withholding may required provide available inspection companys registered office certification nonus status connection payments made available inspection agm received amounts withheld allowed refund credit holders us federal income tax liability provided required information furnished internal revenue service estate gift taxes estate gift tax convention us shareholder generally subject uk inheritance tax gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued financial calendar definitions political donations political expenditure political organisations used legislation wide event date particular definition eu political organisations may extend quarter results announcement aprilmay bodies concerned policy review law reform annual general meeting may representation business community special interest quarter results announcement july groups concerned environment quarter results announcement october company subsidiaries might wish support result preliminaryquarter results announcement february definitions may cover legitimate business activities ordinary sense considered political donations political annual report announcement februarymarch expenditure annual reportsummary distribution march activities designed support political party information company including share price available independent election candidate authority board website wwwgskcom information made available sought annually precautionary measure ensure website constitute part annual report company subsidiaries inadvertently breach results announcements legislation results announcements issued london stock exchange directors available news service also sent us securities exchange commission nyse issued directors powers determined uk legislation media made available website articles association available website articles may amended special resolution members financial reports directors may exercise companys powers provided company publishes annual report shareholder articles applicable legislation stipulate needing full detail annual report summary powers must exercised members documents available website date rules appointment replacement directors publication summary sent shareholders shareholders contained articles provide directors may may elect receive annual report contacting registrar appointed ordinary resolution members resolution alternatively shareholders may elect receive notification directors provided latter instance director email publication financial reports registering appointed way retires first agm following wwwshareviewcouk appointment copies previous financial reports available website articles also provide directors normally subject printed copies obtained registrar uk reelection agm intervals three years annually gsk response center usa see pages held office continuous period nine years contact details however board agreed directors wish continue members board seek reelection donations political organisations annually accordance uk corporate governance code political expenditure members may remove director passing ordinary resolution special notice given passing special effect january ensure consistent approach resolution political contributions across group introduced global policy stop voluntarily corporate political contributions director may automatically cease director period january december becomes bankrupt compounds group make political donations eu noneu creditors generally organisations ceases director virtue companies notwithstanding introduction policy accordance act articles federal election campaign act usa continue suffering mental physical ill health support employeeoperated political action committee pac board resolves shall cease director facilitates voluntary political donations eligible gsk employees missed directors meetings continuous period six months without permission board pac controlled gsk decisions amounts resolves shall cease director recipients contributions made participating employees exercising legal right pool resources make prohibited director law political contributions subject strict limitations resigns total us us donated political organisations gsk employee pac offers resign board accepts offer agm may shareholders first authorised directors least three number require company make donations eu political organisations resign incur eu political expenditure provisions political parties elections referendums act year authority since renewed annually companies act requires companies continue obtain shareholder approval make donations eu political organisations incur eu political expenditure however make intend make donations political parties independent election candidates make donations eu political organisations incur eu political expenditure gsk annual report strategic report governance remuneration financial statements investor information directors conflicts interest us law regulation directors duty companies act avoid number provisions us law regulation apply situation could direct indirect company shares quoted new york stock conflict interest possible conflict company duty exchange nyse form adss applies particular exploitation property information opportunity whether company could take advantage nyse rules articles provide general power board authorise general nyse rules permit company follow uk conflicts corporate governance practices instead applied usa provided explain significant variations nominations committee authorised board explanation contained form f accessed grant periodically event annually review securities exchange commissions sec edgar potential actual conflict authorisations directors database via website nyse rules came effect counted quorum authorisation actual require us file annual interim written affirmations potential conflicts authorisations granted recorded concerning audit risk committee statement company secretary register noted board significant differences corporate governance ongoing basis directors responsible informing sarbanesoxley act company secretary new actual potential conflicts following number corporate accounting scandals may arise changes circumstances usa congress passed sarbanesoxley act may affect authorisation previously given even provided sarbanesoxley wideranging piece legislation concerned authorisation director absolved largely financial reporting corporate governance statutory duty promote success company actual conflict arises postauthorisation board may choose recommended sec company established exclude director receipt relevant information disclosure committee committee reports ceo participation debate suspend director cfo audit risk committee chaired board last resort require director resign company secretary members consist senior managers finance legal corporate communications investor nominations committee reviewed register potential relations conflict authorisations october reported board conflicts appropriately authorised external legal counsel external auditors internal experts process authorisation continues operate effectively except invited attend meetings periodically responsibility described note financial statements related party considering materiality information timely basis transactions end financial year director determining disclosure information responsibility connected person material interest contract timely filing reports sec formal review significance group company annual report form f committee met times independent advice board recognises may occasions one sarbanesoxley requires annual report form f directors feel necessary take independent legal contain statement whether member audit risk andor financial advice companys expense committee arc audit committee financial expert defined agreed procedure set website enable sarbanesoxley statement relevant members arc stacey cartwright judy lewent tom de swaan included audit risk committee report indemnification directors biographies pages additional qualifying third party indemnity provisions defined disclosure requirements arise section section companies act force benefit directors sarbanesoxley respect disclosure controls former directors held office signing procedures internal control financial reporting annual report change control essential contracts contracts arrangements individually fundamental ability business operate effectively company party material agreements would take effect altered terminate upon change control following takeover bid agreements director would provide compensation loss office employment resulting takeover except provisions companys share plans may cause options awards granted plans vest takeover details termination provisions companys framework contracts executive directors given pages gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued section corporate responsibility financial reports management conducted evaluation effectiveness sarbanesoxley also introduced requirement ceo internal control financial reporting based framework cfo complete formal certifications confirming internal control integrated framework issued committee sponsoring organisations treadway reviewed annual report form f commission coso based knowledge annual report form f changes groups internal control contains material misstatements omissions financial reporting materially affected based knowledge financial statements reasonably likely affect materially groups internal financial information fairly present material respects control financial reporting financial condition results operations cash flows management assessed effectiveness internal control dates periods presented annual report financial reporting december form f conclusion filed part groups form f responsible establishing maintaining disclosure pricewaterhousecoopers llp audited consolidated controls procedures ensure material information financial statements group year ended december made known evaluated effectiveness also assessed effectiveness groups internal controls procedures yearend results control financial reporting auditing standard evaluation contained annual report public company accounting oversight board united states form f audit report filed groups form f responsible establishing maintaining internal section r us securities exchange act control financial reporting provides reasonable section r us securities exchange act assurance regarding reliability financial reporting amended requires issuers make specific disclosure annual preparation financial statements external purposes reports certain types dealings iran including transactions accordance generally accepted accounting principles dealings governmentowned entities well dealings entities sanctioned activities related terrorism proliferation disclosed annual report form f weapons mass destruction even activities changes internal controls financial reporting prohibited us law involve us persons group period covered annual report form f legal entity based iran export certain materially affected reasonably likely affect materially pharmaceutical vaccine products iran via sales nonus companys internal control financial reporting entities two privately held iranian distributors group also disclosed based recent evaluation internal business via nonus entities jurisdictions targeted control financial reporting external auditors sanctions laws including syria crimea north korea sudan arc significant deficiencies material weaknesses believe groups direct dealings iran design operation internal controls financial reporting require specific disclosure requirements group reasonably likely affect adversely companys limits sales iran north korea syria sudan cuba essential ability record process summarise report financial medicines determined part using criteria set world health information fraud regardless materiality involving organization group direct knowledge identity persons significant role companys internal distributors downstream customers iran possible control financial reporting customers include entities governmentowned group carried evaluation supervision hospitals pharmacies owned controlled directly participation management including ceo indirectly iranian government persons entities cfo effectiveness design operation sanctioned connection terrorism proliferation activities groups disclosure controls procedures group direct knowledge distributors december customers establish proportion gross revenue sales potentially attributable entities affiliated iranian inherent limitations effectiveness system government parties sanctioned disclosable activities disclosure controls procedures including possibility result group reporting entire gross revenues million human error circumvention overriding controls net losses million groups sales iran procedures accordingly even effective disclosure controls procedures provide reasonable assurance group also aware hospitals medical achieving control objectives facilities lebanon may affiliated controlled hezbollah designated united states terrorist organization ceo cfo expect complete certifications group deal directly facilities sells report conclusions effectiveness disclosure controls distributor group also unable identify procedures february following certificates certainty degree nature affiliation end customers filed sec part groups form f hezbollah group unable establish proportion section managements annual report internal control gross revenue sales potentially attributable reportable financial reporting entities result group reporting entire gross revenues accordance requirements section sarbanes million net profits million groups sales oxley following report provided management respect lebanon companys internal control financial reporting defined rules af df us securities exchange act management responsible establishing maintaining adequate internal control financial reporting group internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance ifrs gsk annual report strategic report governance remuneration financial statements investor information shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may drip election form drip choose reinvest dividends buy gsk downloaded shares wwwshareviewcouk requested telephoning equiniti dividend payment direct bank currently receive dividends cheque dividend bank mandate form account bank mandate post instead paid directly downloaded bank building society account quicker wwwshareviewcouk secure avoids risk cheque going astray requested telephoning equiniti dividend payment direct instead waiting sterling cheque arrive post details service bank account overseas shareholders equiniti convert dividend local currency costs involved please contact equiniti send direct local bank account service available countries worldwide electronic communications shareholders may elect receive electronic notifications register company communications including annual report wwwshareviewcouk dividend payments paid way bank mandate access electronic tax vouchers availability online voting general meetings time gsk mails hard copy shareholder documents receive email containing link document relevant website shareview service enables create free online portfolio view register share balance movements update address wwwshareviewcouk dividend payment instructions register votes agm duplicate publications mailings receive duplicate copies report please contact equiniti mailings please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated internet transactions please log please note market trading hours form held corporate sponsored nominee wwwshareviewcoukdealing pm uk time internet telephone postal dealing service provided telephone transactions please call monday friday excluding uk public equiniti financial services limited uk holidays outside uk postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without application form downloaded requiring share certificate service provides facility hold shares nominee company wwwshareviewcouk sponsored company continue receive requested telephoning equiniti dividend payments annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services details available limited provide gsk corporate isa hold gsk wwwshareviewcouk ordinary shares requested telephoning equiniti uk lines open pm monday friday except uk public holidays calls number charged p per minute plus network extras provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued adr depositary contacts investor relations adr programme administered bank new york mellon investor relations may contacted follows uk bny mellon shareowner services great west road po box brentford middlesex tw gs college station tx tel overnight correspondence sent usa bny mellon shareowner services five crescent drive quality circle suite philadelphia pa college station tx tel us toll free wwwmybnymdrcom tel outside usa tel us toll free tel outside usa gsk response center email shrrelationscpushareownerservicescom tel us toll free depositary also provides global buydirect direct ads share scam alert purchasesale dividend reinvestment plan adr holders receive unsolicited telephone call offering sell buy details enrol please visit wwwmybnymdrcom call shares please take extra care caller may part helpline number obtain enrolment pack highly organised financial scam glaxo wellcome smithkline beecham uk shareholder please contact financial conduct corporate peps authority information similar activities share centre limited wwwfcaorgukconsumers consumer helpline oxford house oxford road aylesbury bucks hp sz tel uk tel lines open pm uk time wwwsharecom monday friday except uk public holidays donating shares save children responsible business supplement gsk embarked ambitious global partnership publishing responsible business supplement save children share expertise resources online outline gsks approach performance aim helping save lives one million children key responsible business areas health behaviour people planet shareholders small number shares value makes uneconomical sell may wish consider donating save children donated shares aggregated sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc corporate integrity agreement cia company entered settlement us federal government related past sales marketing practices part settlement company entered corporate integrity agreement us department health human services improvements built existing compliance programmes currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report strategic report governance remuneration financial statements investor information index accounting principles policies latestage pipeline summary acquisitions disposals legal proceedings adjustments reconciling profit tax operating longterm incentive plans cash flows major restructuring costs annual general meeting movements equity assets held sale net debt associates joint ventures new accounting requirements cash cash equivalents nonexecutive directors fees ceos statement notes financial statements chairmans statement operating profit commitments intangible assets committee reports investments competition noncurrent assets consolidated balance sheet noncurrent liabilities consolidated cash flow statement operating income consolidated income statement provisions consolidated statement changes equity board consolidated statement comprehensive income business consumer healthcare products competition people contingent liabilities strategy priorities corporate executive team outlook corporate governance pensions postemployment benefits critical accounting policies pharmaceutical products competition directors senior management intellectual property directors interests shares pipeline directors statement responsibilities presentation financial statements dividends principal group companies donations political organisations property plant equipment political expenditure proposed novartis transaction earnings per share quarterly trend employee costs reconciliation net cash flow movement net debt employee share schemes registrar exchange rates related party transactions executive director remuneration relations shareholders finance expense remuneration policy report finance income remuneration report financial instruments related disclosures research development financial position resources responsible business financial statements glaxosmithkline plc prepared risk factors uk gaap segment information five year record share capital control glossary terms share capital share premium account goodwill share price group financial review shareholder information independent auditors report taxation inventories tax information shareholders investments associates joint ventures remuneration committee investor relations trade payables key accounting judgements estimates trade receivables key performance indicators us law regulation gsk annual report b gsk annual report strategic report governance remuneration financial statements investor information gsk glaxosmithkline plc incorporated notice regarding limitations director liability english law english public limited company december uk companies act safe harbour limits liability directors respect statements formed merger omissions directors report see strategic report remuneration report glaxo wellcome plc smithkline beecham english law directors would liable company third party one plc gsk acquired two english companies reports contained errors result recklessness knowing misstatement dishonest concealment december part merger material fact would otherwise liable pages inclusive comprise arrangements directors report pages inclusive comprise strategic report pages inclusive comprise remuneration report drawn presented accordance reliance upon english company law liabilities directors shares listed london stock connection reports shall subject limitations restrictions provided law exchange new york stock exchange website gsks website wwwgskcom gives additional information group notwithstanding references make read wwwgskcom annual report gsks website none information made available website constitutes part annual report shall deemed incorporated reference herein cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future find downloadable pdfs operating financial performance particular include statements relating future actions prospective annual report products product approvals future performance results current anticipated products sales efforts annual summary expenses outcome contingencies legal proceedings financial results accordance legal regulatory obligations including form f uk listing rules disclosure transparency rules financial conduct authority group responsible business supplement undertakes obligation update forwardlooking statements whether result new information future events otherwise reader however consult additional disclosures group may make documents publishes andor files sec readers wherever located take note disclosures accordingly assurance given particular expectation met shareholders cautioned place undue reliance forward looking statements forwardlooking statements subject assumptions inherent risks uncertainties many relate brand names factors beyond groups control precise brand names appearing italics throughout report estimate group cautions investors number trade marks either owned andor licensed gsk important factors including document could associated companies exception boniva cause actual results differ materially expressed bonviva trade mark roche nicoderm trade implied forwardlooking statement factors mark johnson johnson merrell novartis sanofi include limited discussed risk glaxosmithkline potiga trade mark valeant prolia factors pages annual report xgeva trade marks amgen vesicare trade mark forwardlooking statements made behalf astellas pharmaceuticals many countries group speak date made yamanouchi pharmaceuticals certain countries volibris based upon knowledge information available trade mark gilead xyzal trade mark ucb gsk directors date annual report zyrtec trade mark ucb gsk used certain countries licence group number adjusted measures used report performance business measures defined acknowledgements reconciliation core results total results set design salterbaxter information document constitute offer sell invitation buy shares glaxosmithkline printing plc invitation inducement engage printed pureprint group iso investment activities past performance relied fsc certified carbonneutral upon guide future performance nothing annual report construed profit forecast paper annual report printed amadeus silk recycled paper full fsc certification pulps used made deinked postconsumer waste elemental chlorine free manufacturing mill holds iso eu ecolabel certificates environmental management gsk annual report doctors like kaali pictured frontline malaria works ghana treats children malaria educates families prevent disease along partners committed fighting malaria fronts improving access medicines encouraging use preventative tools like bed nets searching new treatments well developing potential vaccine head office registered office wwwgskcom glaxosmithkline plc great west road brentford middlesex tw gs also search us united kingdom tel registered number